<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>

<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31059004</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>05</Month>
            <Day>06</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1791-2423</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>May</Month>
                        <Day>06</Day>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of oncology</Title>
                <ISOAbbreviation>Int. J. Oncol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.3892/ijo.2019.4796</ELocationID>
            <Abstract>
                <AbstractText>Triple‑negative breast cancer (TNBC) cells form angiogenesis‑independent vessel‑like structures to survive, known as vasculogenic mimicry (VM), contributing to a poor prognosis for cancer patients. Nuclear localized class I histone deacetylases (HDACs) enzymes, particularly HDACs 1, 2, 3 deacetylate chromatin histones, are overexpressed in cancers and epigenetically regulate the expression of genes involved in cancer initiation and progression. The specific HDAC inhibitor, entinostat, has been shown to attenuate tumor progression and metastasis in TNBC. In this study, we hypothesized that entinostat would enhance the expression of anti‑angiogenic and tumor suppressor genes and would thus suppress VM structures in TNBC cells in a 3D Matrigel cell culture preclinical model. Our data indicated that invasive triple‑negative MDA‑MB‑231, LM2‑4 and BT‑549 breast cancer cells, but not poorly invasive luminal MCF‑7 cells, efficiently underwent matrix‑associated VM formation. Approximately 80% of TNBC cells with the stem cell phenotype potential formed vessel‑like structures when mixed with Matrigel and cultured in the low attachment tissue culture plate. The molecular mechanisms of VM formation are rather complex, while angiogenesis inhibitor genes are downregulated and pro‑angiogenesis genes are upregulated in VM‑forming cells. Our data revealed that treatment of the TNBC VM phenotype cells with entinostat epigenetically led to the re‑expression of the anti‑angiogenic genes, serpin family F member 1 (SERPINF1) and thrombospondin 2 (THBS2), and to that of the tumor suppressor genes, phosphatase and tensin homolog (PTEN) and p21, and reduced VM structures. We also found that treatment of the TNBC VM phenotype cells with entinostat downregulated the expression of vascular endothelial growth factor A (VEGF‑A), and that of the epithelial‑mesenchymal transition (EMT)‑related genes, Vimentin and β‑catenin. METABIRC and TCGA breast cancer cohort mRNA expression data analysis revealed that a high expression of the anti‑angiogenesis‑associated genes, THBS2, SERPINF1 and serpin family B member 5 (SERPINB5), and of the tumor suppressor gene, PTEN, was associated with a better overall survival (OS) of breast cancer patients. Taken together, the findings of this study demonstrate that HDACs 1, 2, 3 partly contribute to VM formation in TNBC cells; thus, HDACs may be an important therapeutic target for TNBC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Maiti</LastName>
                    <ForeName>Aparna</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Breast Surgery, Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qi</LastName>
                    <ForeName>Qianya</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peng</LastName>
                    <ForeName>Xuan</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yan</LastName>
                    <ForeName>Li</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takabe</LastName>
                    <ForeName>Kazuaki</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Breast Surgery, Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hait</LastName>
                    <ForeName>Nitai C</ForeName>
                    <Initials>NC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Breast Surgery, Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Int J Oncol</MedlineTA>
            <NlmUniqueID>9306042</NlmUniqueID>
            <ISSNLinking>1019-6439</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>04</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>5</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>5</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>5</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31059004</ArticleId>
            <ArticleId IdType="doi">10.3892/ijo.2019.4796</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31029033</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>05</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1476-5586</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>21</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Apr</Month>
                        <Day>24</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Neoplasia (New York, N.Y.)</Title>
                <ISOAbbreviation>Neoplasia</ISOAbbreviation>
            </Journal>
            <ArticleTitle>DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors.</ArticleTitle>
            <Pagination>
                <MedlinePgn>533-544</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S1476-5586(19)30015-6</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neo.2019.04.001</ELocationID>
            <Abstract>
                <AbstractText>Treatment options are limited for patients with triple negative breast cancer (TNBC). Understanding genes that participate in cancer progression and DNA damage response (DDR) may improve therapeutic strategies for TNBC. DAXX, a death domain-associated protein, has been reported to be critically involved in cancer progression and drug sensitivity in multiple cancer types. However, its role in breast cancer, especially for TNBC, remains unclear. Here, we demonstrated a tumor suppressor function of DAXX in TNBC proliferation, colony formation, and migration. In Mouse Xenograft Models, DAXX remarkably inhibited tumorigenicity of TNBC cells. Mechanistically, DAXX could directly bind to the promoter region of RAD51 and impede DNA damage repair, which impacted the protection mechanism of tumor cells that much depended on remaining DDR pathways for cell growth. Furthermore, DAXX-mediated inefficient DNA damage repair could sensitize BRCA-proficient TNBC cells to PARP inhibitors. Additionally, we identified that dual RAD51 and PARP inhibition with RI-1 and ABT888 significantly reduced TNBC growth both in vitro and in vivo, which provided the first evidence of combining RAD51 and PARP inhibition in BRCA-proficient TNBC. In conclusion, our data support DAXX as a modulator of DNA damage repair and suppressor of TNBC progression to sensitize tumors to the PARP inhibitor by repressing RAD51 functions. These provide an effective strategy for a better application of PARP inhibition in the treatment of TNBC.</AbstractText>
                <CopyrightInformation>Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Shi</LastName>
                    <ForeName>Yaqin</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China. Electronic address: shiyaqinand@126.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jin</LastName>
                    <ForeName>Juan</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. Electronic address: medjinjuan@126.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Xin</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China. Electronic address: lotus_wx@126.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ji</LastName>
                    <ForeName>Wenfei</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Jinling Hospital, Nanjing Medical University, Nanjing 210002, China. Electronic address: jiwenfei1117@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guan</LastName>
                    <ForeName>Xiaoxiang</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China; Department of Medical Oncology, Jinling Hospital, Nanjing Medical University, Nanjing 210002, China; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China. Electronic address: xguan@nju.edu.cn.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>04</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Neoplasia</MedlineTA>
            <NlmUniqueID>100886622</NlmUniqueID>
            <ISSNLinking>1476-5586</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>01</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>04</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>4</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>4</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>4</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31029033</ArticleId>
            <ArticleId IdType="pii">S1476-5586(19)30015-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.neo.2019.04.001</ArticleId>
            <ArticleId IdType="pmc">PMC6484230</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">31014367</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>05</Month>
            <Day>04</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1465-542X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>21</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Apr</Month>
                        <Day>24</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Breast cancer research : BCR</Title>
                <ISOAbbreviation>Breast Cancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>53</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13058-019-1131-2</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To evaluate the cross-talk between BRCA1-IRIS (IRIS)-overexpressing (IRISOE) TNBC cells and tumor-resident mesenchymal stem cells (MSCs) that triggers the aggressiveness or elimination of IRISOE TNBC tumors.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We analyzed the effect of silencing or inactivating IRIS on the bi-directional interaction between IRISOE TNBC cells and MSCs on tumor formation and progression. We analyzed the downstream signaling in MSCs induced by IL-6 secreted from IRISOE TNBC cells. We compared the effect of MSCs on the formation and progression of IRIS-proficient and deficient-TNBC cells/tumors using in vitro and in vivo models. Finally, we analyzed the association between IL-6, PTGER2, and PTGER4 overexpression and breast cancer subtype; hormone receptor status; and distant metastasis-free or overall survival.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">We show high-level IL-6 secreted from IRISOE TNBC cells that enhances expression of its receptor (IL-6R) in MSCs, their proliferation, and migration toward IRISOE, in vitro, and recruitment into IRISOE TNBC tumors, in vivo. In serum-free medium, recombinant IL-6 and the IL-6-rich IRISOE TNBC cell condition media (CM) decreased STAT3<sup>Y705</sup> phosphorylation (p-STAT3<sup>Y705</sup>) in MSCs. Inhibiting IRIS expression or activity prolonged STAT3<sup>Y705</sup> phosphorylation in MSCs. The interaction with IRISOE TNBC cells skewed MSC differentiation toward prostaglandin E<sub>2</sub> (PGE<sub>2</sub>)-secreting pro-aggressiveness cancer-associated fibroblasts (CAFs). Accordingly, co-injecting human or mouse MSCs with IRISOE TNBC tumor cells promoted the formation of aggressive mammary tumors, high circulating IL-6 and PGE<sub>2</sub> levels, and reduced overall survival. In contrast, IRIS-silenced or inactivated cells showed reduced tumor formation ability, limited MSC recruitment into tumors, reduced circulating IL-6 and PGE<sub>2</sub> levels, and prolonged overall survival. A positive correlation between IL-6, PTGER2, and PTGER4 expression and basal phenotype; ER-negativity; distant metastasis-free and overall survival in basal; or BRCA<sup>mutant</sup> carriers was observed. Finally, the bi-directional interaction with MSCs triggered death rather than growth of IRIS-silenced TNBC cells, in vitro and in vivo.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The IL-6/PGE<sub>2</sub>-positive feedback loop between IRISOE TNBC tumor cells and MSCs enhances tumor aggressiveness. Inhibiting IRIS expression limits TNBC tumor growth and progression through an MSC-induced death of IRIS-silenced/inactivated TNBC cells.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ryan</LastName>
                    <ForeName>Daniel</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Breast Cancer Program, San Diego Biomedical Research Institute, 10865 Road to Cure, Suite 100, San Diego, CA, 92121, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Paul</LastName>
                    <ForeName>Bibbin T</ForeName>
                    <Initials>BT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular Biology and Biophysics, University of Connecticut Health Center, Farmington, CT, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Koziol</LastName>
                    <ForeName>Jim</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>ElShamy</LastName>
                    <ForeName>Wael M</ForeName>
                    <Initials>WM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Breast Cancer Program, San Diego Biomedical Research Institute, 10865 Road to Cure, Suite 100, San Diego, CA, 92121, USA. welshamy@sdbri.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R01 CA194447</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA194447</GrantID>
                    <Agency>National Cancer Institute</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>04</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Breast Cancer Res</MedlineTA>
            <NlmUniqueID>100927353</NlmUniqueID>
            <ISSNLinking>1465-5411</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BRCA1-IRIS</Keyword>
            <Keyword MajorTopicYN="N">IL-6</Keyword>
            <Keyword MajorTopicYN="N">Mesenchymal stem cells</Keyword>
            <Keyword MajorTopicYN="N">Metastasis</Keyword>
            <Keyword MajorTopicYN="N">Prostaglandin E2</Keyword>
            <Keyword MajorTopicYN="N">STAT3</Keyword>
            <Keyword MajorTopicYN="N">Triple-negative breast cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>09</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>4</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>4</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>4</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31014367</ArticleId>
            <ArticleId IdType="doi">10.1186/s13058-019-1131-2</ArticleId>
            <ArticleId IdType="pii">10.1186/s13058-019-1131-2</ArticleId>
            <ArticleId IdType="pmc">PMC6480921</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30996114</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>04</Month>
            <Day>18</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-4935</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Apr</Month>
                        <Day>17</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Bioscience reports</Title>
                <ISOAbbreviation>Biosci. Rep.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>LncRNA NRON downregulates lncRNA snaR and inhibits cancer cell proliferation in triple negative breast cancer (TNBC).</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">BSR20190468</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1042/BSR20190468</ELocationID>
            <Abstract>
                <AbstractText>NRON mediates the degradation of tat protein to participate in HIV-1 infection. Interesting, our study observed the downregulation of NRON in triple negative breast cancer (TNBC) tissues compared with paired adjacent healthy tissues. In contrast, lncRNA snaR was upregulated in TNBC tissues and was inversely correlated with NRON. Expression levels of snaR increased, while expression levels of NRON decreased along with the increase of clinical stages. snaR overexpression resulted in promoted cancer cell proliferation but did not significantly affect NRON expression. NRON overexpression inhibited cancer cell proliferation and downregulated snaR. SnaR overexpression reduced the effects of NRON overexpression. We therefore conclude that NRON may downregulate lncRNA snaR to inhibit cancer cell proliferation in TNBC.</AbstractText>
                <CopyrightInformation>©2019 The Author(s).</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Niu</LastName>
                    <ForeName>Limin</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>The First Affiliated Hospital of Zhengzhou University, zhengzhou, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fan</LastName>
                    <ForeName>Qingxia</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>The First Affiliated Hospital of Zhengzhou University, zhengzhou, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yan</LastName>
                    <ForeName>Min</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Affiliated Cancer Hospital of Zhengzhou University, zhengzhou, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Liuxing</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>The First Affiliated Hospital of Zhengzhou University, zhengzhou, China if27915@163.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>04</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Biosci Rep</MedlineTA>
            <NlmUniqueID>8102797</NlmUniqueID>
            <ISSNLinking>0144-8463</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">lncRNA NRON</Keyword>
            <Keyword MajorTopicYN="N">lncRNA snaR</Keyword>
            <Keyword MajorTopicYN="N">triple negative breast cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>04</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>02</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>4</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>4</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>4</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30996114</ArticleId>
            <ArticleId IdType="pii">BSR20190468</ArticleId>
            <ArticleId IdType="doi">10.1042/BSR20190468</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">30918246</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>04</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2041-4889</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>10</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Mar</Month>
                        <Day>28</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cell death &amp; disease</Title>
                <ISOAbbreviation>Cell Death Dis</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>285</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41419-019-1512-6</ELocationID>
            <Abstract>
                <AbstractText>Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer that harbors enriched cancer stem cell (CSC) populations in tumors. Conventional chemotherapy is a standard treatment for TNBC, but it spares the CSC populations, which cause tumor recurrence and progression. Therefore, identification of the core molecular pathway that controls CSC activity and expansion is essential for developing effective therapeutics for TNBC. In this study, we identify that USP2 deubiquitinating enzyme is upregulated in CSCs and is a novel regulator of CSCs. Genetic and pharmacological targeting of USP2 substantially inhibits the self-renewal, expansion and chemoresistance of CSCs. We show that USP2 maintains the CSC population by activating self-renewing factor Bmi1 and epithelial-mesenchymal transition through Twist upregulation. Mechanistically, USP2 promotes Twist stabilization by removing β-TrCP-mediated ubiquitination of Twist. Animal studies indicate that pharmacological inhibition of USP2 suppresses tumor progression and sensitizes tumor responses to chemotherapy in TNBC. Furthermore, the histological analyses reveal a positive correlation between USP2 upregulation and lymph node metastasis. Our findings together demonstrate a previously unrecognized role of USP2 in mediating Twist activation and CSC enrichment, suggesting that targeting USP2 is a novel therapeutic strategy to tackle TNBC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>He</LastName>
                    <ForeName>Jiabei</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY, 11794, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Hong-Jen</ForeName>
                    <Initials>HJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY, 11794, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY, 11794, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saha</LastName>
                    <ForeName>Suchandrima</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY, 11794, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY, 11794, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ruan</LastName>
                    <ForeName>Diane</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY, 11794, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guo</LastName>
                    <ForeName>Hua</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, 10032, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chan</LastName>
                    <ForeName>Chia-Hsin</ForeName>
                    <Initials>CH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY, 11794, USA. chia-hsin.chan@stonybrook.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY, 11794, USA. chia-hsin.chan@stonybrook.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>28</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Cell Death Dis</MedlineTA>
            <NlmUniqueID>101524092</NlmUniqueID>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>10</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>02</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30918246</ArticleId>
            <ArticleId IdType="doi">10.1038/s41419-019-1512-6</ArticleId>
            <ArticleId IdType="pii">10.1038/s41419-019-1512-6</ArticleId>
            <ArticleId IdType="pmc">PMC6437220</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">30915341</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>03</Month>
            <Day>29</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">2296-889X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>6</Volume>
                    <PubDate>
                        <Year>2019</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Frontiers in molecular biosciences</Title>
                <ISOAbbreviation>Front Mol Biosci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Investigation of TNBC <i>in vitro</i> Antiproliferative Effects of Versatile Pirrolo[1,2-a]quinoxaline Compounds.</ArticleTitle>
            <Pagination>
                <MedlinePgn>12</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3389/fmolb.2019.00012</ELocationID>
            <Abstract>
                <AbstractText>The triple-negative breast cancer (TNBC) is characterized by a more aggressive nature and poorer prognosis, nowadays none pharmaceutical approach is still available. For this reason, the research of new active compounds and attractive targets represents an interesting field. In this context MDA- MB-231 cell line was selected to evaluate the antiproliferative effects of new [1,2-a]-pyrroloquinoxaline derivatives. The MTT assay revealed that the amine forms of synthesized molecules were more active compared to iminic ones at 72 h of incubation. The antiproliferative effect of the most promising compounds highlighted the formation of autophagic vacuoles.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Perri</LastName>
                    <ForeName>Mariarita</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy Health and Nutritional Sciences, University of Calabria, Rende, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aiello</LastName>
                    <ForeName>Francesca</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy Health and Nutritional Sciences, University of Calabria, Rende, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cione</LastName>
                    <ForeName>Erika</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy Health and Nutritional Sciences, University of Calabria, Rende, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Carullo</LastName>
                    <ForeName>Gabriele</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy Health and Nutritional Sciences, University of Calabria, Rende, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Amendola</LastName>
                    <ForeName>Luisa</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy Health and Nutritional Sciences, University of Calabria, Rende, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mazzotta</LastName>
                    <ForeName>Sarah</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Química Orgánica Y Farmacéutica, Universidad de Sevilla, Seville, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Caroleo</LastName>
                    <ForeName>Maria Cristina</ForeName>
                    <Initials>MC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy Health and Nutritional Sciences, University of Calabria, Rende, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>12</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Front Mol Biosci</MedlineTA>
            <NlmUniqueID>101653173</NlmUniqueID>
            <ISSNLinking>2296-889X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">antiproliferative activity</Keyword>
            <Keyword MajorTopicYN="N">autophagy</Keyword>
            <Keyword MajorTopicYN="N">one-pot reaction</Keyword>
            <Keyword MajorTopicYN="N">pyrroloquinoxalines</Keyword>
            <Keyword MajorTopicYN="N">triple-negative breast cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>12</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>02</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30915341</ArticleId>
            <ArticleId IdType="doi">10.3389/fmolb.2019.00012</ArticleId>
            <ArticleId IdType="pmc">PMC6423061</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">30894361</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>05</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2159-8290</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer discovery</Title>
                <ISOAbbreviation>Cancer Discov</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Atezolizumab Combo Approved for PD-L1-positive TNBC.</ArticleTitle>
            <Pagination>
                <MedlinePgn>OF2</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1158/2159-8290.CD-NB2019-038</ELocationID>
            <Abstract>
                <AbstractText>The FDA approved atezolizumab plus nab-paclitaxel for patients with locally advanced or metastatic triple-negative breast tumors expressing PD-L1. The combination is the first immunotherapy regimen to earn marketing authorization for any type of breast cancer.</AbstractText>
                <CopyrightInformation>©2019 American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Cancer Discov</MedlineTA>
            <NlmUniqueID>101561693</NlmUniqueID>
            <ISSNLinking>2159-8274</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30894361</ArticleId>
            <ArticleId IdType="pii">2159-8290.CD-NB2019-038</ArticleId>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-NB2019-038</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">30875891</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>04</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1420-3049</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>24</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Mar</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Molecules (Basel, Switzerland)</Title>
                <ISOAbbreviation>Molecules</ISOAbbreviation>
            </Journal>
            <ArticleTitle>EGCG-Derivative G28 Shows High Efficacy Inhibiting the Mammosphere-Forming Capacity of Sensitive and Resistant TNBC Models.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">E1027</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules24061027</ELocationID>
            <Abstract>
                <AbstractText>Recent studies showed that Fatty Acid Synthase (FASN), a lipogenic enzyme overexpressed in several carcinomas, plays an important role in drug resistance. Furthermore, the enrichment of Breast Cancer Stem Cell (BCSC) features has been found in breast tumors that progressed after chemotherapy. Hence, we used the triple negative breast cancer (TNBC) cell line MDA-MB-231 (231) to evaluate the FASN and BCSC population role in resistance acquisition to chemotherapy. For this reason, parental cell line (231) and its derivatives resistant to doxorubicin (231<b>DXR</b>) and paclitaxel (231<b>PTR</b>) were used. The Mammosphere-Forming Assay and aldehyde dehydrogenase (ALDH) enzyme activity assay showed an increase in BCSCs in the doxorubicin-resistant model. Moreover, the expression of some transcription factors involved in epithelial-mesenchymal transition (EMT), a process that confers BCSC characteristics, was upregulated after chemotherapy treatment. FASN inhibitors C75, (-)-Epigallocatechin 3-gallate (EGCG), and its synthetic derivatives G28, G56 and G37 were used to evaluate the effect of FASN inhibition on the BCSC-enriched population in our cell lines. G28 showed a noticeable antiproliferative effect in adherent conditions and, interestingly, a high mammosphere-forming inhibition capacity in all cell models. Our preliminary results highlight the importance of studying FASN inhibitors for the treatment of TNBC patients, especially those who progress after chemotherapy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Giró-Perafita</LastName>
                    <ForeName>Ariadna</ForeName>
                    <Initials>A</Initials>
                    <Identifier Source="ORCID">0000-0002-1055-7123</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Perlmutter Cancer Center, NYU School of Medicine, 522 First Avenue, Smilow Research Building, Room 1104, New York, NY 10016, USA. ariadna.giroperafita@nyulangone.org.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>New Therapeutic Targets Laboratory (TargetsLab)-Oncology Unit, Department of Medical Sciences, Faculty of Medicine, University of Girona, Emili Grahit 77, 17003 Girona, Spain. ariadna.giroperafita@nyulangone.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rabionet</LastName>
                    <ForeName>Marc</ForeName>
                    <Initials>M</Initials>
                    <Identifier Source="ORCID">0000-0003-1257-9286</Identifier>
                    <AffiliationInfo>
                        <Affiliation>New Therapeutic Targets Laboratory (TargetsLab)-Oncology Unit, Department of Medical Sciences, Faculty of Medicine, University of Girona, Emili Grahit 77, 17003 Girona, Spain. m.rabionet@udg.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Product, Process and Production Engineering Research Group (GREP), Department of Mechanical Engineering and Industrial Construction, University of Girona, Maria Aurèlia Capmany 61, 17003 Girona, Spain. m.rabionet@udg.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Planas</LastName>
                    <ForeName>Marta</ForeName>
                    <Initials>M</Initials>
                    <Identifier Source="ORCID">0000-0003-4988-4970</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Laboratori d'Innovació en Processos i Productes de Síntesi Orgànica (LIPPSO), Department of Chemistry, University of Girona, Maria Aurèlia Capmany 69, 17003 Girona, Spain. marta.planas@udg.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Feliu</LastName>
                    <ForeName>Lidia</ForeName>
                    <Initials>L</Initials>
                    <Identifier Source="ORCID">0000-0001-9792-6106</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Laboratori d'Innovació en Processos i Productes de Síntesi Orgànica (LIPPSO), Department of Chemistry, University of Girona, Maria Aurèlia Capmany 69, 17003 Girona, Spain. lidia.feliu@udg.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ciurana</LastName>
                    <ForeName>Joaquim</ForeName>
                    <Initials>J</Initials>
                    <Identifier Source="ORCID">0000-0002-6574-5551</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Product, Process and Production Engineering Research Group (GREP), Department of Mechanical Engineering and Industrial Construction, University of Girona, Maria Aurèlia Capmany 61, 17003 Girona, Spain. quim.ciurana@udg.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ruiz-Martínez</LastName>
                    <ForeName>Santiago</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>New Therapeutic Targets Laboratory (TargetsLab)-Oncology Unit, Department of Medical Sciences, Faculty of Medicine, University of Girona, Emili Grahit 77, 17003 Girona, Spain. santiago.ruiz@udg.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Puig</LastName>
                    <ForeName>Teresa</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>New Therapeutic Targets Laboratory (TargetsLab)-Oncology Unit, Department of Medical Sciences, Faculty of Medicine, University of Girona, Emili Grahit 77, 17003 Girona, Spain. teresa.puig@udg.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>15</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Molecules</MedlineTA>
            <NlmUniqueID>100964009</NlmUniqueID>
            <ISSNLinking>1420-3049</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">EGCG</Keyword>
            <Keyword MajorTopicYN="N">FASN inhibition</Keyword>
            <Keyword MajorTopicYN="N">G28</Keyword>
            <Keyword MajorTopicYN="N">cancer stem cells</Keyword>
            <Keyword MajorTopicYN="N">fatty acid metabolism</Keyword>
            <Keyword MajorTopicYN="N">polyphenolic compound</Keyword>
            <Keyword MajorTopicYN="N">triple-negative breast cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>01</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30875891</ArticleId>
            <ArticleId IdType="pii">molecules24061027</ArticleId>
            <ArticleId IdType="doi">10.3390/molecules24061027</ArticleId>
            <ArticleId IdType="pmc">PMC6471537</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">30867801</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>03</Month>
            <Day>29</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1792-1074</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>17</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Oncology letters</Title>
                <ISOAbbreviation>Oncol Lett</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Genetic alterations of triple negative breast cancer (TNBC) in women from Northeastern Mexico.</ArticleTitle>
            <Pagination>
                <MedlinePgn>3581-3588</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3892/ol.2019.9984</ELocationID>
            <Abstract>
                <AbstractText>Triple negative breast cancer (TNBC) is a subtype of breast cancer of heterogeneous nature that is negative for estrogen receptor (ER), progesterone receptor (PR) and growth factor human epidermal 2 (HER2) following immunohistochemical analysis. TNBC is frequently characterized by relapse and reduced survival. To date, there is no targeted therapy for this type of cancer. Chemotherapy, radiotherapy, and surgery remain as the standard treatments options. The lack of a target therapy and the heterogeneity of TNBC highlight the need to seek new therapeutic options. In this study, fresh tissue samples of TNBC were analyzed with a panel of 48 driver genes (212 amplicons) that are likely to be therapeutic targets. We found intron variants, missense, stop gained and splicing variants in <i>TP53, PIK3CA</i> and <i>FLT3</i> genes. Interestingly, all the analyzed samples had at least two variants in the <i>TP53</i> gene, one being a drug response variant, rs1042522, found in 94% of our samples. We also found seven additional variants not previously reported in the <i>TP53</i> gene, to the best of our knowledge, with probable deleterious characteristics of the tumor suppressor gene. We found four genetic variants in the <i>PIK3CA</i> gene, including two missense variants. The rs2491231 variant in the <i>FLT3</i> gene was identified in 84% (16/19) of the samples, which not yet reported for TNBC, to the best of our knowledge. In conclusion, genetic variants in <i>TP53</i> were found in all TNBC tumors, with rs1042522 being the most frequent (94% of TNBC biopsies), which had not been previously reported in TNBC. Also, we found two missense variants in the <i>PIK3CA</i> gene. These results justify the validation of these genetic variants in a large cohort, as well as the extensive study of their impact on the prognosis and therapy management of TBNC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Uscanga-Perales</LastName>
                    <ForeName>Grecia I</ForeName>
                    <Initials>GI</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centro de Investigación y Desarrollo en Ciencias de la Salud, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon 66460, Mexico.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Departamento de Bioquimica y Medicina Molecular, Facultad de Medicina, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon 66460, Mexico.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Santuario-Facio</LastName>
                    <ForeName>Sandra K</ForeName>
                    <Initials>SK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, Monterrey, Nuevo Leon 64710, Mexico.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sanchez-Dominguez</LastName>
                    <ForeName>Celia N</ForeName>
                    <Initials>CN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departamento de Bioquimica y Medicina Molecular, Facultad de Medicina, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon 66460, Mexico.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cardona-Huerta</LastName>
                    <ForeName>Servando</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centro de Cancer de Mama, Hospital San Jose, Tecnologico de Monterrey, Monterrey, Nuevo Leon 64710, Mexico.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Muñoz-Maldonado</LastName>
                    <ForeName>Gerardo E</ForeName>
                    <Initials>GE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Servicio de Cirugia General, Hospital Universitario Dr. Jose Eleuterio Gonzalez, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon 66460, Mexico.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ruiz-Flores</LastName>
                    <ForeName>Pablo</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departamento de Medicina Molecular, Facultad de Medicina, Universidad Autonoma de Coahuila, Torreon, Coahuila 27000, Mexico.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barcenas-Walls</LastName>
                    <ForeName>Jose R</ForeName>
                    <Initials>JR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centro de Investigación y Desarrollo en Ciencias de la Salud, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon 66460, Mexico.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Osuna-Rosales</LastName>
                    <ForeName>Luis E</ForeName>
                    <Initials>LE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centro de Investigación y Desarrollo en Ciencias de la Salud, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon 66460, Mexico.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rojas-Martinez</LastName>
                    <ForeName>Augusto</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, Monterrey, Nuevo Leon 64710, Mexico.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gonzalez-Guerrero</LastName>
                    <ForeName>Juan Francisco</ForeName>
                    <Initials>JF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Servicio de Oncologia, Centro Universitario Contra el Cancer, Hospital Universitario Dr. Jose Eleuterio Gonzalez, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon 66460, Mexico.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Valero-Gomez</LastName>
                    <ForeName>Javier</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centro de Cancer de Mama, Hospital San Jose, Tecnologico de Monterrey, Monterrey, Nuevo Leon 64710, Mexico.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gomez-Macias</LastName>
                    <ForeName>Gabriela S</ForeName>
                    <Initials>GS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Servicio de Patología, Hospital San Jose, Tecnologico de Monterrey, Hospital San Jose, Monterrey, Nuevo Leon 64710, Mexico.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barbosa-Quintana</LastName>
                    <ForeName>Alvaro</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Servicio de Patología, Hospital San Jose, Tecnologico de Monterrey, Hospital San Jose, Monterrey, Nuevo Leon 64710, Mexico.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barboza-Quintana</LastName>
                    <ForeName>Oralia</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Servicio de Anatomia Patologica y Citopatologia, Hospital Universitario Dr. Jose Eleuterio Gonzalez, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon 66450, Mexico.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Garza-Guajardo</LastName>
                    <ForeName>Raquel</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Servicio de Anatomia Patologica y Citopatologia, Hospital Universitario Dr. Jose Eleuterio Gonzalez, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon 66450, Mexico.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ortiz-Lopez</LastName>
                    <ForeName>Rocio</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, Monterrey, Nuevo Leon 64710, Mexico.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>01</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Oncol Lett</MedlineTA>
            <NlmUniqueID>101531236</NlmUniqueID>
            <ISSNLinking>1792-1074</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">FLT3</Keyword>
            <Keyword MajorTopicYN="N">PIK3CA</Keyword>
            <Keyword MajorTopicYN="N">TP53</Keyword>
            <Keyword MajorTopicYN="N">new generation sequencing</Keyword>
            <Keyword MajorTopicYN="N">target therapy genes</Keyword>
            <Keyword MajorTopicYN="N">triple negative breast cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30867801</ArticleId>
            <ArticleId IdType="doi">10.3892/ol.2019.9984</ArticleId>
            <ArticleId IdType="pii">OL-0-0-9984</ArticleId>
            <ArticleId IdType="pmc">PMC6396222</ArticleId>
        </ArticleIdList>
        <?pmcsd?>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">30832411</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>04</Month>
            <Day>26</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Print">2072-6694</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>11</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Mar</Month>
                        <Day>03</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancers</Title>
                <ISOAbbreviation>Cancers (Basel)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The Novel Mnk1/2 Degrader and Apoptosis Inducer VNLG-152 Potently Inhibits TNBC Tumor Growth and Metastasis.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">E299</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.3390/cancers11030299</ELocationID>
            <Abstract>
                <AbstractText>Currently, there are no effective therapies for patients with triple-negative breast cancer (TNBC), an aggressive and highly metastatic disease. Activation of eukaryotic initiation factor 4E (eIF4E) by mitogen-activated protein kinase (MAPK)-interacting kinases 1 and 2 (Mnk1/2) play a critical role in the development, progression and metastasis of TNBC. Herein, we undertook a comprehensive study to evaluate the activity of a first-in-class Mnk1/2 protein degraders, racemic VNLG-152R and its two enantiomers (VNLG-152E1 and VNLG-152E2) in in vitro and in vivo models of TNBC. These studies enabled us to identify racemic VNLG-152R as the most efficacious Mnk1/2 degrader, superior to its pure enantiomers. By targeting Mnk1/2 protein degradation (activity), VNLG-152R potently inhibited both Mnk-eIF4E and mTORC1 signaling pathways and strongly regulated downstream factors involved in cell cycle regulation, apoptosis, pro-inflammatory cytokines/chemokines secretion, epithelial-mesenchymal transition (EMT) and metastasis. Most importantly, orally bioavailable VNLG-152R exhibited remarkable antitumor (91 to 100% growth inhibition) and antimetastatic (~80% inhibition) activities against cell line and patient-derived TNBC xenograft models, with no apparent host toxicity. Collectively, these studies demonstrate that targeting Mnk-eIF4E/mTORC1 signaling with a potent Mnk1/2 degrader, VNLG-152R, is a novel therapeutic strategy that can be developed as monotherapy for the effective treatment of patients with primary/metastatic TNBC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ramalingam</LastName>
                    <ForeName>Senthilmurugan</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA. SRamalingam@som.umaryland.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Center for Biomolecular Therapeutics, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA. SRamalingam@som.umaryland.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ramamurthy</LastName>
                    <ForeName>Vidya P</ForeName>
                    <Initials>VP</Initials>
                    <Identifier Source="ORCID">0000-0001-6902-0921</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA. rv.darsini@gmail.com.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Center for Biomolecular Therapeutics, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA. rv.darsini@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gediya</LastName>
                    <ForeName>Lalji K</ForeName>
                    <Initials>LK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA. lalji.gediya@gmail.com.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Center for Biomolecular Therapeutics, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA. lalji.gediya@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Murigi</LastName>
                    <ForeName>Francis N</ForeName>
                    <Initials>FN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA. njamurigi@gmail.com.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Center for Biomolecular Therapeutics, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA. njamurigi@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Purushottamachar</LastName>
                    <ForeName>Puranik</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA. PPuranik@som.umaryland.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Center for Biomolecular Therapeutics, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA. PPuranik@som.umaryland.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Weiliang</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201-1559, USA. whuang@rx.umaryland.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Choi</LastName>
                    <ForeName>Eun Yong</ForeName>
                    <Initials>EY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA. echoi@som.umaryland.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Yuji</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Biostatistics and Bioinformatics, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201-1559, USA. Yuzhang@som.umaryland.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Yuzhang@som.umaryland.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vasaitis</LastName>
                    <ForeName>Tadas S</ForeName>
                    <Initials>TS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmaceutical Sciences, School of Pharmacy and Health Professions, University of Maryland Eastern Shore, 207 Somerset Hall, Princess Anne, MD 21853, USA. tsvasaitis@umes.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kane</LastName>
                    <ForeName>Maureen A</ForeName>
                    <Initials>MA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201-1559, USA. mkane@rx.umaryland.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lapidus</LastName>
                    <ForeName>Rena G</ForeName>
                    <Initials>RG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA. rlapidus@som.umaryland.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Njar</LastName>
                    <ForeName>Vincent C O</ForeName>
                    <Initials>VCO</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA. vnjar@som.umaryland.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Center for Biomolecular Therapeutics, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA. vnjar@som.umaryland.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA. vnjar@som.umaryland.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R01CA129379, R21195694, and R01CA224696</GrantID>
                    <Agency>National Institutes of Health</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>03</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Cancers (Basel)</MedlineTA>
            <NlmUniqueID>101526829</NlmUniqueID>
            <ISSNLinking>2072-6694</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Mnk-eIF4E/mTORC1 signaling pathways</Keyword>
            <Keyword MajorTopicYN="N">Mnk1/2 degraders</Keyword>
            <Keyword MajorTopicYN="N">VNLG-152R</Keyword>
            <Keyword MajorTopicYN="N">apoptosis</Keyword>
            <Keyword MajorTopicYN="N">metastasis</Keyword>
            <Keyword MajorTopicYN="N">triple negative breast cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>01</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>02</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>02</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30832411</ArticleId>
            <ArticleId IdType="pii">cancers11030299</ArticleId>
            <ArticleId IdType="doi">10.3390/cancers11030299</ArticleId>
            <ArticleId IdType="pmc">PMC6468747</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">30810184</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>02</Month>
            <Day>27</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1569-8041</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>30</Volume>
                    <Issue>Supplement_1</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Feb</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title>
                <ISOAbbreviation>Ann. Oncol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>36PStructural diversity of the cardenolide calotropin renders it as a targeted therapy for harnessing TNBC progression through tuning nitric oxide (NO) levels.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">mdz026.007</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1093/annonc/mdz026.007</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>El-Layeh</LastName>
                    <ForeName>R A</ForeName>
                    <Initials>RA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Molecular Genetics Research Team, Pharmacology and Toxicology Department, German University in Cairo, Cairo, Egypt.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Youness</LastName>
                    <ForeName>R A</ForeName>
                    <Initials>RA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Molecular Genetics Research Team, Pharmaceutical Biology Department, German University in Cairo, Cairo, Egypt.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Askary</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pharmacognosy Department, Cairo University, Cairo, Egypt.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abdelmotaal</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pharmacognosy Department, King Khalid University, Abha, Saudi Arabia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Assal</LastName>
                    <ForeName>R A</ForeName>
                    <Initials>RA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Molecular Genetics Research Team, Pharmacology and Toxicology Department, German University in Cairo, Cairo, Egypt.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Ann Oncol</MedlineTA>
            <NlmUniqueID>9007735</NlmUniqueID>
            <ISSNLinking>0923-7534</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>2</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>2</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>2</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30810184</ArticleId>
            <ArticleId IdType="pii">5364354</ArticleId>
            <ArticleId IdType="doi">10.1093/annonc/mdz026.007</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30796656</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>02</Month>
            <Day>23</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-7217</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Feb</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Breast cancer research and treatment</Title>
                <ISOAbbreviation>Breast Cancer Res. Treat.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Trends in utilization of hypofractionated whole breast irradiation (HF-WBI) in triple negative breast cancer (TNBC): a national cancer database (NCDB) analysis.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10549-019-05150-x</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">We sought to identify trends over time with respect to the use of hypofractionated whole breast irradiation (HF-WBI) in women with triple negative breast cancer (TNBC) in the national cancer database (NCDB).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Trends in utilization of HF-WBI in women diagnosed with T1-2N0 TNBC in the NCDB between 2008 and 2013 were analyzed. Case-matched luminal A women were used for comparison. Variables included age, race, year of diagnosis, insurance status, income quartile, receipt of neoadjuvant chemotherapy, and institution (academic vs. community). Chi square, logistic regression, and multivariate analysis was performed.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Utilization of HF-WBI among the 53,269 TNBC women identified steadily increased from 4.7% in 2008 to 14.0% in 2013 for women with TNBC compared to luminal A cancer whose utilization increased from 7.3 to 23.3% over the same time frame (p &lt; 0.001). On univariate analysis, HF-WBI was associated with increasing age (p &lt; 0.001), Medicare insurance (p &lt; 0.001), race (p = 0.041), diagnosis after 2011 (p &lt; 0.001), higher income quartile (p &lt; 0.001), and treatment at academic institutions (p &lt; 0.001). On multivariate analysis, age (p &lt; 0.001, OR 1.038 per year), income quartile (p = 0.002, OR 1.061 per increase in quartile), treatment at an academic institution (p &lt; 0.001, OR 1.78) significantly increased use of HF-WBI.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Treatment at an academic center and year of diagnosis were most correlated with increased HF-WBI in T1-2N0 TNBC women in the NCDB from 2008 to 2013, followed by increasing age and income. Only 14% of T1-2N0 TNBC women received HF-WBI in 2013. Focus on increased utilization is needed for non-academic centers, lower income, and younger women.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Rice</LastName>
                    <ForeName>Stephanie R</ForeName>
                    <Initials>SR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University of Maryland School of Medicine, 22 South Greene Street, Baltimore, MD, 21201, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Feigenberg</LastName>
                    <ForeName>Steven J</ForeName>
                    <Initials>SJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hamza</LastName>
                    <ForeName>Muhammad</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University of Maryland School of Medicine, 22 South Greene Street, Baltimore, MD, 21201, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Molitoris</LastName>
                    <ForeName>Jason K</ForeName>
                    <Initials>JK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University of Maryland School of Medicine, 22 South Greene Street, Baltimore, MD, 21201, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bentzen</LastName>
                    <ForeName>Søren M</ForeName>
                    <Initials>SM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Epidemiology &amp; Public Health, Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tkaczuk</LastName>
                    <ForeName>Katherine H R</ForeName>
                    <Initials>KHR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hematology/Oncology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rosenblatt</LastName>
                    <ForeName>Paula M</ForeName>
                    <Initials>PM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hematology/Oncology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bellavance</LastName>
                    <ForeName>Emily C</ForeName>
                    <Initials>EC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nichols</LastName>
                    <ForeName>Elizabeth M</ForeName>
                    <Initials>EM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University of Maryland School of Medicine, 22 South Greene Street, Baltimore, MD, 21201, USA. enichols1@umm.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>02</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Breast Cancer Res Treat</MedlineTA>
            <NlmUniqueID>8111104</NlmUniqueID>
            <ISSNLinking>0167-6806</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Breast cancer</Keyword>
            <Keyword MajorTopicYN="N">Early stage</Keyword>
            <Keyword MajorTopicYN="N">Hypofractionated</Keyword>
            <Keyword MajorTopicYN="N">Triple negative</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>01</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>01</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>2</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>2</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>2</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30796656</ArticleId>
            <ArticleId IdType="doi">10.1007/s10549-019-05150-x</ArticleId>
            <ArticleId IdType="pii">10.1007/s10549-019-05150-x</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">30731183</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>04</Month>
            <Day>24</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>04</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-7573</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>235</Volume>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>May</Month>
                        <Day>10</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of ethnopharmacology</Title>
                <ISOAbbreviation>J Ethnopharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Genomic and GeneChip expression profiling reveals the inhibitory effects of Amorphophalli Rhizoma in TNBC cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>206-218</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0378-8741(18)34807-4</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jep.2019.02.004</ELocationID>
            <Abstract>
                <AbstractText Label="ETHNOPHARMACOLOGICAL RELEVANCE" NlmCategory="BACKGROUND">Amorphophalli Rhizoma has been widely used as an adjuvant treatment for advanced or metastatic breast cancer, pancreatic cancer, hepatoma, and malignant lymphoma, but its molecular mechanism of action for treatment of metastatic triple-negative breast cancer (TNBC) is generally poorly understood.</AbstractText>
                <AbstractText Label="AIM OF THE STUDY" NlmCategory="OBJECTIVE">To investigate genomic changes related to the inhibitory effect of Amorphophalli Rhizoma and to elucidate the molecular mechanism of this inhibition in MDA-MB-231 TNBC cells.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Gene chip analysis was employed to explore genomic changes caused by Amorphophalli Rhizoma in TNBC cells. Potential classical signaling pathways, upstream regulators, functions, regulatory effects and gene interaction networks were analyzed by Ingenuity Pathway Analysis (IPA). Real-time quantitative PCR (RT-qPCR) and RNA interference (RNAi) assays were used to clarify the roles of potential target genes.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 536 significantly upregulated and 648 significantly downregulated genes were identified between the group treated with Amorphophalli Rhizoma extract and that treated with vehicle. Many of these differentially expressed genes (DEGs) in TNBC cells are involved in DNA replication, recombination and repair, the cell cycle, and cellular assembly and organization. Attenuation of KNL1, OLFML2A, RTKN2 and SGO1 gene expression by Amorphophalli Rhizoma significantly induced cell cycle arrest and suppressed cell proliferation and migration.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The inhibitory effects of Amorphophalli Rhizoma in TNBC cells likely occur through regulation of the spindle checkpoint, chromosomal and centrosomal instability, and cell membrane stability.</AbstractText>
                <CopyrightInformation>Copyright © 2019 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Chunyu</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery (Integrated Traditional and Western Medicine), Longhua Hospital, Shanghai University of Traditional Chinese Medicine, 725 South Wanping Road, Shanghai 200032, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Mingcang</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 100049, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Qiuhua</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>Zhejiang University of Traditional Chinese Medicine, Hangzhou, Zhejiang 310053, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yu</LastName>
                    <ForeName>Linghong</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Zhejiang University of Traditional Chinese Medicine, Hangzhou, Zhejiang 310053, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Jiayan</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Zhejiang University of Traditional Chinese Medicine, Hangzhou, Zhejiang 310053, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gao</LastName>
                    <ForeName>Xiufei</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine, Hangzhou, Zhejiang 310006, China. Electronic address: gaoxiufei@163.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>02</Month>
                <Day>04</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Ireland</Country>
            <MedlineTA>J Ethnopharmacol</MedlineTA>
            <NlmUniqueID>7903310</NlmUniqueID>
            <ISSNLinking>0378-8741</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D031056" MajorTopicYN="N">Amorphophallus</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059447" MajorTopicYN="N">Cell Cycle Checkpoints</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D023281" MajorTopicYN="N">Genomics</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020411" MajorTopicYN="N">Oligonucleotide Array Sequence Analysis</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060888" MajorTopicYN="N">Real-Time Polymerase Chain Reaction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D027343" MajorTopicYN="N">Rhizome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Amorphophalli Rhizoma</Keyword>
            <Keyword MajorTopicYN="N">Gene chip</Keyword>
            <Keyword MajorTopicYN="N">IPA</Keyword>
            <Keyword MajorTopicYN="N">Triple-negative breast cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>12</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>01</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>02</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>2</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>4</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>2</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30731183</ArticleId>
            <ArticleId IdType="pii">S0378-8741(18)34807-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jep.2019.02.004</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">30659204</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>01</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2045-2322</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Jan</Month>
                        <Day>18</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Scientific reports</Title>
                <ISOAbbreviation>Sci Rep</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Disulfiram and BKM120 in Combination with Chemotherapy Impede Tumor Progression and Delay Tumor Recurrence in Tumor Initiating Cell-Rich TNBC.</ArticleTitle>
            <Pagination>
                <MedlinePgn>236</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-018-35619-6</ELocationID>
            <Abstract>
                <AbstractText>Tumor initiating cells (TIC) have been suggested as a mechanism for driving chemoresistance and tumor recurrence in human cancers including triple negative breast cancer (TNBC). Significant progress has been made in targeting TICs. However, methods for simultaneously targeting heterogeneous TIC populations are lacking. In this study, we found that treating TNBC cells with chemotherapeutic agents led to a significant accumulation of the ALDH<sup>+</sup> TIC population. Treating TNBC cells with a disulfiram and copper mixture (DSF/Cu) specifically decreased the ALDH<sup>+</sup> TIC population and treatment with BKM120, a pan-PI3K inhibitor, significantly decreased the CD44<sup>+</sup>/CD24<sup>-</sup> TIC population. Furthermore, treatment with DSF/Cu or BKM120 induced higher levels of apoptosis in ALDH<sup>+</sup> or CD44<sup>+</sup>/CD24<sup>-</sup> populations, respectively, than in bulk tumor cells. Combining DSF/Cu and BKM120 treatment simultaneously decreased the ALDH<sup>+</sup> and CD44<sup>+</sup>/CD24<sup>-</sup> TICs. Using a TNBC tumor xenograft mouse model, we found that DSF/BKM in combination with Taxol significantly reduced the tumor burden and delayed tumor recurrence compared to Taxol treatment alone. Our study is the first of its kind to use two different drugs to abolish two major TIC subtypes simultaneously and inhibit tumor recurrence. These results lay a foundation for developing a novel therapy that can improve chemotherapeutic efficacy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Ling</ForeName>
                    <Initials>L</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-5786-4315</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Barbara Ann Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, 4100 John R, Detroit, MI, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Meng</LastName>
                    <ForeName>Fanyan</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Zhongshan Road, Nanjing, Jiangsu Province, P. R. China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dong</LastName>
                    <ForeName>Lun</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Barbara Ann Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, 4100 John R, Detroit, MI, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery, Qilu Hospital, Shandong University, Jinan, Shandong Province, P. R. China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Block</LastName>
                    <ForeName>C James</ForeName>
                    <Initials>CJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Barbara Ann Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, 4100 John R, Detroit, MI, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mitchell</LastName>
                    <ForeName>Allison V</ForeName>
                    <Initials>AV</Initials>
                    <AffiliationInfo>
                        <Affiliation>Barbara Ann Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, 4100 John R, Detroit, MI, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Jason</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biology, Purdue University, West Lafayette, IN, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jang</LastName>
                    <ForeName>Hyejeong</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Barbara Ann Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, 4100 John R, Detroit, MI, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Barbara Ann Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, 4100 John R, Detroit, MI, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Polin</LastName>
                    <ForeName>Lisa</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Barbara Ann Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, 4100 John R, Detroit, MI, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Qifeng</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery, Qilu Hospital, Shandong University, Jinan, Shandong Province, P. R. China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dou</LastName>
                    <ForeName>Q Ping</ForeName>
                    <Initials>QP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Barbara Ann Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, 4100 John R, Detroit, MI, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Guojun</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Barbara Ann Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, 4100 John R, Detroit, MI, USA. wugu@karmanos.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P30 CA022453</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA172480</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30-CA022453-29</GrantID>
                    <Agency>U.S. Department of Health &amp;amp; Human Services | National Institutes of Health (NIH)</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>01</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Sci Rep</MedlineTA>
            <NlmUniqueID>101563288</NlmUniqueID>
            <ISSNLinking>2045-2322</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>1</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>1</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>1</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30659204</ArticleId>
            <ArticleId IdType="doi">10.1038/s41598-018-35619-6</ArticleId>
            <ArticleId IdType="pii">10.1038/s41598-018-35619-6</ArticleId>
            <ArticleId IdType="pmc">PMC6338744</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">30640712</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>01</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1479-6821</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Jan</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Endocrine-related cancer</Title>
                <ISOAbbreviation>Endocr. Relat. Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Prolactin modulates TNBC aggressive phenotype limiting tumorigenesis.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1530/ERC-18-0523</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">ERC-18-0523.R1</ELocationID>
            <Abstract>
                <AbstractText>Triple negative breast cancer (TNBC) accounts for ~20% of all breast cancer cases. The management of TNBC represents a challenge due to its aggressive phenotype, heterogeneity and lack of targeted therapy. Loss of cell differentiation and enrichment with breast cancer stem-like cells (BCSC) are features of TNBC contributing to its aggressive nature. Here, we found that PRL treatment of TNBC cells to significantly depletes the highly tumorigenic BCSC subpopulations CD44+/CD24- and ALDH+ and differentiate them to the least tumorigenic CD44-/CD24- and ALDH- phenotype with limited tumorsphere formation and self-renewal capacities. Importantly, we found PRL to induce a heterochromatin phenotype marked by histone H3 lysine 9 trimethylation (H3K9me3) and accompanied by ultrastructural cellular architecture associated with differentiation and senescence rendering the cells refractory to growth signals. Crucially, we found PRL to mediate these effects in vivo in a preclinical animal xenograft of TNBC controlling tumor growth. These results reveal that the lactogenic hormone PRL may exert its anti-tumorigenic effects in TNBC through cellular reprogramming indicative of differentiation resulting in depletion of BCSCs and restricting tumorigenesis.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>López-Ozuna</LastName>
                    <ForeName>Vanessa Michel</ForeName>
                    <Initials>VM</Initials>
                    <AffiliationInfo>
                        <Affiliation>V López-Ozuna, Experimental Medicine, McGill University Faculty of Medicine, Montreal, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hachim</LastName>
                    <ForeName>Ibrahim Yaseen</ForeName>
                    <Initials>IY</Initials>
                    <AffiliationInfo>
                        <Affiliation>I Hachim, Experimental Medine, McGill University Faculty of Medicine, Montreal, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hachim</LastName>
                    <ForeName>Mahmood Yaseen</ForeName>
                    <Initials>MY</Initials>
                    <AffiliationInfo>
                        <Affiliation>M Hachim, Experimental Medicine, McGill University Faculty of Medicine, Montreal, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lebrun</LastName>
                    <ForeName>Jean-Jacques</ForeName>
                    <Initials>JJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>J Lebrun, Medicine, McGill University Faculty of Medicine, Montreal, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ali</LastName>
                    <ForeName>Suhad</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>S Ali, Medicine, McGill University, Montreal, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>01</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Endocr Relat Cancer</MedlineTA>
            <NlmUniqueID>9436481</NlmUniqueID>
            <ISSNLinking>1351-0088</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>09</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>01</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>1</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>1</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>1</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30640712</ArticleId>
            <ArticleId IdType="doi">10.1530/ERC-18-0523</ArticleId>
            <ArticleId IdType="pii">ERC-18-0523.R1</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">30630526</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>03</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1479-7364</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>13</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>01</Month>
                        <Day>10</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Human genomics</Title>
                <ISOAbbreviation>Hum. Genomics</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Germline TP53 and MSH6 mutations implicated in sporadic triple-negative breast cancer (TNBC): a preliminary study.</ArticleTitle>
            <Pagination>
                <MedlinePgn>4</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s40246-018-0186-y</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND">Germline BRCA1/2 prevalence is relatively low in sporadic triple-negative breast cancer (TNBC). We hypothesized that non-BRCA genes may also have significant germline contribution to Chinese sporadic TNBC, and the somatic mutational landscape of TNBC may vary between ethnic groups. We therefore conducted this study to investigate germline and somatic mutations in 43 cancer susceptibility genes in Chinese sporadic TNBC.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS">Sixty-six Chinese sporadic TNBC patients were enrolled in this study. Germline and tumor DNA of each patient were subjected to capture-based next-generation sequencing using a 43-gene panel. Standard bioinformatic analysis and variant classification were performed to identify deleterious/likely deleterious germline mutations and somatic mutations. Mutational analysis was conducted to identify significantly mutated genes.</AbstractText>
                <AbstractText Label="RESULTS">Deleterious/likely deleterious germline mutations were identified in 27 (27/66, 40.9%) patients. Among the 27 patients, 9 (9/66, 13.6%) were TP53 carriers, 5 (5/66, 7.6%) were MSH6 carriers, and 5 (5/66, 7.6%) were BRCA1 carriers. Somatic mutations were identified in 64 (64/66, 97.0%) patients. TP53 somatic mutations occurred in most of the patients (45/66, 68.2%) and with highest mean allele frequency (28.1%), while NF1 and POLE were detected to have the highest mutation counts.</AbstractText>
                <AbstractText Label="CONCLUSIONS">Our results supported our hypotheses and suggested great potentials of TP53 and MSH6 as novel candidates for TNBC predisposition genes. The high frequency of somatic NF1 and POLE mutations in this study showed possibilities for clinical benefits from androgen-blockade therapies and immunotherapies in Chinese TNBC patients. Our study indicated necessity of multi-gene testing for TNBC prevention and treatment.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Yi</LastName>
                    <ForeName>Dandan</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General Surgery, Nanjing Drum Tower Hospital, Nanjing, Jiangsu Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Lei</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General Surgery, Drum Tower Clinical Medical College of Nanjing Medical University, Nanjing, Jiangsu Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Luo</LastName>
                    <ForeName>Jiaqi</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Top Gene Tech (Guangzhou) Co., Ltd., Guangzhou, Guangdong Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>You</LastName>
                    <ForeName>Xiaobin</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Top Gene Tech (Guangzhou) Co., Ltd., Guangzhou, Guangdong Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Tao</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Thyroid and Breast, Lianyungang First People's Hospital, Lianyungang, Jiangsu Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zi</LastName>
                    <ForeName>Yi</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Top Gene Tech (Guangzhou) Co., Ltd., Guangzhou, Guangdong Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Xiaoting</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Top Gene Tech (Guangzhou) Co., Ltd., Guangzhou, Guangdong Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Ru</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General Surgery, Drum Tower Clinical Medical College of Nanjing Medical University, Nanjing, Jiangsu Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhong</LastName>
                    <ForeName>Zaixuan</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Top Gene Tech (Guangzhou) Co., Ltd., Guangzhou, Guangdong Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tang</LastName>
                    <ForeName>Xiaoqiao</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General Surgery, Nanjing Drum Tower Hospital, Nanjing, Jiangsu Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Ang</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Top Gene Tech (Guangzhou) Co., Ltd., Guangzhou, Guangdong Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shi</LastName>
                    <ForeName>Yujian</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Top Gene Tech (Guangzhou) Co., Ltd., Guangzhou, Guangdong Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rao</LastName>
                    <ForeName>Jianmei</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Top Gene Tech (Guangzhou) Co., Ltd., Guangzhou, Guangdong Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Yifen</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, Jiangsu Province, China. yifen2001@126.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sang</LastName>
                    <ForeName>Jianfeng</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General Surgery, Nanjing Drum Tower Hospital, Nanjing, Jiangsu Province, China. drsangjianfeng@163.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>01</Month>
                <Day>10</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Hum Genomics</MedlineTA>
            <NlmUniqueID>101202210</NlmUniqueID>
            <ISSNLinking>1473-9542</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">MSH6</Keyword>
            <Keyword MajorTopicYN="Y">Multi-gene testing</Keyword>
            <Keyword MajorTopicYN="Y">NF1</Keyword>
            <Keyword MajorTopicYN="Y">POLE</Keyword>
            <Keyword MajorTopicYN="Y">TNBC</Keyword>
            <Keyword MajorTopicYN="Y">TP53</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>10</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>12</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>1</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>1</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>1</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30630526</ArticleId>
            <ArticleId IdType="doi">10.1186/s40246-018-0186-y</ArticleId>
            <ArticleId IdType="pii">10.1186/s40246-018-0186-y</ArticleId>
            <ArticleId IdType="pmc">PMC6327518</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">30573793</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>01</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1759-4782</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>16</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature reviews. Clinical oncology</Title>
                <ISOAbbreviation>Nat Rev Clin Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Setting dictates efficacy of pembrolizumab in TNBC.</ArticleTitle>
            <Pagination>
                <MedlinePgn>66</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41571-018-0157-1</ELocationID>
            <Abstract>
                <AbstractText/>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sidaway</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nature Reviews Clinical Oncology, . nrclinonc@nature.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Nat Rev Clin Oncol</MedlineTA>
            <NlmUniqueID>101500077</NlmUniqueID>
            <ISSNLinking>1759-4774</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>12</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>12</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>12</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30573793</ArticleId>
            <ArticleId IdType="doi">10.1038/s41571-018-0157-1</ArticleId>
            <ArticleId IdType="pii">10.1038/s41571-018-0157-1</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">30464002</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>01</Month>
            <Day>10</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2159-8290</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer discovery</Title>
                <ISOAbbreviation>Cancer Discov</ISOAbbreviation>
            </Journal>
            <ArticleTitle>PD-L1 Inhibitor Improves Survival in TNBC.</ArticleTitle>
            <Pagination>
                <MedlinePgn>OF5</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1158/2159-8290.CD-NB2018-154</ELocationID>
            <Abstract>
                <AbstractText>Combining the PD-L1 inhibitor atezolizumab with standard chemotherapy improves overall survival among patients with metastatic triple-negative breast cancer relative to chemotherapy alone. These findings could lead to a new treatment option for patients with this disease.</AbstractText>
                <CopyrightInformation>©2018 American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Cancer Discov</MedlineTA>
            <NlmUniqueID>101561693</NlmUniqueID>
            <ISSNLinking>2159-8274</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30464002</ArticleId>
            <ArticleId IdType="pii">2159-8290.CD-NB2018-154</ArticleId>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-NB2018-154</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">30428522</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>01</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Print">1424-8247</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>11</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Nov</Month>
                        <Day>13</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Pharmaceuticals (Basel, Switzerland)</Title>
                <ISOAbbreviation>Pharmaceuticals (Basel)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>TNBC Challenge: Oligonucleotide Aptamers for New Imaging and Therapy Modalities.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">E123</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.3390/ph11040123</ELocationID>
            <Abstract>
                <AbstractText>Compared to other breast cancers, triple-negative breast cancer (TNBC) usually affects younger patients, is larger in size, of higher grade and is biologically more aggressive. To date, conventional cytotoxic chemotherapy remains the only available treatment for TNBC because it lacks expression of the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2), and no alternative targetable molecules have been identified so far. The high biological and clinical heterogeneity adds a further challenge to TNBC management and requires the identification of new biomarkers to improve detection by imaging, thus allowing the specific treatment of each individual TNBC subtype. The Systematic Evolution of Ligands by EXponential enrichment (SELEX) technique holds great promise to the search for novel targetable biomarkers, and aptamer-based molecular approaches have the potential to overcome obstacles of current imaging and therapy modalities. In this review, we highlight recent advances in oligonucleotide aptamers used as imaging and/or therapeutic agents in TNBC, discussing the potential options to discover, image and hit new actionable targets in TNBC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Camorani</LastName>
                    <ForeName>Simona</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Istituto per l'Endocrinologia e l'Oncologia Sperimentale G. Salvatore (IEOS), CNR, 80145 Naples, Italy. s.camorani@ieos.cnr.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fedele</LastName>
                    <ForeName>Monica</ForeName>
                    <Initials>M</Initials>
                    <Identifier Source="ORCID">0000-0002-9171-1312</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Istituto per l'Endocrinologia e l'Oncologia Sperimentale G. Salvatore (IEOS), CNR, 80145 Naples, Italy. mfedele@unina.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zannetti</LastName>
                    <ForeName>Antonella</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Istituto di Biostrutture e Bioimmagini, CNR, 80145 Naples, Italy. antonella.zannetti@cnr.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cerchia</LastName>
                    <ForeName>Laura</ForeName>
                    <Initials>L</Initials>
                    <Identifier Source="ORCID">0000-0002-7633-7932</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Istituto per l'Endocrinologia e l'Oncologia Sperimentale G. Salvatore (IEOS), CNR, 80145 Naples, Italy. cerchia@unina.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>IG18753</GrantID>
                    <Agency>Associazione Italiana per la Ricerca sul Cancro</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>13</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Pharmaceuticals (Basel)</MedlineTA>
            <NlmUniqueID>101238453</NlmUniqueID>
            <ISSNLinking>1424-8247</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">SELEX</Keyword>
            <Keyword MajorTopicYN="N">TNBC</Keyword>
            <Keyword MajorTopicYN="N">aptamer</Keyword>
            <Keyword MajorTopicYN="N">chemoresistance</Keyword>
            <Keyword MajorTopicYN="N">targeted imaging</Keyword>
            <Keyword MajorTopicYN="N">targeted therapy</Keyword>
            <Keyword MajorTopicYN="N">tumor microenvironment</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>10</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30428522</ArticleId>
            <ArticleId IdType="pii">ph11040123</ArticleId>
            <ArticleId IdType="doi">10.3390/ph11040123</ArticleId>
            <ArticleId IdType="pmc">PMC6316260</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">30419349</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>30</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-7980</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>442</Volume>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Feb</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer letters</Title>
                <ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>DEPDC1, negatively regulated by miR-26b, facilitates cell proliferation via the up-regulation of FOXM1 expression in TNBC.</ArticleTitle>
            <Pagination>
                <MedlinePgn>242-251</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0304-3835(18)30666-9</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2018.11.003</ELocationID>
            <Abstract>
                <AbstractText>Triple negative breast cancer (TNBC), characterized by lack of estrogen receptors, progesterone hormone receptors, and HER2 overexpression, is a more aggressive high grade tumor and not sensitive to current targeted drugs. The clinical prognosis of TNBC is poorer than other types of breast cancer, and there is no effective therapy strategy until now. Thus, it is necessary to determine important factors involved in regulating the progression of TNBC. In this study, we found DEPDC1 was up-regulated in the tissues of TNBC compared with their paired peritumoral tissues. DEPDC1 over-expression facilitated cell proliferation and tumor growth through increasing the expression of FOXM1 in TNBC cells. Conversely, knockdown of DEPDC1 had the opposite effects. Moreover, miR-26b, acting as a tumor suppressor in TNBC, directly repressed the expression of DEPDC1 and mitigated its promotive effects on cell growth and colony formation. These results indicate that DEPDC1, negatively regulated by miR-26b, promotes cell proliferation and tumor growth via up-regulating FOXM1 expression, implying an important underlying mechanism of regulating the progression of TNBC.</AbstractText>
                <CopyrightInformation>Copyright © 2018. Published by Elsevier B.V.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Lei</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; Department of Radiation Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Du</LastName>
                    <ForeName>Yueyao</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Shuguang</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jiang</LastName>
                    <ForeName>Yiwei</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yuan</LastName>
                    <ForeName>Chenwei</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Liheng</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Xiumei</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Shanghai Key Laboratory of Visual Impairment and Restoration, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bai</LastName>
                    <ForeName>Yongrui</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Electronic address: baiyongruiz@163.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>Jinsong</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Electronic address: lujjss@163.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Jun</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Research Center, Eye &amp; ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China; Shanghai Key Laboratory of Visual Impairment and Restoration, Shanghai, China. Electronic address: ma886615@126.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>09</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Ireland</Country>
            <MedlineTA>Cancer Lett</MedlineTA>
            <NlmUniqueID>7600053</NlmUniqueID>
            <ISSNLinking>0304-3835</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">DEPDC1</Keyword>
            <Keyword MajorTopicYN="N">FOXM1</Keyword>
            <Keyword MajorTopicYN="N">Proliferation</Keyword>
            <Keyword MajorTopicYN="N">TNBC</Keyword>
            <Keyword MajorTopicYN="N">miR-26b</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>10</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30419349</ArticleId>
            <ArticleId IdType="pii">S0304-3835(18)30666-9</ArticleId>
            <ArticleId IdType="doi">10.1016/j.canlet.2018.11.003</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">30401935</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>18</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1759-4782</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>16</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature reviews. Clinical oncology</Title>
                <ISOAbbreviation>Nat Rev Clin Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Benefit in patients with PD-L1-positive TNBC.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41571-018-0127-7</ELocationID>
            <Abstract>
                <AbstractText/>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Romero</LastName>
                    <ForeName>Diana</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nature Reviews Clinical Oncology, . nrclinonc@nature.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Nat Rev Clin Oncol</MedlineTA>
            <NlmUniqueID>101500077</NlmUniqueID>
            <ISSNLinking>1759-4774</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30401935</ArticleId>
            <ArticleId IdType="doi">10.1038/s41571-018-0127-7</ArticleId>
            <ArticleId IdType="pii">10.1038/s41571-018-0127-7</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">30396169</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>26</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>02</Month>
            <Day>12</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1421-9778</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>50</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2018</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology</Title>
                <ISOAbbreviation>Cell. Physiol. Biochem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Targeting Thioredoxin System with an Organosulfur Compound, Diallyl Trisulfide (DATS), Attenuates Progression and Metastasis of Triple-Negative Breast Cancer (TNBC).</ArticleTitle>
            <Pagination>
                <MedlinePgn>1945-1963</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1159/000494874</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIMS" NlmCategory="OBJECTIVE">Metastasis is the leading cause resulting in high mortality in triple negative breast cancer (TNBC) patients. Cancer cells are skilled at utilizing thioredoxin (Trx) system as an efficient antioxidant system to counteract oxidative damage, facilitating the occurrence of metastasis. Here, we identified an organosulfur compound named DATS isolated from garlic, that inhibits the expression of Trx-1 and the enzyme activity of Trx reductase in breast cancer cells.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Tissue microarray of breast cancer patients and immunohistochemical method were used to analyze the role of Trx-1 in breast cancer metastasis. Spotaneous metastasis model and experimental metastasis model combined with HE staining, immunohistochemistry were used to verify in vivo anti-metastatic effect of DATS as well as its regulation on thioredoxin. Western blot, immunofluorescence, redox state assessment and detection of enzyme activity were employed to determine the effect of DATS on thioredoxin system. Trx-1 siRNA interference was used to investigate the conclusive evidence that Trx-1 was the target of DATS.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In agreement with reduced Trx-1 nuclear translocation from cytoplasm by DATS, the production of reduced form of Trx-1 was dramatically decreased. Furthermore, in vivo, DATS administration was observed to significantly suppress spontaneous and experimental metastasis in nude mice. Delivery of DATS also resulted in decreased expression of Trx-1 as the direct target, as well as expression of NF-κB and MMP2/9 in primary tumor and lung tissue. Notably, the effects of DATS on the expression of downstream metastasis-associated genes were mediated by Trx-1, as demonstrated by the combination use of DATS and Trx-1 siRNA.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Collectively, this present study indicates that targeting Trx system with DATS may provide a promising strategy for treating metastasis of TNBC.</AbstractText>
                <CopyrightInformation>© 2018 The Author(s). Published by S. Karger AG, Basel.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Yuping</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Yang</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wei</LastName>
                    <ForeName>Zhonghong</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tao</LastName>
                    <ForeName>Li</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sheng</LastName>
                    <ForeName>Xiaobo</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Siliang</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Jiao</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Cellular and Molecular Biology, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ruan</LastName>
                    <ForeName>Junshan</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Zhaoguo</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cao</LastName>
                    <ForeName>Yuzhu</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shan</LastName>
                    <ForeName>Yunlong</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Aiyun</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Wenxing</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>Yin</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Chinaprofyinlu@163.com.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, Chinaprofyinlu@163.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>05</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Cell Physiol Biochem</MedlineTA>
            <NlmUniqueID>9113221</NlmUniqueID>
            <ISSNLinking>1015-8987</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000498">Allyl Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004220">Disulfides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013440">Sulfides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0ZO1U5A3XX</RegistryNumber>
                <NameOfSubstance UI="C042577">diallyl trisulfide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>52500-60-4</RegistryNumber>
                <NameOfSubstance UI="D013879">Thioredoxins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8PQ9CZ8BTJ</RegistryNumber>
                <NameOfSubstance UI="C412893">IV 2 compound</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.24.24</RegistryNumber>
                <NameOfSubstance UI="D020778">Matrix Metalloproteinase 2</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000498" MajorTopicYN="N">Allyl Compounds</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004220" MajorTopicYN="N">Disulfides</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020778" MajorTopicYN="N">Matrix Metalloproteinase 2</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013440" MajorTopicYN="N">Sulfides</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013879" MajorTopicYN="N">Thioredoxins</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">DATS</Keyword>
            <Keyword MajorTopicYN="N">Metastatic breast cancer</Keyword>
            <Keyword MajorTopicYN="N">Oxidative stress</Keyword>
            <Keyword MajorTopicYN="N">Thioredoxin system</Keyword>
            <Keyword MajorTopicYN="N">Trx-1</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>01</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>10</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30396169</ArticleId>
            <ArticleId IdType="pii">000494874</ArticleId>
            <ArticleId IdType="doi">10.1159/000494874</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">30367042</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>01</Month>
            <Day>09</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>01</Month>
            <Day>09</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2041-1723</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>10</Month>
                        <Day>26</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Nature communications</Title>
                <ISOAbbreviation>Nat Commun</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Collagen prolyl 4-hydroxylase 1 is essential for HIF-1α stabilization and TNBC chemoresistance.</ArticleTitle>
            <Pagination>
                <MedlinePgn>4456</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-018-06893-9</ELocationID>
            <Abstract>
                <AbstractText>Collagen prolyl 4-hydroxylase (P4H) expression and collagen hydroxylation in cancer cells are necessary for breast cancer progression. Here, we show that P4H alpha 1 subunit (P4HA1) protein expression is induced in triple-negative breast cancer (TNBC) and HER2 positive breast cancer. By modulating alpha ketoglutarate (α-KG) and succinate levels P4HA1 expression reduces proline hydroxylation on hypoxia-inducible factor (HIF) 1α, enhancing its stability in cancer cells. Activation of the P4HA/HIF-1 axis enhances cancer cell stemness, accompanied by decreased oxidative phosphorylation and reactive oxygen species (ROS) levels. Inhibition of P4HA1 sensitizes TNBC to the chemotherapeutic agent docetaxel and doxorubicin in xenografts and patient-derived models. We also show that increased P4HA1 expression correlates with short relapse-free survival in TNBC patients who received chemotherapy. These results suggest that P4HA1 promotes chemoresistance by modulating HIF-1-dependent cancer cell stemness. Targeting collagen P4H is a promising strategy to inhibit tumor progression and sensitize TNBC to chemotherapeutic agents.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Xiong</LastName>
                    <ForeName>Gaofeng</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>UK Markey Cancer Center, University of Kentucky, Lexington, KY, 40536, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY, 40536, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stewart</LastName>
                    <ForeName>Rachel L</ForeName>
                    <Initials>RL</Initials>
                    <Identifier Source="ORCID">0000-0001-8031-5720</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY, 40536, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Jie</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>UK Markey Cancer Center, University of Kentucky, Lexington, KY, 40536, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY, 40536, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gao</LastName>
                    <ForeName>Tianyan</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>UK Markey Cancer Center, University of Kentucky, Lexington, KY, 40536, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY, 40536, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scott</LastName>
                    <ForeName>Timothy L</ForeName>
                    <Initials>TL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Environmental and Systems Biochemistry, University of Kentucky, Lexington, KY, 40536, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY, 40536, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Samayoa</LastName>
                    <ForeName>Luis M</ForeName>
                    <Initials>LM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY, 40536, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>O'Connor</LastName>
                    <ForeName>Kathleen</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>UK Markey Cancer Center, University of Kentucky, Lexington, KY, 40536, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY, 40536, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lane</LastName>
                    <ForeName>Andrew N</ForeName>
                    <Initials>AN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Environmental and Systems Biochemistry, University of Kentucky, Lexington, KY, 40536, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY, 40536, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Ren</ForeName>
                    <Initials>R</Initials>
                    <Identifier Source="ORCID">0000-0002-3591-9522</Identifier>
                    <AffiliationInfo>
                        <Affiliation>UK Markey Cancer Center, University of Kentucky, Lexington, KY, 40536, USA. ren.xu2010@uky.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY, 40536, USA. ren.xu2010@uky.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R01 CA215095</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA109136</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 CA177558</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>CA207772, CA215095, CA209045</GrantID>
                    <Agency>U.S. Department of Health &amp;amp; Human Services | NIH | National Cancer Institute (NCI)</Agency>
                    <Country>International</Country>
                </Grant>
                <Grant>
                    <GrantID>R21 CA209045</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>W81XWH-15-1-0052</GrantID>
                    <Agency>DOD | Congressionally Directed Medical Research Programs (CDMRP)</Agency>
                    <Country>International</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA207772</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>10</Month>
                <Day>26</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Nat Commun</MedlineTA>
            <NlmUniqueID>101528555</NlmUniqueID>
            <ISSNLinking>2041-1723</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C497442">HIF1A protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051795">Hypoxia-Inducible Factor 1, alpha Subunit</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007656">Ketoglutaric Acids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9007-34-5</RegistryNumber>
                <NameOfSubstance UI="D003094">Collagen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.11.2</RegistryNumber>
                <NameOfSubstance UI="C510863">P4HA1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.11.2</RegistryNumber>
                <NameOfSubstance UI="D011393">Procollagen-Proline Dioxygenase</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003094" MajorTopicYN="N">Collagen</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019008" MajorTopicYN="Y">Drug Resistance, Neoplasm</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055785" MajorTopicYN="N">Gene Knockdown Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051795" MajorTopicYN="N">Hypoxia-Inducible Factor 1, alpha Subunit</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007656" MajorTopicYN="N">Ketoglutaric Acids</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
                <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>
                <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011393" MajorTopicYN="N">Procollagen-Proline Dioxygenase</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>10</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>10</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>10</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>1</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30367042</ArticleId>
            <ArticleId IdType="doi">10.1038/s41467-018-06893-9</ArticleId>
            <ArticleId IdType="pii">10.1038/s41467-018-06893-9</ArticleId>
            <ArticleId IdType="pmc">PMC6203834</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Res. 2013 Jun 1;73(11):3285-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23539444</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 1999 May 20;399(6733):271-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10353251</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Struct Biol. 1998;122(1-2):86-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9724608</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2007 Oct 15;110(8):3056-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17595331</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2006 Jan 3;103(1):105-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16373502</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 2001 Apr 20;292(5516):468-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11292861</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Prog Nucl Magn Reson Spectrosc. 2016 Feb;92-93:18-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26952191</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2005 Jul 1;65(13):5506-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15994920</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 2009 Apr 10;324(5924):261-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19359588</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2010 Aug 26;29(34):4741-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20531305</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2014 Apr 3;508(7494):103-107</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24670641</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2014 Jan 02;14:1</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24383403</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Metab. 2006 Mar;3(3):177-85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16517405</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Trends Mol Med. 2012 Sep;18(9):534-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22921864</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 2001 Nov 9;294(5545):1337-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11598268</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Biol. 2012 Feb 20;196(4):395-406</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22351925</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2006 Aug 1;12(15):4562-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16899602</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13820-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19666588</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Transl Med. 2013 Jan 17;2(1):3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23369605</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2002 Oct 31;21(50):7611-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12400004</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 1998 Mar 13;273(11):5989-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9497309</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Stem Cell. 2010 Sep 3;7(3):380-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20804973</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Sci Rep. 2012;2:227</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22355741</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Sci. 2003 Aug 1;116(Pt 15):3041-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12829734</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Stem Cell. 2007 Nov;1(5):555-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18371393</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Mammary Gland Biol Neoplasia. 2009 Mar;14(1):29-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19242781</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2013 Sep 1;73(17):5315-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23733750</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Endocrinol. 2011 Feb;25(2):199-211</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20861225</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2008 May 20;26(15):2568-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18487574</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Med. 2015 Nov;21(11):1364-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26501191</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Crit Rev Biochem Mol Biol. 2010 Apr;45(2):106-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20199358</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Development. 2014 Nov;141(22):4206-18</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25371358</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 2008 May 16;133(4):704-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18485877</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Methods Cell Biol. 2008;84:541-88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17964943</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Drug Discov. 2009 Oct;8(10):806-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19794444</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Biol. 2007 May;27(9):3282-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17325041</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Mol Cell Biol. 2014 Apr;15(4):243-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24651542</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2013 Apr 12;288(15):10819-29</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23423382</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2012 Oct 26;287(44):37245-58</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22948140</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem Biophys Res Commun. 1999 Jul 5;260(2):557-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10403805</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Cell. 2005 Jan;7(1):77-85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15652751</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7539918</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Cell. 2006 Dec;10(6):515-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17157791</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2008 Feb 15;68(4):989-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18281472</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>EMBO J. 2001 Sep 17;20(18):5197-206</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11566883</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2008 Sep;8(9):705-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19143055</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Med. 2008 Apr 28;6:11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18442412</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pathology. 2009 Jan;41(1):40-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19089739</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2012 Apr 18;486(7403):346-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22522925</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2012 Oct 4;490(7418):61-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23000897</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2037-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20133848</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5429-38</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25453096</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 1997 Sep 5;272(36):22642-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9278421</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2012 Jan 07;14(1):R6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22225988</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12629218</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2013 Sep;123(9):3664-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23999440</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Protoc. 2009;4(1):44-57</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19131956</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nucleic Acids Res. 2009 Aug;37(14):4587-602</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19491311</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2003 Aug 15;278(33):30772-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12788921</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2012 Jul 19;487(7407):380-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22801492</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2009 Feb 15;69(4):1302-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19190339</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Med Chem. 2014;21(26):3021-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24735366</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2011 Dec 15;12(1):9-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22169972</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Metab. 2018 Jan 9;27(1):136-150.e5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29249690</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2010 Oct;123(3):725-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20020197</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">30323195</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2041-4889</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Oct</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cell death &amp; disease</Title>
                <ISOAbbreviation>Cell Death Dis</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Positive feedback loop between mitochondrial fission and Notch signaling promotes survivin-mediated survival of TNBC cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1050</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41419-018-1083-y</ELocationID>
            <Abstract>
                <AbstractText>Mitochondrial morphology is remodeled by continuous dynamic cycles of fission and fusion. Emerging data have shown that the disturbance of balance between mitochondrial fission and fusion is involved in the progression of several types of neoplasms. However, the status of mitochondrial dynamics and its potential biological roles in breast cancer (BC), particularly in triple negative BC (TNBC) are not fully clear. Here, we reported that the mitochondrial fission was significantly increased in BC tissues, especially in the TNBC tissues, when compared with that in the corresponding peritumor tissues. Meanwhile, our data showed that Drp1 was upregulated, while Mfn1 was downregulated in TNBC. Moreover, elevated mitochondrial fission was associated with poorer prognosis in TNBC patients. Mitochondrial fission promoted the survival of TNBC cells both in vitro and in vivo. Furthermore, we identified a positive feedback loop between mitochondrial fission and Notch signaling pathway in TNBC cells, as proved by the experimental evidence that the activation of Notch signaling enhanced Drp1-mediated mitochondrial fission and Drp1-mediated mitochondrial fission in turn promoted the activation of Notch signaling, which ultimately promoted the cell survival of TNBC via increasing survivin expression level. Inhibition of either Notch1 or Drp1 significantly impaired the activation of the other, leading to the suppression of TNBC cell survival and proliferation. Collectively, our data reveal a novel mechanism that the positive feedback loop between mitochondrial fission and Notch signaling promotes the survival, proliferation and apoptotic resistance of TNBC cells via increasing survivin expression and thus favors cancer progression.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Li</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Cancer Biology and Experimental Teaching Center of Basic Medicine, Fourth Military Medical University, 710032, Xi'an, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Jing</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Cancer Biology and Experimental Teaching Center of Basic Medicine, Fourth Military Medical University, 710032, Xi'an, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lyu</LastName>
                    <ForeName>Zhuomin</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pain Treatment, Tangdu Hospital, Fourth Military Medical University, 710038, Xi'an, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Yibing</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center of Genetic &amp; Prenatal Diagnosis, First Affiliated Hospital, Zhengzhou University, 450052, Zhengzhou, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ji</LastName>
                    <ForeName>Xiaoying</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Cancer Biology and Experimental Teaching Center of Basic Medicine, Fourth Military Medical University, 710032, Xi'an, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cao</LastName>
                    <ForeName>Haiyan</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Cancer Biology and Experimental Teaching Center of Basic Medicine, Fourth Military Medical University, 710032, Xi'an, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jin</LastName>
                    <ForeName>Mingpeng</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Cancer Biology and Experimental Teaching Center of Basic Medicine, Fourth Military Medical University, 710032, Xi'an, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Jianjun</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Cancer Biology and Experimental Teaching Center of Basic Medicine, Fourth Military Medical University, 710032, Xi'an, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Jin</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Preventive Genomic Medicine, School of Life Sciences, Northwest University, 710069, Xi'an, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ling</LastName>
                    <ForeName>Rui</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Thyroid and Breast Department, Xi'an No. 3 Hospital, 710082, Xi'an, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xing</LastName>
                    <ForeName>Jinliang</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Cancer Biology and Experimental Teaching Center of Basic Medicine, Fourth Military Medical University, 710032, Xi'an, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ren</LastName>
                    <ForeName>Tingting</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Cancer Biology and Experimental Teaching Center of Basic Medicine, Fourth Military Medical University, 710032, Xi'an, China. rtt419@fmmu.edu.cn.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lyu</LastName>
                    <ForeName>Yonggang</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Thyroid and Breast Department, Xi'an No. 3 Hospital, 710082, Xi'an, China. lvygwyt@163.com.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, 710032, Xi'an, China. lvygwyt@163.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>81402281</GrantID>
                    <Agency>National Natural Science Foundation of China (National Science Foundation of China)</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>81402281</GrantID>
                    <Agency>National Natural Science Foundation of China (National Science Foundation of China)</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>81402281</GrantID>
                    <Agency>National Natural Science Foundation of China (National Science Foundation of China)</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>81402281</GrantID>
                    <Agency>National Natural Science Foundation of China (National Science Foundation of China)</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>81402281</GrantID>
                    <Agency>National Natural Science Foundation of China (National Science Foundation of China)</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>81402281</GrantID>
                    <Agency>National Natural Science Foundation of China (National Science Foundation of China)</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>81402281</GrantID>
                    <Agency>National Natural Science Foundation of China (National Science Foundation of China)</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>81402281</GrantID>
                    <Agency>National Natural Science Foundation of China (National Science Foundation of China)</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>81402281</GrantID>
                    <Agency>National Natural Science Foundation of China (National Science Foundation of China)</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>81402281</GrantID>
                    <Agency>National Natural Science Foundation of China (National Science Foundation of China)</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>81402281</GrantID>
                    <Agency>National Natural Science Foundation of China (National Science Foundation of China)</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>81402281</GrantID>
                    <Agency>National Natural Science Foundation of China (National Science Foundation of China)</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>10</Month>
                <Day>15</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Cell Death Dis</MedlineTA>
            <NlmUniqueID>101524092</NlmUniqueID>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>04</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>10</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>10</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>10</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30323195</ArticleId>
            <ArticleId IdType="doi">10.1038/s41419-018-1083-y</ArticleId>
            <ArticleId IdType="pii">10.1038/s41419-018-1083-y</ArticleId>
            <ArticleId IdType="pmc">PMC6189045</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Carcinogenesis. 2014 Jul;35(7):1592-601</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24632494</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Biol. 2008 Jul 28;182(2):315-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18663143</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2004;6(6):R605-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15535842</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2008;10(6):R97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19025652</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Sci. 2012 Dec 1;125(Pt 23):5745-57</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23015593</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2008 Jan;8(1):61-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18075512</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Trends Cell Biol. 2014 Dec;24(12):761-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25189346</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>CA Cancer J Clin. 1999 May-Jun;49(3):138-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10445013</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2014 Dec;13(12):3198-3209</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25253780</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2000 Jun 1;86(5):652-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10797286</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 2013 Nov 8;342(6159):734-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24091702</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2010 Jan 15;70(2):709-18</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20068161</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2014 Jul 22;9(7):e102231</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25050620</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2014 Aug 30;5(16):6896-908</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25071009</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2011 May;11(5):338-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21508972</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2015 Mar 15;21(6):1487-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25564152</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Trends Cell Biol. 2008 Apr;18(4):165-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18296052</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>FASEB J. 2012 May;26(5):2175-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22321727</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2014 Oct;61(4):859-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24801417</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Biol. 2012 May 14;197(4):487-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22584906</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>EMBO J. 2012 Jun 29;31(13):2895-907</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22580825</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochim Biophys Acta. 2011 Apr;1815(2):197-213</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21193018</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2014 Apr 1;134(7):1605-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24114531</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Autophagy. 2016 Jun 2;12(6):999-1014</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27124102</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Clin Exp Pathol. 2015 May 01;8(5):4378-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26191129</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Biol Ther. 2011 Jan 1;11(1):14-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20962575</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antioxid Redox Signal. 2018 Apr 20;28(12):1120-1136</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28938844</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2013 Dec 5;369(23):2236-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24304053</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Annu Rev Cell Dev Biol. 2006;22:79-99</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16704336</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Cycle. 2007 Feb 15;6(4):418-29</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17329972</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Lett. 2013 Jan 28;328(2):261-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23041621</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Liver Int. 2018 Jul;38(7):1263-1272</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29210177</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Sci Signal. 2013 Feb 05;6(261):ra8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23386745</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2008 Sep 1;27(38):5092-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18758477</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2017 Aug 16;8(42):73329-73344</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29069872</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2008 Jul 1;68(13):5273-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18593928</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2006 Feb 1;66(3):1640-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16452223</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Semin Cancer Biol. 2009 Feb;19(1):50-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19138741</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Mol Life Sci. 2017 Jun;74(11):1999-2017</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28083595</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2010 Apr 13;107(15):6882-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20339081</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell. 2015 Feb 5;57(3):537-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25658205</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2003 Jul 19;362(9379):205-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12885482</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Front Oncol. 2018 Feb 22;8:31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29520340</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>CA Cancer J Clin. 2017 Nov;67(6):439-448</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28972651</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem J. 2013 Apr 1;451(1):123-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23323858</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Physiol Rev. 2009 Jul;89(3):799-845</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19584314</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11553815</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Mol Sci. 2013 Jun 24;14(7):13005-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23797661</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Neurosci. 2015 Apr;18(4):501-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25730670</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2010 Apr 29;29(17):2488-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20154720</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">30289427</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>03</Month>
            <Day>11</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>03</Month>
            <Day>11</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1745-7270</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>50</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Nov</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Acta biochimica et biophysica Sinica</Title>
                <ISOAbbreviation>Acta Biochim. Biophys. Sin. (Shanghai)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Bcl-3 promotes proliferation and chemosensitivity in BL1 subtype of TNBC cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1141-1149</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1093/abbs/gmy117</ELocationID>
            <Abstract>
                <AbstractText>Bcl-3 is an established oncogene in diverse malignant tumors. In this study, we investigated a dual role of Bcl-3 in BL1-subtype triple-negative breast cancer (TNBC). The BL1-subtype TNBC is featured by increasing cell cycle gene expression and the highest sensitivity to chemotherapy among all subtypes. Bcl-3 is associated with a better prognosis in BL1 patients. Bcl-3 knockdown in BL1 cell MDA-MB-468 induces the inhibition of cell proliferation and the G1/S transition arrest by promoting p27 and reducing the expressions of c-Myc and skp2 at mRNA and protein levels. Meanwhile, Bcl-3 enhances the sensitivity of MDA-MB-468 to chemotherapeutics ABX and PTX. Furthermore, the regulation mechanisms are restricted to BL1 cell and do not occur in SUM159PT, a typical MSL subtype of TNBC cell. These data suggest that Bcl-3 may be a potential clinical biomarker for diagnosis, treatment, and prognosis of patients with BL1-subtype TNBC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Huo</LastName>
                    <ForeName>Junhaohui</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Stem Cell Biology, Shanghai Jiao Tong University School of Medicine (SJTUSM) &amp; Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS), Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Xi</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Stem Cell Biology, Shanghai Jiao Tong University School of Medicine (SJTUSM) &amp; Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS), Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Haohao</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Stem Cell Biology, Shanghai Jiao Tong University School of Medicine (SJTUSM) &amp; Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS), Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hu</LastName>
                    <ForeName>Yiming</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Stem Cell Biology, Shanghai Jiao Tong University School of Medicine (SJTUSM) &amp; Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS), Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jiang</LastName>
                    <ForeName>Yuhang</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Orthopedics, Shanghai Key Laboratory of Orthopedic Implants, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Sanhong</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Shanghai Institute of Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Xiaoren</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Stem Cell Biology, Shanghai Jiao Tong University School of Medicine (SJTUSM) &amp; Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS), Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>Acta Biochim Biophys Sin (Shanghai)</MedlineTA>
            <NlmUniqueID>101206716</NlmUniqueID>
            <ISSNLinking>1672-9145</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C063503">proto-oncogene protein bcl-3</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>04</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>10</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>10</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30289427</ArticleId>
            <ArticleId IdType="pii">5115861</ArticleId>
            <ArticleId IdType="doi">10.1093/abbs/gmy117</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">30250159</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2041-4889</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Sep</Month>
                        <Day>24</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cell death &amp; disease</Title>
                <ISOAbbreviation>Cell Death Dis</ISOAbbreviation>
            </Journal>
            <ArticleTitle>PYK2 negatively regulates the Hippo pathway in TNBC by stabilizing TAZ protein.</ArticleTitle>
            <Pagination>
                <MedlinePgn>985</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41419-018-1005-z</ELocationID>
            <Abstract>
                <AbstractText>The tumor suppressor Hippo pathway negatively regulates the transcriptional coactivators Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) to inhibit cell growth and control organ size, whereas activation of YAP and TAZ is implicated in tumorigenesis and cancer metastasis. Here, we report that the nonreceptor tyrosine kinase PYK2 positively regulates TAZ and YAP transcriptional activity in triple-negative breast cancer (TNBC). We found that inhibition of PYK2 expression or its kinase activity substantially affects the steady-state level of TAZ and markedly facilitates its proteasomal degradation. This effect was specific to PYK2 inhibition and was not obtained by inhibition of FAK. Destabilization of TAZ was associated with profound effect of PYK2 inhibition on cell growth at low-density concomitant with reduced expression of TAZ-target genes and induction of cell apoptosis. We further show that PYK2 enhances the tyrosine phosphorylation of both TAZ and LATS1/2 and concomitantly TAZ stability, and that PYK2 protein level correlates with the level of TAZ protein in primary breast tumors. Together these observations suggest that PYK2 is an important regulator of the Hippo pathway, and its tyrosine kinase activity has a striking effect on TAZ stabilization and activation in TNBC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kedan</LastName>
                    <ForeName>Amir</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Molecular Cell Biology Department, Weizmann Institute of Science, Rehovot, 76100, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Verma</LastName>
                    <ForeName>Nandini</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Molecular Cell Biology Department, Weizmann Institute of Science, Rehovot, 76100, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saroha</LastName>
                    <ForeName>Ashish</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Molecular Cell Biology Department, Weizmann Institute of Science, Rehovot, 76100, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shreberk-Shaked</LastName>
                    <ForeName>Michal</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Molecular Cell Biology Department, Weizmann Institute of Science, Rehovot, 76100, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Müller</LastName>
                    <ForeName>Anna-Katharina</ForeName>
                    <Initials>AK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Molecular Cell Biology Department, Weizmann Institute of Science, Rehovot, 76100, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nair</LastName>
                    <ForeName>Nishanth Ulhas</ForeName>
                    <Initials>NU</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Bioinformatics and Computational Biology, University of Maryland, College Park, MD, 20742, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lev</LastName>
                    <ForeName>Sima</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Molecular Cell Biology Department, Weizmann Institute of Science, Rehovot, 76100, Israel. sima.lev@weizmann.ac.il.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>09</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Cell Death Dis</MedlineTA>
            <NlmUniqueID>101524092</NlmUniqueID>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>9</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>9</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>9</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30250159</ArticleId>
            <ArticleId IdType="doi">10.1038/s41419-018-1005-z</ArticleId>
            <ArticleId IdType="pii">10.1038/s41419-018-1005-z</ArticleId>
            <ArticleId IdType="pmc">PMC6155151</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Oncogene. 2015 Feb 5;34(6):681-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24531710</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Biol. 2007 Sep;27(18):6383-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17636028</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2011 Jul;121(7):2750-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21633166</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Biol. 2008 Apr;28(7):2426-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18227151</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Elife. 2015 Sep 03;4:null</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26274564</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2012 Jul 27;287(31):26245-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22692215</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Genes Dev. 2010 Nov 1;24(21):2430-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21041411</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Genes Dev. 2016 Jan 1;30(1):1-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26728553</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2017 Sep 15;77(18):4868-4880</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28754671</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Cell Biol. 2015 Sep;17(9):1218-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26258633</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 2014 Jul 3;158(1):157-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24976009</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2009 May 8;284(19):13193-201</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19244237</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Cycle. 2016 Sep 16;15(18):2497-505</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27428284</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Physiol Rev. 2014 Oct;94(4):1287-312</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25287865</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Endocr Relat Cancer. 2015 Jun;22(3):443-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25870251</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>EMBO Rep. 2016 Feb;17(2):188-201</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26691213</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neoplasia. 2005 May;7(5):435-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15967096</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Genes Dev. 2008 Jul 15;22(14):1962-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18579750</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Sci. 2011 Apr 1;124(Pt 7):1136-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21385842</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2017 Jan 1;77(1):86-99</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27793840</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Genes (Basel). 2016 Jun 17;7(6):null</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27322327</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Dev Cell. 2015 Mar 9;32(5):652-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25758863</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2000 Dec 15;275(50):39152-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10995739</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem Biophys Res Commun. 2001 Jun 8;284(2):485-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11394906</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Cell. 2016 Jun 13;29(6):783-803</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27300434</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell. 2008 Feb 15;29(3):350-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18280240</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Biol. 2012 Dec;32(24):4925-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23045390</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Cycle. 2015;14(1):146-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25602524</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 1996 Oct 10;383(6600):547-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8849729</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2009 May 22;284(21):14347-58</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19324876</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Cell Biol. 2003 Oct;5(10):914-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14502294</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>EMBO J. 2004 Feb 25;23(4):790-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14765127</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2007 May 18;282(20):14845-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17395594</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Genes Dev. 2010 Jan 1;24(1):72-85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20048001</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2010 Nov 26;285(48):37159-69</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20858893</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>EMBO Rep. 2013 Oct;14(10):891-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23897088</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 2011 Nov 11;147(4):759-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22078877</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Clin Exp Pathol. 2015 Sep 01;8(9):11248-57</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26617849</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 2005 Aug 12;309(5737):1074-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16099986</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncol Rep. 2016 Aug;36(2):729-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27373987</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2017 Feb 14;114(7):1678-1683</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28154141</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Rep. 2014 Mar 27;6(6):1059-1072</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24613358</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Dis. 2010;32(1-2):35-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21778573</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Genes Dev. 2007 Nov 1;21(21):2747-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17974916</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2000 Oct 20;275(42):32736-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10915788</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">30237308</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>07</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1538-8514</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>17</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular cancer therapeutics</Title>
                <ISOAbbreviation>Mol. Cancer Ther.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>ST8SIA1 Regulates Tumor Growth and Metastasis in TNBC by Activating the FAK-AKT-mTOR Signaling Pathway.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2689-2701</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1158/1535-7163.MCT-18-0399</ELocationID>
            <Abstract>
                <AbstractText>Breast cancer stem-like cells (BCSC) are implicated in cancer recurrence and metastasis of triple-negative breast cancer (TNBC). We have recently discovered that ganglioside GD2 expression defines BCSCs and that ST8SIA1 regulates GD2 expression and BCSC function. In this report, we show that ST8SIA1 is highly expressed in primary TNBC; its expression is positively correlated with the expression of several BCSC-associated genes such as BCL11A, FOXC1, CXCR4, PDGFRβ, SOX2, and mutations in p53. CRISPR knockout of ST8SIA1 completely inhibited BCSC functions, including <i>in vitro</i> tumorigenesis and mammosphere formation. Mechanistic studies discovered activation of the FAK-AKT-mTOR signaling pathway in GD2<sup>+</sup> BCSCs, and its tight regulation by ST8SIA1. Finally, knockout of ST8SIA1 completely blocked <i>in vivo</i> tumor growth and metastasis by TNBC cells. In summary, these data demonstrate the mechanism by which ST8SIA1 regulates tumor growth and metastasis in TNBC and identifies it as a novel therapeutic target.</AbstractText>
                <CopyrightInformation>©2018 American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y" EqualContrib="Y">
                    <LastName>Nguyen</LastName>
                    <ForeName>Khoa</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y" EqualContrib="Y">
                    <LastName>Yan</LastName>
                    <ForeName>Yuanqing</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yuan</LastName>
                    <ForeName>Bin</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dasgupta</LastName>
                    <ForeName>Abhishek</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Jeffrey</ForeName>
                    <Initials>J</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-8693-1310</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mu</LastName>
                    <ForeName>Hong</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Do</LastName>
                    <ForeName>Kim-Anh</ForeName>
                    <Initials>KA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ueno</LastName>
                    <ForeName>Naoto T</ForeName>
                    <Initials>NT</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-0166-7275</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Andreeff</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-1144-1958</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. mandreef@mdanderson.org vbattula@mdanderson.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Battula</LastName>
                    <ForeName>V Lokesh</ForeName>
                    <Initials>VL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. mandreef@mdanderson.org vbattula@mdanderson.org.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P30 CA016672</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>09</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Mol Cancer Ther</MedlineTA>
            <NlmUniqueID>101132535</NlmUniqueID>
            <ISSNLinking>1535-7163</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>04</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>09</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pmc-release">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>9</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>9</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>9</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30237308</ArticleId>
            <ArticleId IdType="pii">1535-7163.MCT-18-0399</ArticleId>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-18-0399</ArticleId>
            <ArticleId IdType="pmc">PMC6279518</ArticleId>
            <ArticleId IdType="mid">NIHMS1506640</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Biol Chem. 2004 Jul 30;279(31):33024-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15166238</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Prog Brain Res. 1994;101:213-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7518092</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Stem Cells. 2010 Aug;28(8):1435-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20572012</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Mol Sci. 2014 Feb 27;15(3):3560-79</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24583847</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2011 Jul;121(7):2750-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21633166</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):4968-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23479608</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Methods. 2012 Mar 04;9(4):357-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22388286</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Bioinformatics. 2010 Jan 1;26(1):139-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19910308</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Bioinformatics. 2011 Aug 04;12:323</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21816040</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2015 Jun 4;34(23):2958-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25109336</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Glycobiology. 2012 Jun;22(6):806-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22301273</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 1997 May 16;272(20):13189-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9148935</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 1987 Oct 15;47(20):5377-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3115567</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer. 2015 Sep;22(5):520-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24415069</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Immunol. 2008 Feb 15;180(4):2357-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18250445</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Stem Cell. 2007 Nov;1(5):555-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18371393</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 1989 Jul 1;49(13):3445-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2471585</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Genes Cancer. 2011 Apr;2(4):404-19</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21779509</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Rep. 2015 Mar 31;10(12):2055-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25801032</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 2008 May 16;133(4):704-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18485877</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neurobiol Aging. 2009 Nov;30(11):1777-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18258340</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11041-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16040804</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neurol Res. 1986 Jun;8(2):123-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2875407</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2013;8(3):e58426</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23484027</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2017 Jul 18;8(29):47454-47473</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28537895</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neurochem Pathol. 1988 Jun;8(3):189-202</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3075728</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2002 Jan 18;277(3):1633-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11682464</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Lett. 2014 Jul 10;349(1):1-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24727284</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2017 Jul 13;36(28):3957-3963</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28288141</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Lett. 2010 Mar 28;289(2):127-39</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19643531</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Oncol. 2016 Jan 11;3(3):e1131668</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27314088</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2013;8(4):e61125</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23577196</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>IUBMB Life. 2010 Apr;62(4):268-76</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20101634</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Front Biosci. 1999 Jan 15;4:D102-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9889179</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2007 May 18;282(20):14845-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17395594</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2017 Jun 6;8(23):36936-36949</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28415808</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Breast Cancer. 2013 Feb;13(1):7-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23127340</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Expert Rev Mol Med. 2010 Jul 26;12:e22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20653987</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12629218</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Sci. 2012 Sep;103(9):1656-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22632091</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2001 May 15;61(10):4244-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11358851</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Sci Rep. 2017 Aug 23;7(1):9170</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28835684</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2017 Jun;16(6):1133-1144</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28270436</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2012 Jun;122(6):2066-78</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22585577</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 2009 Sep 18;138(6):1083-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19766563</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Commun. 2015 Jan 09;6:5987</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25574598</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">30181541</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>03</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2041-1723</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>09</Month>
                        <Day>04</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Nature communications</Title>
                <ISOAbbreviation>Nat Commun</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq.</ArticleTitle>
            <Pagination>
                <MedlinePgn>3588</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-018-06052-0</ELocationID>
            <Abstract>
                <AbstractText>Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by extensive intratumoral heterogeneity. To investigate the underlying biology, we conducted single-cell RNA-sequencing (scRNA-seq) of &gt;1500 cells from six primary TNBC. Here, we show that intercellular heterogeneity of gene expression programs within each tumor is variable and largely correlates with clonality of inferred genomic copy number changes, suggesting that genotype drives the gene expression phenotype of individual subpopulations. Clustering of gene expression profiles identified distinct subgroups of malignant cells shared by multiple tumors, including a single subpopulation associated with multiple signatures of treatment resistance and metastasis, and characterized functionally by activation of glycosphingolipid metabolism and associated innate immunity pathways. A novel signature defining this subpopulation predicts long-term outcomes for TNBC patients in a large cohort. Collectively, this analysis reveals the functional heterogeneity and its association with genomic evolution in TNBC, and uncovers unanticipated biological principles dictating poor outcomes in this disease.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Karaayvaz</LastName>
                    <ForeName>Mihriban</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cristea</LastName>
                    <ForeName>Simona</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA, 02215, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, 02138, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gillespie</LastName>
                    <ForeName>Shawn M</ForeName>
                    <Initials>SM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Patel</LastName>
                    <ForeName>Anoop P</ForeName>
                    <Initials>AP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mylvaganam</LastName>
                    <ForeName>Ravindra</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Luo</LastName>
                    <ForeName>Christina C</ForeName>
                    <Initials>CC</Initials>
                    <Identifier Source="ORCID">0000-0001-9872-7432</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Specht</LastName>
                    <ForeName>Michelle C</ForeName>
                    <Initials>MC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bernstein</LastName>
                    <ForeName>Bradley E</ForeName>
                    <Initials>BE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>The Broad Institute of Harvard and MIT, Cambridge, MA, 02139, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>The Ludwig Center at Harvard, Boston, MA, 02215, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Michor</LastName>
                    <ForeName>Franziska</ForeName>
                    <Initials>F</Initials>
                    <Identifier Source="ORCID">0000-0003-4869-8842</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA. michor@jimmy.harvard.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA, 02215, USA. michor@jimmy.harvard.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, 02138, USA. michor@jimmy.harvard.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>The Broad Institute of Harvard and MIT, Cambridge, MA, 02139, USA. michor@jimmy.harvard.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>The Ludwig Center at Harvard, Boston, MA, 02215, USA. michor@jimmy.harvard.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, MA, 02115, USA. michor@jimmy.harvard.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ellisen</LastName>
                    <ForeName>Leif W</ForeName>
                    <Initials>LW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA. lellisen@mgh.harvard.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>U54 CA193461</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>09</Month>
                <Day>04</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Nat Commun</MedlineTA>
            <NlmUniqueID>101528555</NlmUniqueID>
            <ISSNLinking>2041-1723</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008198" MajorTopicYN="N">Lymph Nodes</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059010" MajorTopicYN="N">Single-Cell Analysis</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>01</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>9</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>9</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>12</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30181541</ArticleId>
            <ArticleId IdType="doi">10.1038/s41467-018-06052-0</ArticleId>
            <ArticleId IdType="pii">10.1038/s41467-018-06052-0</ArticleId>
            <ArticleId IdType="pmc">PMC6123496</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Med. 2015 Jul;21(7):751-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26099045</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Methods. 2017 Mar;14(3):309-315</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28114287</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2011 Jul;121(7):2750-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21633166</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):4968-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23479608</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 1986 Oct 31;234(4776):574-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3020690</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2010 Nov 11;363(20):1938-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21067385</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2017 Aug 15;23(16):4642-4650</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28420720</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Clin Oncol. 2017 Oct;14(10):595-610</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28561071</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Bioinformatics. 2011 Aug 04;12:323</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21816040</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Metastasis Rev. 2007 Dec;26(3-4):725-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17828376</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Biotechnol. 2014 Sep;32(9):896-902</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25150836</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2014 Aug 14;512(7513):155-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25079324</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2002 Jan 31;415(6871):530-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11823860</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pharmacol Exp Ther. 2013 Jan;344(1):167-78</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23086228</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2011;6(6):e21242</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21695058</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 2014 Jun 20;344(6190):1396-401</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24925914</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Med. 2010 Dec;16(12):1421-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21102457</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Commun. 2017 Aug 9;8(1):228</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28794488</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2002 Dec 19-26;420(6917):860-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12490959</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>F1000Res. 2016 Aug 31;5:2122</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27917286</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Surg Oncol. 2014 Feb;21(2):361-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24046116</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Genet. 2016 Oct;48(10):1119-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27526321</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2016 Aug 25;375(8):717-29</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27557300</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Res. 2010 Nov;8(11):1526-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20889649</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Physiol. 2000 Mar;182(3):311-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10653597</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2011 Feb;125(3):687-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20361254</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2016 Jun 16;11(6):e0157368</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27310713</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2008 Mar 10;26(8):1275-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18250347</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Bioinformatics. 2016 Sep 15;32(18):2847-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27207943</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Med. 2012 Jul;18(7):1052-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22683778</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Carcinog. 2017 Nov;56(11):2461-2473</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28618084</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2009 May 5;106(18):7461-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19380734</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Genes Dev. 2014 Jun 1;28(11):1143-58</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24888586</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Genome Biol. 2003;4(5):P3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12734009</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2012 Apr 04;486(7403):395-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22495314</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncologist. 2011;16 Suppl 1:1-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21278435</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Stem Cell. 2010 Sep 3;7(3):271-2</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20804960</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Genome Biol. 2016 Apr 27;17:75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27122128</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2013 Dec 1;19(23):6380-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24298068</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 2017 Mar 31;355(6332):</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28360267</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2011 Oct 1;71(19):6143-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21852386</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2014 Jun 5;510(7503):58-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24899305</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Commun. 2017 May 05;8:15081</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28474673</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS Med. 2016 Dec 6;13(12):e1002174</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27923045</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 2014 Jun 27;344(6191):1492-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24970081</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell. 2015 Nov 19;60(4):537-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26590713</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Breast Cancer. 2009 Feb;9(1):29-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19299237</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Commun. 2016 May 10;7:11479</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27161491</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2014 Aug;25(8):1544-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24608200</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2017 Oct;165(3):531-543</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28695300</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Protoc. 2014 Jan;9(1):171-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24385147</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2012 Aug;23 Suppl 6:vi13-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23012296</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2014 Sep 20;32(27):2959-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25071121</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Med. 2009 Aug;15(8):907-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19648928</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 2016 Apr 8;352(6282):189-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27124452</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Database (Oxford). 2015 Feb 27;2015:null</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25725062</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11553815</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2015 Oct 1;526(7571):131-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26416748</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">30171174</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>03</Month>
            <Day>27</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1557-3125</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>17</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>01</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular cancer research : MCR</Title>
                <ISOAbbreviation>Mol. Cancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers.</ArticleTitle>
            <Pagination>
                <MedlinePgn>97-108</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1158/1541-7786.MCR-18-0619</ELocationID>
            <Abstract>
                <AbstractText>The identification of early breast cancer patients who may benefit from adjuvant chemotherapy has evolved to include assessment of clinicopathologic features such as tumor size and nodal status, as well as several gene-expression profiles for ER-positive, HER2-negative cancers. However, these tools do not reliably identify patients at the greatest risk of recurrence. The mutation and copy-number landscape of triple-negative breast cancer (TNBC) subtypes defined by gene expression is also largely unknown, and elucidation of this landscape may shed light on novel therapeutic opportunities. The USO01062 phase III clinical trial of standard chemotherapy (with or without capecitabine) enrolled a cohort of putatively high-risk patients based on clinical features, yet only observed a 5-year disease-free survival event rate of 11.6%. In order to uncover genomic aberrations associated with recurrence, a targeted next-generation sequencing panel was used to compare tumor specimens from patients who had a recurrence event with a matched set who did not. The somatic mutation and copy-number alteration landscapes of high-risk early breast cancer patients were characterized and alterations associated with relapse were identified. Tumor mutational burden was evaluated but was not prognostic in this study, nor did it correlate with PDL1 or CD8 gene expression. However, TNBC subtypes had substantial genomic heterogeneity with a distinct pattern of genomic alterations and putative underlying driver mutations. IMPLICATIONS: The present study uncovers a compendium of genomic alterations with utility to more precisely identify high-risk patients for adjuvant trials of novel therapeutic agents.</AbstractText>
                <CopyrightInformation>©2018 American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y" EqualContrib="Y">
                    <LastName>Wilson</LastName>
                    <ForeName>Timothy R</ForeName>
                    <Initials>TR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California. wilson.timothy@gene.com marklackner01@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y" EqualContrib="Y">
                    <LastName>Udyavar</LastName>
                    <ForeName>Akshata R</ForeName>
                    <Initials>AR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Bioinformatics and Computational Biology, Genentech, Inc., South San Francisco, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chang</LastName>
                    <ForeName>Ching-Wei</ForeName>
                    <Initials>CW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics, Genentech, Inc., South San Francisco, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Spoerke</LastName>
                    <ForeName>Jill M</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aimi</LastName>
                    <ForeName>Junko</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Savage</LastName>
                    <ForeName>Heidi M</ForeName>
                    <Initials>HM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Daemen</LastName>
                    <ForeName>Anneleen</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Bioinformatics and Computational Biology, Genentech, Inc., South San Francisco, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>O'Shaughnessy</LastName>
                    <ForeName>Joyce A</ForeName>
                    <Initials>JA</Initials>
                    <AffiliationInfo>
                        <Affiliation>US Oncology, Dallas, Texas.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Baylor University Medical Center, Dallas, Texas.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Texas Oncology, Dallas, Texas.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bourgon</LastName>
                    <ForeName>Richard</ForeName>
                    <Initials>R</Initials>
                    <Identifier Source="ORCID">0000-0002-5890-4374</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Bioinformatics and Computational Biology, Genentech, Inc., South San Francisco, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lackner</LastName>
                    <ForeName>Mark R</ForeName>
                    <Initials>MR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California. wilson.timothy@gene.com marklackner01@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>31</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Mol Cancer Res</MedlineTA>
            <NlmUniqueID>101150042</NlmUniqueID>
            <ISSNLinking>1541-7786</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>9</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>9</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>9</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30171174</ArticleId>
            <ArticleId IdType="pii">1541-7786.MCR-18-0619</ArticleId>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-18-0619</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">30136158</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>11</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>11</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-4978</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>45</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular biology reports</Title>
                <ISOAbbreviation>Mol. Biol. Rep.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Whole exome sequencing of breast cancer (TNBC) cases from India: association of MSH6 and BRIP1 variants with TNBC risk and oxidative DNA damage.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1413-1419</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11033-018-4307-4</ELocationID>
            <Abstract>
                <AbstractText>Whole exome sequencing in triple negative breast cancer cases (n = 8) and targeted sequencing in healthy controls (n = 48) revealed BRIP1 rs552752779 (MAF: 75% vs. 6.25%, OR 45.00, 95% CI 9.43-243.32), ERBB2 rs527779103 (MAF: 62.5% vs. 7.29%, OR 21.19, 95% CI 5.11-94.32), ERCC2 rs121913016 (MAF: 56.25% vs. 7.29%, OR 16.34, 95% CI 4.02-70.41), MSH6 rs2020912 (MAF: 56.25% vs. 1.04%, OR 122.13, 95% CI 12.29-2985.48) as risk factors for triple negative breast cancer. Construction of classification and regression tree followed by smart pruning identified MSH6 and BRIP1 variants as the major determinants of TNBC (Triple Negative Breast Cancer) risk. Except for ERBB2, all other genes regulate DNA repair and chromosomal integrity. In TNBC cases, two likely pathogenic variations i.e. NCOR1 rs562300336 and PIM1 rs746748226 were observed at frequencies of 18.75% and 12.5%, respectively. Among the 24 variants of unknown significance, MMP9 rs199676062, SYNE1 rs368709678, AURKA rs373550419, ABCC4 rs11568694 have variant allele frequency ≥ 62.5%. These genes regulate metastasis, nuclear modeling, cell cycle and cellular detoxification, respectively. To conclude, aberrations in DNA mismatch repair, nucleotide excision repair or BRCA1 associated genome surveillance mechanism contribute towards triple negative breast cancer.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Aravind Kumar</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centre for Biotechnology, Institute of Science and Technology, Jawaharlal Nehru Technological University, Hyderabad, 500085, India. aravind@sandor.co.in.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Sandor Life Sciences, Road No. 3, Banjara Hills, Hyderabad, 500034, India. aravind@sandor.co.in.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Naushad</LastName>
                    <ForeName>Shaik Mohammad</ForeName>
                    <Initials>SM</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-8952-9581</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Sandor Life Sciences, Road No. 3, Banjara Hills, Hyderabad, 500034, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Narasimgu</LastName>
                    <ForeName>Narasimhulu</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sandor Life Sciences, Road No. 3, Banjara Hills, Hyderabad, 500034, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nagaraju Naik</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sandor Life Sciences, Road No. 3, Banjara Hills, Hyderabad, 500034, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kadali</LastName>
                    <ForeName>Srilatha</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sandor Life Sciences, Road No. 3, Banjara Hills, Hyderabad, 500034, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shanker</LastName>
                    <ForeName>Uday</ForeName>
                    <Initials>U</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centre for Biotechnology, Institute of Science and Technology, Jawaharlal Nehru Technological University, Hyderabad, 500085, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lakshmi Narasu</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centre for Biotechnology, Institute of Science and Technology, Jawaharlal Nehru Technological University, Hyderabad, 500085, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Mol Biol Rep</MedlineTA>
            <NlmUniqueID>0403234</NlmUniqueID>
            <ISSNLinking>0301-4851</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019313">BRCA1 Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C492913">BRCA1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051856">Fanconi Anemia Complementation Group Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C094443">G-T mismatch-binding protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.4.12</RegistryNumber>
                <NameOfSubstance UI="D051759">Xeroderma Pigmentosum Group D Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.4.13</RegistryNumber>
                <NameOfSubstance UI="C000618935">BRIP1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.4.13</RegistryNumber>
                <NameOfSubstance UI="D020365">RNA Helicases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 5.99.-</RegistryNumber>
                <NameOfSubstance UI="C497292">ERCC2 protein, human</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019313" MajorTopicYN="N">BRCA1 Protein</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004249" MajorTopicYN="N">DNA Damage</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004260" MajorTopicYN="N">DNA Repair</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051856" MajorTopicYN="N">Fanconi Anemia Complementation Group Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020365" MajorTopicYN="N">RNA Helicases</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000073359" MajorTopicYN="N">Whole Exome Sequencing</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051759" MajorTopicYN="N">Xeroderma Pigmentosum Group D Protein</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Exome sequencing</Keyword>
            <Keyword MajorTopicYN="N">Oxidative DNA damage</Keyword>
            <Keyword MajorTopicYN="N">Triple negative breast cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>12</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30136158</ArticleId>
            <ArticleId IdType="doi">10.1007/s11033-018-4307-4</ArticleId>
            <ArticleId IdType="pii">10.1007/s11033-018-4307-4</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Am J Surg Pathol. 2012 Nov;36(11):1700-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22992699</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2015 May 11;10(5):e0126762</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25961742</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2016 Feb 16;7(7):8310-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26824983</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS Genet. 2016 Aug 09;12(8):e1006248</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27504877</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2014 Oct 30;5(20):9952-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25296970</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Cancer Res. 2015 Jun 15;5(7):2113-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26328243</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Front Biosci (Elite Ed). 2016 Jan 01;8:289-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26709662</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Chim Acta. 2003 Sep;335(1-2):27-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12927681</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nutr Cancer. 2014;66(6):955-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25023197</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2017 Feb;161(3):491-499</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27915434</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Genet. 2011 May;43(5):491-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21478889</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2011 Jun 21;11:262</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21693047</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2017 May 15;123(10):1721-1730</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28085182</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Bioinformatics. 2009 Nov 1;25(21):2744-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19734154</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2012 Jun 20;486(7403):405-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22722202</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Biochem. 2018 May;442(1-2):1-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28918577</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Expert Rev Mol Diagn. 2018 Jan;18(1):35-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29172773</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2015 Feb 1;33(4):304-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25452441</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">30040817</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>26</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>26</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>13</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2018</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial).</ArticleTitle>
            <Pagination>
                <MedlinePgn>e0199297</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0199297</ELocationID>
            <Abstract>
                <AbstractText Label="INTRODUCTION">Despite the importance of chemotherapy in the treatment of early stage triple negative breast cancer (TNBC), no one optimal regimen has been identified. We conducted a pilot trial comparing outcomes for the three most commonly used chemotherapy regimens to assess the feasibility of conducting a larger definitive trial.</AbstractText>
                <AbstractText Label="METHODS">Using integrated consent, newly diagnosed TNBC patients were randomised to one of three standard regimens: dose-dense doxorubicin-cyclophosphamide then paclitaxel, doxorubicin-cyclophosphamide then weekly paclitaxel or 5-FU-epirubicin-cyclophosphamide then docetaxel. Feasibility endpoints included; physician engagement, accrual rates, physician compliance and patient satisfaction with the integrated consent model. Our anticipated pilot trial sample size was 35 randomised patients in one year.</AbstractText>
                <AbstractText Label="RESULTS">Between August 30th, 2016 and January 31st 2017, 2 patients met eligibility and were randomised. A survey of 10 participating oncologists was performed to identify potential strategies to enhance accrual. Most investigators (9/10) believed that the best regimen for TNBC was unknown, and 4/10 felt this was a pressing clinical question. Physicians' responses suggested that poor accrual was due to: a lack of interest in some study arms as oncologists already had a preferred regimen (4/10) and concerns about trial demands in busy clinics (3/10). The pilot feasibility endpoints were not met and the study was closed.</AbstractText>
                <AbstractText Label="CONCLUSIONS">Despite initial interest in the trial question and multiple investigators agreeing to approach patients, this trial failed to meet feasibility endpoints. The reasons for poor accrual were multiple and require further evaluation if this important patient-centred question is to be answered.</AbstractText>
                <AbstractText Label="TRIAL REGISTRATION">ClinicalTrials.gov NCT02688803.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hilton</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stober</LastName>
                    <ForeName>Carol</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mazzarello</LastName>
                    <ForeName>Sasha</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vandermeer</LastName>
                    <ForeName>Lisa</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fergusson</LastName>
                    <ForeName>Dean</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, The Ottawa Hospital and University of Ottawa School of Epidemiology, Ottawa, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hutton</LastName>
                    <ForeName>Brian</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, The Ottawa Hospital and University of Ottawa School of Epidemiology, Ottawa, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Public Health and Preventative Medicine, The University of Ottawa, Ottawa, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Clemons</LastName>
                    <ForeName>Mark</ForeName>
                    <Initials>M</Initials>
                    <Identifier Source="ORCID">0000-0002-0738-2713</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Public Health and Preventative Medicine, The University of Ottawa, Ottawa, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT02688803</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>15H5577CQD</RegistryNumber>
                <NameOfSubstance UI="D000077143">Docetaxel</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3Z8479ZZ5X</RegistryNumber>
                <NameOfSubstance UI="D015251">Epirubicin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>80168379AG</RegistryNumber>
                <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8N3DW7272P</RegistryNumber>
                <NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>P88XT4IS4D</RegistryNumber>
                <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>U3P01618RT</RegistryNumber>
                <NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077143" MajorTopicYN="N">Docetaxel</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D023381" MajorTopicYN="N">Endpoint Determination</DescriptorName>
                <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
                <QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015251" MajorTopicYN="N">Epirubicin</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019983" MajorTopicYN="N">Guideline Adherence</DescriptorName>
                <QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011897" MajorTopicYN="N">Random Allocation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <CoiStatement>The authors have declared that no competing interests exist.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>09</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>03</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>7</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>7</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>12</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30040817</ArticleId>
            <ArticleId IdType="doi">10.1371/journal.pone.0199297</ArticleId>
            <ArticleId IdType="pii">PONE-D-17-34204</ArticleId>
            <ArticleId IdType="pmc">PMC6057636</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Support Care Cancer. 2016 Aug;24(8):3633-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27146496</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 2006 Apr 12;295(14):1658-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16609087</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncol Lett. 2014 Mar;7(3):866-870</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24527094</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2014 Aug;146(3):567-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25001611</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Clin Oncol. 2010 Feb;7(2):79-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20118978</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2007 Jan 1;25(1):118-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17159189</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2013;15(5):R88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24063698</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2012 Nov 15;118(22):5463-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22544643</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Causes Control. 2009 Sep;20(7):1071-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19343511</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2014 Feb 20;370(8):769-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24552326</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Oncol Pract. 2016 Dec;12(12):e1016-e1024</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27650842</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Support Care Cancer. 2017 Jun;25(6):1881-1886</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28127659</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Oncol. 2016 Jun;23(3):e276-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27330365</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Breast Cancer. 2009 Feb;9(1):29-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19299237</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Jun 1;28(16):2784-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20404251</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">30035166</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">2331-4737</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>5</Volume>
                    <Issue>5-6</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Oncoscience</Title>
                <ISOAbbreviation>Oncoscience</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Leveraging MYC as a therapeutic treatment option for TNBC.</ArticleTitle>
            <Pagination>
                <MedlinePgn>137-139</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.18632/oncoscience.424</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Carey</LastName>
                    <ForeName>Jason P W</ForeName>
                    <Initials>JPW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Keyomarsi</LastName>
                    <ForeName>Khandan</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016421">Editorial</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Oncoscience</MedlineTA>
            <NlmUniqueID>101636666</NlmUniqueID>
            <ISSNLinking>2331-4737</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CDK</Keyword>
            <Keyword MajorTopicYN="N">MYC</Keyword>
            <Keyword MajorTopicYN="N">PARP</Keyword>
            <Keyword MajorTopicYN="N">TNBC</Keyword>
            <Keyword MajorTopicYN="N">biomarker</Keyword>
        </KeywordList>
        <CoiStatement>CONFLICTS OF INTEREST The authors declare no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>04</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>7</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>7</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>7</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30035166</ArticleId>
            <ArticleId IdType="doi">10.18632/oncoscience.424</ArticleId>
            <ArticleId IdType="pii">424</ArticleId>
            <ArticleId IdType="pmc">PMC6049306</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Cell Rep. 2016 Nov 22;17(9):2367-2381</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27880910</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am Soc Clin Oncol Educ Book. 2016;35:34-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27249684</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Cell. 2018 Mar 12;33(3):401-416.e8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29533782</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 2017 Nov 30;171(6):1301-1315.e14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29195074</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Semin Cell Dev Biol. 2017 Mar;63:144-153</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28087320</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 2017 Nov 30;171(6):1284-1300.e21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29195073</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2018 Feb 1;78(3):742-757</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29180466</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2017 Jul 15;23(14):3711-3720</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28167507</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">30012592</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>09</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>01</Month>
            <Day>31</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1091-6490</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>115</Volume>
                    <Issue>31</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>07</Month>
                        <Day>31</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
                <ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Spatially constrained tandem bromodomain inhibition bolsters sustained repression of BRD4 transcriptional activity for TNBC cell growth.</ArticleTitle>
            <Pagination>
                <MedlinePgn>7949-7954</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1720000115</ELocationID>
            <Abstract>
                <AbstractText>The importance of BET protein BRD4 in gene transcription is well recognized through the study of chemical modulation of its characteristic tandem bromodomain (BrD) binding to lysine-acetylated histones and transcription factors. However, while monovalent inhibition of BRD4 by BET BrD inhibitors such as JQ1 blocks growth of hematopoietic cancers, it is much less effective generally in solid tumors. Here, we report a thienodiazepine-based bivalent BrD inhibitor, MS645, that affords spatially constrained tandem BrD inhibition and consequently sustained repression of BRD4 transcriptional activity in blocking proliferation of solid-tumor cells including a panel of triple-negative breast cancer (TNBC) cells. MS645 blocks BRD4 binding to transcription enhancer/mediator proteins MED1 and YY1 with potency superior to monovalent BET inhibitors, resulting in down-regulation of proinflammatory cytokines and genes for cell-cycle control and DNA damage repair that are largely unaffected by monovalent BrD inhibition. Our study suggests a therapeutic strategy to maximally control BRD4 activity for rapid growth of solid-tumor TNBC cells.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ren</LastName>
                    <ForeName>Chunyan</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Guangtao</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Bethune Institute of Epigenetic Medicine, The First Hospital, Jilin University, 130061 Changchun, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Han</LastName>
                    <ForeName>Fangbin</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bethune Institute of Epigenetic Medicine, The First Hospital, Jilin University, 130061 Changchun, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fu</LastName>
                    <ForeName>Shibo</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bethune Institute of Epigenetic Medicine, The First Hospital, Jilin University, 130061 Changchun, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cao</LastName>
                    <ForeName>Yingdi</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bethune Institute of Epigenetic Medicine, The First Hospital, Jilin University, 130061 Changchun, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Fan</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Qiang</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Bethune Institute of Epigenetic Medicine, The First Hospital, Jilin University, 130061 Changchun, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Meslamani</LastName>
                    <ForeName>Jamel</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Yaoyao</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bethune Institute of Epigenetic Medicine, The First Hospital, Jilin University, 130061 Changchun, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ji</LastName>
                    <ForeName>Donglei</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bethune Institute of Epigenetic Medicine, The First Hospital, Jilin University, 130061 Changchun, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cao</LastName>
                    <ForeName>Lingling</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bethune Institute of Epigenetic Medicine, The First Hospital, Jilin University, 130061 Changchun, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Qian</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bethune Institute of Epigenetic Medicine, The First Hospital, Jilin University, 130061 Changchun, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cheung</LastName>
                    <ForeName>Ka-Lung</ForeName>
                    <Initials>KL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Bethune Institute of Epigenetic Medicine, The First Hospital, Jilin University, 130061 Changchun, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sharma</LastName>
                    <ForeName>Rajal</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Babault</LastName>
                    <ForeName>Nicolas</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yi</LastName>
                    <ForeName>Zhengzi</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Weijia</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Walsh</LastName>
                    <ForeName>Martin J</ForeName>
                    <Initials>MJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zeng</LastName>
                    <ForeName>Lei</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Bethune Institute of Epigenetic Medicine, The First Hospital, Jilin University, 130061 Changchun, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Ming-Ming</ForeName>
                    <Initials>MM</Initials>
                    <Identifier Source="ORCID">0000-0002-7049-0573</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029; ming-ming.zhou@mssm.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>PDB</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>6DJC</AccessionNumber>
                        <AccessionNumber>6DNE</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
            <NlmUniqueID>7505876</NlmUniqueID>
            <ISSNLinking>0027-8424</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C441289">BRD4 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C538855">MED1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D056913">Mediator Complex Subunit 1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D050986">YY1 Transcription Factor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C494698">YY1 protein, human</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D056913" MajorTopicYN="N">Mediator Complex Subunit 1</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D050986" MajorTopicYN="N">YY1 Transcription Factor</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">BRD4</Keyword>
            <Keyword MajorTopicYN="Y">TNBC</Keyword>
            <Keyword MajorTopicYN="Y">bivalent BET inhibitors</Keyword>
            <Keyword MajorTopicYN="Y">drug discovery</Keyword>
            <Keyword MajorTopicYN="Y">gene transcription</Keyword>
        </KeywordList>
        <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>7</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>9</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>7</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30012592</ArticleId>
            <ArticleId IdType="pii">1720000115</ArticleId>
            <ArticleId IdType="doi">10.1073/pnas.1720000115</ArticleId>
            <ArticleId IdType="pmc">PMC6077712</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Nature. 2011 Oct 02;478(7370):529-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21964340</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2004 Aug 1;22(15):3080-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15284258</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 2013 Nov 7;155(4):934-47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24119843</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Chem Rev. 2015 Nov 11;115(21):11625-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26492937</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2014 Jun 12;510(7504):278-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24759320</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 2013 Apr 11;153(2):320-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23582323</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2003 Jan 15;63(2):304-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12543779</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Chem Biol. 2016 Dec;12(12):1089-1096</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27775715</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Rep. 2014 Jul 24;8(2):460-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25017071</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2012 May 21;14(3):R79</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22613095</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):19754-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24248379</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2016 Nov;15(11):2563-2574</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27573426</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>F1000 Biol Rep. 2009;1:98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20495683</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2014 Jan 30;123(5):697-705</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24335499</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 1986 May 15;261(14):6478-85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3700401</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2011 Aug 03;478(7370):524-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21814200</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2010 Dec 23;468(7327):1067-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20871596</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 2011 Sep 16;146(6):904-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21889194</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Chem Biol. 2016 Dec;12(12):1097-1104</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27775716</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 1999 Jun 3;399(6735):491-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10365964</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2013 Jan 1;19(1):291-303</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23136197</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Med Chem. 2013 Nov 27;56(22):9251-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24144283</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>FEBS Lett. 2002 Feb 20;513(1):124-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11911891</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2010 Dec 23;468(7327):1119-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21068722</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2012 Aug 16;367(7):647-57</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22894577</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>ACS Chem Biol. 2016 Mar 18;11(3):598-608</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26596782</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2016 Jan 21;529(7586):413-417</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26735014</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16669-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21949397</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Med Chem. 2016 Sep 8;59(17):7801-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27528113</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell. 2005 Aug 19;19(4):535-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16109377</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Cell. 2014 Feb 10;25(2):210-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24525235</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2012 Aug 17;287(34):28840-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22645123</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell. 2005 Aug 19;19(4):523-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16109376</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">29991529</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>04</Month>
            <Day>17</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1557-3125</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>16</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>11</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular cancer research : MCR</Title>
                <ISOAbbreviation>Mol. Cancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1761-1772</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1158/1541-7786.MCR-18-0410</ELocationID>
            <Abstract>
                <AbstractText>The metastatic cascade is a complex process that requires cancer cells to survive despite conditions of high physiologic stress. Previously, cooperation between the glucocorticoid receptor (GR) and hypoxia-inducible factors (HIF) was reported as a point of convergence for host and cellular stress signaling. These studies indicated p38 MAPK-dependent phosphorylation of GR on Ser134 and subsequent p-GR/HIF-dependent induction of breast tumor kinase (PTK6/Brk), as a mediator of aggressive cancer phenotypes. Herein, p-Ser134 GR was quantified in human primary breast tumors (<i>n</i> = 281) and the levels of p-GR were increased in triple-negative breast cancer (TNBC) relative to luminal breast cancer. Brk was robustly induced following exposure of TNBC model systems to chemotherapeutic agents (Taxol or 5-fluorouracil) and growth in suspension [ultra-low attachment (ULA)]. Notably, both Taxol and ULA resulted in upregulation of the Aryl hydrocarbon receptor (AhR), a known mediator of cancer prosurvival phenotypes. Mechanistically, AhR and GR copurified and following chemotherapy and ULA, these factors assembled at the Brk promoter and induced Brk expression in an HIF-dependent manner. Furthermore, Brk expression was upregulated in Taxol-resistant breast cancer (MCF-7) models. Ultimately, Brk was critical for TNBC cell proliferation and survival during Taxol treatment and in the context of ULA as well as for basal cancer cell migration, acquired biological phenotypes that enable cancer cells to successfully complete the metastatic cascade. These studies nominate AhR as a p-GR binding partner and reveal ways to target epigenetic events such as adaptive and stress-induced acquisition of cancer skill sets required for metastatic cancer spread.<b>Implication:</b> Breast cancer cells enlist intracellular stress response pathways that evade chemotherapy by increasing cancer cell survival and promoting migratory phenotypes. <i>Mol Cancer Res; 16(11); 1761-72. ©2018 AACR</i>.</AbstractText>
                <CopyrightInformation>©2018 American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Regan Anderson</LastName>
                    <ForeName>Tarah M</ForeName>
                    <Initials>TM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hematology, Oncology, and Transplantation, Departments of Medicine and Pharmacology and The Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Shihong</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Perez Kerkvliet</LastName>
                    <ForeName>Carlos</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hematology, Oncology, and Transplantation, Departments of Medicine and Pharmacology and The Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peng</LastName>
                    <ForeName>Yan</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Helle</LastName>
                    <ForeName>Taylor M</ForeName>
                    <Initials>TM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hematology, Oncology, and Transplantation, Departments of Medicine and Pharmacology and The Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Krutilina</LastName>
                    <ForeName>Raisa I</ForeName>
                    <Initials>RI</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, University of Tennessee Health Science Center, Memphis, Tennessee.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Raj</LastName>
                    <ForeName>Ganesh V</ForeName>
                    <Initials>GV</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cidlowski</LastName>
                    <ForeName>John A</ForeName>
                    <Initials>JA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Signal Transduction, National Institute of Environmental Health Sciences, NIH, Department of Health and Human Services, Research Triangle Park, North Carolina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ostrander</LastName>
                    <ForeName>Julie H</ForeName>
                    <Initials>JH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hematology, Oncology, and Transplantation, Departments of Medicine and Pharmacology and The Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schwertfeger</LastName>
                    <ForeName>Kathryn L</ForeName>
                    <Initials>KL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Lab Medicine and Pathology, Masonic Cancer Center and Center for Immunology, University of Minnesota, Minneapolis, Minnesota.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Seagroves</LastName>
                    <ForeName>Tiffany N</ForeName>
                    <Initials>TN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, University of Tennessee Health Science Center, Memphis, Tennessee.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lange</LastName>
                    <ForeName>Carol A</ForeName>
                    <Initials>CA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hematology, Oncology, and Transplantation, Departments of Medicine and Pharmacology and The Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota. lange047@umn.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P30 CA077598</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>F31 CA195877</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>T32 CA009138</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA192178</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA138488</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>10</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Mol Cancer Res</MedlineTA>
            <NlmUniqueID>101150042</NlmUniqueID>
            <ISSNLinking>1541-7786</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>04</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pmc-release">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>7</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>7</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>7</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29991529</ArticleId>
            <ArticleId IdType="pii">1541-7786.MCR-18-0410</ArticleId>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-18-0410</ArticleId>
            <ArticleId IdType="pmc">PMC6214723</ArticleId>
            <ArticleId IdType="mid">NIHMS970885</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Oncotarget. 2014 Aug 15;5(15):6038-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25153721</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Toxicol Sci. 2009 Sep;111(1):151-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19502548</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 2011 Mar 25;331(6024):1559-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21436443</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Genet. 2014 Oct;46(10):1051-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25151356</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Opin Pharmacol. 2010 Dec;10(6):662-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20832360</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2005 Sep 20;116(5):734-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15849727</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2011 Jul;121(7):2750-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21633166</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2011 Oct 15;71(20):6360-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21868756</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncol Lett. 2017 Dec;14(6):7715-7722</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29250173</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2015 Nov 1;75(21):4651-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26363006</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hematol Oncol. 2017 Apr 17;10(1):89</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28412963</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Drug Discov. 2002 Aug;1(8):609-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12402501</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Appl Immunohistochem Mol Morphol. 2010 May;18(3):254-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19875955</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochim Biophys Acta. 2013 Dec;1833(12):3481-3498</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23830918</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2010 Jul 23;5(7):e11729</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20668531</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2004 Mar 1;64(5):1757-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14996737</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2008 Aug;110(3):465-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17805961</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2012 Jun 14;14(3):R95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22697792</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2007 May 1;67(9):4199-209</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17483331</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Pathol. 2009 Sep;175(3):1226-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19661439</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8185-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1325649</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Clin Pathol. 2012 Oct;138(4):511-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23010705</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2016 Mar 15;76(6):1653-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26825173</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>IUBMB Life. 2005 Jul;57(7):483-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16081369</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Springerplus. 2016 Jun 30;5(1):947</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27386391</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2011 Jun 07;13(3):R62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21672245</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Toxicol Appl Pharmacol. 1998 Sep;152(1):200-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9772216</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2016 Jun 16;11(6):e0157368</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27310713</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Horm Cancer. 2016 Apr;7(2):114-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26858237</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Biol Ther. 2014 Oct;15(10):1350-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25019382</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7539918</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Cancer Drug Targets. 2011 Jun;11(5):654-69</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21486221</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mod Pathol. 1998 Feb;11(2):155-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9504686</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Mol Endocrinol. 2016 Apr;56(3):R99-R114</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26831511</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2010;12(4):R60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20687930</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2010 Jun 10;465(7299):803-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20445538</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Compr Canc Netw. 2017 Apr;15(4):433-451</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28404755</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Biol Ther. 2006 Aug;5(8):933-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16775428</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Biol. 2004 Dec;24(24):10558-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15572663</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Lett. 2008 Dec 18;272(2):177-85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18579285</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Death Dis. 2012 Aug 09;3:e361</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22874998</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Biol. 2007 Jan;27(2):466-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17074804</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Biol Ther. 2007 Feb;6(2):278-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17224649</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2017 Feb 14;8(7):11555-11565</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28030791</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Metastasis Rev. 2016 Dec;35(4):645-654</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27878502</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2012 Oct 4;31(40):4372-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22231447</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2013 Sep 15;73(18):5810-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23928995</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Biol. 2011 Dec;31(23):4663-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21930780</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Annu Rev Pharmacol Toxicol. 1982;22:517-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">6282188</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Biol Ther. 2013 Mar;14(3):237-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23291984</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">29924958</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>02</Month>
            <Day>27</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1840-4812</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>19</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Feb</Month>
                        <Day>12</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Bosnian journal of basic medical sciences</Title>
                <ISOAbbreviation>Bosn J Basic Med Sci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway.</ArticleTitle>
            <Pagination>
                <MedlinePgn>52-59</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.17305/bjbms.2018.3399</ELocationID>
            <Abstract>
                <AbstractText>Triple-negative breast cancer (TNBC) is the leading cause of cancer-related death in women. Previous studies indicated that miR-361-5p was downregulated in breast cancer, however, the exact effect of miR-361-5p on TNBC requires further investigation. In the present study, we investigated whether miR-361-5p can act as a tumor suppressor by targeting required for cell differentiation 1 homolog (RQCD1) and inhibiting epidermal growth factor receptor (EGFR)/phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway in TNBC. The expression of miR-361-5p and RQCD1 was determined by quantitative reverse transcription PCR (qRT-PCR) and/or western blot in TNBC and the adjacent tissues. miR-361-5p mimics were constructed and transfected to TNBC cell line MDA-MB-231. Cells were divided into three groups: blank control group, miRNA mimic negative control (NC) group, and miR-361-5p mimics group. Expression of miR-361-5p, mRNA and protein expression of PI3K, Akt, EGFR, phosphorylated (p)-EGFR/PI3K/Akt, and protein expression of RQCD1 and matrix metallopeptidase 9 (MMP-9) in MDA-MB-231 were measured by qRT-PCR/western blot after transfection. Cell viability was determined by CCK-8 assay. Cell migration and invasion ability were evaluated by scratch and transwell assay, respectively. miR-361-5p target gene was determined by bioinformatics analysis and luciferase reporter assay. RQCD1 was identified as a target of miR-361-5p by TargetScan and confirmed by luciferase reporter assay. Downregulated miR-361-5p and upregulated RQCD1 were observed in TNBC tissues. Expression of EGFR, PI3K, Akt and MMP-9 was inhibited in cells treated with miR-361-5p mimics. Transfection of miR-361-5p mimics also inhibited the phosphorylation of EGFR, PI3K, and Akt. Suppressed cell viability, migration, and invasion was found in miR-361-5p mimics groups. Our results indicated that overexpression of miR-361-5p might act as a suppressor in TNBC by targeting RQCD1 to inhibit the EGFR/PI3K/Akt signaling pathway.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Han</LastName>
                    <ForeName>Jianjun</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Breast Surgery, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei, China. dr_hanjianjun@163.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yu</LastName>
                    <ForeName>Jingjing</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dai</LastName>
                    <ForeName>Yu'na</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Jumei</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guo</LastName>
                    <ForeName>Meiyan</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Song</LastName>
                    <ForeName>Jingzhen</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Xuefeng</ForeName>
                    <Initials>X</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>02</Month>
                <Day>12</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Bosnia and Herzegovina</Country>
            <MedlineTA>Bosn J Basic Med Sci</MedlineTA>
            <NlmUniqueID>101200947</NlmUniqueID>
            <ISSNLinking>1512-8601</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>03</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>6</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>6</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>6</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29924958</ArticleId>
            <ArticleId IdType="doi">10.17305/bjbms.2018.3399</ArticleId>
            <ArticleId IdType="pmc">PMC6387672</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">29901185</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>10</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1791-2423</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>53</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of oncology</Title>
                <ISOAbbreviation>Int. J. Oncol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Salidroside inhibits migration, invasion and angiogenesis of MDA‑MB 231 TNBC cells by regulating EGFR/Jak2/STAT3 signaling via MMP2.</ArticleTitle>
            <Pagination>
                <MedlinePgn>877-885</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3892/ijo.2018.4430</ELocationID>
            <Abstract>
                <AbstractText>The major hallmarks of tumor progression are angiogenesis, migration and metastasis. Among the components of Rhodiola rosea, salidroside (p‑hydroxyphenethyl-β‑d-glucoside) is one of the most potent, and is present in all Rhodiola species. Recent data have revealed the anticancer effects of salidroside; however, the mechanism underlying its ability to inhibit tumor angiogenesis remains unknown. The present study aimed to analyze how salidroside affects major factors involved in breast cancer, and to elucidate its ability to inhibit angiogenesis and invasion. Signal transducer and activator of transcription 3 (STAT3) is a marker for tumor angiogenesis and migration, which interacts with matrix metalloproteinases (MMPs). Specifically, MMPs act as a downstream target for STAT3. Using western blotting and reverse transcription-quantitative polymerase chain reaction analysis, the present study demonstrated that treatment of MDA‑MB 231 triple-negative breast cancer (TNBC) cells with salidroside led to inhibition of invasion and migration markers, and of STAT3 signaling. Furthermore, in vitro angiogenesis analyses in human umbilical vein endothelial cells confirmed the anti-angiogenic activity of salidroside. An electrophoretic mobility shift assay also demonstrated that salidroside may inhibit the DNA-binding activity of STAT3, preventing STAT3 from binding to a novel binding site of the MMP2 gene promoter. In conclusion, the present results demonstrated that salidroside may downregulate the STAT3 signaling pathway, and inhibit cell viability, migration and invasion through MMPs in breast cancer cells.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kang</LastName>
                    <ForeName>Dong Young</ForeName>
                    <Initials>DY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, School of Medicine, Institute of Biomedical Science and Technology, Konkuk University, Chungju, Chungcheongbuk 27478, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sp</LastName>
                    <ForeName>Nipin</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, School of Medicine, Institute of Biomedical Science and Technology, Konkuk University, Chungju, Chungcheongbuk 27478, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Doh Hoon</ForeName>
                    <Initials>DH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, School of Medicine, Institute of Biomedical Science and Technology, Konkuk University, Chungju, Chungcheongbuk 27478, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Joung</LastName>
                    <ForeName>Youn Hee</ForeName>
                    <Initials>YH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, School of Medicine, Institute of Biomedical Science and Technology, Konkuk University, Chungju, Chungcheongbuk 27478, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Hyo Gun</ForeName>
                    <Initials>HG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Animal Science, College of Natural Resources and Life Sciences, Pusan National University, Miryang, Gyeongsangnam 50463, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Young Min</ForeName>
                    <Initials>YM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Immunology, Lab of Dendritic Cell Differentiation and Regulation, School of Medicine, Konkuk University, Chungju, Chungcheongbuk 27478, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Young Mok</ForeName>
                    <Initials>YM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, School of Medicine, Institute of Biomedical Science and Technology, Konkuk University, Chungju, Chungcheongbuk 27478, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>05</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Int J Oncol</MedlineTA>
            <NlmUniqueID>9306042</NlmUniqueID>
            <ISSNLinking>1019-6439</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005960">Glucosides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010636">Phenols</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C494086">STAT3 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.2</RegistryNumber>
                <NameOfSubstance UI="C507924">JAK2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.2</RegistryNumber>
                <NameOfSubstance UI="D053614">Janus Kinase 2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.24.24</RegistryNumber>
                <NameOfSubstance UI="C522361">MMP2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.24.24</RegistryNumber>
                <NameOfSubstance UI="D020778">Matrix Metalloproteinase 2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>M983H6N1S9</RegistryNumber>
                <NameOfSubstance UI="C009172">rhodioloside</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D020533" MajorTopicYN="N">Angiogenesis Inhibitors</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005960" MajorTopicYN="N">Glucosides</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053614" MajorTopicYN="N">Janus Kinase 2</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020778" MajorTopicYN="N">Matrix Metalloproteinase 2</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010636" MajorTopicYN="N">Phenols</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D050796" MajorTopicYN="N">STAT3 Transcription Factor</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>02</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>10</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29901185</ArticleId>
            <ArticleId IdType="doi">10.3892/ijo.2018.4430</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">29884726</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>04</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2159-8290</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>8</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer discovery</Title>
                <ISOAbbreviation>Cancer Discov</ISOAbbreviation>
            </Journal>
            <ArticleTitle>An Immunosuppressive Role for Eya3 in TNBC.</ArticleTitle>
            <Pagination>
                <MedlinePgn>OF8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1158/2159-8290.CD-NB2018-072</ELocationID>
            <Abstract>
                <AbstractText>A recent study indicates that the protein Eya3 influences the adaptive immune response to promote tumor growth, not only decreasing the number of tumor-infiltrating CD8+ T cells, but also driving their exhaustion through PD-L1 upregulation. These findings could spur new strategies to treat triple-negative breast cancer, which currently lacks targeted therapies.</AbstractText>
                <CopyrightInformation>©2018 American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>06</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Cancer Discov</MedlineTA>
            <NlmUniqueID>101561693</NlmUniqueID>
            <ISSNLinking>2159-8274</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>6</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>6</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>6</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29884726</ArticleId>
            <ArticleId IdType="pii">2159-8290.CD-NB2018-072</ArticleId>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-NB2018-072</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">29792857</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>05</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>05</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1090-2104</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>502</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>07</Month>
                        <Day>07</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biochemical and biophysical research communications</Title>
                <ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>160-165</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0006-291X(18)31208-7</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2018.05.139</ELocationID>
            <Abstract>
                <AbstractText>Triple negative breast cancer (TNBC) is the most malignant subtype of breast cancer in which the cell surface lacks usual targets for drug to exhibit its effects. Epirubicin (Epi) is widely used for TNBC, but a substantial number of patients develop Epi resistance that is usually associated with poor prognosis. Transforming growth factor (TGF-β) is a multifunctional cytokine. In recent study, it appears that TGF-β influences the cancer stem cell population, thus, the drug resistance of cancer may also be affected. We used epirubicin to treat MDA-MB-231 (MB-231) cells and found that TGF-β and breast cancer stem cell markers CD44<sup>+</sup>CD24<sup>-</sup> were increased and were dose-dependent of epirubicin. We established drug-resistant cell line from parental MB-231 cells by chronic treatment with low-concentration epirubicin. The MB-231/Epi cell line showed relatively slow growth rate with varied morphology. Transwell assay and drug sensitivity assay revealed that the malignant cell behaviors in terms of migration, invasion and epirubicin-resistant properties were markedly increased in the MB-231/Epi cells. Western blot, immunofluorescence assay, and flow cytometry were used to analyze the expression levels of the breast cancer stem cell markers, CD44 and CD24. Mammospheres assay showed that the stemness of MB-231/Epi was increased compared to their parental cells. Interestingly, MB-231/Epi cells showed different expression levels of apoptosis-related markers: Bcl2, Bax; EMT-related markers E-cadherin, N-cadherin and cell cycle-related marker cyclinD1. These genes have all been shown to be regulated by the TGF-β pathway. Taken together, our findings suggest that TGF-β plays a vital role in TNBC epirubicin-resistance through regulating stemness, EMT and apoptosis.</AbstractText>
                <CopyrightInformation>Copyright © 2018 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Xiaodan</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathophysiology, Anhui Medical University, Hefei, Anhui, 230032, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Lu</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathophysiology, Anhui Medical University, Hefei, Anhui, 230032, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>He</LastName>
                    <ForeName>Xiaogang</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathophysiology, Anhui Medical University, Hefei, Anhui, 230032, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Ping</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathophysiology, Anhui Medical University, Hefei, Anhui, 230032, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Caihong</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathophysiology, Anhui Medical University, Hefei, Anhui, 230032, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Xiaojun</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>Yaojuan</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hematological Laboratory Science, Jiangsu Key Laboratory of Medical Science and Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, 212013, Jiangsu, China; Shenzhen Academy of Peptide Targeting Technology at Pingshan, Shenzhen, 518118, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Feifei</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathophysiology, Anhui Medical University, Hefei, Anhui, 230032, China. Electronic address: feifeili717@ahmu.edu.cn.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Biochem Biophys Res Commun</MedlineTA>
            <NlmUniqueID>0372516</NlmUniqueID>
            <ISSNLinking>0006-291X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000903">Antibiotics, Antineoplastic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3Z8479ZZ5X</RegistryNumber>
                <NameOfSubstance UI="D015251">Epirubicin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000903" MajorTopicYN="N">Antibiotics, Antineoplastic</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019008" MajorTopicYN="Y">Drug Resistance, Neoplasm</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015251" MajorTopicYN="N">Epirubicin</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D058750" MajorTopicYN="N">Epithelial-Mesenchymal Transition</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">Apoptosis</Keyword>
            <Keyword MajorTopicYN="Y">Cancer stem cell</Keyword>
            <Keyword MajorTopicYN="Y">Drug resistance</Keyword>
            <Keyword MajorTopicYN="Y">EMT</Keyword>
            <Keyword MajorTopicYN="Y">TGF-β</Keyword>
            <Keyword MajorTopicYN="Y">Triple negative breast cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>5</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>5</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29792857</ArticleId>
            <ArticleId IdType="pii">S0006-291X(18)31208-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbrc.2018.05.139</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">29771420</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>10</Month>
            <Day>23</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">2284-0729</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>22</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>European review for medical and pharmacological sciences</Title>
                <ISOAbbreviation>Eur Rev Med Pharmacol Sci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>IMP3 promotes TNBC stem cell property through miRNA-34a regulation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2688-2696</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">14965</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.26355/eurrev_201805_14965</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To explore the expression and function of insulin-like growth factor II (IGFII) mRNA binding protein (IMP3) in the Triple Negative Breast Cancer (TNBC).</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">According to previously reported gene expression array, we found that IMP3 had significantly higher expression in the CD44+CD24-ESA+ cell cluster, tumor initiating cell or cancer stem cell (CSCs), compared to other tumor cells. Based on the GEO database (GEO accession No. GSE6883), we detected the mRNA levels of IMP 1,2 and 3 by quantitative polymerase chain reaction (q-PCR) in CD44+CD24-ESA+ cell cluster and other breast tumor cell clusters. Besides, we measured IMP3 expression in microsphere of breast cancer, which exerted more significant tumor stem cell properties. The effects of IMP3 on breast cancer cell stem cell properties were studied by RNA interference and overexpression approaches in vitro. Furthermore, we predicted and identified microRNA, which could target and regulate IMP3 from bioinformatics analysis, and verified the interaction by luciferase assays and rescue experiments.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Previously reported data showed that IMP3 expression was significantly upregulated in CD44+CD24-ESA+ cell cluster from breast cancer tissues. Besides, we found IMP3 had higher expression in mesenchymal cells rather than epithelial cells, which was also significantly elevated in SUM159 and T49D cell lines cultured as microsphere rather than adherent cells or differentiated cells. CD44+CD24-ESA+ cell cluster proportion was significantly decreased after silencing IMP3 in SUM1315, and its ability to develop into microsphere was significantly inhibited. By re-expressing IMP3 in SUM315, we restored the self-renewal capacity and tumorigenesis potential of SUM315. Through relative predicting website, we found several miRNAs which could regulate IMP3. miR-34a with highest score was chosen for further analysis. Mimicking miR-34a significantly downregulated IMP3 expression and inhibited its ability to develop into microsphere, while overexpressing IMP3 could rescue this process.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">IMP3 plays a vital role in maintaining stem cell properties of breast cancer cells, which could be regulated by mir-34a.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Q-D</ForeName>
                    <Initials>QD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Thyroid Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. guoguilong@sina.com.cn.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zheng</LastName>
                    <ForeName>S-R</ForeName>
                    <Initials>SR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cai</LastName>
                    <ForeName>Y-J</ForeName>
                    <Initials>YJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>D-L</ForeName>
                    <Initials>DL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shen</LastName>
                    <ForeName>Y-Y</ForeName>
                    <Initials>YY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>C-Q</ForeName>
                    <Initials>CQ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hu</LastName>
                    <ForeName>X-Q</ForeName>
                    <Initials>XQ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>X-H</ForeName>
                    <Initials>XH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shi</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guo</LastName>
                    <ForeName>G-L</ForeName>
                    <Initials>GL</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Italy</Country>
            <MedlineTA>Eur Rev Med Pharmacol Sci</MedlineTA>
            <NlmUniqueID>9717360</NlmUniqueID>
            <ISSNLinking>1128-3602</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>5</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>5</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>5</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29771420</ArticleId>
            <ArticleId IdType="doi">10.26355/eurrev_201805_14965</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">29765774</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>01</Month>
            <Day>30</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">2059-7029</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>3</Volume>
                    <Issue>Suppl 1</Issue>
                    <PubDate>
                        <Year>2018</Year>
                    </PubDate>
                </JournalIssue>
                <Title>ESMO open</Title>
                <ISOAbbreviation>ESMO Open</ISOAbbreviation>
            </Journal>
            <ArticleTitle>How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e000357</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1136/esmoopen-2018-000357</ELocationID>
            <Abstract>
                <AbstractText>Triple-negative breast cancer (TNBC) is a long-lasting orphan disease in terms of little therapeutic progress during the past several decades and still the standard of care remains chemotherapy. Experimental discovery of molecular signatures including the 'BRCAness' highlighted the innate heterogeneity of TNBC, generating the diversity of TNBC phenotypes. As it contributes to enhancing genomic instability, it has widened the therapeutic spectrum of TNBC. In particular, unusual sensitivity to DNA damaging agents was denoted in patients with BRCA deficiency, suggesting therapeutic benefit from platinum and poly(ADP-ribose) polymerase inhibitors. However, regardless of enriched chemosensitivity and immunogenicity, majority of patients with TNBC still suffer from dismal clinical outcomes including early relapse and metastatic spread. Therefore, efforts into more precise and personalised treatment are critical at this point. Accordingly, the advance of multiomics has revealed novel actionable targets including PI3K-Akt-mTOR and epidermal growth factor receptor signalling pathways, which might actively participate in modulating the chemosensitivity and immune system. Also, TNBC has long been considered a potential protagonist of immunotherapy in breast cancer, supported by abundant tumour-infiltrating lymphocytes and heterogeneous tumour microenvironment. Despite that, earlier studies showed somewhat unsatisfactory results of monotherapy with immune-checkpoint inhibitors, consistently durable responses in responders were noteworthy. Based on these results, further combinatorial trials either with other chemotherapy or targeted agents are underway. Incorporating immune-molecular targets into combination as well as refining the standard chemotherapy might be the key to unlock the future of TNBC. In this review, we share the current and upcoming treatment options of TNBC in the framework of scientific and clinical data, especially focusing on early stage of TNBC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Ji Hyun</ForeName>
                    <Initials>JH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Hemato-Oncology, Konkuk Medical Center, University of Konkuk College of Medicine, Gwangjin-gu, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ahn</LastName>
                    <ForeName>Jin-Hee</ForeName>
                    <Initials>JH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Sung-Bae</ForeName>
                    <Initials>SB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>03</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>ESMO Open</MedlineTA>
            <NlmUniqueID>101690685</NlmUniqueID>
            <ISSNLinking>2059-7029</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">triple-negative breast cancer</Keyword>
        </KeywordList>
        <CoiStatement>Competing interests: None declared.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>03</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>5</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>5</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>5</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29765774</ArticleId>
            <ArticleId IdType="doi">10.1136/esmoopen-2018-000357</ArticleId>
            <ArticleId IdType="pii">esmoopen-2018-000357</ArticleId>
            <ArticleId IdType="pmc">PMC5950702</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Nature. 2014 Nov 27;515(7528):563-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25428504</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2016 Nov 8;7(45):73618-73637</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27655662</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2013 Jul 10;31(20):2586-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23733761</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2017 Jul 1;35(19):2193-2202</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28471727</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Cancer Res. 2016 Aug 01;6(8):1609-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27648353</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2011 Jul;121(7):2750-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21633166</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 2006 Apr 12;295(14):1658-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16609087</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 2002 Jan 25;108(2):171-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11832208</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2012 Feb 4;379(9814):432-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22152853</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2004 Oct;4(10 ):814-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15510162</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2017 Aug 25;19(1):99</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28851423</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2016 Jul;15(7):1545-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27196766</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Breast Cancer. 2016 Feb;16(1):23-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26381420</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Oncol. 2014 Jun;15(7):747-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24794243</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2004 Nov 17;96(22):1659-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15547178</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2013 Oct 17;502(7471):333-339</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24132290</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2010 Nov 11;363(20):1938-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21067385</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Drugs. 2013 Aug;73(12):1257-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23842749</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Cancer. 2017 May;77:40-47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28355581</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mutat Res. 2000 Jun 30;460(1):1-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10856830</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2016 Dec 1;22(23 ):5729-5737</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27566765</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Genet. 2002 Sep;32(1):180-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12195423</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2009 May 21;459(7245):460-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19357644</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA Oncol. 2017 Oct 1;3(10 ):1378-1385</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28715532</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Lett. 2012 Jun 28;319(2):232-241</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22266096</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Chemother Pharmacol. 2014 Aug;74(2):229-38</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24871032</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2012 Apr;11(4):873-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22294718</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2011 May 20;29(15):1949-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21483002</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Genes Dev. 2006 Jan 1;20(1):34-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16391231</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2013 Dec 02;8(12 ):e79775</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24312450</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1185-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21601377</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pathol. 2014 Jan;232(2):142-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24114677</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2014 Sep;147(2):401-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25129345</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2017 Aug 1;23 (15):4035-4045</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28270498</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2016 Jun 15;22(12 ):2855-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26801247</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Apr 15;13(8):2329-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17438091</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Breast Cancer. 2015 Feb;15(1):8-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25218708</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Carcinog. 2017 May;56(5):1383-1394</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27864890</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>ESMO Open. 2017 Sep 14;2(4):e000208</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29018573</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2013 Oct 1;19(19):5533-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23948975</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>NPJ Breast Cancer. 2017 Apr 26;3:17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28649657</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2005 Apr 14;434(7035):913-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15829966</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am Soc Clin Oncol Educ Book. 2014;:e32-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24857120</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2014 Dec;148(3):467-76</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25361613</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Discov. 2012 Nov;2(11):1036-47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22915752</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem Soc Trans. 2006 Nov;34(Pt 5):633-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17052168</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2006 Sep 25;25(43):5846-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16998499</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2012 Oct 15;18(20):5816-28</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22932669</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Cell. 2009 Aug 4;16(2):89-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19647219</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Future Oncol. 2017 Feb;13(4):307-320</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27739325</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2014 Jun;25(6):1122-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24669015</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2012 Jul 20;14(4):R110</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22817698</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2002 Oct 1;100(7):2414-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12239151</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2014 Jul 12;384(9938):164-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24529560</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2008 Nov 15;113(10):2638-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18833576</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2010 Jul 24;376(9737):235-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20609467</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Zhonghua Yi Xue Za Zhi. 2015 Oct;95(40):3308-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26815355</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2015 Jun;151(3):629-38</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26006067</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2015 Aug;26(8):1698-704</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25995301</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2016 Jun 16;11(6):e0157368</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27310713</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2008 Mar 10;26(8):1275-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18250347</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Pathol. 2017 Oct;70(10 ):860-867</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28373294</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Mar 1;28(7):1145-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20100965</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2017 Jun 17;389(10087):2430-2442</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27939063</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Oncol. 2017 Oct;18(10 ):1360-1372</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28800861</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2017 Feb 1;28(2):313-320</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27803006</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2009 Jul 15;15(14):4649-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19567590</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Radiother Oncol. 2011 Aug;100(2):200-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21852010</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2013 Nov 12;109(10):2705-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24129232</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Anticancer Res. 2015 Jul;35(7):3829-38</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26124328</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2012 Apr 04;486(7403):395-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22495314</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2016 Apr;156(3):597-606</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27075916</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2017 Aug 10;377(6):523-533</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28578601</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2009 Jul;20(7):1193-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19221152</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2011 Nov;130(2):645-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21717105</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2016 Mar 15;22(6):1499-509</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26515496</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2018 Feb 1;24(3):511-520</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28801472</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2015 Jan;26(1):58-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25344362</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Chemother Pharmacol. 2015 Jan;75(1):183-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25417902</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2018 Jan;167(1):89-99</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28913760</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2012 Jul 20;30(21):2615-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22665533</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Breast Cancer. 2016 Oct;16(5):349-355</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27340049</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2008 Apr 16;100(8):552-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18398094</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>EMBO J. 2008 May 7;27(9):1368-77</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18388863</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Clin Pathol. 2014 Apr;141(4):462-77</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24619745</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2015 Apr 1;21(7):1688-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25208879</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Discov. 2017 Jun;7(6):OF10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28377497</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Breast Cancer. 2018 Feb;18(1):e135-e142</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28935542</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mod Pathol. 2018 Feb;31(2):288-298</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28984302</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Cancer. 2017 Aug;81:116-129</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28623775</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2009 May;115(2):359-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18649131</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2014 Aug;25(8):1570-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24827135</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2004 Dec 31;279(53):55117-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15498778</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2016 Jul 20;34(21):2460-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27138582</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2012 Apr 18;486(7403):346-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22522925</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Sci. 2004 Nov;95(11):866-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15546503</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2012 May 20;30(15):1796-804</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22508812</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2004 Sep;4(9):665-76</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15343273</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2012 Oct 4;490(7418):61-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23000897</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Surg Oncol. 2010 Oct;17 Suppl 3:384-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20853062</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mod Pathol. 2016 May;29(5):476-88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26939876</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2015 Jun 10;33(17):1902-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25847936</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2013 Nov;24 Suppl 8:viii13-viii21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24131964</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Invest New Drugs. 2016 Jun;34(3):355-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26996385</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2003 Apr 15;21(8):1431-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12668651</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Cancer. 2013 Jun;49(9):2077-85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23583440</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Jan 1;28(1):105-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19917869</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2016 May 1;138(9):2274-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26649807</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2009 Jul;116(1):53-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18592370</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2017 Jun 1;376(22):2147-2159</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28564564</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Front Oncol. 2017 Aug 03;7:156</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28824872</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2014 Oct 14;111(8):1532-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25101563</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Rev Peru Med Exp Salud Publica. 2013 Oct-Dec;30(4):649-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24448944</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2017 Jul 15;23 (14 ):3711-3720</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28167507</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2013 Jul;123(7):2873-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23778140</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2014 Aug;25(8):1544-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24608200</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2015 Jun 10;33(17):1895-901</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25847929</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14519755</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2013 Nov 19;15(6):R110</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24252402</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2006 Dec 1;24(34):5373-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17135638</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2012 Jun 20;486(7403):405-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22722202</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Lett. 2001 Feb 10;163(1):1-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11163101</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2017 Aug 1;23 (15):4066-4076</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28356425</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2013 Mar 1;31(7):860-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23341518</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer. 2018 Jan;25(1):34-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28488168</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 1997 Jan 24;88(2):265-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9008167</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA Oncol. 2017 Apr 1;3(4):509-515</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27893038</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2016 Sep 13;7(37):60647-60656</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27447966</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2014 Sep 20;32(27):2959-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25071121</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2005 Apr 14;434(7035):917-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15829967</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Clin Oncol. 2016 Nov;13(11):674-690</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27184417</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Oncol. 2015 Mar;16(3):e113-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25752562</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2008 May;19(5):861-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18174609</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2010 Jul 1;16(13):3485-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20479064</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Pathol. 2017 Oct;187(10 ):2133-2138</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28734944</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2018 Feb;167(3):671-686</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29063313</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17671126</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2012 Dec;136(3):795-804</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23124476</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2015 Mar 20;33(9):983-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25534375</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neuro Oncol. 2017 Oct 19;19(11):1481-1493</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28486691</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2016 Feb;27(2):249-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26598540</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Sci. 2017 Jan;108(1):81-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27801993</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2015 Jan 1;33(1):13-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25092775</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2012 Nov;136(1):107-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22986814</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Nucl Med. 2013 Jun;54(6):913-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23564760</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2017 Feb 28;8(9):15584-15592</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28107186</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">29758456</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>04</Month>
            <Day>30</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-3336</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>355</Volume>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>08</Month>
                        <Day>05</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of hazardous materials</Title>
                <ISOAbbreviation>J. Hazard. Mater.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>GPER/Hippo-YAP signal is involved in Bisphenol S induced migration of triple negative breast cancer (TNBC) cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0304-3894(18)30352-2</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jhazmat.2018.05.013</ELocationID>
            <Abstract>
                <AbstractText>Nowadays, risk factors of triple-negative breast cancer (TNBC) metastasis are not well identified. Our present study reveals that an industrial chemical, bisphenol S (BPS), can promote the migration, but not the proliferation, of TNBC cells in vitro. BPS activates YAP, a key effector of Hippo pathway, by inhibiting its phosphorylation, which promotes YAP nuclear accumulation and up-regulates its downstream genes such as CTGF and ANKRD1. Inhibition of YAP blocks the BPS-triggered cell migration and up-regulation of fibronectin (FN) and vimentin (Vim). BPS rapidly decreases the phosphorylation levels of LATS1 (Ser909) in TNBC cells, which regulates the activation and functions of YAP. Silencing LATS1/2 by siRNA increases BPS-induced dephosphorylation of YAP and extended the half-life of YAP protein. Inhibition of G protein-coupled estrogen receptor 1 (GPER) and its downstream PLCβ/PKC signals attenuate the effects of BPS-induced YAP dephosphorylation and CTGF up-regulation. Targeted inhibition of GPER/YAP inhibits BPS-induced migration of TNBC cells. Collectively, we reveal that GPER/Hippo-YAP signal is involved in BPS-induced migration of TNBC cells.</AbstractText>
                <CopyrightInformation>Copyright © 2018 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Deng</LastName>
                    <ForeName>Qianqian</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Microbial and Biochemical Pharmacy, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jiang</LastName>
                    <ForeName>Guanmin</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Laboratory, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Yingmin</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Microbial and Biochemical Pharmacy, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Jiexin</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Microbial and Biochemical Pharmacy, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liang</LastName>
                    <ForeName>Weiting</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Likun</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Su</LastName>
                    <ForeName>Qiao</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>Animal Experiment Center, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Wuguo</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Animal Experiment Center, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Du</LastName>
                    <ForeName>Jun</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Microbial and Biochemical Pharmacy, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wong</LastName>
                    <ForeName>Chris K C</ForeName>
                    <Initials>CKC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biology, Hong Kong Baptist University, Hong Kong, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Zhuojia</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China. Electronic address: chenzhj@sysucc.org.cn.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Hongsheng</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Microbial and Biochemical Pharmacy, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China. Electronic address: whongsh@mail.sysu.edu.cn.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>J Hazard Mater</MedlineTA>
            <NlmUniqueID>9422688</NlmUniqueID>
            <ISSNLinking>0304-3894</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">Bisphenol S</Keyword>
            <Keyword MajorTopicYN="Y">GPER</Keyword>
            <Keyword MajorTopicYN="Y">TNBC</Keyword>
            <Keyword MajorTopicYN="Y">YAP</Keyword>
            <Keyword MajorTopicYN="Y">migration</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>04</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>05</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>5</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>5</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>5</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29758456</ArticleId>
            <ArticleId IdType="pii">S0304-3894(18)30352-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jhazmat.2018.05.013</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">29602824</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>05</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2159-8290</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>8</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer discovery</Title>
                <ISOAbbreviation>Cancer Discov</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Inhibiting PTPN12-Regulated RTKs May Be Therapeutic in TNBC.</ArticleTitle>
            <Pagination>
                <MedlinePgn>530</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1158/2159-8290.CD-RW2018-056</ELocationID>
            <Abstract>
                <AbstractText>PTPN12 deficiency may confer sensitivity to tyrosine kinase inhibitor combinations in TNBC.</AbstractText>
                <CopyrightInformation>©2018 American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>03</Month>
                <Day>30</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Cancer Discov</MedlineTA>
            <NlmUniqueID>101561693</NlmUniqueID>
            <ISSNLinking>2159-8274</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>4</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>4</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>4</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29602824</ArticleId>
            <ArticleId IdType="pii">2159-8290.CD-RW2018-056</ArticleId>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-RW2018-056</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">29587820</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>05</Month>
            <Day>09</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>05</Month>
            <Day>09</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1756-9966</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>37</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Mar</Month>
                        <Day>27</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of experimental &amp; clinical cancer research : CR</Title>
                <ISOAbbreviation>J. Exp. Clin. Cancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>72</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13046-018-0741-3</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cretella</LastName>
                    <ForeName>Daniele</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine and Surgery, University of Parma, Parma, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ravelli</LastName>
                    <ForeName>Andrea</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine and Surgery, University of Parma, Parma, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fumarola</LastName>
                    <ForeName>Claudia</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine and Surgery, University of Parma, Parma, Italy. claudia.fumarola@unipr.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>La Monica</LastName>
                    <ForeName>Silvia</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine and Surgery, University of Parma, Parma, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Digiacomo</LastName>
                    <ForeName>Graziana</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine and Surgery, University of Parma, Parma, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cavazzoni</LastName>
                    <ForeName>Andrea</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine and Surgery, University of Parma, Parma, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Alfieri</LastName>
                    <ForeName>Roberta</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine and Surgery, University of Parma, Parma, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Biondi</LastName>
                    <ForeName>Alessandra</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine and Surgery, University of Parma, Parma, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Generali</LastName>
                    <ForeName>Daniele</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>U.O. Multidisciplinare di Patologia Mammaria, U.S Terapia Molecolare e Farmacogenomica, ASST Cremona, Cremona, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bonelli</LastName>
                    <ForeName>Mara</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine and Surgery, University of Parma, Parma, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Petronini</LastName>
                    <ForeName>Pier Giorgio</ForeName>
                    <Initials>PG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine and Surgery, University of Parma, Parma, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>03</Month>
                <Day>27</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>J Exp Clin Cancer Res</MedlineTA>
            <NlmUniqueID>8308647</NlmUniqueID>
            <ISSNLinking>0392-9078</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.1.-</RegistryNumber>
                <NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.1.1</RegistryNumber>
                <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.1</RegistryNumber>
                <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.22</RegistryNumber>
                <NameOfSubstance UI="C495900">CDK4 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.22</RegistryNumber>
                <NameOfSubstance UI="C495911">CDK6 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.22</RegistryNumber>
                <NameOfSubstance UI="D051358">Cyclin-Dependent Kinase 4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.22</RegistryNumber>
                <NameOfSubstance UI="D051361">Cyclin-Dependent Kinase 6</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>G9ZF61LE7G</RegistryNumber>
                <NameOfSubstance UI="C500026">palbociclib</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>IY9XDZ35W2</RegistryNumber>
                <NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051358" MajorTopicYN="N">Cyclin-Dependent Kinase 4</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051361" MajorTopicYN="N">Cyclin-Dependent Kinase 6</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CDK4/6 inhibition</Keyword>
            <Keyword MajorTopicYN="N">Glucose metabolism</Keyword>
            <Keyword MajorTopicYN="N">PI3K/mTOR inhibitors</Keyword>
            <Keyword MajorTopicYN="N">Palbociclib</Keyword>
            <Keyword MajorTopicYN="N">Triple-negative breast cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>03</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>3</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>3</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>5</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29587820</ArticleId>
            <ArticleId IdType="doi">10.1186/s13046-018-0741-3</ArticleId>
            <ArticleId IdType="pii">10.1186/s13046-018-0741-3</ArticleId>
            <ArticleId IdType="pmc">PMC5872523</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Exp Clin Cancer Res. 2017 Dec 4;36(1):174</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29202823</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2011 Jul;121(7):2750-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21633166</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2014 May 07;16(3):207</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25223380</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Metab. 2008 Jan;7(1):11-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18177721</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2010 Mar 5;285(10):7324-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20018866</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2016 Sep 15;35(37):4829-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26923330</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2013 Aug;141(1):67-78</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23963659</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2008 Feb;7(2):361-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18281519</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2017 Sep 15;23 (18):5561-5572</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28606920</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Exp Clin Cancer Res. 2015 Oct 06;34:111</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26445347</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ther Adv Med Oncol. 2017 Feb;9(2):83-105</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28203301</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2015 Mar 1;21(5):995-1001</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25501126</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Biol. 2007 Nov;27(21):7381-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17785433</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer. 2011 Nov 23;10:143</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22111840</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2009;11(5):R77</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19874578</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Front Oncol. 2013 Jan 24;3:4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23355973</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pharmgenomics Pers Med. 2014 Aug 06;7:203-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25206307</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2011 Aug 12;13(4):215</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21884641</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2010 Aug 5;29(31):4369-77</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20514019</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2017 Nov 15;23 (22):6958-6968</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28814434</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2016 Nov 17;375(20):1925-1936</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27959613</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2012 Oct 4;490(7418):61-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23000897</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2017 Aug 24;548(7668):471-475</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28813415</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2012 Jun 1;130(11):2568-79</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21717460</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2015 Apr 28;112(17):5425-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25870263</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Cycle. 2017 Jun 18;16(12 ):1193-1200</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28486050</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell. 2016 Jun 16;62(6):929-942</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27237051</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Oncol. 2015 Jan;16(1):25-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25524798</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pharmacol Ther. 2017 Jul;175:91-106</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28216025</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Sci Rep. 2016 Oct 19;6:35383</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27759034</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Tumour Biol. 2014 Mar;35(3):1847-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24096545</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26742998</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Death Differ. 2005 Oct;12 (10 ):1344-57</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15905878</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Thorac Oncol. 2016 Jul;11(7):1051-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27006151</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neoplasia. 2017 Aug;19(8):637-648</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28704762</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer. 2014 Jun 05;13:143</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24898067</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">29552303</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1949-2553</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>15</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Feb</Month>
                        <Day>23</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncotarget</Title>
                <ISOAbbreviation>Oncotarget</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The ERβ4 variant induces transformation of the normal breast mammary epithelial cell line MCF-10A; the ERβ variants ERβ2 and ERβ5 increase aggressiveness of TNBC by regulation of hypoxic signaling.</ArticleTitle>
            <Pagination>
                <MedlinePgn>12201-12211</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.18632/oncotarget.24134</ELocationID>
            <Abstract>
                <AbstractText>Triple negative breast cancer (TNBC) still remains a challenge to treat in the clinic due to a lack of good targets for treatment. Although TNBC lacks expression of ERα, the expression of ERβ and its variants are detected quite frequently in this cancer type and can represent an avenue for treatment. We show that two of the variants of ERβ, namely ERβ2 and ERβ5, control aggressiveness of TNBC by regulating hypoxic signaling through stabilization of HIF-1α. RNA-seq of patient derived xenografts (PDX) from TNBC shows expression of ERβ2, ERβ4 and ERβ5 variants in more than half of the samples. Furthermore, expression of ERβ4 in the immortalized, normal mammary epithelial cell line MCF-10A that is resistant to tumorsphere formation caused transformation and development of tumorspheres. By contrast, ERβ1, ERβ2 or ERβ5 were unable to support tumorsphere formation. We have previously shown that all variants except ERβ1 stabilize HIF-1α but only ERβ4 appears to have the ability to transform normal mammary epithelial cells, pointing towards a unique property of ERβ4. We propose that ERβ variants may be good diagnostic tools and also serve as novel targets for treatment of breast cancer.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Faria</LastName>
                    <ForeName>Michelle</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Houston, Department of Biology and Biochemistry, Center for Nuclear Receptors and Cell Signaling, Science &amp; Engineering Research Center, Houston, Texas, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Karami</LastName>
                    <ForeName>Samaneh</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Houston, Department of Biology and Biochemistry, Center for Nuclear Receptors and Cell Signaling, Science &amp; Engineering Research Center, Houston, Texas, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Granados-Principal</LastName>
                    <ForeName>Sergio</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Hospital of Jaen, Jaen, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dey</LastName>
                    <ForeName>Prasenjit</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Verma</LastName>
                    <ForeName>Akanksha</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute for Computational Biomedicine, Department of Physiology and Biophysics Weill Cornell Medicine, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Choi</LastName>
                    <ForeName>Dong S</ForeName>
                    <Initials>DS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Methodist Cancer Center, Houston Methodist Hospital, Houston, Texas, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Elemento</LastName>
                    <ForeName>Olivier</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute for Computational Biomedicine, Department of Physiology and Biophysics Weill Cornell Medicine, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bawa-Khalfe</LastName>
                    <ForeName>Tasneem</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Houston, Department of Biology and Biochemistry, Center for Nuclear Receptors and Cell Signaling, Science &amp; Engineering Research Center, Houston, Texas, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chang</LastName>
                    <ForeName>Jenny C</ForeName>
                    <Initials>JC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Methodist Cancer Center, Houston Methodist Hospital, Houston, Texas, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Strom</LastName>
                    <ForeName>Anders M</ForeName>
                    <Initials>AM</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Houston, Department of Biology and Biochemistry, Center for Nuclear Receptors and Cell Signaling, Science &amp; Engineering Research Center, Houston, Texas, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gustafsson</LastName>
                    <ForeName>Jan-Åke</ForeName>
                    <Initials>JÅ</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Houston, Department of Biology and Biochemistry, Center for Nuclear Receptors and Cell Signaling, Science &amp; Engineering Research Center, Houston, Texas, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of BioSciences and Nutrition, Karolinska Institutet, Huddinge, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>01</Month>
                <Day>10</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Oncotarget</MedlineTA>
            <NlmUniqueID>101532965</NlmUniqueID>
            <ISSNLinking>1949-2553</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CD133</Keyword>
            <Keyword MajorTopicYN="N">SOX2</Keyword>
            <Keyword MajorTopicYN="N">c-Myc</Keyword>
            <Keyword MajorTopicYN="N">slug</Keyword>
            <Keyword MajorTopicYN="N">twist1</Keyword>
        </KeywordList>
        <CoiStatement>CONFLICTS OF INTEREST The authors declare no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>07</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>3</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>3</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>3</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29552303</ArticleId>
            <ArticleId IdType="doi">10.18632/oncotarget.24134</ArticleId>
            <ArticleId IdType="pii">24134</ArticleId>
            <ArticleId IdType="pmc">PMC5844739</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Bone Miner Res. 2014 Aug;29(8):1886-99</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24619707</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Expert Rev Anticancer Ther. 2008 Oct;8(10):1689-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18925859</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2005 Jul 1;65(13):5506-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15994920</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2005 Sep 20;116(5):734-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15849727</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2002 Feb;71(3):249-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12002343</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2015 May 26;10 (5):e0128239</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26010887</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2008 Aug 15;14(16):5228-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18698041</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Pathol. 2004 Aug;57(8):829-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15280403</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2013 Aug 1;73(15):4885-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23737486</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cancer Res Clin Oncol. 2013 Sep;139(9):1489-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23817696</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2013 Jan 31;32(5):544-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22469978</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2004;6(3):R191-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15084243</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer. 2017 Mar 14;16(1):62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28288641</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2016 Mar 3;35(9):1111-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25982283</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5925-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8650195</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2014 Aug;146(3):657-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25007965</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Trends Pharmacol Sci. 2012 Apr;33(4):207-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22398146</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Histopathology. 2005 Jan;46(1):31-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15656883</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2015 Oct 07;10(10):e0139112</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26444008</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Chemother Pharmacol. 2015 Feb;75(2):235-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25422154</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2010 Dec 15;70(24):10101-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21159632</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Oncol. 2013 Apr;42(4):1289-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23381786</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pathol. 2008 Jan;214(1):25-37</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17973239</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2015 Nov 24;6(37):40247-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26450901</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Surg. 2015 Feb;14:17-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25450264</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Anticancer Agents Med Chem. 2017;17 (4):491-499</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27456662</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2002 Jun;8(6):1831-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12060624</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2010 Feb;120(2):485-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20051626</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Genes Dev. 2006 Mar 1;20(5):557-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16510872</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Cell Int. 2009 Mar 16;9:7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19291318</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):4708-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23487784</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Dis. 2006-2007;26:55-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17473365</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Radiat Biol. 2006 Oct;82(10 ):699-757</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17118889</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2008;10(3):R52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18541018</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 1998 Mar;48(2):97-106</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9596481</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2013 Mar 15;73(6):1981-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23378344</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer (Dove Med Press). 2016 May 20;8:93-107</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27284266</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Endocrinol. 2012 Dec;26(12 ):1991-2003</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23028063</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2003 Dec 4;22(55):8948-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14654791</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 2007 May 4;129(3):465-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17482542</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Sci Rep. 2014 Aug 01;4:5911</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25081383</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Allergy Asthma Rep. 2013 Feb;13(1):44-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22956391</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2011 Jun;11(6):393-410</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21606941</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):1933-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24449868</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochim Biophys Acta. 2009 Apr;1795(2):162-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19344680</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5429-38</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25453096</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2004;6(4):R450-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15217513</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Wien Med Wochenschr. 2002;152(13-14):334-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12168517</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2004 Jun 4;279(23 ):24218-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15044468</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2017 Feb 23;36(8):1157-1166</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27524420</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Adv Exp Med Biol. 2005;566:333-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16594170</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2003 Mar 15;97(6):1573-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12627523</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Methods. 2003 Jul;30(3):256-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12798140</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Clin Oncol. 2016 Nov;13(11):674-690</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27184417</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2009 Feb 15;69(4):1302-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19190339</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2011 Jan 15;71(2):614-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21224357</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2013 Jun 1;73(11):3470-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23633491</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nucleic Acids Res. 1998 Aug 1;26(15):3505-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9671811</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">29547591</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>07</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1420-3049</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>23</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Mar</Month>
                        <Day>16</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Molecules (Basel, Switzerland)</Title>
                <ISOAbbreviation>Molecules</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Discovery of N-(Naphtho[1,2-b]Furan-5-Yl) Benzenesulfonamides as Novel Selective Inhibitors of Triple-Negative Breast Cancer (TNBC).</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">E678</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules23030678</ELocationID>
            <Abstract>
                <AbstractText>Any type of breast cancer not expressing genes of the estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2) is referred to as triple-negative breast cancer (TNBC). Accordingly, TNBCs do not respond to hormonal therapies or medicines targeting the ER, PR, or HER2. Systemic chemotherapy is therefore the only treatment option available today and prognoses remain poor. We report the discovery and characterization of N-(naphtho[1,2-b]furan-5-yl)benzenesulfonamides as selective inhibitors of TNBCs. These inhibitors were identified by virtual screening and inhibited different TNBC cell lines with IC<sub>50</sub> values of 2-3 μM. The compounds did not inhibit normal (i.e. MCF-7 and MCF-10A) cells in vitro, indicating their selectivity against TNBC cells<i>.</i> Considering the selectivity of these inhibitors for TNBC, these compounds and analogs can serve as a promising starting point for further research on effective TNBC inhibitors.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Ya</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China. yachen@pkuddc.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tang</LastName>
                    <ForeName>Yong</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Beijing Shenogen Biomedical Co., Lid, Beijing 102206, China. tang-yong@hotmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mao</LastName>
                    <ForeName>Beibei</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China. beibeimao@pkudddc.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Wenchao</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China. wenchaoli@bjmu.edu.cn.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jin</LastName>
                    <ForeName>Hongwei</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China. jinhw@bjmu.edu.cn.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Liangren</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China. liangren@bjmu.edu.cn.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Zhenming</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China. zmliu@bjmu.edu.cn.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>03</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Molecules</MedlineTA>
            <NlmUniqueID>100964009</NlmUniqueID>
            <ISSNLinking>1420-3049</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005663">Furans</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004354" MajorTopicYN="N">Drug Screening Assays, Antitumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005663" MajorTopicYN="N">Furans</DescriptorName>
                <QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
                <QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">selective inhibitors</Keyword>
            <Keyword MajorTopicYN="N">three-dimensional similarity search</Keyword>
            <Keyword MajorTopicYN="N">triple-negative breast cancer</Keyword>
            <Keyword MajorTopicYN="N">virtual screening</Keyword>
        </KeywordList>
        <CoiStatement>The authors declare that they have no conflict of interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>02</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>03</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>03</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>3</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>3</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29547591</ArticleId>
            <ArticleId IdType="pii">molecules23030678</ArticleId>
            <ArticleId IdType="doi">10.3390/molecules23030678</ArticleId>
            <ArticleId IdType="pmc">PMC6017705</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Lancet Oncol. 2014 Jun;15(7):e279-89</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24872111</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Genome Biol. 2007;8(5):R76</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17493263</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2000 Aug 17;406(6797):747-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10963602</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncologist. 2013;18(2):123-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23404817</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Med Chem. 2007 Jan 11;50(1):74-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17201411</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2009 May 15;69(10):4116-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19435916</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Med Chem. 2014 May 22;57(10):4111-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24749893</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12829800</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BBA Clin. 2015 Mar 12;3:257-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26676166</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancers (Basel). 2014 Oct 24;6(4):2187-223</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25347122</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2006 Dec 20;24(36):5652-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17116942</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Chem Inf Model. 2010 Apr 26;50(4):572-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20235588</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Med Chem. 2005 Mar 10;48(5):1489-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15743191</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Onco Targets Ther. 2014 Jan 23;7:147-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24482576</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26742998</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17671126</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11553815</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Med Res. 2009 Jun;7(1-2):4-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19574486</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">29453319</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>02</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>05</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1557-3125</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>16</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>05</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular cancer research : MCR</Title>
                <ISOAbbreviation>Mol. Cancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Leptin Signaling Mediates Obesity-Associated CSC Enrichment and EMT in Preclinical TNBC Models.</ArticleTitle>
            <Pagination>
                <MedlinePgn>869-879</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1158/1541-7786.MCR-17-0508</ELocationID>
            <Abstract>
                <AbstractText>Obesity is associated with poor prognosis in triple-negative breast cancer (TNBC). Preclinical models of TNBC were used to test the hypothesis that increased leptin signaling drives obesity-associated TNBC development by promoting cancer stem cell (CSC) enrichment and/or epithelial-to-mesenchymal transition (EMT). MMTV-Wnt-1 transgenic mice, which develop spontaneous basal-like, triple-negative mammary tumors, received either a control diet (10% kcal from fat) or a diet-induced obesity regimen (DIO, 60% kcal from fat) for up to 42 weeks (<i>n</i> = 15/group). Mice were monitored for tumor development and euthanized when tumor diameter reached 1.5 cm. Tumoral gene expression was assessed via RNA sequencing (RNA-seq). DIO mice had greater body weight and percent body fat at termination than controls. DIO mice, versus controls, demonstrated reduced survival, increased systemic metabolic and inflammatory perturbations, upregulated tumoral CSC/EMT gene signature, elevated tumoral aldehyde dehydrogenase activity (a CSC marker), and greater leptin signaling. In cell culture experiments using TNBC cells (murine: E-Wnt and M-Wnt; human: MDA-MB-231), leptin enhanced mammosphere formation, and media supplemented with serum from DIO versus control mice increased cell viability, migration, invasion, and CSC- and EMT-related gene expression, including <i>Foxc2, Twist2, Vim, Akt3</i>, and <i>Sox2</i> In E-Wnt cells, knockdown of leptin receptor ablated these procancer effects induced by DIO mouse serum. These findings indicate that increased leptin signaling is causally linked to obesity-associated TNBC development by promoting CSC enrichment and EMT.<b>Implications:</b> Leptin-associated signals impacting CSC and EMT may provide new targets and intervention strategies for decreasing TNBC burden in obese women. <i>Mol Cancer Res; 16(5); 869-79. ©2018 AACR</i>.</AbstractText>
                <CopyrightInformation>©2018 American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bowers</LastName>
                    <ForeName>Laura W</ForeName>
                    <Initials>LW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Nutrition, University of North Carolina, Chapel Hill, North Carolina.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rossi</LastName>
                    <ForeName>Emily L</ForeName>
                    <Initials>EL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Nutrition, University of North Carolina, Chapel Hill, North Carolina.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McDonell</LastName>
                    <ForeName>Shannon B</ForeName>
                    <Initials>SB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Nutrition, University of North Carolina, Chapel Hill, North Carolina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Doerstling</LastName>
                    <ForeName>Steven S</ForeName>
                    <Initials>SS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Nutrition, University of North Carolina, Chapel Hill, North Carolina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Khatib</LastName>
                    <ForeName>Subreen A</ForeName>
                    <Initials>SA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Nutrition, University of North Carolina, Chapel Hill, North Carolina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lineberger</LastName>
                    <ForeName>Claire G</ForeName>
                    <Initials>CG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Nutrition, University of North Carolina, Chapel Hill, North Carolina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Albright</LastName>
                    <ForeName>Jody E</ForeName>
                    <Initials>JE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nutrition Research Institute, University of North Carolina, Kannapolis, North Carolina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tang</LastName>
                    <ForeName>Xiaohu</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biological Sciences, Michigan Technological University, Houghton, Michigan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>deGraffenried</LastName>
                    <ForeName>Linda A</ForeName>
                    <Initials>LA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Nutritional Sciences, University of Texas, Austin, Texas.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hursting</LastName>
                    <ForeName>Stephen D</ForeName>
                    <Initials>SD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Nutrition, University of North Carolina, Chapel Hill, North Carolina. hursting@email.unc.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Nutrition Research Institute, University of North Carolina, Kannapolis, North Carolina.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>T32 LM012420</GrantID>
                    <Acronym>LM</Acronym>
                    <Agency>NLM NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 ES010126</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R35 CA197627</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>T32 CA057726</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R25 CA057726</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>02</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Mol Cancer Res</MedlineTA>
            <NlmUniqueID>101150042</NlmUniqueID>
            <ISSNLinking>1541-7786</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D020738">Leptin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D058750" MajorTopicYN="N">Epithelial-Mesenchymal Transition</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020738" MajorTopicYN="N">Leptin</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>09</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>01</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>2</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29453319</ArticleId>
            <ArticleId IdType="pii">1541-7786.MCR-17-0508</ArticleId>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-17-0508</ArticleId>
            <ArticleId IdType="pmc">PMC5967653</ArticleId>
            <ArticleId IdType="mid">NIHMS938857</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Biol Chem. 1999 Jul 30;274(31):21528-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10419456</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Prev Res (Phila). 2012 Jul;5(7):930-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22588949</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2012 Jan 17;109 (3):829-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22207628</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2015 Sep 18;17 :129</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26385214</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2013;15(4):R59</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23880059</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2017 May 1;77(9):2500-2511</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28373182</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2011 Nov 24;30(47):4707-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21602879</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Causes Control. 2016 Feb;27(2):229-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26621544</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2015 Aug 19;17:112</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26286584</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncologist. 2012;17(10):1240-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22903527</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Breast Cancer Rep. 2014 Sep 1;6(3):154-158</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25419441</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2013 Nov 06;15(6):R105</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24192331</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2008 Sep 1;26(25):4072-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18757321</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2016 Jan 12;7(2):1262-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26556856</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Endocr Relat Cancer. 2011 Jul 11;18(4):491-503</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21636700</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2010 Oct;123(3):627-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20571870</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2012 Jan 10;30(2):164-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22162568</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2008 Oct 16;27(47):6120-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18591932</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Exp Clin Cancer Res. 2016 Oct 21;35(1):166</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27769315</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2017 May 25;12 (5):e0178454</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28542577</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2012;7(7):e41380</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22848477</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Endocr Relat Cancer. 2013 Oct 14;20(6):797-808</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24025407</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Prev Res (Phila). 2015 Dec;8(12 ):1174-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26487401</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2004 Jul 1;10(13):4325-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15240518</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10069-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17537911</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Lett. 2015 Oct 28;367(2):129-37</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26210254</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2015 Feb 06;10(2):e0117097</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25658419</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2017 Jan 31;8(5):7740-7752</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27999190</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2006 Mar 15;118(6):1414-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16206269</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hum Pathol. 2014 Sep;45(9):1839-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24974259</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS Genet. 2012;8(6):e1002751</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22685420</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2015 Aug 28;6(25):21100-19</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26053184</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Endocr Relat Cancer. 2017 Aug;24(8):415-426</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28729467</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2015 Jun 1;75(11):2375-2386</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25840984</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2014 Feb 1;74(3):964-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24335962</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>NPJ Breast Cancer. 2017 Jul 17;3:26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28748213</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Histopathology. 2014 Apr;64(5):660-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24138071</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2016 Nov 17;35(46):5963-5976</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26804168</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Med. 2016 Jan;5(1):41-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26626021</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2013 Mar 15;73(6):1981-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23378344</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2006 Mar 1;12(5):1447-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16533767</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Biol Ther. 2015;16(8):1220-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26121010</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 2012 Feb 1;307(5):491-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22253363</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Clin Oncol. 2016 Nov;13(11):674-690</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27184417</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2012 Mar 9;287(11):8598-612</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22270359</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Carcinogenesis. 2014 Mar;35(3):537-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24193512</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Endocr Relat Cancer. 2015 Jun;22(3):R135-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25876646</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">29424936</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>05</Month>
            <Day>04</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1097-0142</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>124</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>May</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer</Title>
                <ISOAbbreviation>Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2086-2103</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/cncr.31272</ELocationID>
            <Abstract>
                <AbstractText>Advances in cancer immunotherapy and a growing body of research have focused on the role of the antitumor response in breast cancer. Triple-negative breast cancer (TNBC) is the most immunogenic breast cancer subtype, and there is strong evidence that tumor-infiltrating lymphocytes in TNBC have prognostic value and are associated with clinical outcome and improved survival. Evading antitumor immunity is a hallmark for the development and progression of cancer. Immunotherapy studies have focused on the role of the programmed cell death-1 (PD-1) receptor/programmed death-ligand 1 (PD-L1) pathway in maintaining immunosuppression in the tumor microenvironment. Blockade of the PD-1/PD-L1 axis has emerged as a promising therapeutic option to enhance antitumor immunity and is actively being investigated in TNBC, with encouraging results. In this article, the authors review the current literature on checkpoint inhibitors in TNBC with a focus on PD-1/PD-L1 antibodies and discuss combination strategies and novel approaches for improving antitumor immunity and clinical outcome. Cancer 2018;124:2086-103. © 2018 American Cancer Society.</AbstractText>
                <CopyrightInformation>© 2018 American Cancer Society.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kwa</LastName>
                    <ForeName>Maryann J</ForeName>
                    <Initials>MJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laura and Issac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Adams</LastName>
                    <ForeName>Sylvia</ForeName>
                    <Initials>S</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-4737-1952</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Laura and Issac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>02</Month>
                <Day>09</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Cancer</MedlineTA>
            <NlmUniqueID>0374236</NlmUniqueID>
            <ISSNLinking>0008-543X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">checkpoint inhibitors</Keyword>
            <Keyword MajorTopicYN="N">immunotherapy</Keyword>
            <Keyword MajorTopicYN="N">programmed cell death-1 (PD-1) receptor</Keyword>
            <Keyword MajorTopicYN="N">programmed death-ligand 1 (PD-L1)</Keyword>
            <Keyword MajorTopicYN="N">triple-negative breast cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>10</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29424936</ArticleId>
            <ArticleId IdType="doi">10.1002/cncr.31272</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">29417299</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>03</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>03</Month>
            <Day>06</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-7217</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>169</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Breast cancer research and treatment</Title>
                <ISOAbbreviation>Breast Cancer Res. Treat.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>First international TNBC conference meeting report.</ArticleTitle>
            <Pagination>
                <MedlinePgn>407-412</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10549-018-4692-3</ELocationID>
            <Abstract>
                <AbstractText>Recently, Georgia State University's Centennial Hall was the premier location for the 2017 International Conference on Triple Negative Breast Cancer (TNBC): Illuminating Actionable Biology, which was held from Sept. 18 to 20, 2017, in Atlanta, USA. The conference featured a stellar line-up of domestic and international speakers and diverse participants including TNBC survivors, luminaries in breast cancer research, medical students and fellows, clinicians, translational researchers, epidemiologists, biostatisticians, bioinformaticians, and representatives from the industry. This report distills the burning questions that spiked the event and summarizes key themes, findings, unique opportunities and future directions that emerged from this confluence of thought leaders.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Rida</LastName>
                    <ForeName>Padmashree</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biology, Georgia State University, Atlanta, GA, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Novazoi Theranostics, Rolling Hills Estates, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ogden</LastName>
                    <ForeName>Angela</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biology, Georgia State University, Atlanta, GA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ellis</LastName>
                    <ForeName>Ian O</ForeName>
                    <Initials>IO</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Histopathology, Nottingham City Hospital NHS Trust, Nottingham University, Nottingham, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Varga</LastName>
                    <ForeName>Zsuzsanna</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wolff</LastName>
                    <ForeName>Antonio C</ForeName>
                    <Initials>AC</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Traina</LastName>
                    <ForeName>Tiffany A</ForeName>
                    <Initials>TA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Weill Cornell Medicine, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hatzis</LastName>
                    <ForeName>Christos</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Breast Medical Oncology, Yale School of Medicine, Yale University, New Haven, CT, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Palmer</LastName>
                    <ForeName>Julie R</ForeName>
                    <Initials>JR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Slone Epidemiology Center, Boston University, Boston, MA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ambrosone</LastName>
                    <ForeName>Christine B</ForeName>
                    <Initials>CB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lehmann</LastName>
                    <ForeName>Brian D</ForeName>
                    <Initials>BD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry, Vanderbilt University, Nashville, TN, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nanda</LastName>
                    <ForeName>Rita</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Section of Hematology-Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Montgomery Rice</LastName>
                    <ForeName>Valerie</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Morehouse School of Medicine, Atlanta, GA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brawley</LastName>
                    <ForeName>Otis W</ForeName>
                    <Initials>OW</Initials>
                    <AffiliationInfo>
                        <Affiliation>American Cancer Society, Atlanta, GA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Torres</LastName>
                    <ForeName>Mylin A</ForeName>
                    <Initials>MA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Emory University, Atlanta, GA, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Glenn Family Breast Center, Winship Cancer Institute, Emory University, Atlanta, GA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rakha</LastName>
                    <ForeName>Emad</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Histopathology, Nottingham City Hospital NHS Trust, Nottingham University, Nottingham, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aneja</LastName>
                    <ForeName>Ritu</ForeName>
                    <Initials>R</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-4489-5320</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Biology, Georgia State University, Atlanta, GA, USA. raneja@gsu.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R13 MD011558</GrantID>
                    <Acronym>MD</Acronym>
                    <Agency>NIMHD NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R13MD01155801</GrantID>
                    <Agency>National Center on Minority Health and Health Disparities</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016423">Congress</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>02</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Breast Cancer Res Treat</MedlineTA>
            <NlmUniqueID>8111104</NlmUniqueID>
            <ISSNLinking>0167-6806</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003695" MajorTopicYN="N">Delivery of Health Care</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D054625" MajorTopicYN="N">Healthcare Disparities</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
                <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Immunotherapy</Keyword>
            <Keyword MajorTopicYN="N">Molecular subtypes</Keyword>
            <Keyword MajorTopicYN="N">Racial disparities</Keyword>
            <Keyword MajorTopicYN="N">Targeted drugs</Keyword>
            <Keyword MajorTopicYN="N">Triple negative breast cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>01</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>01</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pmc-release">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29417299</ArticleId>
            <ArticleId IdType="doi">10.1007/s10549-018-4692-3</ArticleId>
            <ArticleId IdType="pii">10.1007/s10549-018-4692-3</ArticleId>
            <ArticleId IdType="pmc">PMC5955852</ArticleId>
            <ArticleId IdType="mid">NIHMS941133</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Med Oncol. 2013;30(3):653</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23824643</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS Med. 2016 Dec 13;13(12 ):e1002193</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27959926</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2014 Apr;13(4):890-901</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24523301</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2011 Jul;121(7):2750-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21633166</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hum Pathol. 2017 Jun;64:7-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28153508</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Public Health Rep. 2014 Jan-Feb;129 Suppl 2:5-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24385658</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Med Sci Monit. 2016 Jan 11;22:115-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26752006</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2015 Apr;15(4):248-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25673085</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA Surg. 2017 May 1;152(5):485-493</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28355428</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2013 Oct 1;19(19):5533-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23948975</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Med Insights Oncol. 2016 Apr 05;10(Suppl 1):31-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27081325</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Histopathology. 2016 Jul;69(1):25-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26588661</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2017 Sep 15;23 (18):5561-5572</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28606920</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2017 Nov;166(2):559-568</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28756535</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Acta Oncol. 2013 Jan;52(1):73-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23075422</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12 ):1722-1729</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28903991</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2016 Jun 16;11(6):e0157368</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27310713</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>NPJ Breast Cancer. 2016 Nov 16;2:16036</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28721389</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Transl Med. 2017 Oct 11;15(1):205</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29020960</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2014 Jan 15;5(1):237-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24368439</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2016 May 1;22(9):2105-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26867935</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hum Pathol. 2013 Oct;44(10):2055-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23701942</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2015 Jun 15;21(12):2780-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25724522</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>CA Cancer J Clin. 2018 Jan;68(1):31-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29160902</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Epidemiol. 2016 Dec;45:169-173</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27720130</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Treat Rev. 2018 Jan;62:110-122</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29202431</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2018 Feb;167(3):671-686</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29063313</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Genomics. 2014 Oct 08;15:876</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25294321</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Pathol. 2015 Jul;68(7):506-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25750267</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">29387716</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>07</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2314-6141</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>2017</Volume>
                    <PubDate>
                        <Year>2017</Year>
                    </PubDate>
                </JournalIssue>
                <Title>BioMed research international</Title>
                <ISOAbbreviation>Biomed Res Int</ISOAbbreviation>
            </Journal>
            <ArticleTitle>PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?</ArticleTitle>
            <Pagination>
                <MedlinePgn>1750925</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2017/1750925</ELocationID>
            <Abstract>
                <AbstractText>Triple negative breast cancer (TNBC) has an aggressive clinical behaviour, with a poorer prognosis compared to other subtypes. Recently, tumor-infiltrating lymphocytes (TILs) have been proposed as a predictive biomarker for a better clinical outcome and pathological response (pR) after neoadjuvant chemotherapy (NACT) in TNBC. These data confirm the role of the immune system in the neoplastic progression and in the response to therapy. We performed a retrospective analysis of 54 pre-NACT biopsies of TNBC and compared both the percentage of stromal TILs and the degree of PD-L1 expression with the extent of pR to standard NACT. A pathological complete response (pCR) was achieved in 35% of cases. Univariate analysis showed (i) a significant association between PD-L1 expression in ≥25% of neoplastic cells and the achievement of a pCR (<i>p</i> = 0.024); (ii) a significantly higher frequency of pCR in cases showing ≥50% stromal TILs (<i>p</i> &lt; 0.001). However in the multivariate analysis only PD-L1 expression on tumor cells remained significantly associated with pCR (OR = 1,13; 95% CI 1,01-1,27), suggesting that the expression of this biomarker could be associated with a subpopulation of TNBC more likely to respond to chemotherapy. These data need to be confirmed by larger studies.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y" EqualContrib="Y">
                    <LastName>Cerbelli</LastName>
                    <ForeName>Bruna</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiological, Oncological and Pathological Sciences, Sapienza, University of Rome, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y" EqualContrib="Y">
                    <LastName>Pernazza</LastName>
                    <ForeName>Angelina</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiological, Oncological and Pathological Sciences, Sapienza, University of Rome, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Botticelli</LastName>
                    <ForeName>Andrea</ForeName>
                    <Initials>A</Initials>
                    <Identifier Source="ORCID">0000-0002-6425-9893</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Oncology Unit, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fortunato</LastName>
                    <ForeName>Lucio</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, San Giovanni-Addolorata, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Monti</LastName>
                    <ForeName>Massimo</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgical Sciences, Sapienza University of Rome, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sciattella</LastName>
                    <ForeName>Paolo</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Statistical Sciences, Sapienza University of Rome, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Campagna</LastName>
                    <ForeName>Domenico</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, San Giovanni-Addolorata, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mazzuca</LastName>
                    <ForeName>Federica</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Oncology Unit, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mauri</LastName>
                    <ForeName>Maria</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, San Giovanni-Addolorata, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Naso</LastName>
                    <ForeName>Giuseppe</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Oncology Unit, Sapienza University of Rome, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marchetti</LastName>
                    <ForeName>Paolo</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Oncology Unit, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>d'Amati</LastName>
                    <ForeName>Giulia</ForeName>
                    <Initials>G</Initials>
                    <Identifier Source="ORCID">0000-0002-6959-691X</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiological, Oncological and Pathological Sciences, Sapienza, University of Rome, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Costarelli</LastName>
                    <ForeName>Leopoldo</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, San Giovanni-Addolorata, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Biomed Res Int</MedlineTA>
            <NlmUniqueID>101600173</NlmUniqueID>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C423236">CD274 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>
                <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020360" MajorTopicYN="Y">Neoadjuvant Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
                <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="Y">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>08</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29387716</ArticleId>
            <ArticleId IdType="doi">10.1155/2017/1750925</ArticleId>
            <ArticleId IdType="pmc">PMC5745649</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Virchows Arch. 2016 May;468(5):511-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26915032</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2015 Feb;26(2):259-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25214542</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2010 Nov 11;363(20):1938-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21067385</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2007 Oct 1;25(28):4414-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17785706</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2012 Aug;23 Suppl 6:vi7-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23012306</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Thorac Oncol. 2017 Feb;12 (2):208-222</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27913228</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2012 Apr;132(3):793-805</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21562709</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2011 May 20;29(15):1949-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21483002</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2006 Mar 1;24(7):1037-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16505422</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Surg Pathol. 2017 Mar;41(3):334-342</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28195880</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Physiol. 2018 Mar;233(3):2313-2323</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28710865</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Histopathology. 2016 Jul;69(1):25-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26588661</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2014 Jul;146(1):15-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24842267</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Immunol. 2008 Aug;45(13):3567-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18585785</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2014 May 15;20(10):2773-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24647569</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2013 Nov 12;109(10):2705-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24129232</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Expert Rev Clin Immunol. 2014 Jan;10(1):19-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24308838</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hum Pathol. 2012 Oct;43(10):1688-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22516244</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2001 Oct;7(10):3025-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11595690</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2017 Jan 21;389(10066):255-265</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27979383</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2016 Jul 20;34(21):2460-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27138582</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer. 2018 Jan;25(1):34-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28488168</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2008 Feb 10;26(5):778-85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18258986</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2015 Mar 20;33(9):983-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25534375</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2016 Feb;27(2):249-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26598540</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncol Res. 2016;23 (6):291-302</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27131315</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2017 Feb 28;8(9):15584-15592</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28107186</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">29352988</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1090-2422</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>363</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>02</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Experimental cell research</Title>
                <ISOAbbreviation>Exp. Cell Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>STAT3 as a promising chemoresistance biomarker associated with the CD44<sup>+/high</sup>/CD24<sup>-/low</sup>/ALDH<sup>+</sup> BCSCs-like subset of the triple-negative breast cancer (TNBC) cell line.</ArticleTitle>
            <Pagination>
                <MedlinePgn>283-290</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0014-4827(18)30027-2</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.yexcr.2018.01.018</ELocationID>
            <Abstract>
                <AbstractText>The cancer stem cell (CSC) concept is currently employed to explain the mechanism of multidrug resistance that is implicated in the reduced efficacy of many chemotherapeutic agents, consequently leading to metastatic spread and disease relapse. We searched for potential predictive markers of doxorubicin (DOX) resistance in breast cancer stem cells (BCSCs) of the BT-549 human triple-negative breast cancer (TNBC) cell line classified as a claudin-low subtype. In this study, we show that BT-549 presents a BCSCs-like subset determined by a CD44<sup>+/high</sup>/CD24<sup>-/low</sup>/ALDH1<sup>+</sup> phenotype. The CD44<sup>+/high</sup>/CD24<sup>-/low</sup>/ALDH<sup>+</sup> BCSCs-like subset presented the downregulation of a majority of the genes analyzed (64 genes), and only 3 genes were upregulated after DOX treatment. Among the upregulated genes, MAPK3, PRKCZ and STAT3, STAT3 presented a higher level of upregulation in the DOX-treated CD44<sup>+/high</sup>/CD24<sup>-/low</sup>/ALDH<sup>+</sup> BCSCs-like subset. The identification of biomarkers that predict antitumor responses is at the top of cancer research priorities. STAT3 was highlighted as a molecular signature in the CD44<sup>+/high</sup>/CD24<sup>-/low</sup>/ALDH1<sup>+</sup> BCSCs-like subset obtained from the TNBC BT-549 cell line related to DOX resistance. A majority of the evaluated genes in the EGF pathway appear to be not associated with DOX resistance, as observed in the CD44<sup>+/high</sup>/CD24<sup>-/low</sup>/ALDH1<sup>+</sup> BCSCs-like subset.</AbstractText>
                <CopyrightInformation>Copyright © 2018 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Moreira</LastName>
                    <ForeName>Milene Pereira</ForeName>
                    <Initials>MP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Serviço de Biologia Celular, Diretoria de Pesquisa e Desenvolvimento, Fundação Ezequiel Dias - Rua Conde Pereira Carneiro, 80, Gameleira, Belo Horizonte 30510-010, Minas Gerais, Brazil; Laboratório de Patologia Comparada, Departamento de Patologia Geral, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais - Avenida Presidente Antônio Carlos, 6627 - Pampulha, Belo Horizonte 31270-901, Minas Gerais, Brazil. Electronic address: mipmoreira@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>da Conceição Braga</LastName>
                    <ForeName>Letícia</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina, Universidade Federal de Minas Gerais - Av. Prof. Alfredo Balena, 190, Santa Efigênia, Belo Horizonte 30130-100, Minas Gerais, Brazil; Instituto de Ciências Biológicas e Saúde, Centro Universitário UNA - Rua dos Guajajaras, 175, Centro, Belo Horizonte 30180-100, Minas Gerais, Brazil. Electronic address: braga.ltc@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cassali</LastName>
                    <ForeName>Geovanni Dantas</ForeName>
                    <Initials>GD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratório de Patologia Comparada, Departamento de Patologia Geral, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais - Avenida Presidente Antônio Carlos, 6627 - Pampulha, Belo Horizonte 31270-901, Minas Gerais, Brazil. Electronic address: geovanni.cassali@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Silva</LastName>
                    <ForeName>Luciana Maria</ForeName>
                    <Initials>LM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Serviço de Biologia Celular, Diretoria de Pesquisa e Desenvolvimento, Fundação Ezequiel Dias - Rua Conde Pereira Carneiro, 80, Gameleira, Belo Horizonte 30510-010, Minas Gerais, Brazil. Electronic address: luciana.silva@funed.mg.gov.br.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>01</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Exp Cell Res</MedlineTA>
            <NlmUniqueID>0373226</NlmUniqueID>
            <ISSNLinking>0014-4827</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051927">CD24 Antigen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C497889">CD24 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C497483">CD44 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018960">Hyaluronan Receptors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051927" MajorTopicYN="N">CD24 Antigen</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018960" MajorTopicYN="N">Hyaluronan Receptors</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D050796" MajorTopicYN="N">STAT3 Transcription Factor</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">Breast cancer</Keyword>
            <Keyword MajorTopicYN="Y">Cancer stem cell</Keyword>
            <Keyword MajorTopicYN="Y">Chemoresistance</Keyword>
            <Keyword MajorTopicYN="Y">Doxorubicin</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>08</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>01</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>01</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>1</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>1</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29352988</ArticleId>
            <ArticleId IdType="pii">S0014-4827(18)30027-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.yexcr.2018.01.018</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">29334665</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1950-6007</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>99</Volume>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</Title>
                <ISOAbbreviation>Biomed. Pharmacother.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>I-7ab inhibited the growth of TNBC cells via targeting HDAC3 and promoting the acetylation of p53.</ArticleTitle>
            <Pagination>
                <MedlinePgn>220-226</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0753-3322(17)36299-6</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biopha.2018.01.063</ELocationID>
            <Abstract>
                <AbstractText>Triple negative breast cancer (TNBC) is a heterogenous disease with high aggressive and poor outcome. The lack of biomarkers and targeted therapies makes it a challenge for the treatment of TNBC. Histone deacetylase inhibitors (HDACis) are emerging as novel anti-tumor agents in many types of human cancers. In this study, we found that I-7ab, a novel HDACi, inhibited the cell viability of TNBC cells and induced the cell apoptosis. Mechanistically, I-7ab specifically decreased the expression of HDAC3 and promoted the acetylation of p53 at both Lys373 and Lys382 amino acids. The up-regulated acetylation of p53 promoted the transcriptional activity of p53 and induced the expression of p21, which consequently caused cell cycle arrest at G1 phase. Administration of I-7ab inhibited the colony formation of TNBC cells. Collectively, these results indicated I-7ab as a promising anti-cancer agent in the treatment of TNBC.</AbstractText>
                <CopyrightInformation>Copyright © 2018 Elsevier Masson SAS. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Mei</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Brunch of MinHang, Fudan University Shanghai Cancer Hospital, Shanghai, 200240, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dang</LastName>
                    <ForeName>Xuefei</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Brunch of MinHang, Fudan University Shanghai Cancer Hospital, Shanghai, 200240, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tan</LastName>
                    <ForeName>Yue</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Brunch of MinHang, Fudan University Shanghai Cancer Hospital, Shanghai, 200240, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Meixing</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Brunch of MinHang, Fudan University Shanghai Cancer Hospital, Shanghai, 200240, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Xiaojing</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Fifth People's Hospital Affiliated to Fudan University, Shanghai, 200240, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Gang</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Brunch of MinHang, Fudan University Shanghai Cancer Hospital, Shanghai, 200240, China. Electronic address: pf_gangli@163.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>France</Country>
            <MedlineTA>Biomed Pharmacother</MedlineTA>
            <NlmUniqueID>8213295</NlmUniqueID>
            <ISSNLinking>0753-3322</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D050759">Cyclin-Dependent Kinase Inhibitor p21</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006877">Hydroxamic Acids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000604789">N-hydroxy-3-(2-phenyl-4-((2-(piperidin-1-yl)ethyl)amino)-2H-pyrazolo(3,4-c)quinolin-8-yl)acrylamide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011804">Quinolines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.5.1.98</RegistryNumber>
                <NameOfSubstance UI="D006655">Histone Deacetylases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.5.1.98</RegistryNumber>
                <NameOfSubstance UI="C438596">histone deacetylase 3</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000107" MajorTopicYN="N">Acetylation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059447" MajorTopicYN="N">Cell Cycle Checkpoints</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D050759" MajorTopicYN="N">Cyclin-Dependent Kinase Inhibitor p21</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006655" MajorTopicYN="N">Histone Deacetylases</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006877" MajorTopicYN="N">Hydroxamic Acids</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011804" MajorTopicYN="N">Quinolines</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014410" MajorTopicYN="N">Tumor Stem Cell Assay</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cell apoptosis</Keyword>
            <Keyword MajorTopicYN="N">Cell cycle arrest</Keyword>
            <Keyword MajorTopicYN="N">HDAC3</Keyword>
            <Keyword MajorTopicYN="N">I-7ab</Keyword>
            <Keyword MajorTopicYN="N">TNBC</Keyword>
            <Keyword MajorTopicYN="N">p53</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>01</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>1</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>1</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29334665</ArticleId>
            <ArticleId IdType="pii">S0753-3322(17)36299-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.biopha.2018.01.063</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">29301506</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1471-2407</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>18</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>01</Month>
                        <Day>04</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMC cancer</Title>
                <ISOAbbreviation>BMC Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC).</ArticleTitle>
            <Pagination>
                <MedlinePgn>22</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-017-3939-4</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND">Triple Negative Breast Cancers (TNBCs) lack the appropriate targets for currently used breast cancer therapies, conferring an aggressive phenotype, more frequent relapse and poorer survival rates. The biological heterogeneity of TNBC complicates the clinical treatment further. We have explored and compared the biological pathways in TNBC and other subtypes of breast cancers, using an in silico approach and the hypothesis that two opposing effects (Yin and Yang) pathways in cancer cells determine the fate of cancer cells. Identifying breast subgroup specific components of these opposing pathways may aid in selecting potential therapeutic targets as well as further classifying the heterogeneous TNBC subtype.</AbstractText>
                <AbstractText Label="METHODS">Gene expression and patient clinical data from The Cancer Genome Atlas (TCGA) and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) were used for this study. Gene Set Enrichment Analysis (GSEA) was used to identify the more active pathways in cancer (Yin) than in normal and the more active pathways in normal (Yang) than in cancer. The clustering analysis was performed to compare pathways of TNBC with other types of breast cancers. The association of pathway classified TNBC sub-groups to clinical outcomes was tested using Cox regression model.</AbstractText>
                <AbstractText Label="RESULTS">Among 4729 curated canonical pathways in GSEA database, 133 Yin pathways (FDR &lt; 0.05) and 71 Yang pathways (p-value &lt;0.05) were discovered in TNBC. The FOXM1 is the top Yin pathway while PPARα is the top Yang pathway in TNBC. The TNBC and other types of breast cancers showed different pathways enrichment significance profiles. Using top Yin and Yang pathways as classifier, the TNBC can be further subtyped into six sub-groups each having different clinical outcomes.</AbstractText>
                <AbstractText Label="CONCLUSION">We first reported that the FOMX1 pathway is the most upregulated and the PPARα pathway is the most downregulated pathway in TNBC. These two pathways could be simultaneously targeted in further studies. Also the pathway classifier we performed in this study provided insight into the TNBC heterogeneity.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Narrandes</LastName>
                    <ForeName>Shavira</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Research Institute of Oncology and Hematology, CancerCare Manitoba &amp; University of Manitoba, Winnipeg, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Shujun</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Research Institute of Oncology and Hematology, CancerCare Manitoba &amp; University of Manitoba, Winnipeg, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>College of Pharmacy, University of Manitoba, Winnipeg, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Murphy</LastName>
                    <ForeName>Leigh</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>College of Pharmacy, University of Manitoba, Winnipeg, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Wayne</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Research Institute of Oncology and Hematology, CancerCare Manitoba &amp; University of Manitoba, Winnipeg, Canada. Wayne.xu@umanitoba.ca.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Canada. Wayne.xu@umanitoba.ca.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>College of Pharmacy, University of Manitoba, Winnipeg, Canada. Wayne.xu@umanitoba.ca.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>130,000 CAD</GrantID>
                    <Agency>Canadian Breast Cancer Foundation</Agency>
                    <Country>International</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>01</Month>
                <Day>04</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>BMC Cancer</MedlineTA>
            <NlmUniqueID>100967800</NlmUniqueID>
            <ISSNLinking>1471-2407</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C107585">FOXM1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000072278">Forkhead Box Protein M1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D047493">PPAR alpha</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000072278" MajorTopicYN="N">Forkhead Box Protein M1</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018740" MajorTopicYN="N">Genetic Heterogeneity</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D047493" MajorTopicYN="N">PPAR alpha</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">Drug target</Keyword>
            <Keyword MajorTopicYN="Y">FOXM1</Keyword>
            <Keyword MajorTopicYN="Y">PPARα</Keyword>
            <Keyword MajorTopicYN="Y">Pathway</Keyword>
            <Keyword MajorTopicYN="Y">Triple Negative Breast Cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>08</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>1</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>1</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29301506</ArticleId>
            <ArticleId IdType="doi">10.1186/s12885-017-3939-4</ArticleId>
            <ArticleId IdType="pii">10.1186/s12885-017-3939-4</ArticleId>
            <ArticleId IdType="pmc">PMC5753474</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16199517</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Control. 2010 Jul;17(3):173-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20664514</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2011 Jul;121(7):2750-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21633166</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochim Biophys Acta. 2015 Aug;1856(1):73-85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26071880</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2014 Apr 28;106(5):null</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24777110</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2014 Dec 1;32(34):3840-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25349301</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2005 Nov;5(11):845-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16239904</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Oncol. 2007 Mar;8(3):235-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17329194</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Adv Drug Deliv Rev. 2010 Oct 30;62(13):1285-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20654663</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS Med. 2010 May 25;7(5):e1000279</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20520800</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Lett. 2006 Jun 18;237(2):155-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16084011</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2014 May 1;33(18):2375-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23708664</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2017 Mar 15;140(6):1413-1424</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27925180</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>CA Cancer J Clin. 2016 Jan-Feb;66(1):31-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26513636</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2008 Mar 10;26(8):1275-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18250347</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2004;6(5):R546-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15318936</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Eval Clin Pract. 2008 Apr;14(2):275-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18284517</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2011 Jan 20;364(3):205-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21208101</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2015 Apr 1;21(7):1688-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25208879</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2013 Jul 17;8(7):e68742</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23874744</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2013 May 15;19(10):2723-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23549873</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2012 Apr 18;486(7403):346-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22522925</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Med. 2001 Jan;7(1):53-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11135616</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Drug Discov. 2007 Oct;6(10):793-810</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17906642</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Genet. 2013 Oct;45(10):1113-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24071849</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2015 Jun 10;33(17):1895-901</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25847929</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Sci. 2009 Jan;100(1):111-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19038001</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2010;12 Suppl 2:S3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21050424</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Thorac Oncol. 2016 Dec;11(12 ):2150-2160</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27498386</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Endocr Relat Cancer. 2006 Jun;13(2):279-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16728564</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Trends Immunol. 2004 Jun;25(6):280-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15145317</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2012 Jan;131(1):159-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21830014</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17671126</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biostatistics. 2003 Apr;4(2):249-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12925520</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">29215701</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>07</Month>
            <Day>12</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1097-4652</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>233</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of cellular physiology</Title>
                <ISOAbbreviation>J. Cell. Physiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Long non-coding RNA (LncRNA) RMST in triple-negative breast cancer (TNBC): Expression analysis and biological roles research.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6603-6612</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/jcp.26311</ELocationID>
            <Abstract>
                <AbstractText>Microarray showed that lncRNA RMST was differentially expressed in cervical cancer. Further experiments were conducted to detect the expression and biological function of RMST in triple-negative breast cancer (TNBC). Microarray was used to screen the differentially expressed lncRNAs in TNBC. QRT-PCR was applied to uncover the expression of RMST in TNBC tissues. The cell viability of RMST-transfected TNBC cells were probed by CKK-8 assay and colony formation assay. TUNEL assay was conducted to test the cell apoptosis and FCM assay was exerted to detect the cell cycle. The invasion and migration ability of transfected cells were examined by transwell assay. RMST played its biological function through regulating the mRNA or protein expression in cytoplasm. CCK-8 and colony formation assay unveiled that RMST could slow down the proliferation of TNBC cells to influence the tumor progression. TUNEL results revealed that RMST could enhance cell apoptosis in TNBC. The cell cycle detected by FCM assay indicated that RMST might induce the block of G0/G1 phase thus inhibiting TNBC cell proliferation. RMST overexpression could also restrain the invasion and migration abilities of TNBC cells. RMST played a role of tumor suppressor in TNBC through inhibiting cell proliferation, invasion and migration, enhancing cell apoptosis, and regulating cell cycle.</AbstractText>
                <CopyrightInformation>© 2017 Wiley Periodicals, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Li</ForeName>
                    <Initials>L</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-1256-3762</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Yunnan Cancer Hospital and The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Dequan</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery, Yunnan Cancer Hospital and The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Xingrao</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Yunnan Cancer Hospital and The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zeng</LastName>
                    <ForeName>Yueqin</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Molecular and Clinical Medicine, Kunming Medical University, Kunming, Yunnan, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Lan</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Yunnan Cancer Hospital and The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hou</LastName>
                    <ForeName>Yu</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Yunnan Cancer Hospital and The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Wenhui</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Yunnan Cancer Hospital and The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Zhijie</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Molecular and Clinical Medicine, Kunming Medical University, Kunming, Yunnan, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>04</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Cell Physiol</MedlineTA>
            <NlmUniqueID>0050222</NlmUniqueID>
            <ISSNLinking>0021-9541</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">TNBC</Keyword>
            <Keyword MajorTopicYN="N">lncRNA RMST</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>09</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29215701</ArticleId>
            <ArticleId IdType="doi">10.1002/jcp.26311</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">29159771</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>07</Month>
            <Day>10</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>11</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-4919</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>443</Volume>
                    <Issue>1-2</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular and cellular biochemistry</Title>
                <ISOAbbreviation>Mol. Cell. Biochem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>CLDN6 enhances chemoresistance to ADM via AF-6/ERKs pathway in TNBC cell line MDAMB231.</ArticleTitle>
            <Pagination>
                <MedlinePgn>169-180</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11010-017-3221-8</ELocationID>
            <Abstract>
                <AbstractText>Claudin-6 (CLDN6), a critical tight junction protein acting as a tumor suppressor in breast cancer, is also considered to be a stem cell marker. Triple-negative breast cancer (TNBC) is a subtype of claudin-low and stem cell-like breast cancer which is chemoresistant to multiple anti-cancer drugs. The aim of our study was to determine whether CLDN6 plays a role in chemoresistance of TNBC. We found that overexpression of CLDN6 in TNBC cell line MDAMB231 significantly inhibited cell growth, migration, and invasion. The expression of CLDN6 increased the IC<sub>50</sub> of adriamycin (ADM) and promoted the clonogenic survival. CLDN6 inhibited ADM-induced apoptosis and senescence in MDAMB231 cells. However, P-gp, a resistance-related protein highly associated with chemoresistance, was downregulated by CLDN6 overexpression in MDAMB231 cells. Epithelial mesenchymal transition (EMT) marker E-cadherin was increased, and vimentin was decreased by CLDN6. In addition, stem cell markers OCT4, SOX2, and Nanog were dramatically increased. CLDN6 colocalized and interacted with AF-6. Overexpression of CLDN6 increased the expression of afadin (AF-6) and hampered the activation of ERK signaling. PMA, a specific ERK activator, reversed the expression of EMT and stem cell markers, and decreased chemoresistance of MDAMB231 cells to ADM with a decreased IC<sub>50</sub> and an increased apoptosis resulting from CLDN6. Together, we conclude that CLDN6 enhances the chemoresistance to ADM via activating the AF-6/ERK signaling pathway and up-regulating cancer stem cell characters in MDAMB231 cells.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Minlan</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Key Laboratory of Pathobiology, Ministry of Education, College of Basic Medical Sciences, Jilin University, 126 Xinmin Avenue, Changchun, 310021, Jilin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Yanru</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Key Laboratory of Pathobiology, Ministry of Education, College of Basic Medical Sciences, Jilin University, 126 Xinmin Avenue, Changchun, 310021, Jilin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ruan</LastName>
                    <ForeName>Yang</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Key Laboratory of Pathobiology, Ministry of Education, College of Basic Medical Sciences, Jilin University, 126 Xinmin Avenue, Changchun, 310021, Jilin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>Yan</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Key Laboratory of Pathobiology, Ministry of Education, College of Basic Medical Sciences, Jilin University, 126 Xinmin Avenue, Changchun, 310021, Jilin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Dongjing</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Key Laboratory of Pathobiology, Ministry of Education, College of Basic Medical Sciences, Jilin University, 126 Xinmin Avenue, Changchun, 310021, Jilin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xie</LastName>
                    <ForeName>Yinping</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Key Laboratory of Pathobiology, Ministry of Education, College of Basic Medical Sciences, Jilin University, 126 Xinmin Avenue, Changchun, 310021, Jilin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dong</LastName>
                    <ForeName>Bing</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Key Laboratory of Pathobiology, Ministry of Education, College of Basic Medical Sciences, Jilin University, 126 Xinmin Avenue, Changchun, 310021, Jilin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dang</LastName>
                    <ForeName>Qihua</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Key Laboratory of Pathobiology, Ministry of Education, College of Basic Medical Sciences, Jilin University, 126 Xinmin Avenue, Changchun, 310021, Jilin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Quan</LastName>
                    <ForeName>Chengshi</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Key Laboratory of Pathobiology, Ministry of Education, College of Basic Medical Sciences, Jilin University, 126 Xinmin Avenue, Changchun, 310021, Jilin, China. quancs14@163.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>81172499</GrantID>
                    <Agency>the National Natural Science Foundation of China</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>20140414036GH</GrantID>
                    <Agency>Science and Technology Development Plan of the Office of Science and Technology Project in Jilin Province</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Mol Cell Biochem</MedlineTA>
            <NlmUniqueID>0364456</NlmUniqueID>
            <ISSNLinking>0300-8177</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D057167">Claudins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C095516">MLLT4 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>80168379AG</RegistryNumber>
                <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.4.1</RegistryNumber>
                <NameOfSubstance UI="D009218">Myosins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.4.4</RegistryNumber>
                <NameOfSubstance UI="D016547">Kinesin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>MRC5FX426I</RegistryNumber>
                <NameOfSubstance UI="C122101">claudin 6</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D057167" MajorTopicYN="N">Claudins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019008" MajorTopicYN="Y">Drug Resistance, Neoplasm</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016547" MajorTopicYN="N">Kinesin</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009218" MajorTopicYN="N">Myosins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">AF-6</Keyword>
            <Keyword MajorTopicYN="N">CLDN6</Keyword>
            <Keyword MajorTopicYN="N">Chemoresistance</Keyword>
            <Keyword MajorTopicYN="N">ERKs</Keyword>
            <Keyword MajorTopicYN="N">Epithelial mesenchymal transition</Keyword>
            <Keyword MajorTopicYN="N">Triple-negative breast cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>05</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>7</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29159771</ArticleId>
            <ArticleId IdType="doi">10.1007/s11010-017-3221-8</ArticleId>
            <ArticleId IdType="pii">10.1007/s11010-017-3221-8</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Nature. 2015 Nov 26;527(7579):472-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26560033</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Med Rep. 2013 Nov;8(5):1505-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24026616</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Tumour Biol. 2015 Jun;36(6):4327-38</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25596703</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem Biophys Res Commun. 2012 May 4;421(2):349-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22510406</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Carcinogenesis. 2003 Oct;24(10):1593-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12896909</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Treat Rev. 2010 May;36(3):206-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20060649</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Biol. 2006 Aug;26(15):5876-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16847338</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2010 Dec 15;70(24):10433-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21159654</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncologist. 2011;16 Suppl 1:71-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21278443</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Biol. 1997 Nov 3;139(3):785-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9348294</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2015 Nov 26;527(7579):525-530</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26560028</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Cancer Prev. 2010 May;19(3):186-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20215972</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Diagn Pathol. 2012 Aug 27;7:111</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22925655</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Biochem. 2013 Jun;114(6):1395-403</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23255418</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Transl Med. 2013 Jan 17;2(1):3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23369605</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Sci. 2007 Oct;98(10):1557-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17645772</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Biol. 1999 Dec 13;147(6):1351-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10601346</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Oncol. 2016 Jun;48(6):2435-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27035750</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2013 Aug 15;133(4):855-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23390083</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2012 Feb 1;18(3):869-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22142828</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2011 Apr 15;17(8):2350-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21220476</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Dev Dyn. 2001 Oct;222(2):292-300</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11668606</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2015 Apr 12;15:275</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25879875</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Biol. 1999 Aug 26;9(16):880-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10469590</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pharmacol Exp Ther. 2008 Jan;324(1):95-102</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17947497</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Res. 2012 Jun;22(6):1082-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22565286</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2015 Jan 8;517(7533):152-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25470047</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Pharmacol. 2013 Jan;83(1):85-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23053666</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2011 Dec 15;117(24):5519-28</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21692061</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Mol Sci. 2013 Sep 04;14(9):18148-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24009024</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gan To Kagaku Ryoho. 1996 Dec;23(14):1911-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8978796</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Cancer. 2011 Apr;47(6):918-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21134740</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2013 Jun 21;8(6):e67496</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23805314</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Invest. 2011 Jan;29(1):1-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20874001</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2016 Oct 25;7(43):70011-70027</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27588398</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pharmacol Exp Ther. 2006 Jun;317(3):1372-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16547167</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Commun. 2013;4:1992</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23778593</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Diagn Pathol. 2012 Mar 29;7:33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22455563</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">29120811</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>09</Month>
            <Day>11</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-4499</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>49</Volume>
                    <PubDate>
                        <MedlineDate>2018 May - Jun</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical imaging</Title>
                <ISOAbbreviation>Clin Imaging</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Magnetic resonance (MR) features in triple negative breast cancer (TNBC) vs receptor positive cancer (nTNBC).</ArticleTitle>
            <Pagination>
                <MedlinePgn>12-16</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0899-7071(17)30211-5</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clinimag.2017.10.016</ELocationID>
            <Abstract>
                <AbstractText>Few reports in literature describe triple negative breast cancer (TNBC) imaging findings. Aim of the study is to determine MR-features of TNBC compared to receptor positive cancer (nTNBC). From May 2014 to May 2015, we retrospectively enrolled 31 consecutive patients with histological diagnosis of TNBC and a control group of 31 consecutive nTNBC observed in the same period, out of 602 cancer, diagnosed in our department in the same year. Histopathological analysis and MR-features of TNBC (31 patients) were compared to nTNBC (31 patients). MR-features included dimension, fibroglandular tissue (FGT), background parenchimal enhancement (BPE), mass shape, margins, presence of rim, intratumoral signal intensity in T2w, uni-multifocality, kinetic curves. All patients were examined with MR 1,5T (Magnetom Simphony Tim, Siemens Healthcare) performing T2w fat-sat and contrast enhanced high temporal and spatial resolution T1w before and after injection of Gadolinium. 62 staging MR were reviewed. Median age was 50 (30-78ys) with a standard deviation of 10,9. TNBC showed 3 MR features in concordance with current literature: rim enhancement, hyperintensity in T2 sequence and unifocality. Rim enhancement was shown in 67.7% of TNBC (21/31) and 29% of nTNBC (9/31). Higher T2w values were shown in 83.9% of TNBC (26/31) and 58.1% of nTNBC (18/31). Cancer was multifocal in 7/31 (22.6%) of TNBC and 19/31 (61.3%) nTNBC. No correlation was found for dimension (p=0.12), FGT (p=0.959), BPE (p=0.596), homogeneity of enhancement (p=0.43), margins (p=0.671) and kinetic (p=0.37). Multivariate analysis demonstrated that rim enhancement and unifocality correlated independently with TNBC group. Area under ROC curve of our model is 0.835. Furthermore, we evaluated the clinical outcome of all 31 TNBC patients in a follow-up time ranging from 24months to 36months separating them in a free-survival group (23 women) and a recurrence group (8 women with local recurrence or distant metastasis): only kinetic curves resulted to be significantly higher in recurrence group (p=0.042).</AbstractText>
                <CopyrightInformation>Copyright © 2017 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Angelini</LastName>
                    <ForeName>Giulia</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Translational Research and New Technologies in Medicine and Surgery, Diagnostic and Interventional Radiology, 56124 Pisa, Italy. Electronic address: giu.angelini@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marini</LastName>
                    <ForeName>Carolina</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Azienda Ospedaliero-Universitaria Pisana, Via Roma 67, 56100 Pisa, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Iacconi</LastName>
                    <ForeName>Chiara</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, From the Breast Unit, USL1 Massa-Carrara, Piazza Monzoni 2, 54033 Carrara, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mazzotta</LastName>
                    <ForeName>Dionisia</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Azienda Ospedaliero-Universitaria Pisana, Via Roma 67, 56100 Pisa, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moretti</LastName>
                    <ForeName>Monica</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Azienda Ospedaliero-Universitaria Pisana, Via Roma 67, 56100 Pisa, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Picano</LastName>
                    <ForeName>Eugenia</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Azienda Ospedaliero-Universitaria Pisana, Via Roma 67, 56100 Pisa, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morganti</LastName>
                    <ForeName>Riccardo</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Biostatistical Consulting, University Hospital S. Chiara, Pisa, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>10</Month>
                <Day>27</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Imaging</MedlineTA>
            <NlmUniqueID>8911831</NlmUniqueID>
            <ISSNLinking>0899-7071</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011980">Receptors, Progesterone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009682" MajorTopicYN="N">Magnetic Resonance Spectroscopy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011980" MajorTopicYN="N">Receptors, Progesterone</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>05</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2017</Year>
                <Month>09</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>10</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>9</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29120811</ArticleId>
            <ArticleId IdType="pii">S0899-7071(17)30211-5</ArticleId>
            <ArticleId IdType="doi">10.1016/j.clinimag.2017.10.016</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28962890</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>07</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>07</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-7573</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>211</Volume>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Jan</Month>
                        <Day>30</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of ethnopharmacology</Title>
                <ISOAbbreviation>J Ethnopharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Rhizoma Amorphophalli inhibits TNBC cell proliferation, migration, invasion and metastasis through the PI3K/Akt/mTOR pathway.</ArticleTitle>
            <Pagination>
                <MedlinePgn>89-100</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0378-8741(17)32515-1</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jep.2017.09.033</ELocationID>
            <Abstract>
                <AbstractText Label="ETHNOPHARMACOLOGICAL RELEVANCE" NlmCategory="BACKGROUND">Triple-negative breast cancer (TNBC) often presents with a high histological grade and high malignancy, which greatly contribute to patient morbidity and mortality. Rhizoma Amorphophalli exhibits many biological and pharmacological activities, but its potential as a therapeutic agent for the treatment of metastatic TNBC patients remains poorly understood.</AbstractText>
                <AbstractText Label="AIM OF THE STUDY" NlmCategory="OBJECTIVE">The aim of this study was to determine whether Rhizoma Amorphophalli inhibits metastasis in the human TNBC MDA-MB-231 cell line.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">CCK-8 and colony formation assays were adopted for the analysis of cell activity and cell proliferation, respectively. Flow cytometry was used for cell cycle analysis. Wound healing and transwell assays were performed to assess cell migration and invasion, respectively. PI3K/Akt/mTOR signaling pathways were analyzed through western blotting. Breast cancer cell metastasis to the lung in a xenograft model was evaluated by in vivo fluorescence imaging. A GC-MS analysis was performed to determine the main components of the petroleum ether fraction from the ethanol extract of Rhizoma Amorphophalli (abbreviated RhA).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">RhA significantly reduced breast cancer cell viability and proliferation. The flow cytometry analysis indicated that RhA induced MDA-MB-231 cell arrest at the S phase. Additionally, RhA decreased MDA-MB-231 cell migration and invasion and inhibited the PI3K/Akt/mTOR signaling pathway. In addition, mice treated with RhA exhibited a significant reduction in tumor infiltration and a decrease in breast cancer cell metastasis to the lung. The GC-MS analysis results showed that RhA contained a large number of unsaturated fatty acids, such as octadecadienoic acid (linoleic acid), octadecatrienoic acid (linolenic acid), and oleate, which might represent the anticancer components of the extract.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results of this study suggest that RhA has potential as a therapeutic candidate for metastatic TNBC treatment.</AbstractText>
                <CopyrightInformation>Copyright © 2017 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Chunyu</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery (Integrated Traditional and Western Medicine), Longhua Hospital, Shanghai University of Traditional Chinese Medicine, 725 South Wanping Road, Shanghai 200032, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qiu</LastName>
                    <ForeName>Shengliang</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310006, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Pei</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310006, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ge</LastName>
                    <ForeName>Yuqing</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310006, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gao</LastName>
                    <ForeName>Xiufei</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310006, China. Electronic address: gaoxiufei@163.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>09</Month>
                <Day>27</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Ireland</Country>
            <MedlineTA>J Ethnopharmacol</MedlineTA>
            <NlmUniqueID>7903310</NlmUniqueID>
            <ISSNLinking>0378-8741</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D064209">Phytochemicals</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.1.-</RegistryNumber>
                <NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.1.1</RegistryNumber>
                <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.1</RegistryNumber>
                <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D031056" MajorTopicYN="Y">Amorphophallus</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064209" MajorTopicYN="N">Phytochemicals</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D027343" MajorTopicYN="N">Rhizome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014945" MajorTopicYN="N">Wound Healing</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">PI3K/Akt pathway</Keyword>
            <Keyword MajorTopicYN="N">Rhizoma Amorphophalli</Keyword>
            <Keyword MajorTopicYN="N">Triple-negative breast cancer</Keyword>
            <Keyword MajorTopicYN="N">Tumor metastasis</Keyword>
            <Keyword MajorTopicYN="N">mTOR pathway</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>07</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2017</Year>
                <Month>09</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>09</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>7</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28962890</ArticleId>
            <ArticleId IdType="pii">S0378-8741(17)32515-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jep.2017.09.033</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">28947965</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1949-2553</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>8</Volume>
                    <Issue>36</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>Sep</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncotarget</Title>
                <ISOAbbreviation>Oncotarget</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Crosstalk between stromal components and tumor cells of TNBC via secreted factors enhances tumor growth and metastasis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>60210-60222</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.18632/oncotarget.19417</ELocationID>
            <Abstract>
                <AbstractText>Triple negative breast cancer (TNBC) as a metastatic disease is currently incurable. Reliable and reproducible methods for testing drugs against metastasis are not available. Stromal cells may play a critical role in tumor progression and metastasis. In this study, we determined that fibroblasts and macrophages secreted IL-8 upon induction by tumor cell-conditioned media (TCM) from MDA-MB-231 cancer cells. Our data showed that the proliferation of MDA-MB-231 cells co-cultured with fibroblasts or macrophages was enhanced compared to the monoculture. Furthermore, TNBC cell migration, a key step in tumor metastasis, was promoted by conditioned media (CM) from TCM-induced fibroblasts or macrophages. Knockdown of the IL-8 receptor CXCR2 by CRISPR-Cas9 reduces MDA-MB-231 cell proliferation and migration compared to wild type. In a mouse xenograft tumor model, the growth of MDA-MB-231-CXCR2<sup>-/-</sup> tumor was significantly decreased compared to the growth of tumors from wild-type cells. In addition, the incidence of thoracic metastasis of MDA-MB-231-CXCR2<sup>-/-</sup> tumors was reduced compared to wild type. We found that the auto- and paracrine loop exists between TNBC cells and stroma, which results in enhanced IL-8 secretion from the stromal components. Significantly, inhibition of the IL-8 signaling pathway by reparixin, an inhibitor of the IL-8 receptor, CXCR1/2, reduced MDA-MB-231 tumor growth and metastasis. Taken together, these findings implicate IL-8 signaling as a critical event in TNBC tumor growth and metastasis via crosstalk with stromal components.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jin</LastName>
                    <ForeName>Kideok</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pandey</LastName>
                    <ForeName>Niranjan B</ForeName>
                    <Initials>NB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Popel</LastName>
                    <ForeName>Aleksander S</ForeName>
                    <Initials>AS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>07</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Oncotarget</MedlineTA>
            <NlmUniqueID>101532965</NlmUniqueID>
            <ISSNLinking>1949-2553</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CXCR1/2</Keyword>
            <Keyword MajorTopicYN="N">IL-8</Keyword>
            <Keyword MajorTopicYN="N">TNBC</Keyword>
            <Keyword MajorTopicYN="N">breast cancer</Keyword>
            <Keyword MajorTopicYN="N">tumor microenvironment</Keyword>
        </KeywordList>
        <CoiStatement>CONFLICTS OF INTEREST The authors confirm that there are no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>02</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>07</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>9</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>9</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>9</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28947965</ArticleId>
            <ArticleId IdType="doi">10.18632/oncotarget.19417</ArticleId>
            <ArticleId IdType="pii">19417</ArticleId>
            <ArticleId IdType="pmc">PMC5601133</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Nature. 2015 Apr 16;520(7547):368-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25807485</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2016 Aug 23;16(9):582-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27550820</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neoplasia. 2013 Feb;15(2):112-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23441126</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Asian Pac J Cancer Prev. 2012;13 Suppl:115-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23480772</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Discov. 2015 Sep;5(9):944-59</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26180042</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11791-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15282370</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Pathol. 2007 Feb;170(2):774-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17255343</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Mol Med. 2009 Nov-Dec;13(11-12):4319-28</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19900215</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2015 Dec 22;6(41):43375-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26517518</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clinics (Sao Paulo). 2013;68(3):391-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23644861</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Oncol. 2016 Jan;48(1):5-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26548401</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochim Biophys Acta. 2013 Nov;1834(11):2242-58</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23376433</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2013 Sep 19;501(7467):346-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24048067</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2016 Jul;16(7):447-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27339708</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2012 May 15;72(10):2473-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22414581</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2011;13(6):227</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22078026</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gastroenterology. 2011 Jul;141(1):279-91, 291.e1-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21640118</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biol Pharm Bull. 2011;34(1):120-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21212529</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2013 Feb 1;73(3):1128-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23221383</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 2011 Mar 4;144(5):646-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21376230</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2012 Jul 26;487(7408):500-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22763439</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Metastasis Rev. 2013 Jun;32(1-2):303-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23114846</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem Pharmacol. 2013 Apr 15;85(8):1033-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23376122</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2011 Oct;121(10):4106-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21926469</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2010 Feb;120(2):485-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20051626</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochemistry. 1997 Mar 4;36(9):2716-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9054580</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Immunol. 1995 Sep 1;155(5):2587-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7650389</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Med. 2009 Jan;15(1):68-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19122658</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2013 Jan 15;73(2):571-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23204236</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Immunol. 2015 Nov;15(11):669-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26471778</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Future Oncol. 2012 Nov;8(11):1427-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23148616</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Biochem Cell Biol. 2011 Dec;43(12):1812-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21920451</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2016 Oct 15;76(20):6030-6042</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27550451</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2016 Nov 15;76(22):6495-6506</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27671678</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Mol Med. 2009 Aug;13(8A):1405-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19583813</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Commun. 2014 Sep 02;5:4715</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25178650</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Exp Metastasis. 2014 Jan;31(1):67-79</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23963763</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Cell. 2008 Jan;13(1):23-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18167337</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2004 Jul;4(7):540-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15229479</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Oncol. 2012;2012:204946</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22481918</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Clin Oncol. 2016 Nov;13(11):674-690</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27184417</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2005 Aug 5;280(31):28663-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15946947</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pharmacol Exp Ther. 2007 Sep;322(3):973-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17601981</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2012 Dec;136(3):795-804</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23124476</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Med Chem. 2007 Aug 23;50(17):3984-4002</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17665889</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2015 Nov 19;527(7578):329-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26524530</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Sci Rep. 2016 Dec 20;6:39460</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27995973</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28918577</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>07</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-4919</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>442</Volume>
                    <Issue>1-2</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular and cellular biochemistry</Title>
                <ISOAbbreviation>Mol. Cell. Biochem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Microarray-based SNP genotyping to identify genetic risk factors of triple-negative breast cancer (TNBC) in South Indian population.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1-10</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11010-017-3187-6</ELocationID>
            <Abstract>
                <AbstractText>In the view of aggressive nature of Triple-Negative Breast cancer (TNBC) due to the lack of receptors (ER, PR, HER2) and high incidence of drug resistance associated with it, a case-control association study was conducted to identify the contributing genetic risk factors for Triple-negative breast cancer (TNBC). A total of 30 TNBC patients and 50 age and gender-matched controls of Indian origin were screened for 9,00,000 SNP markers using microarray-based SNP genotyping approach. The initial PLINK association analysis (p &lt; 0.01, MAF 0.14-0.44, OR 10-24) identified 28 non-synonymous SNPs and one stop gain mutation in the exonic region as possible determinants of TNBC risk. All the 29 SNPs were annotated using ANNOVAR. The interactions between these markers were evaluated using Multifactor dimensionality reduction (MDR) analysis. The interactions were in the following order: exm408776 &gt; exm1278309 &gt; rs316389 &gt; rs1651654 &gt; rs635538 &gt; exm1292477. Recursive partitioning analysis (RPA) was performed to construct decision tree useful in predicting TNBC risk. As shown in this analysis, rs1651654 and exm585172 SNPs are found to be determinants of TNBC risk. Artificial neural network model was used to generate the Receiver operating characteristic curves (ROC), which showed high sensitivity and specificity (AUC-0.94) of these markers. To conclude, among the 9,00,000 SNPs tested, CCDC42 exm1292477, ANXA3 exm408776, SASH1 exm585172 are found to be the most significant genetic predicting factors for TNBC. The interactions among exm408776, exm1278309, rs316389, rs1651654, rs635538, exm1292477 SNPs inflate the risk for TNBC further. Targeted analysis of these SNPs and genes alone also will have similar clinical utility in predicting TNBC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Aravind Kumar</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centre for Biotechnology, Institute of Science and Technology, Jawaharlal Nehru Technological University, Hyderabad, 500085, India. vidyarthi83@gmail.com.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Sandor Life Sciences, Road No. 3, Banjara Hills, Hyderabad, 500034, India. vidyarthi83@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Singh</LastName>
                    <ForeName>Vineeta</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sandor Life Sciences, Road No. 3, Banjara Hills, Hyderabad, 500034, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Naushad</LastName>
                    <ForeName>Shaik Mohammad</ForeName>
                    <Initials>SM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sandor Life Sciences, Road No. 3, Banjara Hills, Hyderabad, 500034, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shanker</LastName>
                    <ForeName>Uday</ForeName>
                    <Initials>U</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centre for Biotechnology, Institute of Science and Technology, Jawaharlal Nehru Technological University, Hyderabad, 500085, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lakshmi Narasu</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centre for Biotechnology, Institute of Science and Technology, Jawaharlal Nehru Technological University, Hyderabad, 500085, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>09</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Mol Cell Biochem</MedlineTA>
            <NlmUniqueID>0364456</NlmUniqueID>
            <ISSNLinking>0300-8177</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="Y">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060005" MajorTopicYN="N">Genotyping Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007194" MajorTopicYN="N">India</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Breast cancer</Keyword>
            <Keyword MajorTopicYN="N">Microarray genotyping</Keyword>
            <Keyword MajorTopicYN="N">Risk prediction models</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>06</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>09</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>9</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>7</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>9</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28918577</ArticleId>
            <ArticleId IdType="doi">10.1007/s11010-017-3187-6</ArticleId>
            <ArticleId IdType="pii">10.1007/s11010-017-3187-6</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>PLoS One. 2013;8(3):e59503</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23555683</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):359-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26677205</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ther Adv Med Oncol. 2010 Mar;2(2):125-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21789130</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2012 Aug;23 Suppl 6:vi7-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23012306</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biomed Res Int. 2017;2017:2603685</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28497041</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Transl Med. 2015 Mar;3(3):36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25815297</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Glob Oncol. 2016 Jun 29;2(6):412-421</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28717728</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Thorac Oncol. 2016 Apr;11(4 Suppl):S62-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27198373</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2016 Dec 27;7(52):86972-86984</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27894078</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Anal Cell Pathol (Amst). 2016;2016:4131403</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27995049</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncol Lett. 2016 May;11(5):3123-3130</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27123075</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Bioinformatics. 2008 Oct 02;9:409</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18831757</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Stem Cells. 2015 Feb;33(2):354-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25267273</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Methods. 2006 Jan;3(1):31-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16369550</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Inform. 2014 Sep 21;13(Suppl 2):19-28</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25288876</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Stem Cell Reports. 2015 Jul 14;5(1):45-59</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26095609</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncol Rep. 2017 Jan;37(1):388-398</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27878264</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Oncol. 2016 Mar;10 (3):464-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26776681</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Semin Oncol. 2009 Jun;36(3):237-49</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19460581</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Genet. 2005 May;37(5):549-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15838508</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2003 May 15;22(19):2972-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12771949</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biostatistics. 2007 Apr;8(2):485-99</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17189563</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J BUON. 2013 Oct-Dec;18(4):891-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24344014</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>South Asian J Cancer. 2013 Jul;2(3):121-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24455581</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Clin Pathol. 2009 Aug;132(2):237-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19605818</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2016 Nov 8;7(45):72807-72818</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27637080</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Bioinformatics. 2008 Feb 06;9:85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18254947</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncol Rep. 2016 Sep;36(3):1739-47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27461876</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">28887687</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>05</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-7225</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>28</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer causes &amp; control : CCC</Title>
                <ISOAbbreviation>Cancer Causes Control</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Kaiso is highly expressed in TNBC tissues of women of African ancestry compared to Caucasian women.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1295-1304</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10552-017-0955-2</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Triple-negative breast cancer (TNBC) is most prevalent in young women of African ancestry (WAA) compared to women of other ethnicities. Recent studies found a correlation between high expression of the transcription factor Kaiso, TNBC aggressiveness, and ethnicity. However, little is known about Kaiso expression and localization patterns in TNBC tissues of WAA. Herein, we analyze Kaiso expression patterns in TNBC tissues of African (Nigerian), Caribbean (Barbados), African American (AA), and Caucasian American (CA) women.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Formalin-fixed and paraffin embedded (FFPE) TNBC tissue blocks from Nigeria and Barbados were utilized to construct a Nigerian/Barbadian tissue microarray (NB-TMA). This NB-TMA and a commercially available TMA comprising AA and CA TNBC tissues (AA-CA-YTMA) were subjected to immunohistochemistry to assess Kaiso expression and subcellular localization patterns, and correlate Kaiso expression with TNBC clinical features.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Nigerian and Barbadian women in our study were diagnosed with TNBC at a younger age than AA and CA women. Nuclear and cytoplasmic Kaiso expression was observed in all tissues analyzed. Analysis of Kaiso expression in the NB-TMA and AA-CA-YTMA revealed that nuclear Kaiso H scores were significantly higher in Nigerian, Barbadian, and AA women compared with CA women. However, there was no statistically significant difference in nuclear Kaiso expression between Nigerian versus Barbadian women, or Barbadian versus AA women.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">High levels of nuclear Kaiso expression were detected in patients with a higher degree of African heritage compared to their Caucasian counterparts, suggesting a role for Kaiso in TNBC racial disparity.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bassey-Archibong</LastName>
                    <ForeName>Blessing I</ForeName>
                    <Initials>BI</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biology, McMaster University, Hamilton, ON, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hercules</LastName>
                    <ForeName>Shawn M</ForeName>
                    <Initials>SM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biology, McMaster University, Hamilton, ON, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rayner</LastName>
                    <ForeName>Lyndsay G A</ForeName>
                    <Initials>LGA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biology, McMaster University, Hamilton, ON, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Skeete</LastName>
                    <ForeName>Desiree H A</ForeName>
                    <Initials>DHA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Queen Elizabeth Hospital (QEH), Bridgetown, Barbados.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Faculty of Medical Sciences, The University of the West Indies, Cave Hill Campus, Bridgetown, Barbados.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Smith Connell</LastName>
                    <ForeName>Suzanne P</ForeName>
                    <Initials>SP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Faculty of Medical Sciences, The University of the West Indies, Cave Hill Campus, Bridgetown, Barbados.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Queen Elizabeth Hospital (QEH), Bridgetown, Barbados.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brain</LastName>
                    <ForeName>Ian</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Daramola</LastName>
                    <ForeName>Adetola</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Anatomic and Molecular Pathology, Lagos University Teaching Hospital (LUTH), Lagos, Nigeria.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Banjo</LastName>
                    <ForeName>Adekunbiola A F</ForeName>
                    <Initials>AAF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Anatomic and Molecular Pathology, Lagos University Teaching Hospital (LUTH), Lagos, Nigeria.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Byun</LastName>
                    <ForeName>Jung S</ForeName>
                    <Initials>JS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Genetics Branch, National Institute of Health, Bethesda, MD, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gardner</LastName>
                    <ForeName>Kevin</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Genetics Branch, National Institute of Health, Bethesda, MD, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dushoff</LastName>
                    <ForeName>Jonathan</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biology, McMaster University, Hamilton, ON, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Daniel</LastName>
                    <ForeName>Juliet M</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biology, McMaster University, Hamilton, ON, Canada. danielj@mcmaster.ca.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>None</GrantID>
                    <Agency>Natural Sciences and Engineering Research Council of Canada</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>09</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Cancer Causes Control</MedlineTA>
            <NlmUniqueID>9100846</NlmUniqueID>
            <ISSNLinking>0957-5243</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C492254">ZNF-kaiso protein, human</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001460" MajorTopicYN="N">Barbados</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005006" MajorTopicYN="N">Ethnic Groups</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009549" MajorTopicYN="N">Nigeria</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Breast cancer racial disparity</Keyword>
            <Keyword MajorTopicYN="N">Kaiso</Keyword>
            <Keyword MajorTopicYN="N">TNBC</Keyword>
            <Keyword MajorTopicYN="N">Women of African ancestry</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>02</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>08</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>9</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>5</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>9</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28887687</ArticleId>
            <ArticleId IdType="doi">10.1007/s10552-017-0955-2</ArticleId>
            <ArticleId IdType="pii">10.1007/s10552-017-0955-2</ArticleId>
            <ArticleId IdType="pmc">PMC5681979</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2012 Sep;135(2):555-69</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22842985</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochim Biophys Acta. 2015 Sep;1852(9):1846-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26073433</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2010 Nov 1;116(21):4926-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20629078</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochim Biophys Acta. 2007 Jan;1773(1):59-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17050009</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2009 Sep 20;27(27):4515-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19704069</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2012;7(11):e50398</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23226276</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncologist. 2011;16 Suppl 1:71-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21278443</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2010 Nov 11;363(20):1938-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21067385</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Genes Dev. 2001 Jul 1;15(13):1613-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11445535</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2012;7(5):e37864</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22662240</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2012 Aug;23 Suppl 6:vi7-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23012306</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Biol. 2006 Jan;26(1):199-208</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16354691</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2013 Sep 05;8(9):e74160</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24040197</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Death Dis. 2017 Mar 23;8(3):e2689</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28333150</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2009 Jun 09;9:178</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19508730</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2008 Sep 15;68(18):7258-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18794111</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2015 Apr;15(4):248-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25673085</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2011 Jul 07;11(8):558-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21734724</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Biol. 2004 Aug;24(16):7188-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15282317</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Afr Med. 2012 Jul-Sep;11(3):169-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22684136</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Hum Biol. 2008 Mar-Apr;20(2):165-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18205202</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Biol. 1999 May;19(5):3614-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10207085</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gut. 1999 Aug;45(2):252-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10403738</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2008 May 15;68(10 ):3645-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18483246</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancers (Basel). 2011 May 13;3(2):2358-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24212814</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hybridoma. 2001 Jun;20(3):159-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11461664</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogenesis. 2016 Mar 21;5:e208</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26999717</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Trends Cell Biol. 2006 Nov;16(11):578-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16996269</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Pathol. 2012 Nov;181(5):1836-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22974583</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Lett. 2016 Oct 1;380(2):513-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27424525</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2016 Mar 10;16:204</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26964534</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2011 Jun 15;117(12):2747-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21656753</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Epigenetics Chromatin. 2013 May 21;6(1):13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23693142</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Genet Epidemiol. 2010 Sep;34(6):561-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20717976</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2006 Sep 1;66(17):8327-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16951137</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2005 Aug;5(8):591-602</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16056258</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2007 May 1;109(9):1721-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17387718</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2009 Jan;113(2):357-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18324472</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Exp Metastasis. 2014 Jun;31(5):497-510</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24570268</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast. 2010 Oct;19(5):312-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20382530</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21296855</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2005 Dec 21;97(24):1808-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16368942</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Opin Oncol. 2011 Nov;23(6):566-77</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21986848</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Breast Cancer. 2005 Dec;6(5):391-401</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16381622</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nucleic Acids Res. 2002 Jul 1;30(13):2911-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12087177</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2012 Aug;23 Suppl 6:vi46-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23012302</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):786-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20080753</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 2006 Jun 7;295(21):2492-502</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16757721</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28870198</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>05</Month>
            <Day>03</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1471-2407</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>17</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>Sep</Month>
                        <Day>04</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMC cancer</Title>
                <ISOAbbreviation>BMC Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Up-modulation of PLC-β2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133<sup>+</sup>/EpCAM<sup>+</sup> phenotype: a promising target for preventing progression of TNBC.</ArticleTitle>
            <Pagination>
                <MedlinePgn>617</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-017-3592-y</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The malignant potential of triple negative breast cancer (TNBC) is also dependent on a sub-population of cells with a stem-like phenotype. Among the cancer stem cell markers, CD133 and EpCAM strongly correlate with breast tumor aggressiveness, suggesting that simultaneous targeting of the two surface antigens may be beneficial in treatment of TNBC. Since in TNBC-derived cells we demonstrated that PLC-β2 induces the conversion of CD133<sup>high</sup> to CD133<sup>low</sup> cells, here we explored its possible role in down-modulating the expression of both CD133 and EpCAM and, ultimately, in reducing the number of TNBC cells with a stem-like phenotype.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A magnetic step-by-step cell isolation with antibodies directed against CD133 and/or EpCAM was performed on the TNBC-derived MDA-MB-231 cell line. In the same cell model, PLC-β2 was over-expressed or down-modulated and cell proliferation and invasion capability were evaluated by Real-time cell assays. The surface expression of CD133, EpCAM and CD44 in the different experimental conditions were measured by multi-color flow cytometry immunophenotyping.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A CD133<sup>+</sup>/EpCAM<sup>+</sup> sub-population with high proliferation rate and invasion capability is present in the MDA-MB-231 cell line. Over-expression of PLC-β2 in CD133<sup>+</sup>/EpCAM<sup>+</sup> cells reduced the surface expression of both CD133 and EpCAM, as well as proliferation and invasion capability of this cellular subset. On the other hand, the up-modulation of PLC-β2 in the whole MDA-MB-231 cell population reduced the number of cells with a CD44<sup>+</sup>/CD133<sup>+</sup>/EpCAM<sup>+</sup> stem-like phenotype.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Since selective targeting of the cells with the highest aggressive potential may have a great clinical importance for TNBC, the up-modulation of PLC-β2, reducing the number of cells with a stem-like phenotype, may be a promising goal for novel therapies aimed to prevent the progression of aggressive breast tumors.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Brugnoli</LastName>
                    <ForeName>Federica</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Signal Transduction Unit, Division of Anatomy and Histology, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Fossato di Mortara, 70, 44121, Ferrara, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grassilli</LastName>
                    <ForeName>Silvia</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Signal Transduction Unit, Division of Anatomy and Histology, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Fossato di Mortara, 70, 44121, Ferrara, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lanuti</LastName>
                    <ForeName>Paola</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine and Aging Science, &quot;G. d'Annunzio&quot; University of Chieti-Pescara, Chieti, Italy.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Center of Aging Sciences and Translational Medicine (CeSI-MeT), &quot;G. d'Annunzio&quot; University of Chieti-Pescara, Chieti, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marchisio</LastName>
                    <ForeName>Marco</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine and Aging Science, &quot;G. d'Annunzio&quot; University of Chieti-Pescara, Chieti, Italy.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Center of Aging Sciences and Translational Medicine (CeSI-MeT), &quot;G. d'Annunzio&quot; University of Chieti-Pescara, Chieti, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Al-Qassab</LastName>
                    <ForeName>Yasamin</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Signal Transduction Unit, Division of Anatomy and Histology, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Fossato di Mortara, 70, 44121, Ferrara, Italy.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>College of Medicine, Department of Anatomy, University of Baghdad, Baghdad, Iraq.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vezzali</LastName>
                    <ForeName>Federica</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Signal Transduction Unit, Division of Anatomy and Histology, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Fossato di Mortara, 70, 44121, Ferrara, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Capitani</LastName>
                    <ForeName>Silvano</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Signal Transduction Unit, Division of Anatomy and Histology, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Fossato di Mortara, 70, 44121, Ferrara, Italy.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>LTTA Centre, University of Ferrara, Ferrara, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bertagnolo</LastName>
                    <ForeName>Valeria</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Signal Transduction Unit, Division of Anatomy and Histology, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Fossato di Mortara, 70, 44121, Ferrara, Italy. bgv@unife.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>09</Month>
                <Day>04</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>BMC Cancer</MedlineTA>
            <NlmUniqueID>100967800</NlmUniqueID>
            <ISSNLinking>1471-2407</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000071916">AC133 Antigen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C499379">EPCAM protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000071858">Epithelial Cell Adhesion Molecule</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.4.11</RegistryNumber>
                <NameOfSubstance UI="D054799">Phospholipase C beta</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000071916" MajorTopicYN="N">AC133 Antigen</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000071858" MajorTopicYN="N">Epithelial Cell Adhesion Molecule</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016130" MajorTopicYN="N">Immunophenotyping</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060787" MajorTopicYN="N">Neoplasm Grading</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D054799" MajorTopicYN="N">Phospholipase C beta</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Breast cancer stem cell (BCSC)</Keyword>
            <Keyword MajorTopicYN="N">CD133</Keyword>
            <Keyword MajorTopicYN="N">EpCAM</Keyword>
            <Keyword MajorTopicYN="N">Invasiveness</Keyword>
            <Keyword MajorTopicYN="N">PLC-β2</Keyword>
            <Keyword MajorTopicYN="N">Proliferation</Keyword>
            <Keyword MajorTopicYN="N">Triple-negative breast cancer (TNBC)</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>08</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>9</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>9</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>5</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28870198</ArticleId>
            <ArticleId IdType="doi">10.1186/s12885-017-3592-y</ArticleId>
            <ArticleId IdType="pii">10.1186/s12885-017-3592-y</ArticleId>
            <ArticleId IdType="pmc">PMC5584040</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Arch Immunol Ther Exp (Warsz). 2014 Feb;62(1):67-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23959111</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neurobiol Aging. 2009 Mar;30(3):394-406</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17850925</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Onco Targets Ther. 2016 Jan 21;9:431-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26855592</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Oncol. 2006 Apr;28(4):863-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16525635</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Carcinog. 2016 Dec;55(12 ):2210-2221</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26785288</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2015 Sep 29;6(29):27187-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26356670</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2013 Jan 31;32(5):544-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22469978</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biomedicines. 2016 Jun 01;4(2):</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28536379</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2015 Oct;14 (10 ):2279-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26264278</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2009 Jul 03;4(7):e6146</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19582160</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2016 Apr 1;138(7):1698-708</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26576938</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2014 May 23;289(21):14520-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24719318</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Pathol. 2012 Jul;181(1):257-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22626806</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Biol Sci. 2012;8(7):992-1004</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22904667</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Target Oncol. 2014 Sep;9(3):239-49</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23900680</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Chin Med J (Engl). 2009 Nov 20;122(22):2763-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19951611</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer. 2013 Dec 13;12 :165</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24330829</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2013 Nov 15;133(10 ):2398-407</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23661576</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pathol Int. 2016 Apr;66(4):210-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27041736</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2012;7(9):e45865</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23049880</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Lett. 2014 Jul 10;349(1):1-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24727284</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Clin Pathol. 2014 Apr;141(4):462-77</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24619745</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2015 Apr 1;21(7):1688-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25208879</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Carcinogenesis. 2007 Aug;28(8):1638-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17429106</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2013 Sep 06;8(9):e74745</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24040334</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Lett. 2014 Oct 28;353(2):153-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25130168</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Lett. 2016 Mar 28;372(2):201-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26806809</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Tumori. 2013 Sep-Oct;99(5):e245-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24362879</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Stem Cells Transl Med. 2016 Jan;5(1):20-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26607175</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biomed Res Int. 2015;2015:158682</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26504780</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2013 Apr 16;108(7):1480-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23519058</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Biol Sci. 2016 Dec 7;12 (12 ):1568-1577</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27994520</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Leukoc Biol. 2002 Jun;71(6):957-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12050180</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2009 Feb 15;69(4):1302-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19190339</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Sci. 2011 May;102(5):1107-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21276138</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2011 Jan 31;11:45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21281469</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">28857074</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>05</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1759-4782</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>14</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature reviews. Clinical oncology</Title>
                <ISOAbbreviation>Nat Rev Clin Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Breast cancer: AKT inhibition effective against TNBC.</ArticleTitle>
            <Pagination>
                <MedlinePgn>648</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/nrclinonc.2017.147</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sidaway</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>08</Month>
                <Day>31</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Nat Rev Clin Oncol</MedlineTA>
            <NlmUniqueID>101500077</NlmUniqueID>
            <ISSNLinking>1759-4774</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>9</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>9</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>9</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28857074</ArticleId>
            <ArticleId IdType="pii">nrclinonc.2017.147</ArticleId>
            <ArticleId IdType="doi">10.1038/nrclinonc.2017.147</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Lancet Oncol. 2017 Oct;18(10 ):1360-1372</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28800861</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28848054</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>05</Month>
            <Day>23</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2326-6074</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>5</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>10</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer immunology research</Title>
                <ISOAbbreviation>Cancer Immunol Res</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC.</ArticleTitle>
            <Pagination>
                <MedlinePgn>871-884</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1158/2326-6066.CIR-17-0150</ELocationID>
            <Abstract>
                <AbstractText>The lack of targeted therapies available for triple-negative breast cancer (TNBC) patients who fail to respond to first-line chemotherapy has sparked interest in immunotherapeutic approaches. However, trials utilizing checkpoint inhibitors targeting the PD-1/PD-L1 axis in TNBC have had underwhelming responses. Here, we investigated the interplay between type I IFN signaling and the PD-1/PD-L1 axis and tested the impact of combining IFN inducers, as immune activators, with anti-PD-1, to induce an antimetastatic immune response. Using models of TNBC, we demonstrated an interplay between type I IFN signaling and tumor cell PD-L1 expression that affected therapeutic response. The data revealed that the type I IFN-inducer poly(I:C) was an effective immune activator and antimetastatic agent, functioning better than anti-PD-1, which was ineffective as a single agent. Poly(I:C) treatment induced PD-L1 expression on TNBC cells, and combined poly(I:C) and anti-PD-1 treatment prolonged metastasis-free survival in a neoadjuvant setting via the induction of a tumor-specific T-cell response. Use of this combination in a late treatment setting did not impact metastasis-free survival, indicating that timing was critical for immunotherapeutic benefit. Together, these data demonstrated anti-PD-1 as an ineffective single agent in preclinical models of TNBC. However, type I IFN inducers were effective immune activators, and neoadjuvant trials combining them with anti-PD-1 to induce a sustained antitumor immune response are warranted. <i>Cancer Immunol Res; 5(10); 871-84. ©2017 AACR</i>.</AbstractText>
                <CopyrightInformation>©2017 American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Brockwell</LastName>
                    <ForeName>Natasha K</ForeName>
                    <Initials>NK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Owen</LastName>
                    <ForeName>Katie L</ForeName>
                    <Initials>KL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zanker</LastName>
                    <ForeName>Damien</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Spurling</LastName>
                    <ForeName>Alex</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rautela</LastName>
                    <ForeName>Jai</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Duivenvoorden</LastName>
                    <ForeName>Hendrika M</ForeName>
                    <Initials>HM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baschuk</LastName>
                    <ForeName>Nikola</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Caramia</LastName>
                    <ForeName>Franco</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Immunology Program, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Loi</LastName>
                    <ForeName>Sherene</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Immunology Program, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Darcy</LastName>
                    <ForeName>Phillip K</ForeName>
                    <Initials>PK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Immunology Program, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, University of Melbourne, Parkville, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Immunology, Monash University, Clayton, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lim</LastName>
                    <ForeName>Elgene</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>St. Vincent's Hospital, University of New South Wales, Darlinghurst, Sydney, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Parker</LastName>
                    <ForeName>Belinda S</ForeName>
                    <Initials>BS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia. Belinda.Parker@latrobe.edu.au.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>08</Month>
                <Day>28</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Cancer Immunol Res</MedlineTA>
            <NlmUniqueID>101614637</NlmUniqueID>
            <ISSNLinking>2326-6066</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9008-11-1</RegistryNumber>
                <NameOfSubstance UI="D007372">Interferons</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000074322" MajorTopicYN="N">Antineoplastic Agents, Immunological</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D061026" MajorTopicYN="N">Programmed Cell Death 1 Receptor</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D047368" MajorTopicYN="N">Tumor Burden</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>03</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2017</Year>
                <Month>07</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>08</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>8</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>5</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>8</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28848054</ArticleId>
            <ArticleId IdType="pii">2326-6066.CIR-17-0150</ArticleId>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-17-0150</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28832678</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>11</Month>
            <Day>07</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>12</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2017</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Recurrent triple-negative breast cancer (TNBC) tissues contain a higher amount of phosphatidylcholine (32:1) than non-recurrent TNBC tissues.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e0183724</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0183724</ELocationID>
            <Abstract>
                <AbstractText>Triple-negative breast cancer (TNBC) is one of the breast cancer subtype that displays a high risk of early recurrence and short overall survival. Improvement of the prognosis of patients with TNBC requires identifying a predictive factor of recurrence, which would make it possible to provide beneficial personalized treatment. However, no clinically reliable predictive factor is currently known. In this study, we investigated the predictive factor of recurrence in TNBC using matrix-assisted laser desorption/ionization-imaging mass spectrometry for lipid profiling of breast cancer specimens obtained from three and six patients with recurrent and non-recurrent TNBC, respectively. The signal for phosphatidylcholine (PC) (32:1) at m/z 732.5 was significantly higher in the recurrence group compared to the non-recurrence group (P = 0.024). PC (32:1) was more abundant in the cancer epithelial area than it was in the surrounding stroma, suggesting that abnormal lipid metabolism was associated with malignant transformation. Our results indicate PC (32:1) as a candidate predictive factor of TNBC recurrence. A future prospective study investigating whether personalized therapy based on PC (32:1) intensity improves the prognosis of patients with TNBC is recommended.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hosokawa</LastName>
                    <ForeName>Yuko</ForeName>
                    <Initials>Y</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-9638-0815</Identifier>
                    <AffiliationInfo>
                        <Affiliation>1st Department of Surgery, Hamamatsu University School of Medicine, Handayama, Higashi-ku, Hamamatsu, Shizuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>International Mass Imaging Center and Department of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, Handayama, Higashi-ku, Hamamatsu, Shizuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Masaki</LastName>
                    <ForeName>Noritaka</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>International Mass Imaging Center and Department of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, Handayama, Higashi-ku, Hamamatsu, Shizuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takei</LastName>
                    <ForeName>Shiro</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>International Mass Imaging Center and Department of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, Handayama, Higashi-ku, Hamamatsu, Shizuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Horikawa</LastName>
                    <ForeName>Makoto</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>International Mass Imaging Center and Department of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, Handayama, Higashi-ku, Hamamatsu, Shizuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matsushita</LastName>
                    <ForeName>Shoko</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>International Mass Imaging Center and Department of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, Handayama, Higashi-ku, Hamamatsu, Shizuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sugiyama</LastName>
                    <ForeName>Eiji</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>International Mass Imaging Center and Department of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, Handayama, Higashi-ku, Hamamatsu, Shizuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ogura</LastName>
                    <ForeName>Hiroyuki</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>1st Department of Surgery, Hamamatsu University School of Medicine, Handayama, Higashi-ku, Hamamatsu, Shizuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shiiya</LastName>
                    <ForeName>Norihiko</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>1st Department of Surgery, Hamamatsu University School of Medicine, Handayama, Higashi-ku, Hamamatsu, Shizuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Setou</LastName>
                    <ForeName>Mitsutoshi</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>International Mass Imaging Center and Department of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, Handayama, Higashi-ku, Hamamatsu, Shizuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Preeminent Medical Photonics Education &amp; Research Center, Handayama, Higashi-ku, Hamamatsu, Shizuoka, Japan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Anatomy, The University of Hong Kong, 6/F, William MW Mong Block Sassoon Road, Pokfulam, Hong Kong SAR, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Riken Center for Molecular Imaging Science, Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>08</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010713">Phosphatidylcholines</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010713" MajorTopicYN="N">Phosphatidylcholines</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019032" MajorTopicYN="N">Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>01</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>08</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28832678</ArticleId>
            <ArticleId IdType="doi">10.1371/journal.pone.0183724</ArticleId>
            <ArticleId IdType="pii">PONE-D-17-02111</ArticleId>
            <ArticleId IdType="pmc">PMC5568295</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Oncotarget. 2016 Oct 11;7(41):67111-67128</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27564096</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2011 May 1;71(9):3236-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21415164</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2013 Aug;59(2):292-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23567080</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Am Soc Mass Spectrom. 2003 Apr;14(4):352-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12686482</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Sci Rep. 2016 Feb 12;6:21043</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26868906</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochim Biophys Acta. 2013 Oct;1831(10):1509-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23562840</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cell Biol. 2014 Dec 10;15:43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25491198</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochim Biophys Acta. 2011 Nov;1811(11):961-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21440085</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer (Dove Med Press). 2016 Oct 06;8:183-197</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27785100</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Breast Cancer Rep. 2014 Sep 1;6(3):154-158</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25419441</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2011 Oct 27;11:465</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22029885</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Front Oncol. 2016 Sep 30;6:205</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27747192</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2013 Jan;137(1):319-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23208590</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Crit Rev Biochem Mol Biol. 2013 Jan-Feb;48(1):20-38</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23350810</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Tumour Biol. 2015 Jul;36(7):5473-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25683484</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Mol Med. 2008 Oct;22(4):559-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18813865</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Biol Med. 2015 Jun;12(2):106-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26175926</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>CA Cancer J Clin. 2015 Mar;65(2):87-108</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25651787</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2011;6(10):e26721</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22039541</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Chem Rev. 2011 Oct 12;111(10):6491-512</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21942646</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2012 Mar 19;14 (2):R50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22429397</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Sci. 2013 Oct;104(10):1295-302</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23815430</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Sci Rep. 2015 Jun 10;5:11298</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26061164</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2013 Apr 16;8(4):e61204</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23613812</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Metab. 2016 Apr 01;4:6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27042297</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Anal Methods. 2011 Aug 1;3(8):1729-1736</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21961026</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28764577</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>09</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>02</Month>
            <Day>12</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1744-7631</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>21</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>09</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Expert opinion on therapeutic targets</Title>
                <ISOAbbreviation>Expert Opin. Ther. Targets</ISOAbbreviation>
            </Journal>
            <ArticleTitle>MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies.</ArticleTitle>
            <Pagination>
                <MedlinePgn>849-859</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1080/14728222.2017.1363183</ELocationID>
            <Abstract>
                <AbstractText Label="INTRODUCTION">There is an unmet need in triple-negative breast cancer (TNBC) patients for targeted therapies. Maternal embryonic leucine zipper kinase (MELK) is a promising target for inhibition based on the abundance of correlative and functional data supporting its role in various cancer types. Areas covered: This review endeavors to outline the role of MELK in cancer. Studies covering a range of biological functions including proliferation, apoptosis, cancer stem cell phenotypes, epithelial-to-mesenchymal transition, metastasis, and therapy resistance are discussed here in order to understand the potential of MELK as a clinically significant target for TNBC patients. Expert opinion: Targeting MELK may offer a novel therapeutic opportunity in TNBC and other cancers. Despite the abundance of correlative data, there is still much we do not know. There are a lack of potent, specific inhibitors against MELK, as well as an insufficient understanding of MELK's downstream substrates. Addressing these issues is the first step toward identifying a patient population that could benefit from MELK inhibition in combination with other therapies.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Pitner</LastName>
                    <ForeName>Mary Kathryn</ForeName>
                    <Initials>MK</Initials>
                    <AffiliationInfo>
                        <Affiliation>a Section of Translational Breast Cancer Research, Department of Breast Medical Oncology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Taliaferro</LastName>
                    <ForeName>Juliana M</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>b Division of Medicinal Chemistry , The University of Texas at Austin, College of Pharmacy , Austin , TX , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dalby</LastName>
                    <ForeName>Kevin N</ForeName>
                    <Initials>KN</Initials>
                    <AffiliationInfo>
                        <Affiliation>b Division of Medicinal Chemistry , The University of Texas at Austin, College of Pharmacy , Austin , TX , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bartholomeusz</LastName>
                    <ForeName>Chandra</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>a Section of Translational Breast Cancer Research, Department of Breast Medical Oncology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>08</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Expert Opin Ther Targets</MedlineTA>
            <NlmUniqueID>101127833</NlmUniqueID>
            <ISSNLinking>1472-8222</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.1.-</RegistryNumber>
                <NameOfSubstance UI="C484610">MELK protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.1</RegistryNumber>
                <NameOfSubstance UI="D017346">Protein-Serine-Threonine Kinases</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015195" MajorTopicYN="N">Drug Design</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017346" MajorTopicYN="N">Protein-Serine-Threonine Kinases</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">Breast cancer</Keyword>
            <Keyword MajorTopicYN="Y">EMT</Keyword>
            <Keyword MajorTopicYN="Y">MELK</Keyword>
            <Keyword MajorTopicYN="Y">TNBC</Keyword>
            <Keyword MajorTopicYN="Y">cancer stem cells</Keyword>
            <Keyword MajorTopicYN="Y">metastasis</Keyword>
            <Keyword MajorTopicYN="Y">therapy resistance</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>8</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>9</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>8</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28764577</ArticleId>
            <ArticleId IdType="doi">10.1080/14728222.2017.1363183</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28729467</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>04</Month>
            <Day>17</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1479-6821</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>24</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>08</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Endocrine-related cancer</Title>
                <ISOAbbreviation>Endocr. Relat. Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>STAT3 activation by leptin receptor is essential for TNBC stem cell maintenance.</ArticleTitle>
            <Pagination>
                <MedlinePgn>415-426</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1530/ERC-16-0349</ELocationID>
            <Abstract>
                <AbstractText>Leptin (LEP) binds to the long form of the leptin receptor (LEPRb), leading to the activation of multiple signaling pathways that are potential targets for disrupting the obesity-breast cancer link. In triple-negative breast cancer (TNBC), LEP is hypothesized to predominantly mediate its tumorigenic effects via a subpopulation of LEPRb-positive tumor cells termed cancer stem cells (CSCs) that can initiate tumors and induce tumor progression. Previously, we showed that LEP promotes CSC survival <i>in vivo</i> Moreover, silencing LEPRb in TNBC cells compromised the CSC state. The mechanisms by which LEPRb regulates TNBC CSC intracellular signaling are not clear. We hypothesized that activation of LEPRb signaling is sufficient to drive CSC maintenance in TNBC. Here, we show that activation of LEPRb in non-CSCs isolated using our CSC reporter system resulted in a transition to the stem cell state. In CSCs, LEP induced STAT3 phosphorylation, whereas LEP did not induce STAT3 phosphorylation in non-CSCs. Introduction of constitutively active STAT3 into LEPRb-transfected non-CSCs significantly induced NANOG, SOX2 and OCT4 expression compared with control non-CSCs. To determine the intracellular phospho-tyrosine residue of LEPRb that is necessary for the induction of the stem cell state in non-CSCs, we transfected the tyrosine residue point mutants L985, F1077 and S1138 into non-CSCs. Non-CSCs transfected with the L985 mutant exhibited increased STAT3 phosphorylation, increased SOCS3 expression and an induction of GFP expression compared with non-CSCs expressing the F1077 and S1138 mutants. Our data demonstrate that LEPRb-induced STAT3 activation is essential for the induction and maintenance of TNBC CSCs.</AbstractText>
                <CopyrightInformation>© 2017 Society for Endocrinology.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Thiagarajan</LastName>
                    <ForeName>Praveena S</ForeName>
                    <Initials>PS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cellular and Molecular MedicineLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular MedicineCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zheng</LastName>
                    <ForeName>Qiao</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cellular and Molecular MedicineLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bhagrath</LastName>
                    <ForeName>Manvir</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cellular and Molecular MedicineLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mulkearns-Hubert</LastName>
                    <ForeName>Erin E</ForeName>
                    <Initials>EE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cellular and Molecular MedicineLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Myers</LastName>
                    <ForeName>Martin G</ForeName>
                    <Initials>MG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departments of Internal Medicine and Molecular and Integrative PhysiologyUniversity of Michigan, Ann Arbor, Michigan, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lathia</LastName>
                    <ForeName>Justin D</ForeName>
                    <Initials>JD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cellular and Molecular MedicineLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA lathiaj@ccf.org reizeso@ccf.org.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular MedicineCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Case Comprehensive Cancer CenterCase Western Reserve University, Cleveland, Ohio, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reizes</LastName>
                    <ForeName>Ofer</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cellular and Molecular MedicineLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA lathiaj@ccf.org reizeso@ccf.org.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular MedicineCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Case Comprehensive Cancer CenterCase Western Reserve University, Cleveland, Ohio, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>K99 CA157948</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R21 CA191263</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R37 DK056731</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 CA043703</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>UL1 TR000439</GrantID>
                    <Acronym>TR</Acronym>
                    <Agency>NCATS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 DK020572</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R00 CA157948</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 NS089641</GrantID>
                    <Acronym>NS</Acronym>
                    <Agency>NINDS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 NS083629</GrantID>
                    <Acronym>NS</Acronym>
                    <Agency>NINDS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Endocr Relat Cancer</MedlineTA>
            <NlmUniqueID>9436481</NlmUniqueID>
            <ISSNLinking>1351-0088</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C486780">NANOG protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000071317">Nanog Homeobox Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D054411">Receptors, Leptin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C494086">STAT3 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C515448">leptin receptor, human</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020868" MajorTopicYN="N">Gene Silencing</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000071317" MajorTopicYN="N">Nanog Homeobox Protein</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D054411" MajorTopicYN="N">Receptors, Leptin</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D050796" MajorTopicYN="N">STAT3 Transcription Factor</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">breast</Keyword>
            <Keyword MajorTopicYN="Y">carcinoma</Keyword>
            <Keyword MajorTopicYN="Y">leptin</Keyword>
            <Keyword MajorTopicYN="Y">receptors</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>06</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>06</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>7</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>7</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>4</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28729467</ArticleId>
            <ArticleId IdType="pii">24/8/415</ArticleId>
            <ArticleId IdType="doi">10.1530/ERC-16-0349</ArticleId>
            <ArticleId IdType="pmc">PMC5551450</ArticleId>
            <ArticleId IdType="mid">NIHMS885973</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Res. 2012 Mar 15;72(6):1416-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22282662</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2003 Apr 24;348(17):1625-38</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12711737</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Recent Prog Horm Res. 2004;59:287-304</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14749507</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pathol Res Pract. 2014 Jul;210(7):432-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24726267</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Oncol. 2006 Apr;28(4):985-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16525650</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2010 Nov 11;363(20):1938-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21067385</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2006 Feb 20;6:38</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16504019</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2000 Dec 22;275(51):40649-57</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11018044</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hum Pathol. 2012 Mar;43(3):364-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21835433</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2004 Aug 23;23(38):6365-78</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15322511</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Mol Med. 2000 Apr;5(4):421-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10719061</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Epidemiol. 2016 Apr;41:8-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26775081</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 2006 Aug 25;126(4):663-76</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16904174</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Endocr Relat Cancer. 2013 Oct 14;20(6):797-808</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24025407</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Stem Cells. 2015 Jul;33(7):2114-2125</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25827713</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Stem Cell. 2012 Jun 14;10(6):717-28</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22704512</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Annu Rev Physiol. 2008;70:537-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17937601</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2007 Oct 19;282(42):31019-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17726024</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2005 Dec 1;65(23 ):10946-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16322242</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2011 Jan 4;104(1):128-37</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21139583</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Endocrinol. 2014 Jan 25;382(1):570-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23562747</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2007 May 4;282(18):13316-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17344214</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Oncol. 2004 Jun;24(6):1529-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15138597</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2007;9(1):301</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17274833</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Obes Rev. 2006 Nov;7(4):333-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17038127</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Obes Rev. 2003 Aug;4(3):157-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12916817</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Genes Dev. 2015 Jun 15;29(12):1203-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26109046</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancers (Basel). 2013 Sep 06;5(3):1140-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24202338</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Obes (Lond). 2008 Dec;32 Suppl 7:S8-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19136996</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncology (Williston Park). 2011 Oct;25(11):994-1000</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22106549</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Immunol Methods. 2009 Aug 15;347(1-2):70-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19567251</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Med Oncol. 2012 Sep;29(3):1510-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21877194</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Arch Physiol Biochem. 2008 Feb;114(1):71-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18465361</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 2007 Nov 30;131(5):861-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18035408</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12629218</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem Biophys Res Commun. 1999 Jun 16;259(3):695-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10364481</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2004 Aug 15;64(16):5870-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15313931</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17671126</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Endocr Relat Cancer. 2007 Jun;14(2):189-206</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17639037</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Histopathology. 2011 Oct;59(4):776-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22014057</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28668293</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>05</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>05</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1532-3080</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>34 Suppl 1</Volume>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Breast (Edinburgh, Scotland)</Title>
                <ISOAbbreviation>Breast</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC).</ArticleTitle>
            <Pagination>
                <MedlinePgn>S27-S30</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0960-9776(17)30495-2</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.breast.2017.06.023</ELocationID>
            <Abstract>
                <AbstractText>Triple negative breast cancer (TNBC) a clinically aggressive subtype of breast cancer with poor outcomes. Chromosomal instability is a hallmark of many TNBCs, and likely underlies its ability to adapt and rapidly become resistant to chemotherapy. A study of residual disease after neoadjuvant chemotherapy have identified biological mechanisms driving this resistance to chemotherapy. Copy number amplifications such as MCL1, MYC and JAK2, as well as PTEN deletions or mutations have all been identified at a higher frequency in residual disease, suggesting they may play a role in de novo or acquired chemotherapy resistance. Increased copy number and expression of the PIM1 proto-oncogene in TNBC has also been identified as a new target of chemotherapy resistance. However, given the genomic instability and subclonal nature of driver mutations in TNBC, single agent targeted therapy is unlikely to be effective. Lately immune evasion has also been identified as another key characteristic of poor prognostic and chemo-resistant primary TNBCs. Combinations of checkpoint inhibition with targeted therapy and/or chemotherapy are currently being investigated.</AbstractText>
                <CopyrightInformation>Copyright © 2017 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wein</LastName>
                    <ForeName>Lironne</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Peter MacCallum Cancer Centre, Melbourne, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Loi</LastName>
                    <ForeName>Sherene</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Peter MacCallum Cancer Centre, Melbourne, Australia; University of Melbourne, Melbourne, Australia. Electronic address: sherene.loi@petermac.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>06</Month>
                <Day>28</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Breast</MedlineTA>
            <NlmUniqueID>9213011</NlmUniqueID>
            <ISSNLinking>0960-9776</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C423236">CD274 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D060908">CTLA-4 Antigen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C556706">CTLA4 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C105992">PDCD1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060908" MajorTopicYN="N">CTLA-4 Antigen</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016246" MajorTopicYN="N">Lymphocytes, Tumor-Infiltrating</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D061026" MajorTopicYN="N">Programmed Cell Death 1 Receptor</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>7</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>5</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>7</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28668293</ArticleId>
            <ArticleId IdType="pii">S0960-9776(17)30495-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.breast.2017.06.023</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">28625320</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>08</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1873-5487</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>48</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Archives of medical research</Title>
                <ISOAbbreviation>Arch. Med. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Expression of Jagged1/Notch3 Signaling Pathway and their Relationship with the Tumor Angiogenesis in TNBC.</ArticleTitle>
            <Pagination>
                <MedlinePgn>169-179</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0188-4409(17)30065-6</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.arcmed.2017.03.014</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND AND AIMS" NlmCategory="OBJECTIVE">Jagged1/Notch3 signaling pathway plays a key role in angiogenesis of breast cancer, but little is known in TNBC. This study was designed to investigate the expression of Jagged1/Notch3 mRNA and protein in TNBC, analyze their correlations with clinicopathological characteristics and prognosis. Moreover, the interrelationship among Jagged1/Notch3 and VEGF was initially evaluated.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Jagged1/Notch3 mRNA and protein expression levels were determined by Q-RT-PCR and Western blotting. Additionally, Immunohistochemistry for Jagged1/Notch3 was detected by Ventana platform, VEGF and CD34 was performed using the EnVision/HRP technique.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">mRNA transcriptionof Jagged1/Notch3 was in accord with protein expression. TNBC patients with positive Jagged1 expression had poorer DFS (p = 0.008) and OS (p = 0.004). Jagged1 expression was independent predictors of OS (p = 0.038). The expression of VEGF was positively correlative to MVD (p = 0.018), MVD was significantly associated with Jagged1 (p &lt;0.0001) and Notch3 (p &lt;0.0001). The expression of Jagged1/Notch3 has no correlation with VEGF, only in positive VEGF expression of TNBC patients Jagged1/Notch3 had influence on DFS and OS (p &lt;0.05).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Jagged1/Notch3 was -expressed at both the mRNA and protein levels, Jagged1 served as an independent predictor of poor prognosis. We speculate that there is a cross-talk between Jagged1/Notch3 and VEGF in TNBC angiogenesis. Jagged1/Notch3 is expected to be an important signaling pathway for TNBC progression and a potential target for TNBC neovascularization therapy.</AbstractText>
                <CopyrightInformation>Copyright © 2017 IMSS. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Xue</LastName>
                    <ForeName>Siliang</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Dermatology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>He</LastName>
                    <ForeName>Lang</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Center, The Second Clinical Medical College of North Sichuan Medical College, Nanchong Central Hospital, Nanchong, Sichuan, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Xiao</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery, Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, Sichuan, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Jin</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemotherapy, Sichuan Cancer Hospital, Chengdu, Sichuan, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Fanghua</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, Sichuan, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Xiaoshan</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Center, Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, Sichuan, China. Electronic address: xiaoshanwangxue@163.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Arch Med Res</MedlineTA>
            <NlmUniqueID>9312706</NlmUniqueID>
            <ISSNLinking>0188-4409</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000072100">Jagged-1 Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000071656">Receptor, Notch3</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C467484">VEGFA protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000072100" MajorTopicYN="N">Jagged-1 Protein</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009389" MajorTopicYN="N">Neovascularization, Pathologic</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000071656" MajorTopicYN="N">Receptor, Notch3</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName>
                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Angiogenesis</Keyword>
            <Keyword MajorTopicYN="N">Jagged1</Keyword>
            <Keyword MajorTopicYN="N">Notch3</Keyword>
            <Keyword MajorTopicYN="N">Triple-negative breast cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>09</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>03</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>6</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>6</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>8</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28625320</ArticleId>
            <ArticleId IdType="pii">S0188-4409(17)30065-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.arcmed.2017.03.014</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28488168</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1880-4233</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>25</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Breast cancer (Tokyo, Japan)</Title>
                <ISOAbbreviation>Breast Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).</ArticleTitle>
            <Pagination>
                <MedlinePgn>34-42</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12282-017-0781-0</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The status of tumor-infiltrating lymphocytes (TILs) is a prognostic factor for triple negative breast cancer (TNBC). Recent studies have shown that programmed cell death 1 (PD-1) or programmed death ligand 1 (PD-L1) is expressed on T lymphocytes or tumor cells modulating antitumor immunity. The regulation of immune checkpoints between tumor cells and T lymphocytes may serve as a target for improvement of TNBC prognosis. We investigated TILs and PD-L1 status in TNBCs before or after preoperative systemic therapy (PST) to elucidate the clinical significance of PD-L1 expression.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Ninety patients received PST, and materials of core needle biopsies (CNB) taken before PST were available for 32 patients. TILs were scored as &quot;% stromal&quot;, and tumors were defined as High-TILs (≥30%) or Low-TILs (&lt;30%). The expression of PD-L1 was assessed by immunohistochemistry.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">TILs status in CNB is significant in pathological therapeutic grade: 1 vs. 2 or 3 (p = 0.0359). Disease-free survival (DFS) in patients with Low-TIL tumors were significantly worse than those with High-TIL tumors (p = 0.0383), but overall survival (OS) showed no significance (p = 0.0772). However, in patients with Low-TIL tumors, both DFS and OS in patients with High-PD-L1 expression were extremely unfavorable than in patients with Low-PD-L1 expression (p = 0.0032, p = 0.0002).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The patients with TNBCs with combined Low-TILs and High-PD-L1 status in pre-PST situation showed unfavorable prognosis. The subset of TNBCs with Low-TILs and High-PD-L1 status could be the therapeutic target for immune checkpoint inhibitor.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tomioka</LastName>
                    <ForeName>Nobumoto</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery, National Hospital Organization (NHO) Hokkaido Cancer Center, 4-2 Kikusui, Shiroishi-ku, Sapporo, 003-0804, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Azuma</LastName>
                    <ForeName>Manabu</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Pathology, National Hospital Organization (NHO) Hokkaido Cancer Center, 4-2 Kikusui, Shiroishi-ku, Sapporo, 003-0804, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ikarashi</LastName>
                    <ForeName>Mayuko</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Digestive and General Surgery, Niigata University, 1-757 Asahimachi-dori, chuou-ku, Niigata, 951-8510, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamamoto</LastName>
                    <ForeName>Mitsugu</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery, National Hospital Organization (NHO) Hokkaido Cancer Center, 4-2 Kikusui, Shiroishi-ku, Sapporo, 003-0804, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sato</LastName>
                    <ForeName>Masako</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery, National Hospital Organization (NHO) Hokkaido Cancer Center, 4-2 Kikusui, Shiroishi-ku, Sapporo, 003-0804, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Watanabe</LastName>
                    <ForeName>Ken-Ichi</ForeName>
                    <Initials>KI</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery, National Hospital Organization (NHO) Hokkaido Cancer Center, 4-2 Kikusui, Shiroishi-ku, Sapporo, 003-0804, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamashiro</LastName>
                    <ForeName>Katsushige</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Pathology, National Hospital Organization (NHO) Hokkaido Cancer Center, 4-2 Kikusui, Shiroishi-ku, Sapporo, 003-0804, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takahashi</LastName>
                    <ForeName>Masato</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery, National Hospital Organization (NHO) Hokkaido Cancer Center, 4-2 Kikusui, Shiroishi-ku, Sapporo, 003-0804, Japan. masatotk@sap-cc.go.jp.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>05</Month>
                <Day>09</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Japan</Country>
            <MedlineTA>Breast Cancer</MedlineTA>
            <NlmUniqueID>100888201</NlmUniqueID>
            <ISSNLinking>1340-6868</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C423236">CD274 protein, human</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016246" MajorTopicYN="N">Lymphocytes, Tumor-Infiltrating</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Immune checkpoints</Keyword>
            <Keyword MajorTopicYN="N">PD-L1</Keyword>
            <Keyword MajorTopicYN="N">TILs</Keyword>
            <Keyword MajorTopicYN="N">TNBC</Keyword>
            <Keyword MajorTopicYN="N">Tumor-infiltrating lymphocytes</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>09</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>05</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>5</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>5</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28488168</ArticleId>
            <ArticleId IdType="doi">10.1007/s12282-017-0781-0</ArticleId>
            <ArticleId IdType="pii">10.1007/s12282-017-0781-0</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28383433</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>05</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1536-5964</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>96</Volume>
                    <Issue>14</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Medicine</Title>
                <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Aldehyde dehydrogenase 1 (ALDH1) expression is an independent prognostic factor in triple negative breast cancer (TNBC).</ArticleTitle>
            <Pagination>
                <MedlinePgn>e6561</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000006561</ELocationID>
            <Abstract>
                <AbstractText>Triple negative breast cancer (TNBC) is a subset of breast cancer that is highly aggressive and has a poor prognosis. Meanwhile, cancer stem cells (CSCs) are also characterized by a strong tumorigenic potential, which might be partly responsible for the aggressive behavior of TNBC. We previously showed that CSCs are enriched in TNBC cell lines and tissues. Further experiments in animal models revealed higher tumorigenicity of CSCs sorted from TNBC cell lines. In this study, we aimed to determine the clinical relationship between CSCs and TNBC by exploring the expression of aldehyde dehydrogenase 1 (ALDH1), which is a putative marker of breast CSCs, in TNBC tissues.ALDH1 levels in paraffin-embedded tumor tissues from 158 TNBC patients were evaluated by immunohistochemistry staining using an ALDH1A1 primary antibody. Staining evaluation was performed independently by two pathologists, and the expression level of ALDH1 was evaluated in terms of the percentage and intensity of positive cells. The association of immunohistochemistry staining of ALDH1 expression with clinical parameters was also analyzed.ALDH1 expression in tumor cells was observed in 88 out of 158 cases (55.7%). Analysis of clinicopathological parameters showed that the immunohistochemistry staining of ALDH1 was significantly correlated with tumor size (P = 0.02) and stage (P = 0.04). Survival analysis in patients with ALDH1 expression demonstrated shorter relapse-free survival (RFS) and overall survival (OS) times (P = 0.01; P = 0.001). Moreover, Cox multivariate analysis revealed that ALDH1 expression was an independent prognostic indicator of RFS and OS (P = 0.04; P = 0.04).Immunohistochemistry staining of ALDH1 in tumor cells is an independent prognostic indicator of RFS and OS in TNBC patients.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Fei</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>aDepartment of Medical Oncology, National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College bDepartment of Medical Oncology, Shandong Cancer Hospital/Institute, Jinan, Shandong cDepartment of Medical Oncology, Beijing Ditan Hospital, Capital Medical University dState Key Laboratory of Molecular Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Huihui</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Yiqun</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ding</LastName>
                    <ForeName>Xiaoyan</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Haijuan</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fan</LastName>
                    <ForeName>Ying</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Chen</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qian</LastName>
                    <ForeName>Haili</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Binghe</ForeName>
                    <Initials>B</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D064888">Observational Study</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Medicine (Baltimore)</MedlineTA>
            <NlmUniqueID>2985248R</NlmUniqueID>
            <ISSNLinking>0025-7974</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007527">Isoenzymes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.2.1.-</RegistryNumber>
                <NameOfSubstance UI="C105537">aldehyde dehydrogenase 1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.2.1.36</RegistryNumber>
                <NameOfSubstance UI="D050697">Retinal Dehydrogenase</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001940" MajorTopicYN="N">Breast</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002277" MajorTopicYN="N">Carcinoma</DescriptorName>
                <QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002681" MajorTopicYN="N">China</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007527" MajorTopicYN="N">Isoenzymes</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D050697" MajorTopicYN="N">Retinal Dehydrogenase</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>4</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>4</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>5</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28383433</ArticleId>
            <ArticleId IdType="doi">10.1097/MD.0000000000006561</ArticleId>
            <ArticleId IdType="pii">00005792-201704070-00040</ArticleId>
            <ArticleId IdType="pmc">PMC5411217</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Sci. 2009 Jun;100(6):1062-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19385968</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2004 Aug 15;10(16):5367-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15328174</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2006 Dec 20;98 (24):1755-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17179471</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2007 Jan 1;25(1):118-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17159189</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2008 Jun 10;26(17):2839-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18539962</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer. 2006;13(3):232-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16929115</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Pathol. 2002 Oct;161(4):1223-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12368196</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2010 Jan 1;16(1):45-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20028757</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Biol Markers. 2013 Dec 17;28(4):e357-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24338721</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2006 Dec 20;98 (24):1777-85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17179479</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2010 Aug;123(1):97-108</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19911270</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2008 May 7;100(9):672-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18445819</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pathology. 2012 Jun;44(4):303-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22544210</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Clin Oncol. 2010 Dec;7(12):683-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20877296</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Clin Exp Med. 2015 Jun 15;8(6):8425-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26309495</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Lett. 2014 Oct 28;353(2):153-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25130168</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Dis. 2008;29:83-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19029627</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2014 Jun 17;14:444</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24938375</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Jun 1;28(16):2784-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20404251</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2008 Oct;8(10):755-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18784658</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Histopathology. 2011 Oct;59(4):776-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22014057</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28351607</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>12</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>01</Month>
            <Day>06</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1464-3391</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>25</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>05</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Bioorganic &amp; medicinal chemistry</Title>
                <ISOAbbreviation>Bioorg. Med. Chem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2609-2616</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0968-0896(17)30192-X</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bmc.2017.03.018</ELocationID>
            <Abstract>
                <AbstractText>Despite recent advances in molecularly directed therapy, triple negative breast cancer (TNBC) remains one of the most aggressive forms of breast cancer, still without a suitable target for specific inhibitors. Maternal embryonic leucine zipper kinase (MELK) is highly expressed in TNBC, where level of overexpression correlates with poor prognosis and an aggressive disease course. Herein, we describe the discovery through targeted kinase inhibitor library screening, and structure-guided design of a series of ATP-competitive indolinone derivatives with subnanomolar inhibition constants towards MELK. The most potent compound, 17, inhibits the expression of the anti-apoptotic protein Mcl-1 and proliferation of TNBC cells exhibiting selectivity for cells expressing high levels of MELK. These studies suggest that further elaboration of 17 will furnish MELK-selective inhibitors with potential for development in preclinical models of TNBC and other cancers.</AbstractText>
                <CopyrightInformation>Copyright © 2017 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Edupuganti</LastName>
                    <ForeName>Ramakrishna</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Chemical Biology &amp; Medicinal Chemistry, The University of Texas at Austin, TX 78712, USA; The Targeted Drug Discovery and Development Program, College of Pharmacy, The University of Texas at Austin, TX 78712, USA; Department of Chemistry, The University of Texas at Austin, TX 78712, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Taliaferro</LastName>
                    <ForeName>Juliana M</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Chemical Biology &amp; Medicinal Chemistry, The University of Texas at Austin, TX 78712, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Qiantao</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Chemical Biology &amp; Medicinal Chemistry, The University of Texas at Austin, TX 78712, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xie</LastName>
                    <ForeName>Xuemei</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cho</LastName>
                    <ForeName>Eun Jeong</ForeName>
                    <Initials>EJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Targeted Drug Discovery and Development Program, College of Pharmacy, The University of Texas at Austin, TX 78712, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vidhu</LastName>
                    <ForeName>Fnu</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ren</LastName>
                    <ForeName>Pengyu</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical Engineering, Cockrell School of Engineering, The University of Texas at Austin, TX 78712, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Anslyn</LastName>
                    <ForeName>Eric V</ForeName>
                    <Initials>EV</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemistry, The University of Texas at Austin, TX 78712, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bartholomeusz</LastName>
                    <ForeName>Chandra</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dalby</LastName>
                    <ForeName>Kevin N</ForeName>
                    <Initials>KN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Chemical Biology &amp; Medicinal Chemistry, The University of Texas at Austin, TX 78712, USA; The Targeted Drug Discovery and Development Program, College of Pharmacy, The University of Texas at Austin, TX 78712, USA. Electronic address: dalby@austin.utexas.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>03</Month>
                <Day>10</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Bioorg Med Chem</MedlineTA>
            <NlmUniqueID>9413298</NlmUniqueID>
            <ISSNLinking>0968-0896</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000083">Acetanilides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007211">Indoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C579095">MCL1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D064549">Myeloid Cell Leukemia Sequence 1 Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000625356">methyl 3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-5-carboxylate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.1.-</RegistryNumber>
                <NameOfSubstance UI="C484610">MELK protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.1</RegistryNumber>
                <NameOfSubstance UI="D017346">Protein-Serine-Threonine Kinases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>G6HRD2P839</RegistryNumber>
                <NameOfSubstance UI="C530716">nintedanib</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000083" MajorTopicYN="N">Acetanilides</DescriptorName>
                <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName>
                <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064549" MajorTopicYN="N">Myeloid Cell Leukemia Sequence 1 Protein</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
                <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017346" MajorTopicYN="N">Protein-Serine-Threonine Kinases</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">Indolinone derivatives</Keyword>
            <Keyword MajorTopicYN="Y">Kinase inhibitor</Keyword>
            <Keyword MajorTopicYN="Y">MELK inhibitor</Keyword>
            <Keyword MajorTopicYN="Y">Maternal embryonic leucine zipper kinase (MELK)</Keyword>
            <Keyword MajorTopicYN="Y">Screening hits</Keyword>
            <Keyword MajorTopicYN="Y">Triple negative breast cancer (TNBC)</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>02</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2017</Year>
                <Month>03</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>03</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>3</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>3</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28351607</ArticleId>
            <ArticleId IdType="pii">S0968-0896(17)30192-X</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bmc.2017.03.018</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28270498</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>04</Month>
            <Day>23</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1078-0432</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>23</Volume>
                    <Issue>15</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>Aug</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title>
                <ISOAbbreviation>Clin. Cancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.</ArticleTitle>
            <Pagination>
                <MedlinePgn>4035-4045</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1158/1078-0432.CCR-16-3055</ELocationID>
            <Abstract>
                <AbstractText><b>Purpose:</b> Because of inherent disease heterogeneity, targeted therapies have eluded triple-negative breast cancer (TNBC), and biomarkers predictive of treatment response have not yet been identified. This study was designed to determine whether the mTOR inhibitor everolimus with cisplatin and paclitaxel would provide synergistic antitumor effects in TNBC.<b>Methods:</b> Patients with stage II/III TNBC were enrolled in a randomized phase II trial of preoperative weekly cisplatin, paclitaxel and daily everolimus or placebo for 12 weeks, until definitive surgery. Tumor specimens were obtained at baseline, cycle 1, and surgery. Primary endpoint was pathologic complete response (pCR); secondary endpoints included clinical responses, breast conservation rate, safety, and discovery of molecular features associated with outcome.<b>Results:</b> Between 2009 and 2013, 145 patients were accrued; 36% of patients in the everolimus arm and 49% of patients in the placebo arm achieved pCR; in each arm, 50% of patients achieved complete responses by imaging. Higher rates of neutropenia, mucositis, and transaminase elevation were seen with everolimus. Clinical response to therapy and long-term outcome correlated with increased frequency of DNA damage response (DDR) gene mutations, Basal-like1 and Mesenchymal TNBC-subtypes, AR-negative status, and high Ki67, but not with tumor-infiltrating lymphocytes.<b>Conclusions:</b> The paclitaxel/cisplatin combination was well tolerated and active, but addition of everolimus was associated with more adverse events without improvement in pCR or clinical response. However, discoveries made from correlative studies could lead to predictive TNBC biomarkers that may impact clinical decision-making and provide new avenues for mechanistic exploration that could lead to clinical utility. <i>Clin Cancer Res; 23(15); 4035-45. ©2017 AACR</i>.</AbstractText>
                <CopyrightInformation>©2017 American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jovanović</LastName>
                    <ForeName>Bojana</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Dana-Farber Cancer Institute, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mayer</LastName>
                    <ForeName>Ingrid A</ForeName>
                    <Initials>IA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Vanderbilt-Ingram Cancer Center, Nashville, Tennessee. ingrid.mayer@vanderbilt.edu jennifer.pietenpol@vanderbilt.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mayer</LastName>
                    <ForeName>Erica L</ForeName>
                    <Initials>EL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Dana-Farber Cancer Institute, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abramson</LastName>
                    <ForeName>Vandana G</ForeName>
                    <Initials>VG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bardia</LastName>
                    <ForeName>Aditya</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sanders</LastName>
                    <ForeName>Melinda E</ForeName>
                    <Initials>ME</Initials>
                    <AffiliationInfo>
                        <Affiliation>Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kuba</LastName>
                    <ForeName>M Gabriela</ForeName>
                    <Initials>MG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Estrada</LastName>
                    <ForeName>Monica V</ForeName>
                    <Initials>MV</Initials>
                    <AffiliationInfo>
                        <Affiliation>Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Beeler</LastName>
                    <ForeName>J Scott</ForeName>
                    <Initials>JS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shaver</LastName>
                    <ForeName>Timothy M</ForeName>
                    <Initials>TM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Johnson</LastName>
                    <ForeName>Kimberly C</ForeName>
                    <Initials>KC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sanchez</LastName>
                    <ForeName>Violeta</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rosenbluth</LastName>
                    <ForeName>Jennifer M</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Dana-Farber Cancer Institute, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dillon</LastName>
                    <ForeName>Patrick M</ForeName>
                    <Initials>PM</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Virginia Health Sciences Center, Charlottesville, Virginia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Forero-Torres</LastName>
                    <ForeName>Andres</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Alabama, Birmingham, Alabama.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chang</LastName>
                    <ForeName>Jenny C</ForeName>
                    <Initials>JC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Methodist Hospital Research Institute, Houston, Texas.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Meszoely</LastName>
                    <ForeName>Ingrid M</ForeName>
                    <Initials>IM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grau</LastName>
                    <ForeName>Ana M</ForeName>
                    <Initials>AM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lehmann</LastName>
                    <ForeName>Brian D</ForeName>
                    <Initials>BD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shyr</LastName>
                    <ForeName>Yu</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sheng</LastName>
                    <ForeName>Quanhu</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Sheau-Chiann</ForeName>
                    <Initials>SC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arteaga</LastName>
                    <ForeName>Carlos L</ForeName>
                    <Initials>CL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pietenpol</LastName>
                    <ForeName>Jennifer A</ForeName>
                    <Initials>JA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Vanderbilt-Ingram Cancer Center, Nashville, Tennessee. ingrid.mayer@vanderbilt.edu jennifer.pietenpol@vanderbilt.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R01 CA105436</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA070856</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P50 CA098131</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 CA068485</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>K23 CA127469</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>03</Month>
                <Day>07</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Cancer Res</MedlineTA>
            <NlmUniqueID>9502500</NlmUniqueID>
            <ISSNLinking>1078-0432</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019394">Ki-67 Antigen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011944">Receptors, Androgen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9HW64Q8G6G</RegistryNumber>
                <NameOfSubstance UI="D000068338">Everolimus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>P88XT4IS4D</RegistryNumber>
                <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Q20Q21Q62J</RegistryNumber>
                <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004249" MajorTopicYN="N">DNA Damage</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000068338" MajorTopicYN="N">Everolimus</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019394" MajorTopicYN="N">Ki-67 Antigen</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016246" MajorTopicYN="N">Lymphocytes, Tumor-Infiltrating</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011944" MajorTopicYN="N">Receptors, Androgen</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>12</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2017</Year>
                <Month>01</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>03</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>3</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>4</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>3</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28270498</ArticleId>
            <ArticleId IdType="pii">1078-0432.CCR-16-3055</ArticleId>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-16-3055</ArticleId>
            <ArticleId IdType="pmc">PMC5540799</ArticleId>
            <ArticleId IdType="mid">NIHMS859109</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Natl Cancer Inst Monogr. 2015 May;2015 (51):21-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26063880</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Bioinformatics. 2015 Jan 15;31(2):166-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25260700</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2015 Feb;26(2):259-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25214542</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Biol. 2008 Oct;28(19):5951-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18678646</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS Comput Biol. 2013;9(7):e1003153</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23874191</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2011 Jul;121(7):2750-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21633166</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2004 Nov 17;96(22):1659-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15547178</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2010 Dec 15;16(24):6159-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20802015</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2007 Oct 1;25(28):4414-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17785706</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Exp Cell Res. 2006 Apr 1;312(6):695-706</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16406339</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Stand Genomic Sci. 2009 Sep 25;1(2):204-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21304658</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Bioinformatics. 2013 Jan 1;29(1):15-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23104886</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Protoc Bioinformatics. 2013;43:11.10.1-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25431634</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2011;13(6):R126</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22151962</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Genome Res. 2010 Sep;20(9):1297-303</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20644199</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mod Pathol. 2015 Jul;28(7):913-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25932963</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast. 2008 Aug;17(4):323-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18455396</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Bioinformatics. 2010 Mar 1;26(5):589-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20080505</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2008 Mar 10;26(8):1275-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18250347</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Breast Cancer. 2014 Mar;17(1):40-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24744796</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):2076-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21245298</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hum Mutat. 2003 Mar;21(3):292-300</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12619115</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2003 Jun 1;63(11):2742-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12782577</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Genet. 2011 May;43(5):491-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21478889</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2012 Apr 04;486(7403):395-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22495314</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Methods. 2013 Dec;10(12):1185-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24185836</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer. 2010 Oct;17(4):269-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19730975</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Inform. 2012;11:147-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22872785</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2012 May 20;30(15):1796-804</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22508812</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 2006 Sep 29;313(5795):1929-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17008526</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2012 Oct 4;490(7418):61-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23000897</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2015 Jun 10;33(17):1902-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25847936</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Jan 1;28(1):105-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19917869</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2015 Jul;26(7):1280-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26019189</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2008 May;109(1):123-39</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17578664</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2007 May;117(5):1370-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17446929</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2013 Mar 1;31(7):860-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23341518</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2014 Sep 20;32(27):2959-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25071121</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2005 Apr 14;434(7035):917-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15829967</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Bioinformatics. 2010 Aug 15;26(16):2069-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20562413</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2006 Aug 15;66(16):7864-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16912159</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17671126</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2015 Mar 20;33(9):983-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25534375</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11553815</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28270088</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>06</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>06</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1876-1038</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>12</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2017</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Reviews on recent clinical trials</Title>
                <ISOAbbreviation>Rev Recent Clin Trials</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Neoadjuvant Therapy for Patients with Triple Negative Breast Cancer (TNBC).</ArticleTitle>
            <Pagination>
                <MedlinePgn>73-80</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.2174/1574887112666170307095945</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND">Patients with triple negative breast cancer (TNBC) are characterized by an unfavorable prognosis particularly when not responding well to anthracycline-taxane chemotherapy. This is due to a more aggressive biology in some cases but most importantly to a lack of agents other than conventional chemotherapy. Hence, there is an urgent need to optimize therapy of patients with TNBC in order to improve prognosis.</AbstractText>
                <AbstractText Label="OBJECTIVE">The objective of this review is to present the current understanding of TNBC biology and give an insight of current therapeutic concepts in the neoadjuvant treatment setting.</AbstractText>
                <AbstractText Label="METHOD">Current literature has been selected based on a literature search and current therapeutic concepts are explained and commented on.</AbstractText>
                <AbstractText Label="RESULTS">Novel therapeutic concepts for patients with TNBC focus on a) chemotherapy optimization through alternate scheduling, dosing or alternative/additional chemotherapeutic agents, b) evaluation of novel targeted agents and c) identification of clinically relevant patient subgroups through prognostic/ predictive biomarkers to enable a more personalized treatment approach. Potential novel therapeutic targets include inhibition of Poly-A-Ribose-Polymerase (PARP), checkpoint inhibition and antiandrogenic agents.</AbstractText>
                <AbstractText Label="CONCLUSION">Treatment of TNBC is currently been optimized both through optimization of chemotherapy and introduction of novel targeted agents which should enhance treatment response rates in the future.</AbstractText>
                <CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Liedtke</LastName>
                    <ForeName>Cornelia</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, University Medical Center Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rody</LastName>
                    <ForeName>Achim</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, University Medical Center Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United Arab Emirates</Country>
            <MedlineTA>Rev Recent Clin Trials</MedlineTA>
            <NlmUniqueID>101270873</NlmUniqueID>
            <ISSNLinking>1574-8871</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020360" MajorTopicYN="Y">Neoadjuvant Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">BRCA1/2</Keyword>
            <Keyword MajorTopicYN="Y">checkpoint inhibition</Keyword>
            <Keyword MajorTopicYN="Y">chemotherapy PARP inhibition</Keyword>
            <Keyword MajorTopicYN="Y">platinum-salts</Keyword>
            <Keyword MajorTopicYN="Y">triple negative breast cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>09</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2016</Year>
                <Month>12</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>01</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>3</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>6</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>3</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28270088</ArticleId>
            <ArticleId IdType="pii">RRCT-EPUB-82159</ArticleId>
            <ArticleId IdType="doi">10.2174/1574887112666170307095945</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28258353</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>02</Month>
            <Day>19</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-7217</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>163</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Breast cancer research and treatment</Title>
                <ISOAbbreviation>Breast Cancer Res. Treat.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Health-related quality of life in Black breast cancer survivors with and without triple-negative breast cancer (TNBC).</ArticleTitle>
            <Pagination>
                <MedlinePgn>331-342</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10549-017-4173-0</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Black women are more likely to develop early-onset (≤50 years) breast cancer (BC) and have the lowest five-year, cause-specific survival rate of any United States (U.S.) racial or ethnic group. These disparities can be attributed partially to the higher rate of triple-negative BC (TNBC) in Blacks. Yet, little is known about health-related quality of life (HRQOL) among Black women with TNBC.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Black women with invasive BC ≤ 50 years were recruited via the Florida Cancer Data System as part of a population-based case-only study of etiology and outcomes of early-onset invasive BC. Of 460 consented participants, a subset of 355 self-reported sociodemographic, clinical, and psychosocial variables. Descriptive analyses included participants with known TNBC (n = 85) or non-TNBC (n = 245) disease. Univariable and multivariable analyses were conducted to examine differences in factors associated with HRQOL.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In unadjusted analyses, TNBC participants had significantly lower FACT-B total scores (90.1 ± 27.9) compared to non-TNBC (98.5 ± 27.6) participants (p &lt; 0.05). For the TNBC group, multivariable analyses indicated five individual-level, and three systemic-level factors explain 80% of the response variation in HRQOL. For the non-TNBC group, seven individual-level factors and three systemic-level factors account for 76% of the variation in HRQOL scores.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Compared to Black women with non-TNBC, TNBC women have worse HRQOL. There are key individual and systemic-level factors that are unique to both groups. Findings can inform future HRQOL interventions to support young Black BC survivors.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Vadaparampil</LastName>
                    <ForeName>Susan T</ForeName>
                    <Initials>ST</Initials>
                    <AffiliationInfo>
                        <Affiliation>Moffitt Cancer Center, 12902 Magnolia Drive, MRC-CANCONT, Tampa, FL, 33612, USA. susan.vadaparampil@moffitt.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Christie</LastName>
                    <ForeName>Juliette</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Maryland, 4200 Valley Drive, Room 1242W, College Park, MD, 20742, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Donovan</LastName>
                    <ForeName>Kristine A</ForeName>
                    <Initials>KA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Moffitt Cancer Center, 12902 Magnolia Drive, MRC-CANCONT, Tampa, FL, 33612, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Jongphil</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Moffitt Cancer Center, 12902 Magnolia Drive, MRC-CANCONT, Tampa, FL, 33612, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Augusto</LastName>
                    <ForeName>Bianca</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Moffitt Cancer Center, 12902 Magnolia Drive, MRC-CANCONT, Tampa, FL, 33612, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kasting</LastName>
                    <ForeName>Monica L</ForeName>
                    <Initials>ML</Initials>
                    <AffiliationInfo>
                        <Affiliation>Moffitt Cancer Center, 12902 Magnolia Drive, MRC-CANCONT, Tampa, FL, 33612, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Holt</LastName>
                    <ForeName>Cheryl L</ForeName>
                    <Initials>CL</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Maryland, 4200 Valley Drive, Room 1242W, College Park, MD, 20742, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ashing</LastName>
                    <ForeName>Kimlin</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>City of Hope, 1500 East Duarte Road, Duarte, CA, 91010, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Halbert</LastName>
                    <ForeName>Chanita Hughes</ForeName>
                    <Initials>CH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical University of South Carolina, 68 President Street, Charleston, SC, 29425, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pal</LastName>
                    <ForeName>Tuya</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Moffitt Cancer Center, 12902 Magnolia Drive, MRC-CANCONT, Tampa, FL, 33612, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>K05 CA181320</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 CA076292</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 CA138313</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R25 CA090314</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>03</Month>
                <Day>03</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Breast Cancer Res Treat</MedlineTA>
            <NlmUniqueID>8111104</NlmUniqueID>
            <ISSNLinking>0167-6806</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001741" MajorTopicYN="N">African Americans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000073116" MajorTopicYN="N">Cancer Survivors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Black women</Keyword>
            <Keyword MajorTopicYN="N">Breast cancer</Keyword>
            <Keyword MajorTopicYN="N">Quality of life</Keyword>
            <Keyword MajorTopicYN="N">Triple-negative breast cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>01</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>02</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>3</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>2</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>3</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28258353</ArticleId>
            <ArticleId IdType="doi">10.1007/s10549-017-4173-0</ArticleId>
            <ArticleId IdType="pii">10.1007/s10549-017-4173-0</ArticleId>
            <ArticleId IdType="pmc">PMC5568024</ArticleId>
            <ArticleId IdType="mid">NIHMS895064</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Am Acad Nurse Pract. 2005 Aug;17(8):318-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16045592</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2013 Apr 23;8(4):e61854</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23626740</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Breast Cancer. 2014 Apr;14(2):e21-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24461458</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Environ Res Public Health. 2015 Dec 23;13(1):ijerph13010046</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26703650</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Sports Exerc Med. 2015;1(3):null</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26640827</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2016 Nov;160(1):1-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27601138</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1997 Mar;15(3):974-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9060536</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Health Psychol. 1997 Jul;2(3):335-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22013026</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Springerplus. 2016 Mar 31;5:390</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27047716</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2015 Apr;15(4):248-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25673085</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Prev Med. 2014 Oct;67:89-99</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25034729</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Nurs. 2015 Jan-Feb;38(1):16-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24406383</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast J. 2016 Mar-Apr;22(2):166-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26661631</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Soc Sci Med. 1991;32(6):705-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2035047</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychooncology. 2015 Jul;24(7):771-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25060288</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Health Serv Res. 2007 Jun;42(3 Pt 1):1235-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17489912</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Prev Med. 1996 Nov-Dec;12(6):450-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8955775</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2002 Oct 1;20(19):4050-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12351603</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Community Genet. 2014 Apr;5(2):157-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24013928</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Acta Psychiatr Scand. 1983 Jun;67(6):361-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">6880820</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychosom Med. 1979 May;41(3):209-18</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">472086</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Prev Med Rep. 2015 Jun 12;2:517-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26844112</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>CA Cancer J Clin. 2016 Jan-Feb;66(1):31-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26513636</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychol Health. 2009 Jun;24(5):597-613</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20205014</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncol Nurs Forum. 2009 Jan;36(1):79-88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19136341</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2005 May 20;23(15):3322-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15908646</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2012 Aug 1;118(15):3822-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22180125</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2015 Dec 1;121(23 ):4173-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26287763</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Qual Life Res. 2007 Apr;16(3):413-28</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17279444</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Integr Cancer Ther. 2014 Mar;13(2):121-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24105359</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1410-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19383889</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychooncology. 2010 Jan;19(1):62-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19267384</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JMIR Cancer. 2015 Aug 17;1(2):e9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28410162</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Fam Community Health. 2001 Oct;24(3):63-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11563945</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Epidemiol. 2004 Sep;57(9):898-910</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15504633</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Adolesc Young Adult Oncol. 2015 Mar;4(1):34-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26812429</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2014 Jul 15;120(14):2174-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24911404</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst Monogr. 2014 Nov;2014(50):315-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25749598</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>CA Cancer J Clin. 2015 May-Jun;65(3):221-38</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25960198</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Qual Life Res. 2005 Mar;14(2):297-307</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15892421</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2016 Feb 20;34(6):611-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26644543</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 2015 Jan 13;313(2):165-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25585328</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Phys Ther Health Promot. 2013 Dec 1;1(1):15-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24707505</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Health Psychol. 1991;10(4):259-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1915212</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2016 Oct;159(3):535-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27585477</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cancer Educ. 2016 Mar;31(1):166-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25869580</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Am Geriatr Soc. 1998 Jul;46(7):889-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9670878</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast. 2017 Feb;31:309-317</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27453572</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cancer Surviv. 2015 Sep;9(3):441-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25576214</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2015 Sep;153(2):253-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26303657</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Res Theory Nurs Pract. 2011;25(4):252-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22329080</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28249200</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>04</Month>
            <Day>17</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-4367</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>153</Volume>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>May</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Colloids and surfaces. B, Biointerfaces</Title>
                <ISOAbbreviation>Colloids Surf B Biointerfaces</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC).</ArticleTitle>
            <Pagination>
                <MedlinePgn>208-219</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0927-7765(17)30057-7</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.colsurfb.2017.01.038</ELocationID>
            <Abstract>
                <AbstractText>Triple negative breast cancer (TNBC), owing to its aggressive behavior and toxicity associated with available chemotherapy; currently no suitable therapy is available. Honokiol (HNK) is a promising anticancer drug but has poor bioavailability. In the current study, we evaluated the anticancer effects of an oral Honokiol nanomicellar (NM) formulation (size range of 20-40nm) in vitro against various TNBC cells lines. Cytotoxicity, clonogenic and wound healing assays demonstrated the promising anticancer effects. In vitro Caco-2 permeability studies suggested increased absorption of Honokiol. Compared to HNK-FD, nanomicellar formulations resulted in significant increase in the oral bioavailability. C<sub>max</sub> (4.06 and 3.60-fold) and AUC (6.26 and 5.83-fold) were significantly increased in comparison to oral 40 and 80mg/kg free drug respectively. Further, anticancer effects of these formulations were studied in BALB/c nude mice transplanted with orthotopic MDA-MB-231 cell induced xenografts. After 4 weeks of daily administration of HNK-NM formulation, significant reduction in the tumor volumes and weights compared to free drug (p&lt;0.001) treated groups was observed. Surprisingly, in some of the animals (25%), the treatment resulted in complete eradication of tumors. Increased apoptosis and antiangiogenic effect was observed in HNK-NM groups compared to free drug and untreated control animals. This is the first report demonstrating that HNK-FD possesses anticancer effects against TNBC.</AbstractText>
                <CopyrightInformation>Copyright © 2017 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Godugu</LastName>
                    <ForeName>Chandraiah</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>College of Pharmacy Pharmaceutical Sciences, Florida A &amp; M University, Tallahassee, FL 32307, USA; Department of Regulatory Toxicology, National Institute of Pharmaceutical Education and Research, Balanagar, Hyderabad, Telangana 500037 India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Doddapaneni</LastName>
                    <ForeName>Ravi</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>College of Pharmacy Pharmaceutical Sciences, Florida A &amp; M University, Tallahassee, FL 32307, USA; Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Singh</LastName>
                    <ForeName>Mandip</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>College of Pharmacy Pharmaceutical Sciences, Florida A &amp; M University, Tallahassee, FL 32307, USA. Electronic address: mandip.sachdeva@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P20 MD006738</GrantID>
                    <Acronym>MD</Acronym>
                    <Agency>NIMHD NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>SC1 CA161676</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>01</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Colloids Surf B Biointerfaces</MedlineTA>
            <NlmUniqueID>9315133</NlmUniqueID>
            <ISSNLinking>0927-7765</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001713">Biphenyl Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017705">Lignans</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008823">Micelles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>11513CCO0N</RegistryNumber>
                <NameOfSubstance UI="C005499">honokiol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001682" MajorTopicYN="N">Biological Availability</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001713" MajorTopicYN="N">Biphenyl Compounds</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018938" MajorTopicYN="N">Caco-2 Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017705" MajorTopicYN="N">Lignans</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008325" MajorTopicYN="N">Mammary Neoplasms, Experimental</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008823" MajorTopicYN="N">Micelles</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010316" MajorTopicYN="N">Particle Size</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013499" MajorTopicYN="N">Surface Properties</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Anticancer</Keyword>
            <Keyword MajorTopicYN="N">Bioavailability</Keyword>
            <Keyword MajorTopicYN="N">Honokiol</Keyword>
            <Keyword MajorTopicYN="N">Nanomicellar formulation</Keyword>
            <Keyword MajorTopicYN="N">TNBC</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2017</Year>
                <Month>01</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>01</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>3</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>4</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>3</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28249200</ArticleId>
            <ArticleId IdType="pii">S0927-7765(17)30057-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.colsurfb.2017.01.038</ArticleId>
            <ArticleId IdType="pmc">PMC5745346</ArticleId>
            <ArticleId IdType="mid">NIHMS923545</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Mol Pharm. 2016 Jun 6;13(6):2049-58</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27070720</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2011;6(6):e21573</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21720559</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Mol Med. 2012 Dec;12(10):1244-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22834827</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Pharm. 2010 Feb 15;386(1-2):262-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19932160</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Commun. 2015 Apr 14;6:6656</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25871545</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2010 Nov 11;363(20):1938-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21067385</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biomaterials. 2011 Jun;32(16):4058-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21396707</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Oncol. 2012 Oct;41(4):1358-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22895699</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Chem Rev. 2009 Jul;109(7):3012-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19422222</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nanomedicine (Lond). 2016 Jun;11(11):1377-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27171485</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem Pharmacol. 2002 May 1;63(9):1641-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12007567</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2014 Mar 10;9(3):e89919</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24614362</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Pharmacol. 2015 Sep;172(17):4228-37</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26040571</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Chromatogr B Biomed Appl. 1994 Apr 22;655(1):41-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8061832</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Drug Target. 2012 Aug;20(7):615-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22726209</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Drug Deliv. 2016 Sep;23 (7):2513-2523</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25835221</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pharm Res. 2016 Jan;33(1):137-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26286185</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Orthop Res. 2014 Apr;32(4):573-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24375705</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncologist. 2013;18(2):123-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23404817</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Control Release. 2016 Aug 10;235:276-290</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27242199</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pharm Pharmacol. 2015 Dec;67(12 ):1663-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26454249</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Drug Deliv. 2016 May;23 (4):1232-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26701717</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2013 Aug 07;8(8):e69519</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23950896</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Drug Deliv. 2010 Apr;17(3):138-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20175649</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Semin Oncol. 2010 Jun;37(3):258-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20709209</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2005 Jul 15;106(2):690-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15802533</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Control Release. 2013 Nov 28;172(1):86-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23838154</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Res. 2006 Sep;4(9):621-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16966432</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Pharmacol. 2008 Sep 4;591(1-3):43-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18588872</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pharm Pharmacol. 1999 Jan;51(1):97-103</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10197425</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Obstet Gynecol Reprod Biol. 2008 Sep;140(1):95-102</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18440692</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2007 Oct;6(10 ):2686-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17938262</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pharm Sci. 2015 Dec;104(12 ):4417-4426</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26372815</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Colloids Surf B Biointerfaces. 2014 Apr 1;116:114-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24448177</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Pharm. 2011 Aug 1;8(4):1140-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21557558</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nanotechnology. 2010 May 28;21(21):215103</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20431208</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Pharm Biopharm. 2016 Nov;108:168-179</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27586082</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2009 Jun 1;27(16):2712-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19414669</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Springerplus. 2016 Sep 20;5(1):1618</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27652191</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pharm Res. 2015 Jul;32(7):2292-300</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25576245</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Exp Cell Res. 2016 Aug 1;346(1):65-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27177833</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Control Release. 2015 Sep 10;213:18-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26079185</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Epigenetics. 2013 Jan;8(1):54-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23221619</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Med Rep. 2016 Feb;13(2):1353-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26647858</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>World J Gastroenterol. 2004 Dec 1;10(23):3459-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15526365</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Exp Mol Med. 2008 Dec 31;40(6):617-28</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19116447</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Carbohydr Polym. 2015 Nov 20;133:31-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26344251</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Chem Biol Interact. 2014 Nov 5;223:125-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25301743</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antioxid Redox Signal. 2009 May;11(5):1139-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19203212</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2009 Dec;20(12):1913-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19901010</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">28199968</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>01</Month>
            <Day>11</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1949-2553</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>8</Volume>
                    <Issue>13</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>Mar</Month>
                        <Day>28</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncotarget</Title>
                <ISOAbbreviation>Oncotarget</ISOAbbreviation>
            </Journal>
            <ArticleTitle>TNBC invasion: downstream of STAT3.</ArticleTitle>
            <Pagination>
                <MedlinePgn>20517-20518</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.18632/oncotarget.15259</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jackson</LastName>
                    <ForeName>James G</ForeName>
                    <Initials>JG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lozano</LastName>
                    <ForeName>Guillermina</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016433">News</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Oncotarget</MedlineTA>
            <NlmUniqueID>101532965</NlmUniqueID>
            <ISSNLinking>1949-2553</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">ChIP</Keyword>
            <Keyword MajorTopicYN="N">STAT3</Keyword>
            <Keyword MajorTopicYN="N">breast cancer</Keyword>
            <Keyword MajorTopicYN="N">mutant p53</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>2</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>2</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>2</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28199968</ArticleId>
            <ArticleId IdType="pii">15259</ArticleId>
            <ArticleId IdType="doi">10.18632/oncotarget.15259</ArticleId>
            <ArticleId IdType="pmc">PMC5400520</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Nature. 2000 Aug 17;406(6797):747-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10963602</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2009 Oct;9(10):701-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19693097</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Cell. 2012 Jun 12;21(6):793-806</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22698404</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 2012 Jan 20;148(1-2):244-58</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22265415</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2011 Jul;121(7):2723-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21633165</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2012 Oct 4;490(7418):61-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23000897</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2017 Jan 31;8(5):8226-8238</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28030809</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2015 Jul 16;523(7560):352-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26009011</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28196852</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>03</Month>
            <Day>26</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1557-3125</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>15</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>06</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular cancer research : MCR</Title>
                <ISOAbbreviation>Mol. Cancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>INPP4B and PTEN Loss Leads to PI-3,4-P2 Accumulation and Inhibition of PI3K in TNBC.</ArticleTitle>
            <Pagination>
                <MedlinePgn>765-775</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1158/1541-7786.MCR-16-0183</ELocationID>
            <Abstract>
                <AbstractText>Triple-negative breast cancer [TNBC, lacks expression of estrogen receptor (ER), progesterone receptor (PR), and amplification of HER2/Neu] remains one of the most aggressive subtypes, affects the youngest patients, and still lacks an effective targeted therapy. Both phosphatidylinositol-3-kinase (PI3K)-α and -β contribute to oncogenesis of solid tumors, including the development of breast cancer. Inositol polyphosphate-4-phosphatase type II (INPP4B) catalyzes the removal of the 4'-phosphate of phosphatidylinositol-(3, 4)-bisphosphate (PI-3,4-P2), creating phosphatidylinositol-3-phosphate. There is debate concerning whether PI-3,4-P2 contributes to Akt and downstream effector activation with the known canonical signaling second messenger, phosphatidylinositol-(3, 4, 5)-trisphosphate (PIP3). If PI-3,4-P2 is a positive effector, INPP4B would be a negative regulator of PI3K signaling, and there is some evidence to support this. Utilizing phosphatase and tensin homolog deleted on chromosome ten (PTEN)-null triple-negative breast tumor cell lines, it was unexpectedly found that silencing INPP4B decreased basal phospho-Akt (pAkt) and cellular proliferation, and in most cases sensitized cells to PI3K-α and PI3K-β isoform-specific inhibitors. Conversely, overexpression of INPP4B desensitized cells to PI3K inhibitors in a phosphatase activity-dependent manner. In summary, the current investigation of INPP4B in PTEN-null TNBC suggests new mechanistic insight and the potential for targeted therapy for this aggressive subset of breast cancer.<b>Implications:</b> These data support a model where PI-3,4-P2 is inhibitory toward PI3K, revealing a novel feedback mechanism under conditions of excessive signaling, and potentially an indication for PI3K-β isoform-specific inhibitors in PTEN-null TNBC that have lost INPP4B expression. <i>Mol Cancer Res; 15(6); 765-75. ©2017 AACR</i>.</AbstractText>
                <CopyrightInformation>©2017 American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Reed</LastName>
                    <ForeName>Darien E</ForeName>
                    <Initials>DE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cellular and Molecular Pharmacology, University of California, San Francisco, California.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Howard Hughes Medical Institute, University of California, San Francisco, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shokat</LastName>
                    <ForeName>Kevan M</ForeName>
                    <Initials>KM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cellular and Molecular Pharmacology, University of California, San Francisco, California. kevan.shokat@ucsf.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Howard Hughes Medical Institute, University of California, San Francisco, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R01 AI099245</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>T32 GM007618</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>02</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Mol Cancer Res</MedlineTA>
            <NlmUniqueID>101150042</NlmUniqueID>
            <ISSNLinking>1541-7786</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C532162">2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007191">Indazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018129">Phosphatidylinositol Phosphates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C060980">phosphatidylinositol 3,4-diphosphate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C055525">phosphatidylinositol 3-phosphate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.1.-</RegistryNumber>
                <NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.1</RegistryNumber>
                <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.3.2</RegistryNumber>
                <NameOfSubstance UI="D010744">Phosphoric Monoester Hydrolases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.3.66</RegistryNumber>
                <NameOfSubstance UI="C053153">phosphatidylinositol-3,4-bisphosphate 4-phosphatase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.3.67</RegistryNumber>
                <NameOfSubstance UI="D051059">PTEN Phosphohydrolase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.3.67</RegistryNumber>
                <NameOfSubstance UI="C494929">PTEN protein, human</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007191" MajorTopicYN="N">Indazoles</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051059" MajorTopicYN="N">PTEN Phosphohydrolase</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018129" MajorTopicYN="N">Phosphatidylinositol Phosphates</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010744" MajorTopicYN="N">Phosphoric Monoester Hydrolases</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>05</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2016</Year>
                <Month>07</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>01</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>2</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>3</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>2</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28196852</ArticleId>
            <ArticleId IdType="pii">1541-7786.MCR-16-0183</ArticleId>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-16-0183</ArticleId>
            <ArticleId IdType="pmc">PMC5502826</ArticleId>
            <ArticleId IdType="mid">NIHMS851803</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Bioorg Med Chem Lett. 2013 Jul 1;23(13):3741-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23726034</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Annu Rev Pathol. 2009;4:127-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18767981</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem Soc Trans. 2016 Feb;44(1):307-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26862220</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Invest New Drugs. 2012 Dec;30(6):2219-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22270257</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Elife. 2013 Jan 29;2:e00471</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23386978</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncologist. 2011;16 Suppl 1:12-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21278436</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Med Chem. 2008 Sep 25;51(18):5522-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18754654</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Cell. 2015 Jan 12;27(1):97-108</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25544637</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Drug Discov. 2005 Dec;4(12):988-1004</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16341064</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2000 Aug 17;406(6797):747-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10963602</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Bioorg Med Chem Lett. 2016 May 1;26(9):2318-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26996374</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Discov. 2015 Jul;5(7):730-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25883023</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2009 Jul 03;4(7):e6146</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19582160</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mod Pathol. 2001 Jul;14 (7):672-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11454999</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Virchows Arch. 2010 Mar;456(3):235-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20130907</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Discov. 2012 May;2(5):425-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22588880</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Discov. 2015 Jul;5(7):740-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25883022</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2010 Mar 1;126(5):1121-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19685490</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell. 2014 Nov 20;56(4):595-607</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25458846</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2008 Aug 1;68(15):6084-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18676830</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Cell. 2009 Aug 4;16(2):115-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19647222</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer (Auckl). 2010 May 20;4:35-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20697531</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Thromb Haemost. 2012 Oct;10(10):2127-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22906130</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2005 Apr 1;65(7):2554-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15805248</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Protoc. 2007;2(10):2459-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17947987</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2010 Dec 21;107(51):22231-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21127264</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncologist. 2011;16 Suppl 1:1-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21278435</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncologist. 2011;16(4):404-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21406469</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 1990 Nov 15;265(32):19704-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2174051</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2016 Jan 5;7(1):5-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26700619</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13057-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18755892</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Adv Biol Regul. 2014 Jan;54:142-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24091101</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1289-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16432180</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2008 Nov;112(2):217-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18074223</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11553815</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2008 Sep 18;27(41):5497-510</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18794884</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28189679</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>06</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>11</Month>
            <Day>27</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1090-2104</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>485</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>04</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biochemical and biophysical research communications</Title>
                <ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>SOX10 induced Nestin expression regulates cancer stem cell properties of TNBC cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>522-528</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0006-291X(17)30276-0</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2017.02.014</ELocationID>
            <Abstract>
                <AbstractText>The mechanisms modulating the cancer stem cell (CSC) properties of triple negative breast cancer (TNBC) cells were not fully understood. In this study, we performed data mining in Breast Cancer Gene-Expression Miner v4.0 and found that TNBC tumors had significantly higher NES mRNA expression than other breast cancer subtypes. Pooled data suggested that NES mRNA expression is associated worse metastatic relapse (MR) free survival and also worse any event (AE) free survival in TNBC patients. Following data mining in multiple big data databases confirmed a positive correlation between SOX10 mRNA expression and NES mRNA expression in breast cancer tissues. In addition, the expression of SOX10 mRNA is significantly higher in TNBC tissues than in other breast cancer subtypes. SOX10 overexpression resulted in Nestin upregulation at both mRNA and protein levels. Bioinformatic analysis predicted a SOX10 binding site in NES promoter and the following dual luciferase assay verified the binding site. Functionally, SOX10 overexpression substantially increased CSC properties of TNBC cells, while SOX10 knockdown decreased the CSC properties, in terms of CD24<sup>-</sup>/CD44<sup>+</sup> cell ratio and tumorsphere-forming capabilities. Enforced Nestin expression partly counteracted the effect of SOX10 knockdown on reducing the CSC properties. Based on these findings, we infer that SOX10 regulates cancer stem cell properties of TNBC cells via inducing Nestin expression.</AbstractText>
                <CopyrightInformation>Copyright © 2017 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Feng</LastName>
                    <ForeName>Wen</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Zaozhuang Mining Group Central Hospital, Zaozhuang 277800, Shandong, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Sihai</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Zaozhuang Mining Group Central Hospital, Zaozhuang 277800, Shandong, China. Electronic address: sihailiu@hotmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Ruixia</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Zaozhuang Mining Group Central Hospital, Zaozhuang 277800, Shandong, China. Electronic address: ruixiazhu@outlook.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Baojian</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Zaozhuang Mining Group Central Hospital, Zaozhuang 277800, Shandong, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Zhu</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Zaozhuang Mining Group Central Hospital, Zaozhuang 277800, Shandong, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Jinshan</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Zaozhuang Mining Group Central Hospital, Zaozhuang 277800, Shandong, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Song</LastName>
                    <ForeName>Chunhui</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Zaozhuang Mining Group Central Hospital, Zaozhuang 277800, Shandong, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>02</Month>
                <Day>09</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Biochem Biophys Res Commun</MedlineTA>
            <NlmUniqueID>0372516</NlmUniqueID>
            <ISSNLinking>0006-291X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C577484">NES protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D064231">Nestin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C527923">SOX10 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D055757">SOXE Transcription Factors</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064231" MajorTopicYN="N">Nestin</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055757" MajorTopicYN="N">SOXE Transcription Factors</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018874" MajorTopicYN="N">Spheroids, Cellular</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">Cancer stem cell</Keyword>
            <Keyword MajorTopicYN="Y">Nestin</Keyword>
            <Keyword MajorTopicYN="Y">SOX10</Keyword>
            <Keyword MajorTopicYN="Y">TNBC</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>01</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>02</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>2</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>6</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>2</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28189679</ArticleId>
            <ArticleId IdType="pii">S0006-291X(17)30276-0</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbrc.2017.02.014</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28168712</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>08</Month>
            <Day>07</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>08</Month>
            <Day>07</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1096-9098</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>115</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of surgical oncology</Title>
                <ISOAbbreviation>J Surg Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Incidence and prognosis of non-metastatic triple negative breast cancer (TNBC) among different races in Southeast Asia.</ArticleTitle>
            <Pagination>
                <MedlinePgn>523-537</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/jso.24559</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">Triple negative breast cancer (TNBC) carries a worse prognosis compared to the other subtypes. There have been conflicting studies that race may impact the prognosis of TNBC patients. We aim to determine the incidence and prognosis of TNBC among the different ethnic races in Singapore, and to determine its associated risk factors for prognosis.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Patients diagnosed with invasive breast cancer (BC) from 2005 to 2013 at our tertiary institution were included and divided according to race and subtypes. Demographic and clinical information of non-metastatic TNBC patients were analyzed. Log-rank test, univariate and multivariate Cox proportional hazard regression models were used to find associated risk factors related with overall survival (OS) and disease-free survival (DFS).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 1227 BC patients, 129 (10.5%) had TNBC. TNBC patients had the worst OS (P: 0.0005) and DFS (P: 0.0016) among the subtypes. However, variations in race did not have any difference in OS or DFS among TNBC patients. Axillary lymph node involvement, invasive lobular histology, larger tumor size, and the presence of lymphovascular invasion (LVI) were factors associated with both poor DFS and OS among TNBC patients.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Racial variation did not have any impact on the prognosis of the TNBC.</AbstractText>
                <CopyrightInformation>© 2017 Wiley Periodicals, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Alcantara</LastName>
                    <ForeName>Veronica Siton</ForeName>
                    <Initials>VS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Breast Department, KK Women's and Children's Hospital, Singapore, Republic of Singapore.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lim</LastName>
                    <ForeName>Geok Hoon</ForeName>
                    <Initials>GH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Breast Department, KK Women's and Children's Hospital, Singapore, Republic of Singapore.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Duke-NUS Graduate Medical School, Singapore, Republic of Singapore.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lim</LastName>
                    <ForeName>Swee Ho</ForeName>
                    <Initials>SH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Breast Department, KK Women's and Children's Hospital, Singapore, Republic of Singapore.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Duke-NUS Graduate Medical School, Singapore, Republic of Singapore.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sultana</LastName>
                    <ForeName>Rehena</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Duke-NUS Graduate Medical School, Singapore, Republic of Singapore.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Jung Ah</ForeName>
                    <Initials>JA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Breast Department, KK Women's and Children's Hospital, Singapore, Republic of Singapore.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>02</Month>
                <Day>07</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Surg Oncol</MedlineTA>
            <NlmUniqueID>0222643</NlmUniqueID>
            <ISSNLinking>0022-4790</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D002288" MajorTopicYN="N">Adenocarcinoma, Mucinous</DescriptorName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D044466" MajorTopicYN="Y">Asian Continental Ancestry Group</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018270" MajorTopicYN="N">Carcinoma, Ductal, Breast</DescriptorName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018275" MajorTopicYN="N">Carcinoma, Lobular</DescriptorName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002681" MajorTopicYN="N">China</DescriptorName>
                <QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D044465" MajorTopicYN="Y">European Continental Ancestry Group</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007194" MajorTopicYN="N">India</DescriptorName>
                <QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008197" MajorTopicYN="N">Lymph Node Excision</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008198" MajorTopicYN="N">Lymph Nodes</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008296" MajorTopicYN="N">Malaysia</DescriptorName>
                <QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008408" MajorTopicYN="N">Mastectomy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015412" MajorTopicYN="N">Mastectomy, Segmental</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018714" MajorTopicYN="N">Radiotherapy, Adjuvant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012846" MajorTopicYN="N">Singapore</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Asian race</Keyword>
            <Keyword MajorTopicYN="N">incidence</Keyword>
            <Keyword MajorTopicYN="N">prognosis</Keyword>
            <Keyword MajorTopicYN="N">risk factors</Keyword>
            <Keyword MajorTopicYN="N">triple-negative breast cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>12</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>01</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>2</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>8</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>2</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28168712</ArticleId>
            <ArticleId IdType="doi">10.1002/jso.24559</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28141839</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>08</Month>
            <Day>09</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>02</Month>
            <Day>08</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>12</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2017</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP).</ArticleTitle>
            <Pagination>
                <MedlinePgn>e0171169</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0171169</ELocationID>
            <Abstract>
                <AbstractText>Triple negative breast cancer (TNBC) progresses rapidly but lacks effective targeted therapies. Our previous study showed that downregulating syndecan-binding protein (SDCBP) in TNBC inhibits the proliferation of TNBC cells. Dasatinib is a new small-molecule inhibitor of c-src phosphorylation. The aim of this study was to investigate if SDCBP is a potential marker to indicate whether a TNBC is suitable for dasatinib therapy. This study applied co-immunoprecipitation to identify the interaction between SDCBP and c-src in TNBC cell lines. In addition, immunohistochemistry was used to investigate SDCBP and tyrosine-419 phosphorylated c-src (p-c-src-Y419) expression in TNBC tissues. SDCBP-overexpressing MDA-MB-231 cells were then constructed to evaluate the effects of dasatinib on SDCBP-induced TNBC progression in vitro and tumor formation in nude mice. We found wild-type SDCBP interacted with c-src and promoted the phosphorylation of c-src; this phosphorylation was completely blocked by dasatinib. SDCBP lacking the PDZ domain had no such effect. Among the 52 consecutive random TNBC cases examined, the expression of SDCBP was consistent with that of p-c-src-Y419, and positively correlated with histological grading or Ki-67 levels. SDCBP overexpression significantly accelerated the proliferation and cell cycle progression of the TNBC cell line MDA-MB-231; these effects were prevented by dasatinib treatment. However, the subsequent inhibition of p27 expression partially restored the proliferation and viability of the TNBC cells. The results of this study suggest that SDCBP interacts with c-src, regulates G1/S in TNBC cells, and enhances tumor cell proliferation by promoting the tyrosine phosphorylation of c-src at residue 419. Dasatinib inhibits such phosphorylation and blocks SDCBP-induced cell cycle progression. Therefore, SDCBP might be an important marker for identifying TNBC cases that are suitable for dasatinib therapy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Qian</LastName>
                    <ForeName>Xiao-Long</ForeName>
                    <Initials>XL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Pathology and Lab, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Jun</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Pei-Ze</ForeName>
                    <Initials>PZ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Mathematics, Tianjin Polytechnic University, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lang</LastName>
                    <ForeName>Rong-Gang</ForeName>
                    <Initials>RG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Pathology and Lab, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Wei-Dong</ForeName>
                    <Initials>WD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Pathology and Lab, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Hui</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Pathology and Lab, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Fang-Fang</ForeName>
                    <Initials>FF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Pathology and Lab, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guo</LastName>
                    <ForeName>Xiao-Jing</ForeName>
                    <Initials>XJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Pathology and Lab, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gu</LastName>
                    <ForeName>Feng</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Pathology and Lab, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fu</LastName>
                    <ForeName>Li</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Pathology and Lab, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Tianjin's Clinical Research Center for Cancer, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>01</Month>
                <Day>31</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C109621">SDCBP protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D053676">Syntenins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.2</RegistryNumber>
                <NameOfSubstance UI="C073097">CSK tyrosine-protein kinase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.2</RegistryNumber>
                <NameOfSubstance UI="D019061">src-Family Kinases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>RBZ1571X5H</RegistryNumber>
                <NameOfSubstance UI="D000069439">Dasatinib</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D063646" MajorTopicYN="N">Carcinogenesis</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069439" MajorTopicYN="N">Dasatinib</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D054731" MajorTopicYN="N">PDZ Domains</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053676" MajorTopicYN="N">Syntenins</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019061" MajorTopicYN="N">src-Family Kinases</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <CoiStatement>The authors have declared that no competing interests exist.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>01</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>8</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28141839</ArticleId>
            <ArticleId IdType="doi">10.1371/journal.pone.0171169</ArticleId>
            <ArticleId IdType="pii">PONE-D-16-46963</ArticleId>
            <ArticleId IdType="pmc">PMC5283743</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Res. 2005 Dec 1;65(23):10901-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16322237</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2010 May 27;29(21):3054-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20228839</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2011 Sep 23;286(38):33601-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21828040</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2006 Jul 28;281(30):20851-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16728403</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Med Rep. 2015 Sep;12(3):4063-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26130370</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neoplasia. 2010 Aug;12(8):599-607</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20689754</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2013 Jan 15;73(2):844-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23233738</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Biol. 2004 Sep;24(18):8113-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15340073</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2012 Jul 1;18(13):3580-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22586301</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Biol Ther. 2009 Aug;8(16):1550-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19830888</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2007 Nov;105(3):319-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17268817</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2007 Mar 1;67(5):2226-38</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17332353</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2002 Nov 14;347(20):1566-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12432043</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2009 Aug;20(8):1319-29</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19535820</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2004 Jun;4(6):470-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15170449</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2015 Sep 29;6(29):26560-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26387133</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2013 Jun 20;15(3):R50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23786877</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>FEBS Lett. 2005 Jul 18;579(18):3932-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15996662</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13683-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9391086</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hum Genet. 1989 Oct;83(3):297-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2571566</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Sci. 2008 May 1;121(Pt 9):1349-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18434645</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2006 Oct 15;107(8):1918-29</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16986126</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2008 Jan 15;14(2):352-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18223208</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochemistry. 1996 Jul 23;35(29):9519-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8755732</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2007;9(1):R4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17217540</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2009 Jul 7;101(1):38-47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19513066</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2012 Jul;134(2):459-78</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22689091</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2009 Mar 10;27(8):1168-76</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19204205</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Acta Biochim Biophys Sin (Shanghai). 2013 Jul;45(7):586-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23615537</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Signal. 2012 Jun;24(6):1276-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22570868</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Hematol Malig Rep. 2010 Apr;5(2):70-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20425399</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2011 Nov 1;17(21):6905-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22028489</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 2007 Jan 26;128(2):281-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17254967</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):15914-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18832467</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2006 Jun 1;66(11):5542-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16740687</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2007 May 1;109(9):1721-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17387718</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2015 Feb 6;290(6):3333-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25505176</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast. 2010 Oct;19(5):312-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20382530</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2016 Aug;159(1):31-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27455837</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Endocrinol. 2003 Nov;17(11):2268-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12907754</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Clin Oncol. 2016 Nov;13(11):674-690</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27184417</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>EMBO J. 1994 Aug 15;13(16):3748-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8070403</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Pathol. 2011 Jul;64(7):578-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21490376</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gynecol Oncol. 2004 Jun;93(3):680-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15196864</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17671126</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2013;8(3):e60046</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23533663</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11553815</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Opin Obstet Gynecol. 2015 Feb;27(1):77-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25502428</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2000 Nov 20;19(49):5636-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11114744</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28039356</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>10</Month>
            <Day>17</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>07</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1557-3125</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>15</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>04</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular cancer research : MCR</Title>
                <ISOAbbreviation>Mol. Cancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Immunophenotyping and Transcriptomic Outcomes in PDX-Derived TNBC Tissue.</ArticleTitle>
            <Pagination>
                <MedlinePgn>429-438</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1158/1541-7786.MCR-16-0286-T</ELocationID>
            <Abstract>
                <AbstractText>Cancer tissue functions as an ecosystem of a diverse set of cells that interact in a complex tumor microenvironment. Genomic tools applied to biopsies in bulk fail to account for this tumor heterogeneity, whereas single-cell imaging methods limit the number of cells which can be assessed or are very resource intensive. The current study presents methods based on flow cytometric analysis and cell sorting using known cell surface markers (CXCR4/CD184, CD24, THY1/CD90) to identify and interrogate distinct groups of cells in triple-negative breast cancer clinical biopsy specimens from patient-derived xenograft (PDX) models. The results demonstrate that flow cytometric analysis allows a relevant subgrouping of cancer tissue and that sorting of these subgroups provides insights into cancer cell populations with unique, reproducible, and functionally divergent gene expression profiles. The discovery of a drug resistance signature implies that uncovering the functional interaction between these populations will lead to deeper understanding of cancer progression and drug response.<b>Implications:</b> PDX-derived human breast cancer tissue was investigated at the single-cell level, and cell subpopulations defined by surface markers were identified which suggest specific roles for distinct cellular compartments within a solid tumor. <i>Mol Cancer Res; 15(4); 429-38. ©2016 AACR</i>.</AbstractText>
                <CopyrightInformation>©2016 American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Snowden</LastName>
                    <ForeName>Eileen</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>BD Technologies, Research Triangle Park, Durham, North Carolina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Porter</LastName>
                    <ForeName>Warren</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>BD Technologies, Research Triangle Park, Durham, North Carolina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hahn</LastName>
                    <ForeName>Friedrich</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>BD Technologies, Research Triangle Park, Durham, North Carolina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ferguson</LastName>
                    <ForeName>Mitchell</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>BD Technologies, Research Triangle Park, Durham, North Carolina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tong</LastName>
                    <ForeName>Frances</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>BD Technologies, Research Triangle Park, Durham, North Carolina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Parker</LastName>
                    <ForeName>Joel S</ForeName>
                    <Initials>JS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Genetics, University of North Carolina, Chapel Hill, North Carolina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Middlebrook</LastName>
                    <ForeName>Aaron</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>BD Biosciences, San Jose, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ghanekar</LastName>
                    <ForeName>Smita</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>BD Biosciences, San Jose, California.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dillmore</LastName>
                    <ForeName>W Shannon</ForeName>
                    <Initials>WS</Initials>
                    <AffiliationInfo>
                        <Affiliation>BD Technologies, Research Triangle Park, Durham, North Carolina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Blaesius</LastName>
                    <ForeName>Rainer</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>BD Technologies, Research Triangle Park, Durham, North Carolina. rblaesius@bd.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>12</Month>
                <Day>30</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Mol Cancer Res</MedlineTA>
            <NlmUniqueID>101150042</NlmUniqueID>
            <ISSNLinking>1541-7786</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051927">CD24 Antigen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C497889">CD24 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C527276">CXCR4 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019718">Receptors, CXCR4</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051927" MajorTopicYN="N">CD24 Antigen</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016130" MajorTopicYN="N">Immunophenotyping</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009368" MajorTopicYN="N">Neoplasm Transplantation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019718" MajorTopicYN="N">Receptors, CXCR4</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059010" MajorTopicYN="N">Single-Cell Analysis</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>08</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>12</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>10</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28039356</ArticleId>
            <ArticleId IdType="pii">1541-7786.MCR-16-0286-T</ArticleId>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-16-0286-T</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">30047683</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>08</Month>
            <Day>23</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0580-7247</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>49</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>MLO: medical laboratory observer</Title>
                <ISOAbbreviation>MLO Med Lab Obs</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Liquid biopsy testing in monitoring TNBC.</ArticleTitle>
            <Pagination>
                <MedlinePgn>26</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Song</LastName>
                    <ForeName>Paul Y</ForeName>
                    <Initials>PY</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>MLO Med Lab Obs</MedlineTA>
            <NlmUniqueID>0225602</NlmUniqueID>
            <ISSNLinking>0580-7247</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>H</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000073890" MajorTopicYN="Y">Liquid Biopsy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>7</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30047683</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27959276</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>08</Month>
            <Day>03</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>08</Month>
            <Day>03</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1532-2777</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>96</Volume>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Medical hypotheses</Title>
                <ISOAbbreviation>Med. Hypotheses</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Identification and targeting of microRNAs modulating acquired chemotherapy resistance in Triple negative breast cancer (TNBC): A better strategy to combat chemoresistance.</ArticleTitle>
            <Pagination>
                <MedlinePgn>5-8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0306-9877(16)30588-6</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.mehy.2016.09.004</ELocationID>
            <Abstract>
                <AbstractText>Triple negative breast cancer (TNBC) is a heterogeneous form of malignant disease. Due to lack of proper therapeutic target treatment options are restricted and relies primarily on chemotherapeutic modality for treatment of patients. Despite significant early regression of the disease in response to chemotherapy, complete cure is not assured with development of resistant tumors which is difficult to manage clinically. In the last decades, the regulation and contribution of microRNAs in tumorigenesis including breast cancers have been well-documented. Thus, here it is hypothesized that by identifying the microRNAs responsible for chemoresistance in TNBC and targeting the microRNAs along with chemotherapeutic approaches might exert an improved response. To accomplish this, an in vivo screening has to be performed by transfecting tumor cell line with lentiviral pool of library expressing microRNAs. Following treatment of primary tumors in mice and growth of relapsed tumors, microRNA profile has to be analyzed by qRT-PCR and sequencing to detect the microRNAs contributing to the chemoresistance which can be targeted by anti-microRNA strategies.</AbstractText>
                <CopyrightInformation>Copyright © 2016 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Das</LastName>
                    <ForeName>Samayita</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Biosciences and Technology (SBST), VIT University, Vellore, Tamil Nadu 632014, India. Electronic address: das.samayita@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>09</Month>
                <Day>15</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Med Hypotheses</MedlineTA>
            <NlmUniqueID>7505668</NlmUniqueID>
            <ISSNLinking>0306-9877</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019008" MajorTopicYN="Y">Drug Resistance, Neoplasm</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007107" MajorTopicYN="N">Immune System</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>02</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>09</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>12</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>12</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>8</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27959276</ArticleId>
            <ArticleId IdType="pii">S0306-9877(16)30588-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.mehy.2016.09.004</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27793840</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>07</Month>
            <Day>24</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1538-7445</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>77</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>01</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer research</Title>
                <ISOAbbreviation>Cancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>86-99</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1158/0008-5472.CAN-16-1797</ELocationID>
            <Abstract>
                <AbstractText>Triple-negative breast cancer (TNBC) is a highly aggressive, heterogeneous disease with poor prognosis and no effective targeted therapies. EGFR is highly expressed in basal-like TNBC and is considered as a potential therapeutic target. However, EGFR targeting exerts only marginal clinical benefits, possibly due to activation of compensatory signaling pathways, which are frequently associated with HER3 upregulation. Here we show that concomitant targeting of EGFR and the nonreceptor tyrosine kinases PYK2/FAK synergistically inhibits the proliferation of basal-like TNBC cells in vitro and attenuates tumor growth in a mouse xenograft model. Dual targeting of EGFR and PYK2/FAK inhibited complementary key growth and survival pathways mediated by AKT, S6K, STAT3, and ERK1/2 activation. PYK2 inhibition also abrogated HER3 upregulation in response to EGFR antagonists, thereby circumventing HER3-associated drug resistance. Mechanistically, PYK2 inhibition facilitated the proteasomal degradation of HER3 while inducing upregulation of NDRG1 (N-myc downstream regulated 1 gene). NDRG1 enhanced the interaction of HER3 with the ubiquitin ligase NEDD4, while PYK2, which interacts with NEDD4 and HER3, interfered with NEDD4-HER3 binding, suggesting that the PYK2-NDRG1-NEDD4 circuit has a critical role in receptor degradation, drug response, and resistance mechanism. Our studies offer a preclinical proof of concept for a strategy of cotargeting the EGFR and PYK2/FAK kinases to improve TNBC therapy. Cancer Res; 77(1); 86-99. ©2016 AACR.</AbstractText>
                <CopyrightInformation>©2016 American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Verma</LastName>
                    <ForeName>Nandini</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Müller</LastName>
                    <ForeName>Anna-Katharina</ForeName>
                    <Initials>AK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kothari</LastName>
                    <ForeName>Charu</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Panayotopoulou</LastName>
                    <ForeName>Effrosini</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kedan</LastName>
                    <ForeName>Amir</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Selitrennik</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mills</LastName>
                    <ForeName>Gordon B</ForeName>
                    <Initials>GB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nguyen</LastName>
                    <ForeName>Lan K</ForeName>
                    <Initials>LK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shin</LastName>
                    <ForeName>Sungyoung</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Karn</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, Goethe University Frankfurt, Frankfurt, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Holtrich</LastName>
                    <ForeName>Uwe</ForeName>
                    <Initials>U</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, Goethe University Frankfurt, Frankfurt, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lev</LastName>
                    <ForeName>Sima</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel. sima.lev@weizmann.ac.il.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>28</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Cancer Res</MedlineTA>
            <NlmUniqueID>2984705R</NlmUniqueID>
            <ISSNLinking>0008-5472</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D056827">Endosomal Sorting Complexes Required for Transport</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C102600">N-myc downstream-regulated gene 1 protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.3.2.26</RegistryNumber>
                <NameOfSubstance UI="D000075702">Nedd4 Ubiquitin Protein Ligases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.3.2.26</RegistryNumber>
                <NameOfSubstance UI="C000618483">Nedd4 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.3.2.26</RegistryNumber>
                <NameOfSubstance UI="C000618461">Nedd4l protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.3.2.27</RegistryNumber>
                <NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C581292">ERBB3 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D020893">Receptor, ErbB-3</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.2</RegistryNumber>
                <NameOfSubstance UI="D051418">Focal Adhesion Kinase 2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>S65743JHBS</RegistryNumber>
                <NameOfSubstance UI="D000077156">Gefitinib</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D056827" MajorTopicYN="N">Endosomal Sorting Complexes Required for Transport</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051418" MajorTopicYN="N">Focal Adhesion Kinase 2</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077156" MajorTopicYN="N">Gefitinib</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015151" MajorTopicYN="N">Immunoblotting</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000075702" MajorTopicYN="N">Nedd4 Ubiquitin Protein Ligases</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020411" MajorTopicYN="N">Oligonucleotide Array Sequence Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011799" MajorTopicYN="N">Quinazolines</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020893" MajorTopicYN="N">Receptor, ErbB-3</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D044767" MajorTopicYN="N">Ubiquitin-Protein Ligases</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>06</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2016</Year>
                <Month>09</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>7</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27793840</ArticleId>
            <ArticleId IdType="pii">0008-5472.CAN-16-1797</ArticleId>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-16-1797</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">27725895</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">2156-6976</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>6</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2016</Year>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of cancer research</Title>
                <ISOAbbreviation>Am J Cancer Res</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Breast cancer molecular subtypes: from TNBC to QNBC.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1864-1872</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Treatment protocols for breast cancer depend predominantly on receptor status with respect to estrogen (estrogen receptor alpha), progesterone (progesterone receptor) and human epidermal growth factor [human epidermal growth factor receptor 2 (HER2)]. The presence of one or more of these receptors suggests that a treatment targeting these pathways might be effective, while the absence of, or in the case of HER2, lack of overexpression of, all of these receptors, termed triple negative breast cancer (TNBC), indicates a need for the more toxic chemotherapy. In an effort to develop targeted therapies for TNBC, it will be necessary to differentiate among specific TNBC subtypes. The subset of TNBC that expresses androgen receptor (AR) has been determined to express genes consistent with a luminal subtype and therefore may be amenable to therapies targeting either AR, itself, or other pathways typical of a luminal subtype. Recent investigations of the AR signal pathway within breast cancer lead to AR as a significant target for breast cancer therapy with several clinical trials currently in progress. The subclass of TNBC that lacks AR, which we have termed quadruple negative breast cancer (QNBC) currently lacks a defined targetable pathway. Unlike AR-positive TNBC, QNBC predominantly exhibits a basal-like molecular subtype. Several subtypes and related pathway proteins are preferentially expressed in QNBC that may serve as effective targets for treatment, such as ACSL4, SKP2 and EGFR. ACSL4 expression has been demonstrated to be inversely correlated with expression of hormone/growth factor receptors and may thus serve as a biomarker for QNBC as well as a target for therapy. In the following review we summarize some of the current efforts to develop alternatives to chemotherapy for TNBC and QNBC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hon</LastName>
                    <ForeName>Jane Date C</ForeName>
                    <Initials>JD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Rutgers Robert Wood Johnson Medical School Piscataway, NJ, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Singh</LastName>
                    <ForeName>Baljit</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, New York University School of Medicine New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sahin</LastName>
                    <ForeName>Aysegul</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, UT MD Anderson Cancer Center Houston, TX, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Du</LastName>
                    <ForeName>Gang</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, New York University School of MedicineNew York, NY, USA; Department of NYU Cancer Institute, New York University School of MedicineNew York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Jinhua</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, New York University School of MedicineNew York, NY, USA; Department of NYU Cancer Institute, New York University School of MedicineNew York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Vincent Y</ForeName>
                    <Initials>VY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Association of Chinese American Physicians Flushing, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Deng</LastName>
                    <ForeName>Fang-Ming</ForeName>
                    <Initials>FM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, New York University School of MedicineNew York, NY, USA; Association of Chinese American PhysiciansFlushing, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>David Y</ForeName>
                    <Initials>DY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Association of Chinese American Physicians Flushing, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Monaco</LastName>
                    <ForeName>Marie E</ForeName>
                    <Initials>ME</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of NYU Cancer Institute, New York University School of MedicineNew York, NY, USA; Department of Neuroscience &amp; Physiology, New York University School of MedicineNew York, NY, USA; New York Harbor Healthcare SystemNew York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Peng</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, New York University School of MedicineNew York, NY, USA; Department of NYU Cancer Institute, New York University School of MedicineNew York, NY, USA; Association of Chinese American PhysiciansFlushing, NY, USA; New York Harbor Healthcare SystemNew York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016454">Review</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>09</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Am J Cancer Res</MedlineTA>
            <NlmUniqueID>101549944</NlmUniqueID>
            <ISSNLinking>2156-6976</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">ACSL4</Keyword>
            <Keyword MajorTopicYN="N">QNBC</Keyword>
            <Keyword MajorTopicYN="N">TNBC</Keyword>
            <Keyword MajorTopicYN="N">breast cancer</Keyword>
            <Keyword MajorTopicYN="N">quadruple negative</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>02</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>03</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27725895</ArticleId>
            <ArticleId IdType="pmc">PMC5043099</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Pathol Int. 2015 Dec;65(12):644-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26530981</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2015 Feb;26(2):259-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25214542</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2016 Feb 2;7(5):5416-28</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26734993</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Arch Pathol Lab Med. 2015 May;139(5):612-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25310144</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Jpn J Clin Oncol. 2012 May;42(5):375-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22450930</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2011 Jul;121(7):2750-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21633166</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Anticancer Drugs. 2016 Mar;27(3):147-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26682525</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Chem Biol. 2012 Dec 21;19(12):1515-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23261596</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochim Biophys Acta. 2015 Aug;1856(1):73-85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26071880</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Surg Oncol. 2015 Jan;22(1):82-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25145503</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2015 Dec 15;6(40):42632-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26536660</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2012;7(7):e40794</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22808264</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2004 Aug 15;10(16):5367-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15328174</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2009 Mar 10;27(8):1160-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19204204</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2012 Apr;132(3):793-805</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21562709</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Mol Sci. 2015 Nov 30;16(12):28347-76</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26633365</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Onco Targets Ther. 2015 Jul 23;8:1843-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26229492</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Breast Cancer. 2015 Jun;18(2):134-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26155289</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2000 Aug 17;406(6797):747-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10963602</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2014 May 02;9(5):e96228</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24788655</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Genomics. 2006 Apr 27;7:96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16643655</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Oncol Rep. 2015 Feb;17(2):4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25665553</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2013 Oct 1;19(19):5533-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23948975</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2013 Oct 14;8(10):e77060</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24155918</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Exp Mol Med. 2007 Aug 31;39(4):477-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17934335</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Clin Exp Urol. 2013 Dec 25;1(1):18-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25374896</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2016 Jul 7;35(27):3535-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26522726</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2001 Dec 1;61(23):8429-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11731423</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Arch Gynecol Obstet. 2016 Feb;293(2):247-69</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26341644</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Surg Oncol. 2014 Feb;21(2):361-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24046116</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12829800</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2011 Aug;22(8):1736-47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21709140</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2015 Dec 29;6(42):44728-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26554309</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Biol Med. 2015 Jun;12(2):106-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26175926</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Dis. 2010;32(1-2):73-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21778575</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2009 Apr 1;15(7):2302-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19318481</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Mol Med. 2011 Jul;28(1):109-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21503567</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2013 Oct 1;19(19):5505-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23965901</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Med Oncol. 2012 Jun;29(2):406-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21264529</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Transl Oncol. 2010 Apr;3(2):91-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20360933</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Cancer Res. 2014 Jul 16;4(4):353-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25057438</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Cancer Res. 2015 Jun 15;5(7):2330-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26328265</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancers (Basel). 2014 Jun 27;6(3):1351-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24978437</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Acta Histochem. 2013 May;115(4):344-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23031358</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2015 Apr 1;21(7):1688-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25208879</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25559415</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 2012 Apr 13;149(2):274-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22500797</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2010 Sep 23;10:507</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20860845</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast. 2015 Nov;24 Suppl 2:S26-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26253814</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Horm Cancer. 2015 Dec;6(5-6):206-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26201402</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2010;12(5):R68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20813035</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Sci. 2013 May;104(5):639-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23373898</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer (Auckl). 2015 Aug 04;9(Suppl 1):13-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26309408</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Genet Mol Res. 2015 Aug 10;14(3):9244-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26345857</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2002 Sep;110(5):633-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12208864</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Endocr Relat Cancer. 2015 Jun;22(3):R87-R106</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25722318</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2011 Oct;121(10):3786-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21965334</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Prostate. 2011 Nov;71(15):1656-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21446008</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2010 Nov 11;5(11):e15540</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21085606</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2016 Feb;27(2):249-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26598540</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2015 Mar;14(3):769-78</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25713333</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27599500</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>10</Month>
            <Day>27</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>12</Month>
            <Day>04</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2159-8290</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>6</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>10</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer discovery</Title>
                <ISOAbbreviation>Cancer Discov</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Bursts of Chromosome Changes Drive TNBC.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1075</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>A recent study suggests that complex genomic rearrangements in triple-negative breast cancer cells occur through a &quot;Big Bang&quot; model-early, short bursts of copy number aberrations, rather than progressive accumulation over time. Afterward, these aberrations are stably maintained in a handful of clones that expand to form the tumor mass.</AbstractText>
                <CopyrightInformation>©2016 American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>09</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Cancer Discov</MedlineTA>
            <NlmUniqueID>101561693</NlmUniqueID>
            <ISSNLinking>2159-8274</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000782" MajorTopicYN="Y">Aneuploidy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018740" MajorTopicYN="N">Genetic Heterogeneity</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008957" MajorTopicYN="N">Models, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059010" MajorTopicYN="N">Single-Cell Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>9</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>10</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>9</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27599500</ArticleId>
            <ArticleId IdType="pii">2159-8290.CD-NB2016-110</ArticleId>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-NB2016-110</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27561099</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>08</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>11</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2016</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Nomograms for Predicting the Prognostic Value of Pre-Therapeutic CA15-3 and CEA Serum Levels in TNBC Patients.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e0161902</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0161902</ELocationID>
            <Abstract>
                <AbstractText>Previous studies have indicated that carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) levels are both independent prognostic factors in breast cancer. However, the utility of CEA and CA15-3 levels as conventional cancer biomarkers in patients with triple-negative breast cancer (TNBC) remains controversial. The current study was performed to explore the predictive value of pre-therapeutic serum CEA and CA15-3 levels, and nomograms were developed including these serum cancer biomarkers to improve the prognostic evaluation of TNBC patients. Pre-therapeutic CA15-3 and CEA concentrations were measured in 247 patients with stage I-IV TNBC. Kaplan-Meier analysis showed that TNBC patients with high levels of both CEA and CA15-3 had shorter overall survival (OS) and disease-free survival (DFS) rates than those in the low-level groups (p&lt;0.05). Multivariate analysis suggested that pre-therapeutic CA15-3 and CEA levels are independent predictive elements for OS (p = 0.022 and p = 0.040, respectively) and DFS (p = 0.023 and p = 0.028, respectively). In addition, novel nomograms were established and validated to provide personal forecasts of OS and DFS for patients with TNBC. These novel nomograms may help physicians to select the optimal treatment plans to ensure the best outcomes for TNBC patients. </AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Dai</LastName>
                    <ForeName>Danian</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Bo</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tang</LastName>
                    <ForeName>Hailin</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Bin</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Life Science, Chongqing Medical University, Chongqing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Zhiping</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Hepatopancreatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xie</LastName>
                    <ForeName>Xiaoming</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wei</LastName>
                    <ForeName>Weidong</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>08</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002272">Carcinoembryonic Antigen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C060192">MUC1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018396">Mucin-1</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002272" MajorTopicYN="N">Carcinoembryonic Antigen</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018396" MajorTopicYN="N">Mucin-1</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049451" MajorTopicYN="Y">Nomograms</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment (Health Care)</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
                <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <CoiStatement>The authors have declared that no competing interests exist.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>06</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>08</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>8</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>8</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27561099</ArticleId>
            <ArticleId IdType="doi">10.1371/journal.pone.0161902</ArticleId>
            <ArticleId IdType="pii">PONE-D-16-24475</ArticleId>
            <ArticleId IdType="pmc">PMC4999206</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>PLoS One. 2015 Jul 24;10(7):e0133830</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26207909</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Asian Pac J Cancer Prev. 2015;16(17):7809-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26625802</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Cancer Res. 2015 Sep 15;5(10):2929-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26693050</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast. 2015 Dec;24(6):745-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26482138</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>East Mediterr Health J. 2012 Oct;18(10):1055-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23301361</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Zhonghua Zhong Liu Za Zhi. 2011 Nov;33(11):842-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22335950</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Tumour Biol. 2005 Nov-Dec;26(6):281-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16254457</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2004 Nov 1;10(21):7252-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15534099</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Zhongguo Fei Ai Za Zhi. 2006;9(4):337-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21176450</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cancer. 2016 Jan 01;7(1):37-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26722358</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antioxid Redox Signal. 2015 Dec 1;23(16):1298-302</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26079659</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2015 Mar 10;33(8):861-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25624438</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Tumour Biol. 2010 Jun;31(3):171-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20361287</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2010 Dec 15;16(24):6100-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21169259</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J BUON. 2015 Nov-Dec;20(6):1432-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26854438</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Immunol Immunother. 2012 Feb;61(2):239-47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22080408</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2006 Dec 20;24(36):5652-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17116942</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Surg Treat Res. 2016 Feb;90(2):57-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26878012</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 1998 Dec 15;83(12):2521-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9874458</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Chim Acta. 2015 Feb 2;440:16-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25444743</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2006 Aug 20;24(24):3819-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16864852</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast. 2015 Oct;24(5):667-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26346586</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biomed Pharmacother. 2003 Dec;57(10):452-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14637388</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast. 2014 Feb;23(1):88-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24291374</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2001 Mar 15;19(6):1865-78</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11251019</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Histopathology. 2008 Jan;52(1):108-18</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18171422</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2008 Mar 10;26(8):1364-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18323559</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2013 Mar 20;31(9):1188-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23358969</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 1995 Jul;72(1):174-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7599049</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2008 Apr;19(4):675-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18037623</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Womens Health. 2012;4:511-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23071421</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Chem Lab Med. 2013 Jan;51(1):99-112</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22987835</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Tumour Biol. 2001 Sep-Oct;22(5):273-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11553856</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Chem. 2004 Mar;50(3):559-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14726467</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer. 2016 Nov;23 (6):813-819</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26898373</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer (Auckl). 2011;5:175-99</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21863131</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Support Oncol. 2006 Jul-Aug;4(7):341-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16892696</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17671126</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Cancer. 2006 Dec;42(18):3149-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17055256</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27545642</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>05</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2045-2322</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>6</Volume>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>08</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Scientific reports</Title>
                <ISOAbbreviation>Sci Rep</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The relationship between nuclear factor (NF)-κB family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment.</ArticleTitle>
            <Pagination>
                <MedlinePgn>31804</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/srep31804</ELocationID>
            <Abstract>
                <AbstractText>We investigated gene expression profiles of the NF-κB pathway in patients with triple-negative breast cancer (TNBC) receiving adjuvant chemotherapy to determine the prognostic value of NF-κB pathway genes according to chemotherapeutic regimen. We used the nCounter expression assay to measure expression of 11 genes (NFKB1, NFKB2, RELA, RELB, REL, TP53, FOXC1, TBP, SP1, STAT3 and IRF1 genes) belonging to the NF-κB pathway using mRNA extracted from paraffin-embedded tumor tissues from 203 patients diagnosed with TNBC. Of the 203 patients, 116 were treated with a chemotherapeutic regimen containing doxorubicin. As revealed by the expression profiles of the 11 genes, increased expression of SP1 was associated with poor prognosis in TNBC patients treated with adjuvant doxorubicin chemotherapy (5-year distant recurrence-free survival [5Y DRFS], low vs. high expression [cut-off: median]: 92.3% vs. 71.6%, P = 0.001). In a multivariate Cox regression model, SP1 expression was a useful marker for predicting long-term prognosis in TNBC patients receiving doxorubicin treatment, and we thus suggest that SP1 expression could serve as a prognostic marker in these patients.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Ji-Yeon</ForeName>
                    <Initials>JY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University Seoul 06351, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jung</LastName>
                    <ForeName>Hae Hyun</ForeName>
                    <Initials>HH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul 06351, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ahn</LastName>
                    <ForeName>Soomin</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Innovative Cancer Medicine Institute, Samsung Medical Center, Sungkyunkwan University Seoul 06351, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bae</LastName>
                    <ForeName>SooYoun</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Samsung Medical Center, Seoul 06351, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Se Kyung</ForeName>
                    <Initials>SK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Samsung Medical Center, Seoul 06351, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Seok Won</ForeName>
                    <Initials>SW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Samsung Medical Center, Seoul 06351, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Jeong Eon</ForeName>
                    <Initials>JE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Samsung Medical Center, Seoul 06351, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nam</LastName>
                    <ForeName>Seok Jin</ForeName>
                    <Initials>SJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Samsung Medical Center, Seoul 06351, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ahn</LastName>
                    <ForeName>Jin Seok</ForeName>
                    <Initials>JS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University Seoul 06351, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Im</LastName>
                    <ForeName>Young-Hyuck</ForeName>
                    <Initials>YH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University Seoul 06351, Korea.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University, Seoul 06351, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Yeon Hee</ForeName>
                    <Initials>YH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University Seoul 06351, Korea.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul 06351, Korea.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University, Seoul 06351, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>08</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Sci Rep</MedlineTA>
            <NlmUniqueID>101563288</NlmUniqueID>
            <ISSNLinking>2045-2322</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016329">Sp1 Transcription Factor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C108209">Sp1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>80168379AG</RegistryNumber>
                <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016329" MajorTopicYN="N">Sp1 Transcription Factor</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>02</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>07</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>8</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>5</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27545642</ArticleId>
            <ArticleId IdType="pii">srep31804</ArticleId>
            <ArticleId IdType="doi">10.1038/srep31804</ArticleId>
            <ArticleId IdType="pmc">PMC4992884</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Mol Cell Biol. 1990 Oct;10(10):5541-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2204818</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Cancer. 2003 Mar;39(4):447-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12751374</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Biotechnol. 2008 Mar;26(3):317-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18278033</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Virol. 1994 Nov;68(11):7131-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7933095</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Clin Oncol. 1991 Feb;14(1):38-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1987737</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Am Coll Surg. 2004 Aug;199(2):249-58</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15275881</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2012 May 20;30(15):1879-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22454417</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2005 Apr 20;23(12):2676-85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15837982</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Surg Res. 1999 May 1;83(1):56-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10210643</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Endocr Relat Cancer. 2006 Jun;13(2):607-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16728586</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2010 Nov 11;363(20):1938-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21067385</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2010 Oct 05;10:527</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20920367</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Immunol. 2011 Jul 19;12(8):695-708</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21772278</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Biol. 1998 Mar;18(3):1266-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9488441</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Pharmacol. 1994 Apr;45(4):649-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8183243</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2008 Feb 15;111(4):2364-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18083845</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2014 Jan 15;5(1):196-210</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24344116</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1990 Sep;8(9):1483-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2202791</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 1999 Nov 22;18(49):6853-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10602461</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 1998 Jun 15;91(12):4624-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9616159</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 1984 Oct 26;226(4673):466-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">6093249</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cytokine Growth Factor Rev. 2010 Feb;21(1):11-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20018552</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2005 Dec 1;11(23):8398-402</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16322301</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2005 Jun 1;23(16):3686-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15897552</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Immunol. 2010 Mar 15;184(6):2908-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20164420</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 1998 Sep 19;352(9132):930-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9752815</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2015 Apr 15;136(8):1976-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25537444</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Surg Res. 2004 Aug;120(2):178-88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15234211</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Cancer. 2005 Nov;41(16):2438-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16209919</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Histopathology. 2008 Jan;52(1):108-18</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18171422</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2006 Nov;100(2):229-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16932852</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2013 Feb 15;132(4):795-806</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22815231</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Immunol. 2001 Sep 1;167(5):2911-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11509639</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 1976 Aug;36(8):2891-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1277199</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2005 Aug 1;65(15):6934-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16061678</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2011 Oct 15;17(20):6500-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21856768</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 1957 Sep;11(3):359-77</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">13499785</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2016 May 02;534(7605):47-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27135926</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2003 Dec 15;9(17):6371-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14695137</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2005 Dec 20;23(36):9067-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16172462</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2005 Jun 16;352(24):2487-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15958804</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncol Rep. 2014 Jun;31(6):2735-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24715151</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17671126</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Cycle. 2007 Sep 15;6(18):2284-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17890907</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1648-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18628415</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Genes Dev. 2004 Sep 15;18(18):2195-224</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15371334</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2008 May;19(5):871-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18209010</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27462789</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>01</Month>
            <Day>29</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1949-2553</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>7</Volume>
                    <Issue>33</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>Aug</Month>
                        <Day>16</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncotarget</Title>
                <ISOAbbreviation>Oncotarget</ISOAbbreviation>
            </Journal>
            <ArticleTitle>IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>53350-53361</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.18632/oncotarget.10804</ELocationID>
            <Abstract>
                <AbstractText>Estrogen receptor-, progesterone receptor- and HER2-negative breast cancers, also known as triple-negative breast cancers (TNBCs), have poor prognoses and are refractory to current therapeutic agents, including epidermal growth factor receptor (EGFR) inhibitors. Resistance to anti-EGFR therapeutic agents is often associated with sustained kinase phosphorylation, which promotes EGFR activation and translocation to the nucleus and prevents these agents from acting on their targets. The mechanisms underlying this resistance have not been fully elucidated. In addition, the IL-17E receptor is overexpressed in TNBC tumors and is associated with a poor prognosis. We have previously reported that IL-17E promotes TNBC resistance to anti-mitotic therapies. Here, we investigated whether IL-17E promotes TNBC resistance to anti-EGFR therapeutic agents by exploring the link between the IL-17E/IL-17E receptor axis and EGF signaling. We found that IL-17E, similarly to EGF, activates the EGFR in TNBC cells that are resistant to EGFR inhibitors. It also activates the PYK-2, Src and STAT3 kinases, which are essential for EGFR activation and nuclear translocation. IL-17E binds its specific receptor, IL-17RA/IL17RB, on these TNBC cells and synergizes with the EGF signaling pathway, thereby inducing Src-dependent EGFR transactivation and pSTAT3 and pEGFR translocation to the nucleus. Collectively, our data indicate that the IL-17E/IL-17E receptor axis may underlie TNBC resistance to EGFR inhibitors and suggest that inhibiting IL-17E or its receptor in combination with EGFR inhibitor administration may improve TNBC management.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Merrouche</LastName>
                    <ForeName>Yacine</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut Jean Godinot, Unicancer, F-51726 Reims, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Université Reims-Champagne-Ardenne, DERM-I-C, EA7319, 51095 Reims, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fabre</LastName>
                    <ForeName>Joseph</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut Jean Godinot, Unicancer, F-51726 Reims, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Université Reims-Champagne-Ardenne, DERM-I-C, EA7319, 51095 Reims, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cure</LastName>
                    <ForeName>Herve</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>CHU-Grenoble Alpes, CS 10217, 38043 La Tronche, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Institut National de la Santé et de la Recherche Médicale (INSERM) U823, Centre de Recherche (CRI), Institut Albert Bonniot, 38043 La Tronche, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Garbar</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut Jean Godinot, Unicancer, F-51726 Reims, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Université Reims-Champagne-Ardenne, DERM-I-C, EA7319, 51095 Reims, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fuselier</LastName>
                    <ForeName>Camille</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut Jean Godinot, Unicancer, F-51726 Reims, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Université Reims-Champagne-Ardenne, DERM-I-C, EA7319, 51095 Reims, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bastid</LastName>
                    <ForeName>Jeremy</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>OREGA Biotech, F-69130 Ecully, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Antonicelli</LastName>
                    <ForeName>Frank</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Université Reims-Champagne-Ardenne, DERM-I-C, EA7319, 51095 Reims, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Al-Daccak</LastName>
                    <ForeName>Reem</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut National de la Santé et de la Recherche Médicale (INSERM) UMR-S 976, Hôpital Saint Louis, 75010 Paris, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Université Paris Diderot, Sorbonne Paris Cité, Laboratoire Immunologie Dermatologie and Oncologie, UMR-S 976, F-75475, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bensussan</LastName>
                    <ForeName>Armand</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>OREGA Biotech, F-69130 Ecully, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Institut National de la Santé et de la Recherche Médicale (INSERM) UMR-S 976, Hôpital Saint Louis, 75010 Paris, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Université Paris Diderot, Sorbonne Paris Cité, Laboratoire Immunologie Dermatologie and Oncologie, UMR-S 976, F-75475, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Giustiniani</LastName>
                    <ForeName>Jerome</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut Jean Godinot, Unicancer, F-51726 Reims, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Université Reims-Champagne-Ardenne, DERM-I-C, EA7319, 51095 Reims, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Oncotarget</MedlineTA>
            <NlmUniqueID>101532965</NlmUniqueID>
            <ISSNLinking>1949-2553</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D020381">Interleukin-17</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>62229-50-9</RegistryNumber>
                <NameOfSubstance UI="D004815">Epidermal Growth Factor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>S65743JHBS</RegistryNumber>
                <NameOfSubstance UI="D000077156">Gefitinib</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004815" MajorTopicYN="N">Epidermal Growth Factor</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077156" MajorTopicYN="N">Gefitinib</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020381" MajorTopicYN="N">Interleukin-17</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011799" MajorTopicYN="N">Quinazolines</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D050796" MajorTopicYN="N">STAT3 Transcription Factor</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">EGFR</Keyword>
            <Keyword MajorTopicYN="N">IL-17E</Keyword>
            <Keyword MajorTopicYN="N">TNBC</Keyword>
            <Keyword MajorTopicYN="N">breast cancer</Keyword>
            <Keyword MajorTopicYN="N">resistance</Keyword>
        </KeywordList>
        <CoiStatement>Y.M., C.G., J.B., R.D., A.B., J.G. hold patent EP16305540, “Combination therapy for the treatment of cancer”. AB is the co-founder of OREGA Biotech, and JB is an employee of OREGA Biotech.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>05</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>07</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>7</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>1</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>7</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27462789</ArticleId>
            <ArticleId IdType="pii">10804</ArticleId>
            <ArticleId IdType="doi">10.18632/oncotarget.10804</ArticleId>
            <ArticleId IdType="pmc">PMC5288192</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Res. 2008 May 1;68(9):3314-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18451158</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Immunol. 2001 Dec 1;167(11):6559-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11714825</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Immunol Immunother. 2008 Dec;57(12):1757-69</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18351336</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2004 Aug 6;279(32):33315-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15166227</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2011 Jul;121(7):2750-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21633166</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2003 Jan 23;22(3):319-29</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12545153</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2002 Mar 27;21(13):2000-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11960372</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Cell Biol. 2001 Sep;3(9):802-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11533659</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Biol. 1994 Aug;14(8):5192-201</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7518560</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2001 Jan 12;276(2):1660-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11058597</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Sci Rep. 2016 May 11;6:25643</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27165713</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mediators Inflamm. 2014;2014:623759</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25110397</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Lett. 2012 May 28;318(2):124-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22261334</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Respirology. 2016 May;21(4):638-47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26699081</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2014 Dec 09;9(12):e114647</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25489847</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2009 Oct 29;28(43):3801-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19684613</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S159-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16113092</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Commun. 2016 Apr 18;7:11311</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27089063</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2009 May;20(5):862-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19150933</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2003 Jul 15;63(14):3923-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12873986</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Immunity. 2001 Dec;15(6):985-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11754819</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2002 Oct 1;100(7):2330-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12239140</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Exp Med. 2007 Aug 6;204(8):1837-47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17635955</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2007 Jan 1;109(1):25-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17146782</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Immunol. 2009 Aug;9(8):556-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19575028</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mediators Inflamm. 2015;2015:804347</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26783383</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 1993 Jun 18;73(6):1051-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7685656</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Sci Rep. 2013 Dec 09;3:3456</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24316750</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2009 Nov 13;284(46):31834-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19776017</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Sci Transl Med. 2011 Apr 13;3(78):78ra31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21490275</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2011 Jun 10;286(23 ):20558-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21487020</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 1999 Aug 6;98(3):295-303</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10458605</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Sci Rep. 2015 Jul 08;5:11874</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26154409</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13704-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8942998</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Cell. 2005 Jun;7(6):575-89</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15950906</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Exp Med. 2009 Jul 6;206(7):1457-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19564351</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2010 Oct 21;29(42):5653-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20729908</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cytokine. 2017 Jan;89:34-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26883678</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Commun. 2015 Feb 04;6:6064</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25648557</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Lett. 2016 Jun 1;375(2):390-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27000993</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Exp Cell Res. 2003 Mar 10;284(1):78-88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12648467</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2012 Jul 12;12 (8):553-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22785351</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Immunol. 2015 Nov 15;195(10 ):4771-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26423151</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2014 May;13(5):1356-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24634415</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2003 Dec 1;21(23 Suppl):289s-291s</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14645415</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Care (Basel). 2015 Jul;10(3):159-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26557820</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2014 Jun 5;33(23):2968-77</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23851503</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">27401651</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>12</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1976-2437</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>57</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Yonsei medical journal</Title>
                <ISOAbbreviation>Yonsei Med. J.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Comparisons of Oncologic Outcomes between Triple-Negative Breast Cancer (TNBC) and Non-TNBC among Patients Treated with Breast-Conserving Therapy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1192-8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3349/ymj.2016.57.5.1192</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The optimum local surgical strategy regarding breast-conserving therapy (BCT) for triple-negative breast cancer (TNBC) is controversial. To investigate whether BCT is appropriate for patients with TNBC, we evaluated the clinical outcomes of BCT in women with TNBC compared to those of women without TNBC, using a large, single-center cohort.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We performed a retrospective analysis of 1533 women (TNBC n=321; non-TNBC n=1212) who underwent BCT for primary breast cancer between 2000 and 2010. Clinicopathological characteristics, locoregional recurrence-free survival (LRFS), and overall survival (OS) were analyzed.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Tumors from the TNBC group had a higher T stage (T2 37.4% vs. 21.0%, p&lt;0.001), a lower N stage (N0 86.9% vs. 75.5%, p&lt;0.001), and a higher histologic grade (Grade III 66.8% vs. 15.4%, p&lt;0.001) than the non-TNBC group. There were no differences in 5-year LRFS rates between the TNBC and non-TNBC groups (98.7% vs. 97.8%, p=0.63). The non-TNBC group showed a slightly better 5-year OS than the TNBC group; however, the difference was not significant (96.2% vs. 97.3%, p=0.72). In multivariate analyses, TNBC was not associated with poor clinical outcomes in terms of LRFS and OS [hazard ratio (HR) for LRFS=0.37, 95% confidence interval (CI): 0.10-1.31; HR for OS=1.03, 95% CI: 0.31-3.39].</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">TNBC patients who underwent BCT showed non-inferior locoregional recurrence compared to non-TNBC patients with BCT. Thus, BCT is an acceptable surgical approach in patients with TNBC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Sanghwa</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Hyung Seok</ForeName>
                    <Initials>HS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Jee Ye</ForeName>
                    <Initials>JY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ryu</LastName>
                    <ForeName>Jegyu</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Seho</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Seung Il</ForeName>
                    <Initials>SI</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Yonsei University College of Medicine, Seoul, Korea. skim@yuhs.ac.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Korea (South)</Country>
            <MedlineTA>Yonsei Med J</MedlineTA>
            <NlmUniqueID>0414003</NlmUniqueID>
            <ISSNLinking>0513-5796</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015412" MajorTopicYN="Y">Mastectomy, Segmental</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009364" MajorTopicYN="Y">Neoplasm Recurrence, Local</DescriptorName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Breast neoplasms</Keyword>
            <Keyword MajorTopicYN="N">mastectomy, segmental</Keyword>
            <Keyword MajorTopicYN="N">triple negative breast neoplasms</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2015</Year>
                <Month>06</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2016</Year>
                <Month>01</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>01</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>7</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>7</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>12</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27401651</ArticleId>
            <ArticleId IdType="pii">57.1192</ArticleId>
            <ArticleId IdType="doi">10.3349/ymj.2016.57.5.1192</ArticleId>
            <ArticleId IdType="pmc">PMC4960386</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Control. 2010 Jul;17(3):173-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20664514</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Surg Oncol. 2011 Oct;18(10):2858-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21442346</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2003 Aug 15;98(4):697-702</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12910512</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Yonsei Med J. 2014 Sep;55(5):1187-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25048474</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>CA Cancer J Clin. 2006 Jan-Feb;56(1):37-47; quiz 50-1</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16449185</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2012 Aug;23 Suppl 6:vi7-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23012306</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 1991 Jan 16;265(3):391-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1984541</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2000 Aug 17;406(6797):747-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10963602</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2000 Jul 19;92(14):1143-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10904087</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2009 Jun 15;15(12):4181-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19470741</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2013 Jul 1;119(13):2366-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23576181</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Surg Oncol. 2013 Dec;108(8):531-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24115142</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am Soc Clin Oncol Educ Book. 2014;:e32-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24857120</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Diagn Mol Pathol. 2009 Sep;18(3):125-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19704256</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2011 Oct 10;29(29):3885-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21900114</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Breast Cancer. 2014 Jun;17(2):99-106</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25013429</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Surg Oncol. 2013 Oct;20(11):3469-76</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23686101</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2002 Oct 17;347(16):1233-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12393820</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast. 2012 Feb;21(1):50-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21865043</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2006 Dec 20;24(36):5652-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17116942</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Asian Pac J Cancer Prev. 2014;15(6):2577-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24761867</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2002 Oct 17;347(16):1227-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12393819</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2005 Oct 10;23(29):7350-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16145060</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Surg Oncol. 2010 Jul;17(7):1966-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20443141</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA Surg. 2014 Mar;149(3):252-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24382582</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2008 May 10;26(14):2373-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18413639</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2007 May 1;109(9):1721-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17387718</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Apr 1;28(10):1684-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20194857</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Surg Oncol. 2013 Dec;22(4):247-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24144808</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17671126</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2011 Jul 20;29(21):2852-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21670451</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Jun 1;28(16):2784-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20404251</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2014 May;25(5):1004-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24562447</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 2006 Jun 7;295(21):2492-502</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16757721</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">27386241</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>07</Month>
            <Day>07</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">2193-1801</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>5</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2016</Year>
                    </PubDate>
                </JournalIssue>
                <Title>SpringerPlus</Title>
                <ISOAbbreviation>Springerplus</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Failure patterns and survival outcomes in triple negative breast cancer (TNBC): a 15 year comparison of 448 non-Hispanic black and white women.</ArticleTitle>
            <Pagination>
                <MedlinePgn>756</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s40064-016-2444-6</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Triple negative breast cancer (TNBC) is a distinct subtype of breast cancer with unique pathologic, molecular and clinical behavior. It occurs more frequently in young blacks and has been reported to have a shorter disease-free interval. We undertook this study to analyze the demographic characteristics, failure patterns, and survival outcomes in this disease.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A total of 448 non-Hispanic black and white women were identified over a 15 year period from 1996 to 2011. Demographic and clinical information including age, race, menopausal status, stage, tumor characteristics, and treatments were collected. Fisher's exact test and multivariable Cox regression were used to compare failure patterns and survival outcomes between races.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">49 % (n = 223) were black. 59 % patients were between 41 and 60 years, with 18 % ≤40 years. 57 % were premenopausal and 89 % had grade 3 tumors. Stage II (47 %) was most frequent stage at diagnosis followed by stage III (28 %). 32 % had lymphovascular invasion. Adjusting for age, stage, and grade, there was no difference in survival outcomes (OS, DFS, LFFS, and DFFS) between the two races. 62 (14 %) patients failed locally either in ipsilateral breast or chest wall, and 19 (4 %) failed in the regional lymphatics. Lung (18 %) was the most frequent distant failure site with &lt;12 % each failing in brain, liver and bones.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Failure patterns and survival outcomes did not differ by race in this large collection of TNBC cases. Lung was the predominate site of distant failure followed by brain, bone, and liver. Few patients failed in the regional lymphatics.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Prasad</LastName>
                    <ForeName>Shreya</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, North Shore-Long Island Jewish Medical Center, Manhasset, NY USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Efird</LastName>
                    <ForeName>Jimmy T</ForeName>
                    <Initials>JT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Health Disparities, Brody School of Medicine, Office of Research, College of Nursing, East Carolina University, Greenville, NC USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>James</LastName>
                    <ForeName>Sarah E</ForeName>
                    <Initials>SE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Mayo Clinic, Rochester, MN USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Walker</LastName>
                    <ForeName>Paul R</ForeName>
                    <Initials>PR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hematology/Oncology, Department of Internal Medicine, East Carolina University, Greenville, NC USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zagar</LastName>
                    <ForeName>Timothy M</ForeName>
                    <Initials>TM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology and Neurosurgery, Cyberknife Radiosurgery Program, University of North Carolina at Chapel Hill, Chapel Hill, NC USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Biswas</LastName>
                    <ForeName>Tithi</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University Hospitals Sideman Cancer Center, Case Western Reserve University, Cleveland, OH USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>06</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Springerplus</MedlineTA>
            <NlmUniqueID>101597967</NlmUniqueID>
            <ISSNLinking>2193-1801</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>05</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>05</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>7</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>7</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>7</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27386241</ArticleId>
            <ArticleId IdType="doi">10.1186/s40064-016-2444-6</ArticleId>
            <ArticleId IdType="pii">2444</ArticleId>
            <ArticleId IdType="pmc">PMC4912515</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Am J Public Health. 1987 Dec;77(12):1515-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2823619</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2008 Jan 29;98 (2):277-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18182985</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2009 Sep 20;27(27):4515-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19704069</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2008 Oct 23;8:307</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18947390</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2010 Nov 11;363(20):1938-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21067385</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Onkologie. 2008 Nov;31(11):610-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19145094</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1095-101</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20638197</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer. 2008;15(4):303-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18369692</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Oncol. 2010 Jun;4(3):209-29</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20537966</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Surg Res. 2007 Nov;143(1):109-18</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17950079</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2008 Mar 10;26(8):1275-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18250347</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2006 Dec 20;24(36):5652-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17116942</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2009 Jan 10;27(2):220-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19047281</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2001 Jul;68(1):33-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11678307</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2010 Nov;124(1):187-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20814819</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Jul 10;28(20):3271-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20498394</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2009 Mar 1;115(5):946-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19156929</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2007 Aug 15;110(4):876-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17620276</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 1993 Jul 29;329(5):326-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8321261</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2008 May 10;26(14):2373-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18413639</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2007 May 1;109(9):1721-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17387718</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2009 Jan;113(2):357-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18324472</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Breast Cancer. 2009 Jun;9 Suppl 2:S73-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19596646</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2002 Apr 3;94(7):490-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11929949</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Breast Cancer. 2009 May;9(2):96-100</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19433390</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2012 Jun;133(3):831-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22147079</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Apr 1;28(10):1684-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20194857</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>CA Cancer J Clin. 2016 Jul;66(4):290-308</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26910411</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17671126</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2011 Jul 20;29(21):2852-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21670451</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer. 2011 Jul;18(3):165-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21290263</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 2006 Jun 7;295(21):2492-502</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16757721</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM">
        <PMID Version="1">27337767</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>07</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0002-8045</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>101</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Bulletin of the American College of Surgeons</Title>
                <ISOAbbreviation>Bull Am Coll Surg</ISOAbbreviation>
            </Journal>
            <ArticleTitle>How successful is NST in increasing breast-conserving surgery rates in TNBC patients?</ArticleTitle>
            <Pagination>
                <MedlinePgn>40-2</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ollila</LastName>
                    <ForeName>David W</ForeName>
                    <Initials>DW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Golshan</LastName>
                    <ForeName>Mehra</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boughey</LastName>
                    <ForeName>Judy C</ForeName>
                    <Initials>JC</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016420">Comment</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Bull Am Coll Surg</MedlineTA>
            <NlmUniqueID>7507024</NlmUniqueID>
            <ISSNLinking>0002-8045</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>H</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentOn">
                <RefSource>J Clin Oncol. 2015 Jan 1;33(1):13-21</RefSource>
                <PMID Version="1">25092775</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>6</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>6</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>7</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27337767</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27276499</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>01</Month>
            <Day>23</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>01</Month>
            <Day>23</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1477-9234</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>45</Volume>
                    <Issue>33</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>Aug</Month>
                        <Day>16</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Dalton transactions (Cambridge, England : 2003)</Title>
                <ISOAbbreviation>Dalton Trans</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The length of the bridging chain in ansa-metallocenes influences their antiproliferative activity against triple negative breast cancer cells (TNBC).</ArticleTitle>
            <Pagination>
                <MedlinePgn>13126-34</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1039/c6dt01640e</ELocationID>
            <Abstract>
                <AbstractText>In order to examine whether the length of the bridging chain in ansa-ferrocenes affects their antiproliferative activity against MDA-MB-231 triple negative breast cancer cell lines (TNBC), we synthesized derivatives of the type 1-[bis-(4-hydroxyphenyl)]methylidene-[n]ferrocenophane and 1-[(4-hydroxyphenyl)-phenyl]methylidene-[n]ferrocenophane with n = 3, 4, 5. We found that the derivatives of [3]ferrocenophane, the compounds with the shortest bridging chains, are the most active. IC50 values were 0.09 ± 0.01, 2.41 ± 0.10, and 1.85 ± 0.25 μM for the dihydroxyphenyl derivatives, with n = 3, 4, 5, respectively. These differences can be explained in terms of modification of the key metabolites (radical versus quinone methides) within the ansa series depending on the length of the bridging chain. The derivative of [5]ferrocenophane, possessing two -[bis-(4-hydroxyphenyl)]methylidene groups, was also prepared. Surprisingly, this relatively large molecule is also active (IC50 = 2.7 ± 0.3 μM). Two ruthenocenophane analogs were also synthesized. These ruthenium compounds are practically inactive against MDA-MB-231 cells. The unusual chemistry of these different compounds is discussed in terms of elucidating the mechanism underlying their diverse antiproliferative activity, and their specific advantages are evaluated. </AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Beauperin</LastName>
                    <ForeName>Matthieu</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sorbonne Universités, UPMC Univ Paris 6, UMR 8232, IPCM, F-75005 Paris, France and CNRS, UMR 8232, IPCM, F-75005 Paris, France. siden.top@upmc.fr gerard.jaouen@chimie-paristech.fr.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Top</LastName>
                    <ForeName>Siden</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sorbonne Universités, UPMC Univ Paris 6, UMR 8232, IPCM, F-75005 Paris, France and CNRS, UMR 8232, IPCM, F-75005 Paris, France. siden.top@upmc.fr gerard.jaouen@chimie-paristech.fr.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Richard</LastName>
                    <ForeName>Marie-Aude</ForeName>
                    <Initials>MA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sorbonne Universités, UPMC Univ Paris 6, UMR 8232, IPCM, F-75005 Paris, France and CNRS, UMR 8232, IPCM, F-75005 Paris, France. siden.top@upmc.fr gerard.jaouen@chimie-paristech.fr.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Plażuk</LastName>
                    <ForeName>Damian</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Lodz, Faculty of Chemistry, Department of Organic Chemistry, ul. Tamka 12, Lodz 91-403, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pigeon</LastName>
                    <ForeName>Pascal</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sorbonne Universités, UPMC Univ Paris 6, UMR 8232, IPCM, F-75005 Paris, France and CNRS, UMR 8232, IPCM, F-75005 Paris, France. siden.top@upmc.fr gerard.jaouen@chimie-paristech.fr and PSL, Chimie ParisTech, 11 rue Pierre et Marie Curie, F-75005 Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Toma</LastName>
                    <ForeName>Stefan</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Faculty of Natural Sciences, Comenius University, SK-84215 Bratislava, Slovakia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Poláčková</LastName>
                    <ForeName>Viera</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Faculty of Natural Sciences, Comenius University, SK-84215 Bratislava, Slovakia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jaouen</LastName>
                    <ForeName>Gérard</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sorbonne Universités, UPMC Univ Paris 6, UMR 8232, IPCM, F-75005 Paris, France and CNRS, UMR 8232, IPCM, F-75005 Paris, France. siden.top@upmc.fr gerard.jaouen@chimie-paristech.fr and PSL, Chimie ParisTech, 11 rue Pierre et Marie Curie, F-75005 Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Dalton Trans</MedlineTA>
            <NlmUniqueID>101176026</NlmUniqueID>
            <ISSNLinking>1477-9226</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000075163">Metallocenes</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000075163" MajorTopicYN="N">Metallocenes</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>6</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>6</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>1</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27276499</ArticleId>
            <ArticleId IdType="doi">10.1039/c6dt01640e</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM">
        <PMID Version="1">27027858</PMID>
        <DateCompleted>
            <Year>2018</Year>
            <Month>07</Month>
            <Day>16</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1551-4005</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>15</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>06</Month>
                        <Day>02</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cell cycle (Georgetown, Tex.)</Title>
                <ISOAbbreviation>Cell Cycle</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Targeting the untargetable? Nodal expression in TNBC.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1400</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1080/15384101.2016.1166816</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Young</LastName>
                    <ForeName>Eric D</ForeName>
                    <Initials>ED</Initials>
                    <AffiliationInfo>
                        <Affiliation>a Department of Cancer Biology , University of Kansas Medical Center , Kansas City , KS , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Welch</LastName>
                    <ForeName>Danny R</ForeName>
                    <Initials>DR</Initials>
                    <AffiliationInfo>
                        <Affiliation>a Department of Cancer Biology , University of Kansas Medical Center , Kansas City , KS , USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>b University of Kansas Cancer Center, University of Kansas Medical Center , Kansas City , KS , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016420">Comment</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>03</Month>
                <Day>30</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Cell Cycle</MedlineTA>
            <NlmUniqueID>101137841</NlmUniqueID>
            <ISSNLinking>1551-4005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentOn">
                <RefSource>Cell Cycle. 2016 May 2;15(9):1295-302</RefSource>
                <PMID Version="1">27007464</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018719" MajorTopicYN="Y">Receptor, ErbB-2</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="Y">Triple Negative Breast Neoplasms</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">TNBC</Keyword>
            <Keyword MajorTopicYN="Y">breast cancer</Keyword>
            <Keyword MajorTopicYN="Y">nodal</Keyword>
            <Keyword MajorTopicYN="Y">triple negative breast cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>3</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>3</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>7</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27027858</ArticleId>
            <ArticleId IdType="doi">10.1080/15384101.2016.1166816</ArticleId>
            <ArticleId IdType="pmc">PMC4934075</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):133-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15300009</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Clin Exp Med. 2015 Nov 15;8(11):20227-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26884935</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Histopathology. 2008 Jan;52(1):108-18</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18171422</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Cycle. 2016 May 2;15(9):1295-302</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27007464</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Physiol. 2004 Nov;201(2):266-76</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15334661</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Development. 2011 Sep;138(17):3613-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21828090</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">26988771</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>04</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>04</Month>
            <Day>18</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1938-0666</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>16</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical breast cancer</Title>
                <ISOAbbreviation>Clin. Breast Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Inflammatory TNBC Breast Cancer: Demography and Clinical Outcome in a Large Cohort of Patients With TNBC.</ArticleTitle>
            <Pagination>
                <MedlinePgn>212-6</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clbc.2016.02.004</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S1526-8209(16)30024-6</ELocationID>
            <Abstract>
                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer with poor 5-year survival. Knowledge and information about IBC with the triple negative (TNBC) phenotype are limited. Here, we report the characteristics and outcome of inflammatory TNBC (I-TNBC) cancer cohorts from a large TNBC dataset.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">After obtaining institutional review board approval, we collected information on 476 women with a diagnosis of TNBC from 1996 to 2011. Data on patient characteristics, tumor, and treatment were collected. Overall survival (OS) was computed from the date of diagnosis to the date of death or last follow-up. For disease-free survival (DFS), patients were scored if they failed. Statistical analysis was performed using SAS v9.3.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 34 (7%) patients were diagnosed with inflammatory TNBC. The median age was 52 years, and 56% were white. The median follow-up was 13 months (interquartile range, 2-126 months). Twenty-one percent (n = 7) presented with stage IV disease, while 91% had axillary nodal involvement. All but 2 (94%; n = 32) patients had neoadjuvant chemotherapy, with 6% (n = 2) achieving complete response. Twenty-one (62%) patients underwent mastectomy; 71% (n = 24) received radiation. The 2- and 5-year OS and DFS were 34%, 26% (vs. 65%, 46%) and 27%, 23% (vs. 53%, 40%), respectively, for I-TNBC and non-inflammatory stage III-IV TNBC. Compared with the non-inflammatory group, the 2- and 5-year OS (P &lt; .0005) and DFS (P &lt; .0073) were significantly inferior for I-TNBC.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">IBC with the triple negative phenotype is an aggressive disease with a significantly inferior outcome compared with non-inflammatory locally advanced TNBC. Newer strategies are required to improve survival outcome.</AbstractText>
                <CopyrightInformation>Copyright © 2016 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Biswas</LastName>
                    <ForeName>Tithi</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University Hospitals, Case Western Reserve University, Cleveland, OH. Electronic address: tithi.biswas@uhhospitals.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Efird</LastName>
                    <ForeName>Jimmy T</ForeName>
                    <Initials>JT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Health Disparities, Brody School of Medicine and Office of Research, College of Nursing, East Carolina University, Greenville, NC.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Prasad</LastName>
                    <ForeName>Shreya</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University of North Carolina, Chapel Hill, Chapel Hill, NC.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>James</LastName>
                    <ForeName>Sarah E</ForeName>
                    <Initials>SE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Mayo Clinic, Rochester, MN.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Walker</LastName>
                    <ForeName>Paul R</ForeName>
                    <Initials>PR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Public Health, East Carolina University, Greenville, NC; Division of Medical Oncology, Department of Medicine, East Carolina University, Greenville, NC.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zagar</LastName>
                    <ForeName>Timothy M</ForeName>
                    <Initials>TM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University of North Carolina, Chapel Hill, Chapel Hill, NC.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>02</Month>
                <Day>13</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Breast Cancer</MedlineTA>
            <NlmUniqueID>100898731</NlmUniqueID>
            <ISSNLinking>1526-8209</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D058922" MajorTopicYN="N">Inflammatory Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Inflammatory breast cancer</Keyword>
            <Keyword MajorTopicYN="N">Neoadjuvant chemotherapy</Keyword>
            <Keyword MajorTopicYN="N">Pathological complete response</Keyword>
            <Keyword MajorTopicYN="N">Survival</Keyword>
            <Keyword MajorTopicYN="N">Triple negative</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2015</Year>
                <Month>09</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2015</Year>
                <Month>12</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>02</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>3</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>3</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>4</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26988771</ArticleId>
            <ArticleId IdType="pii">S1526-8209(16)30024-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.clbc.2016.02.004</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">26842691</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>02</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1432-2323</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>40</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>World journal of surgery</Title>
                <ISOAbbreviation>World J Surg</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?</ArticleTitle>
            <Pagination>
                <MedlinePgn>1362-72</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00268-016-3422-4</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Triple-negative breast cancer (TNBC) is associated with aggressive tumor behavior and worse outcomes. In a study at a tertiary care breast unit in a developing country, clinico-pathological attributes and outcomes of patients with TNBC were compared with (c.w.) ER, PR, and/or HER2 expressing tumors (non-TNBC).</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Medical records of 1213 consecutive breast cancer patients managed during 2004-2010 were reviewed. An evaluable cohort of 705 patients with complete treatment and follow-up (median 36 months) information was thus identified. Patients were categorized per ER, PR &amp; HER2 status into TNBC, and ER/PR+ and/or HER2+ groups. Clinico-pathological parameters, response to NACT, and OS &amp; DFS were compared between TNBC and non-TNBC groups.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">TNBC patients (n = 249) comprised 35.3 % of the study cohort (n = 705), and were significantly younger than non-TNBC patients (mean age 49.1 ± 11.2y c.w. 51.8 ± 11.3, p = 0.02). The TNM stage at presentation was similar in the two groups (Stage I and II-37 % c.w. 44.3 %, Stage III-47.5 % c.w. 39.5 %, Stage IV-15.5 % c.w. 16.2 % in TNBC c.w. Non-TNBC; p = 0.09). Tumor size (5.7 ± 2.9 cm TNBC c.w. 5.4 ± 2.8 cm non-TNBC, p = 0.22) was similar but lymph nodal (cN) metastases were more frequent in TNBC (77.3 % c.w. 69.8 %; p = 0.03). TNBC had higher histologic grade (97.1 % gr II/III in TNBC c.w. 91.2 % non-TNBC, p = 0.01) and higher incidence of LVI (20.4 % in TNBC c.w. 13.5 %, p = 0.03). Patient groups received similar multi-disciplinary surgical, radiation, and systemic treatment. Comparable proportion of patients in 2 groups were treated with NACT (42 % c.w. 38 %), which resulted in pathological complete response (pCR) in 27.5 % TNBC patients c.w. 17.1 % non-TNBC patients (p = 0.04). Both OS (81.8 ± 4.52 c.w. 97.90 ± 3.87 months, p &lt; 0.001) and DFS (89.2 ± 5.1 c.w. 113.8 ± 4.3 months, p &lt; 0.001) were shorter in TNBC than non-TNBC group. On stage-wise comparison, OS differed significantly only in stage III (47.4 ± 5.3 months in TNBC c.w. 74.5 ± 4.4 in non-TNBC; p &lt; 0.001). Univariate and multivariate analyses revealed tumor stage and IHC subtyping into TNBC c.w. non-TNBC as most important factors predictive of survival.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">TNBC occurred at younger age and exhibited aggressive pathology as compared to non-TNBC patients. Although patients with TNBC exhibited better chemo-sensitivity, they had worse DFS and OS compared to the non-TNBC patients. The survival of Stage III TNBC patients was significantly worse compared to non-TNBC group; while in stages I, II, and IV, survival were not significantly different.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Agarwal</LastName>
                    <ForeName>Gaurav</ForeName>
                    <Initials>G</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-4194-2670</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Endocrine and Breast Surgery, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. gaurav@sgpgi.ac.in.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nanda</LastName>
                    <ForeName>Gitika</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Endocrine and Breast Surgery, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lal</LastName>
                    <ForeName>Punita</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mishra</LastName>
                    <ForeName>Anjali</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Endocrine and Breast Surgery, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Agarwal</LastName>
                    <ForeName>Amit</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Endocrine and Breast Surgery, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Agrawal</LastName>
                    <ForeName>Vinita</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Krishnani</LastName>
                    <ForeName>Narendra</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>World J Surg</MedlineTA>
            <NlmUniqueID>7704052</NlmUniqueID>
            <ISSNLinking>0364-2313</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011980">Receptors, Progesterone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060787" MajorTopicYN="N">Neoplasm Grading</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011980" MajorTopicYN="N">Receptors, Progesterone</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>2</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>2</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>2</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26842691</ArticleId>
            <ArticleId IdType="doi">10.1007/s00268-016-3422-4</ArticleId>
            <ArticleId IdType="pii">10.1007/s00268-016-3422-4</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Indian J Pathol Microbiol. 2009 Apr-Jun;52(2):171-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19332904</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2011 Jul;22(7):1554-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21242587</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>World J Surg Oncol. 2007 May 23;5:56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17519044</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2009 Oct 1;125(7):1663-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19452528</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>World J Surg. 2010 Oct;34(10):2308-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20607258</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast J. 2008 Sep-Oct;14(5):456-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18657139</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Virchows Arch. 2005 Oct;447(4):688-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16012853</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Apr 15;13(8):2329-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17438091</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2012 Nov 15;118(22):5463-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22544643</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2011 Aug;22(8):1736-47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21709140</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Oncol. 2011 Aug;18(4):191-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21874118</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2004 Dec 13;91(12):2012-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15558072</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2008 Mar 10;26(8):1275-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18250347</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2011 Jul;128(1):127-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21465170</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Med Oncol. 2013 Mar;30(1):388</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23292831</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2005 Oct 10;23(29):7265-77</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16145055</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Oncol Pharm Pract. 2012 Mar;18(1):68-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21422149</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2010 Aug;123(1):177-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20574671</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>World J Surg. 2007 May;31(5):1031-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17387549</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2008 May;109(1):123-39</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17578664</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2007 May 1;109(9):1721-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17387718</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11553815</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Jun 1;28(16):2784-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20404251</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Med Res. 2009 Jun;7(1-2):4-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19574486</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 2006 Jun 7;295(21):2492-502</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16757721</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">26682260</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>12</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">2331-4737</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>2</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2015</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Oncoscience</Title>
                <ISOAbbreviation>Oncoscience</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Chemotherapy with ceramide in TNBC.</ArticleTitle>
            <Pagination>
                <MedlinePgn>817-8</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Legembre</LastName>
                    <ForeName>Patrick</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centre Eugène Marquis, rue bataille Flandres Dunkerque, Université de Rennes-1, INSERM ERL440, Equipe Labellisée Ligue Contre Le Cancer, rue bataille Flandres-Dunkerque, Rennes, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Micheau</LastName>
                    <ForeName>Olivier</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centre Eugène Marquis, rue bataille Flandres Dunkerque, Université de Rennes-1, INSERM ERL440, Equipe Labellisée Ligue Contre Le Cancer, rue bataille Flandres-Dunkerque, Rennes, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ségui</LastName>
                    <ForeName>Bruno</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centre Eugène Marquis, rue bataille Flandres Dunkerque, Université de Rennes-1, INSERM ERL440, Equipe Labellisée Ligue Contre Le Cancer, rue bataille Flandres-Dunkerque, Rennes, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Oncoscience</MedlineTA>
            <NlmUniqueID>101636666</NlmUniqueID>
            <ISSNLinking>2331-4737</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CD95</Keyword>
            <Keyword MajorTopicYN="N">EMT</Keyword>
            <Keyword MajorTopicYN="N">TRAIL</Keyword>
            <Keyword MajorTopicYN="N">metastasis</Keyword>
            <Keyword MajorTopicYN="N">sphingolipids</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2015</Year>
                <Month>07</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2015</Year>
                <Month>08</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>12</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>12</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>12</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26682260</ArticleId>
            <ArticleId IdType="pmc">PMC4671935</ArticleId>
            <ArticleId IdType="pii">196</ArticleId>
            <ArticleId IdType="doi">10.18632/oncoscience.196</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Oncotarget. 2015 Apr 20;6(11):9502-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25909161</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2009 May 5;106(18):7461-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19380734</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2013 Nov 15;73(22):6711-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24072745</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2015 Feb 19;34(8):996-1005</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24632610</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Apoptosis. 2013 Mar;18(3):324-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23179179</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11445-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14504390</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Cell. 2015 Apr 13;27(4):561-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25843002</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochim Biophys Acta. 2014 Aug;1846(1):130-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24780723</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">26676166</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>12</Month>
            <Day>17</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">2214-6474</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>3</Volume>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>BBA clinical</Title>
                <ISOAbbreviation>BBA Clin</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The fate of chemoresistance in triple negative breast cancer (TNBC).</ArticleTitle>
            <Pagination>
                <MedlinePgn>257-75</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbacli.2015.03.003</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Treatment options for women presenting with triple negative breast cancer (TNBC) are limited due to the lack of a therapeutic target and as a result, are managed with standard chemotherapy such as paclitaxel (Taxol®). Following chemotherapy, the ideal tumour response is apoptotic cell death. Post-chemotherapy, cells can maintain viability by undergoing viable cellular responses such as cellular senescence, generating secretomes which can directly enhance the malignant phenotype.</AbstractText>
                <AbstractText Label="SCOPE OF REVIEW" NlmCategory="METHODS">How tumour cells retain viability in response to chemotherapeutic engagement is discussed. In addition we discuss the implications of this retained tumour cell viability in the context of the development of recurrent and metastatic TNBC disease. Current adjuvant and neo-adjuvant treatments available and the novel potential therapies that are being researched are also reviewed.</AbstractText>
                <AbstractText Label="MAJOR CONCLUSIONS" NlmCategory="CONCLUSIONS">Cellular senescence and cytoprotective autophagy are potential mechanisms of chemoresistance in TNBC. These two non-apoptotic outcomes in response to chemotherapy are inextricably linked and are neglected outcomes of investigation in the chemotherapeutic arena. Cellular fate assessments may therefore have the potential to predict TNBC patient outcome.</AbstractText>
                <AbstractText Label="GENERAL SIGNIFICANCE" NlmCategory="CONCLUSIONS">Focusing on the fact that cancer cells can bypass the desired cellular apoptotic response to chemotherapy through cellular senescence and cytoprotective autophagy will highlight the importance of targeting non-apoptotic survival pathways to enhance chemotherapeutic efficacy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>O'Reilly</LastName>
                    <ForeName>Elma A</ForeName>
                    <Initials>EA</Initials>
                    <AffiliationInfo>
                        <Affiliation>UCD Conway Institute of Biomolecular and Biomedical Research, UCD School of Medicine and Medical Science (SMMS), Belfield, Dublin 4, Ireland ; Department of Surgery, Mater Misericordiae Hospital, Dublin 7, Ireland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gubbins</LastName>
                    <ForeName>Luke</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>UCD Conway Institute of Biomolecular and Biomedical Research, UCD School of Medicine and Medical Science (SMMS), Belfield, Dublin 4, Ireland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sharma</LastName>
                    <ForeName>Shiva</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>UCD Conway Institute of Biomolecular and Biomedical Research, UCD School of Medicine and Medical Science (SMMS), Belfield, Dublin 4, Ireland ; Department of Surgery, Mater Misericordiae Hospital, Dublin 7, Ireland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tully</LastName>
                    <ForeName>Riona</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>UCD Conway Institute of Biomolecular and Biomedical Research, UCD School of Medicine and Medical Science (SMMS), Belfield, Dublin 4, Ireland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guang</LastName>
                    <ForeName>Matthew Ho Zhing</ForeName>
                    <Initials>MH</Initials>
                    <AffiliationInfo>
                        <Affiliation>UCD Conway Institute of Biomolecular and Biomedical Research, UCD School of Medicine and Medical Science (SMMS), Belfield, Dublin 4, Ireland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Weiner-Gorzel</LastName>
                    <ForeName>Karolina</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>UCD Conway Institute of Biomolecular and Biomedical Research, UCD School of Medicine and Medical Science (SMMS), Belfield, Dublin 4, Ireland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McCaffrey</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Mater Misericordiae Hospital, Dublin 7, Ireland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Harrison</LastName>
                    <ForeName>Michele</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Mater Misericordiae Hospital, Dublin 7, Ireland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Furlong</LastName>
                    <ForeName>Fiona</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Queens University Belfast, Belfast BT7 1NN, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kell</LastName>
                    <ForeName>Malcolm</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Mater Misericordiae Hospital, Dublin 7, Ireland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McCann</LastName>
                    <ForeName>Amanda</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>UCD Conway Institute of Biomolecular and Biomedical Research, UCD School of Medicine and Medical Science (SMMS), Belfield, Dublin 4, Ireland.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>03</Month>
                <Day>12</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>BBA Clin</MedlineTA>
            <NlmUniqueID>101633879</NlmUniqueID>
            <ISSNLinking>2214-6474</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cellular fates</Keyword>
            <Keyword MajorTopicYN="N">Cellular senescence</Keyword>
            <Keyword MajorTopicYN="N">Chemoresistance</Keyword>
            <Keyword MajorTopicYN="N">Hypoxia</Keyword>
            <Keyword MajorTopicYN="N">Triple negative breast cancer (TNBC)</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>12</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2015</Year>
                <Month>03</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2015</Year>
                <Month>03</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>12</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>12</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>12</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26676166</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbacli.2015.03.003</ArticleId>
            <ArticleId IdType="pii">S2214-6474(15)00017-3</ArticleId>
            <ArticleId IdType="pmc">PMC4661576</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Cell. 2011 Mar 4;144(5):703-18</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21376233</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochim Biophys Acta. 2011 Jul;1813(7):1263-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20732359</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncol Lett. 2013 Mar;5(3):983-991</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23426861</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Cycle. 2011 Jun 1;10(11):1772-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21558814</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Med Oncol. 2013 Mar;30(1):475</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23371253</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2006 May 1;66(9):4636-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16651414</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Autophagy. 2012 Jun;8(6):927-37</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22692030</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Biol. 2000 Sep 18;150(6):1467-78</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10995450</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Apoptosis. 2008 Jan;13(1):1-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17990121</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2001 Aug 28;98 (18):10314-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11504908</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2013 Oct 22;8(10 ):e78259</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24167614</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Crit Rev Oncol Hematol. 2011 Dec;80(3):347-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21288735</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2011 Jul;121(7):2750-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21633166</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1997 Aug;15(8):2894-904</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9256133</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2009 Oct;20(10):1639-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19549711</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2008 Dec 15;14(24):8010-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19088017</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2009 Jul;116(2):317-28</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18839307</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Sci (Lond). 2009 May;116(9):697-712</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19323652</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2009 Jul;20(7):1185-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19218307</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Clin Oncol. 2010 Jan;7(1):22-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19997076</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Pathol. 2013 Jun;66(6):491-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23539738</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Res. 2011 May;9(5):538-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21385881</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Lett. 2011 Jun 1;305(1):94-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21421285</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncology (Williston Park). 2008 Oct;22(11):1233-9; discussion 1239-40, 1243</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18980022</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Chemother Pharmacol. 2002 Apr;49(4):309-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11914911</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2008 Oct;111(3):411-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17968656</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biomed Res Int. 2014;2014:603980</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25328887</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2010 Jan 15;16(2):681-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20068102</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2004 Aug 15;10(16):5367-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15328174</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2007 Nov;105(3):319-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17268817</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Pathol. 2009 Apr;174(4):1230-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19246646</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2007 Dec;7(12 ):961-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17972889</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Autophagy. 2007 Jul-Aug;3(4):295-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17404494</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2002 Jan 15;99(2):507-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11781231</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast J. 2012 Jan-Feb;18(1):41-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22098334</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gerontology. 1999 Jan-Feb;45(1):23-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9852377</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 1973 Jan;52(1):73-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">4345203</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2000 Aug 17;406(6797):747-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10963602</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2001 May 15;19(10):2714-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11352964</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ther Adv Med Oncol. 2013 May;5(3):169-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23634195</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>FEBS J. 2007 Oct;274(19):5137-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17803681</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2011 Feb;125(3):627-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21161370</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2008 Apr 10;26(11):1810-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18347007</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 1994 Feb 17;367(6464):645-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7509044</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Med Genomics. 2011 Nov 01;4:77</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22044755</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13820-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19666588</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Apr 15;13(8):2329-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17438091</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Transl Med. 2013 Jan 17;2(1):3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23369605</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Emerg Med. 2000 Apr;35(4):363-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10736123</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2004 Mar 12;279(11):9987-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14679207</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16472-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17060621</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2013;15(5):R88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24063698</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Proteome Res. 2009 Jul;8(7):3430-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19485423</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2012 Aug;23 Suppl 6:vi56-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23012305</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann N Y Acad Sci. 2006 Dec;1090:298-304</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17384273</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>NMR Biomed. 2012 Feb;25(2):369-78</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21823183</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 1996 Jul 4;13(1):63-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8700555</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2011 Aug 3;103(15):1148-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21768534</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2001 Aug 15;93(4):571-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11477562</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hum Mol Genet. 2009 Oct 1;18(19):3594-604</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19584087</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Acta Oncol. 2000;39(3):327-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10987229</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Autophagy. 2011 Aug;7(8):829-39</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21685724</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2005 Aug 4;436(7051):642</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16079833</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Cycle. 2012 Mar 15;11(6):1108-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22313602</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Arch Anat Microsc Morphol Exp. 1967;56(3):547-69</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">5615176</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem Biophys Res Commun. 2005 Jun 10;331(3):718-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15865928</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Cycle. 2011 Jun 1;10(11):1794-809</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21521946</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2012 Nov;136(2):487-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23053638</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12829800</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Cycle. 2012 Nov 15;11(22):4167-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23047605</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2009 Apr 1;15(7):2472-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19276248</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2012 Oct;56(4):1331-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22505225</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1999 Mar;17(3):1061-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10071301</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Antioxid Redox Signal. 2005 May-Jun;7(5-6):711-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15890017</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2012 Sep;23 (9):2223-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22517820</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2014 Jun;25(6):1122-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24669015</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Oncol. 1998 Aug;13(2):217-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9664114</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2009 Jul 9;361(2):123-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19553641</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Cycle. 2012 Dec 1;11(23):4402-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23172369</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pathol. 2005 Jan;205(2):275-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15641020</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2001 Jan 15;19(2):354-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11208826</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2012 Nov;136(1):67-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22976806</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2006 Oct 1;12(19):5794-800</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17020986</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2005 Oct;115(10):2679-88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16200202</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2008 May 20;26(15):2568-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18487574</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2004 Feb 1;10(3):1013-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14871980</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2009 May 15;69(10 ):4116-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19435916</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2010 Jul 24;376(9737):235-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20609467</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2011 May 10;104(10):1564-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21487404</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2009 Jun;8(6):1702-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19509259</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Imaging Biol. 2010 Dec;12(6):657-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20012701</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 2008 May 16;133(4):704-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18485877</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Respir Med. 2009 Mar;103(3):434-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18993042</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Nucl Med. 2012 Feb;26(2):175-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22139552</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2008 Mar 10;26(8):1275-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18250347</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2008 Mar 1;112(5):995-1000</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18098228</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2009 Nov 18;101(22):1536-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19880812</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2011 Apr;126(2):421-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20957430</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer J. 2010 Jan-Feb;16(1):62-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20164692</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2006 Dec 20;24(36):5652-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17116942</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2009 Apr 15;69(8):3589-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19351835</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Semin Cancer Biol. 2011 Dec;21(6):397-404</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21945348</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2004 Aug 31;91(5):954-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15328513</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cell Biol. 2012;2012:317645</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22496691</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Semin Cancer Biol. 2011 Dec;21(6):385-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21982725</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oxid Med Cell Longev. 2010 May-Jun;3(3):168-77</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20716941</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biomed Pharmacother. 2012 Feb;66(1):70-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22264882</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Cell. 2006 Jul;10 (1):51-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16843265</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2005 May;16 Suppl 4:iv14-19</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15923415</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Biochem Cell Biol. 2011 Jul;43(7):1045-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21300172</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2009 Sep 20;27(27):4536-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19687332</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2008;10(3):R45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18474099</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Pathol. 2004 May;164(5):1683-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15111315</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Pathol. 2013 Jun;66(6):530-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23436929</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2013;15(5):R78</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24020991</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2011 Aug 1;29(22):2978-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21709197</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem J. 2013 Jan 15;449(2):389-400</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23078367</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Acta Pharmacol Sin. 2005 Dec;26(12 ):1421-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16297339</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2008 Jun 18;100(12):836-7, 844</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18544732</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Cell Int. 2011 Feb 14;11:3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21320311</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2012 Jun;133(2):607-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22005836</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer. 2010 Jul 13;9:191</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20626868</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1999 Jul;17(7):1983-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10561248</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncologist. 2011;16 Suppl 1:1-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21278435</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Dev Immunol. 2013;2013:785317</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23861693</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Med Oncol. 2011 Dec;28(4):1302-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20652449</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>ScientificWorldJournal. 2010 Apr 13;10:727-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20419281</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2005 Jul 15;11(14):5175-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16033833</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Lett. 2012 Dec 1;325(1):63-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22664238</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Carcinogenesis. 2001 Jul;22(7):999-1013</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11408342</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2006 Jun 29;25(28):3994-4008</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16491124</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2012 Jul 20;30(21):2615-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22665533</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Breast Cancer. 2008 Jun;8(3):234-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18650153</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2009 Nov 1;125(9):2198-204</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19623660</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2007 Aug 15;110(4):876-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17620276</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2011 Jan 20;364(3):205-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21208101</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2011 Nov 24;30(47):4687-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21666712</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncologist. 1996;1(1 &amp; 2):82-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10387972</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Oncol. 2011 Sep;12(9):852-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21862407</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2009 May 1;27(13):2278-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19332717</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2010 Aug;123(1):139-47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19921427</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2002 Mar 1;62(5):1443-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11888918</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Nucl Med. 2012 Feb;53(2):249-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22241914</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2012 Mar 20;30(9):921-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22331954</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2001 Nov 15;61(22):8171-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11719447</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Lett. 2011 Aug 28;307(2):141-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21511395</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Semin Hematol. 1997 Oct;34(4 Suppl 5):48-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9408961</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Lett. 2012 Feb 28;315(2):112-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22093617</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2012 Jan 26;366(4):299-309</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22276820</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2008 Jul 3;27(29):4086-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18332865</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2005 May;16(5):743-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15802278</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2012 Jan 26;366(4):310-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22276821</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Death Dis. 2013 Jan 17;4:e457</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23328664</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2012 Aug;23 Suppl 6:vi23-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23012298</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Oncol (R Coll Radiol). 2012 Aug;24(6):387-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22032864</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pathobiology. 2010;77(6):289-300</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21266827</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2011 Mar 1;17(5):1082-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21233401</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2014 Feb;143(3):485-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24395109</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2004 Oct;4(10):814-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15510162</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Res. 2014 Aug;24(8):904-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24810303</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 2011 Feb 2;305(5):487-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21285426</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5429-38</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25453096</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2011 Nov 1;17(21):6905-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22028489</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cold Spring Harb Symp Quant Biol. 2011;76:389-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22442109</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2011 Jul 08;13(4):213</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21867571</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Anticancer Agents Med Chem. 2008 Oct;8(7):790-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18855580</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Jan 1;28(1):105-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19917869</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Nucl Med. 2008 Jun;49 Suppl 2:43S-63S</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18523065</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem Pharmacol. 2011 Sep 1;82(5):427-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21704023</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Semin Cancer Biol. 2013 Oct;23(5):361-79</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23811268</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Biochem. 1997 Nov 15;250(1):115-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9431998</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2010 Oct 1;16(19):4702-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20858840</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Cell. 2007 Sep;12(3):230-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17785204</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Biochem Cell Biol. 2002 Nov;34(11):1401-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12200035</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2010;12(5):R68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20813035</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2011 Nov 15;71(22):6921-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22084445</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14519755</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Med. 1996 Jul;2(7):811-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8673929</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Physiol. 1990 Feb;142(2):425-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1689321</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Breast Cancer. 2009 Jun;9 Suppl 2:S73-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19596646</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2009 Jan 27;100(2):405-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19165203</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2012 Mar 15;12 (4):298-306</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22419253</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Clin Oncol. 2011 May 17;8(9):528-39</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21587219</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neoplasia. 2014 Mar;16(3):247-56, 256.e2</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24784001</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2008 Apr 18;283(16):10892-903</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18281291</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cancer Res Clin Oncol. 2011 Feb;137(2):183-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21069385</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2014 Sep 20;32(27):2959-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25071121</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2010;12 Suppl 2:S3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21050424</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Circ Res. 2008 Aug 15;103(4):343-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18703786</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2007 May 15;120(10):2078-85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17285590</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2012 Aug;23 Suppl 6:vi46-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23012302</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):467-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17255267</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2005 Apr 14;434(7035):917-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15829967</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2007 Nov 20;25(33):5210-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17968020</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2013 Nov 1;31(31):3997-4013</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24101045</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2003 Jan;3(1):23-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12509764</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer (Auckl). 2011;5:175-99</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21863131</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Biol. 2009 May;29(10 ):2570-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19273585</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2011 Oct 20;11:452</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22011459</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Death Dis. 2013 May 16;4:e638</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23681233</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Autophagy. 2008 Feb;4(2):195-204</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18059169</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17671126</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2010 Mar;21(3):488-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19887463</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ther Adv Med Oncol. 2012 Jul;4(4):195-210</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22754593</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11553815</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Endocr Relat Cancer. 2003 Mar;10(1):43-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12653670</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2008 Mar 1;14(5):1368-76</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18316557</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2015 Jan 1;33(1):13-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25092775</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Jun 1;28(16):2784-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20404251</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 1998 Feb 5;391(6667):597-601</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9468139</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Exp Oncol. 2009 Jun;31(2):123-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19550405</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Annu Rev Med. 2007;58:267-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17002552</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Exp Gerontol. 2000 Mar;35(2):187-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10767578</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Histopathology. 2014 Apr;64(5):609-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24382093</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 2006 Jun 7;295(21):2492-502</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16757721</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2001 May 17;411(6835):366-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11357144</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 1997 Oct 1;57(19):4285-300</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9331090</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Cycle. 2010 Jul 15;9(14 ):2856-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20676051</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2013 Mar;123(3):1348-58</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23391723</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Jpn J Clin Oncol. 2008 Apr;38(4):250-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18407934</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Discov. 2014 Feb;4(2):232-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24356096</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">26432786</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>11</Month>
            <Day>03</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1078-0432</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>22</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>Feb</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title>
                <ISOAbbreviation>Clin. Cancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.</ArticleTitle>
            <Pagination>
                <MedlinePgn>923-34</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1158/1078-0432.CCR-15-0187</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype that is associated with poor clinical outcome. There is a vital need for effective targeted therapeutics for TNBC patients, yet treatment strategies are challenged by the significant intertumoral heterogeneity within the TNBC subtype and its surrounding microenvironment. Receptor tyrosine kinases (RTK) are highly expressed in several TNBC subtypes and are promising therapeutic targets. In this study, we targeted the MET receptor, which is highly expressed across several TNBC subtypes.</AbstractText>
                <AbstractText Label="EXPERIMENTAL DESIGN" NlmCategory="METHODS">Using the small-molecule inhibitor cabozantinib (XL184), we examined the efficacy of MET inhibition in preclinical models that recapitulate human TNBC and its microenvironment. To analyze the dynamic interactions between TNBC cells and fibroblasts over time, we utilized a 3D model referred to as MAME (Mammary Architecture and Microenvironment Engineering) with quantitative image analysis. To investigate cabozantinib inhibition in vivo, we used a novel xenograft model that expresses human HGF and supports paracrine MET signaling.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">XL184 treatment of MAME cultures of MDA-MB-231 and HCC70 cells (± HGF-expressing fibroblasts) was cytotoxic and significantly reduced multicellular invasive outgrowths, even in cultures with HGF-expressing fibroblasts. Treatment with XL184 had no significant effects on MET(neg) breast cancer cell growth. In vivo assays demonstrated that cabozantinib treatment significantly inhibited TNBC growth and metastasis.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Using preclinical TNBC models that recapitulate the breast tumor microenvironment, we demonstrate that cabozantinib inhibition is an effective therapeutic strategy in several TNBC subtypes.</AbstractText>
                <CopyrightInformation>©2015 American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sameni</LastName>
                    <ForeName>Mansoureh</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology, Wayne State University School of Medicine, Detroit, Michigan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tovar</LastName>
                    <ForeName>Elizabeth A</ForeName>
                    <Initials>EA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Cancer and Cell Biology, Van Andel Research Institute, Grand Rapids, Michigan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Essenburg</LastName>
                    <ForeName>Curt J</ForeName>
                    <Initials>CJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Cancer and Cell Biology, Van Andel Research Institute, Grand Rapids, Michigan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chalasani</LastName>
                    <ForeName>Anita</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology, Wayne State University School of Medicine, Detroit, Michigan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Linklater</LastName>
                    <ForeName>Erik S</ForeName>
                    <Initials>ES</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Cancer and Cell Biology, Van Andel Research Institute, Grand Rapids, Michigan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Borgman</LastName>
                    <ForeName>Andrew</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bioinformatics and Biostatistics Core, Van Andel Research Institute, Grand Rapids, Michigan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cherba</LastName>
                    <ForeName>David M</ForeName>
                    <Initials>DM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bioinformatics and Biostatistics Core, Van Andel Research Institute, Grand Rapids, Michigan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Anbalagan</LastName>
                    <ForeName>Arulselvi</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology, Wayne State University School of Medicine, Detroit, Michigan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Winn</LastName>
                    <ForeName>Mary E</ForeName>
                    <Initials>ME</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bioinformatics and Biostatistics Core, Van Andel Research Institute, Grand Rapids, Michigan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Graveel</LastName>
                    <ForeName>Carrie R</ForeName>
                    <Initials>CR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Cancer and Cell Biology, Van Andel Research Institute, Grand Rapids, Michigan. carrie.graveel@vai.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sloane</LastName>
                    <ForeName>Bonnie F</ForeName>
                    <Initials>BF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology, Wayne State University School of Medicine, Detroit, Michigan. Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P30 CA022453</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA056586</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA131990</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>10</Month>
                <Day>02</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Cancer Res</MedlineTA>
            <NlmUniqueID>9502500</NlmUniqueID>
            <ISSNLinking>1078-0432</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000813">Anilides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>1C39JW444G</RegistryNumber>
                <NameOfSubstance UI="C558660">cabozantinib</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C491743">MET protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D019859">Proto-Oncogene Proteins c-met</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000813" MajorTopicYN="N">Anilides</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018920" MajorTopicYN="N">Coculture Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008809" MajorTopicYN="N">Mice, Inbred C3H</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019859" MajorTopicYN="N">Proto-Oncogene Proteins c-met</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D047368" MajorTopicYN="N">Tumor Burden</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2015</Year>
                <Month>01</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2015</Year>
                <Month>09</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>10</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>10</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26432786</ArticleId>
            <ArticleId IdType="pii">1078-0432.CCR-15-0187</ArticleId>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-15-0187</ArticleId>
            <ArticleId IdType="pmc">PMC5500174</ArticleId>
            <ArticleId IdType="mid">NIHMS869740</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Med. 2008 May;14(5):518-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18438415</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Methods Enzymol. 2012;506:175-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22341225</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12909-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19567831</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2014 Jan 15;120(2):163-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24150964</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2011 Jul;121(7):2750-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21633166</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pathol Int. 2001 Mar;51(3):172-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11328532</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Res. 2011 Jan;9(1):3-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21131600</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2010 Nov 11;363(20):1938-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21067385</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biol Chem. 2012 Dec;393(12):1405-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23667900</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Dec 15;13(24):7280-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18094408</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2011 Dec;10(12):2298-308</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21926191</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Med Oncol. 2014 Jan;31(1):801</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24326984</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Drug Discov. 2014 Aug;13(8):563-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25082276</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4966-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15051869</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Cell. 2003 Apr;3(4):347-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12726861</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14685170</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2012 Jul 26;487(7408):505-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22763448</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2009 Dec 1;69(23):9148-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19920187</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Adv Pharmacol. 2012;65:45-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22959023</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Biol. 1992 Nov;12(11):5152-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1406687</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2002 Aug 30;277(35):32220-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12072442</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2008 Mar 10;26(8):1275-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18250347</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2010 Sep 1;70(17):6880-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20643778</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 1998 Apr 15;82(8):1513-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9554529</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2003 Apr 15;97(8):1841-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12673709</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Res. 2013 Sep;11(9):1112-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23825050</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Med. 2009 Jan;15(1):68-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19122658</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Vis Exp. 2012 Feb 17;(60):null</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22371028</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2010 May 15;70(10):3857-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20406984</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Biotechnol. 2014 May;32(5):399-400</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24811494</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2015 Apr 1;21(7):1688-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25208879</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2007 Jun;103(2):167-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17028975</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2013 Jun 1;19(11):3088-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23553848</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2011 Jun;11(6):393-410</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21606941</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2005 Jan 6;24(1):101-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15531925</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Endocrinol Metab. 2000 Feb;85(2):837-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10690899</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2014 Sep 4;33(36):4474-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24077280</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 1999 Dec 1;86(11):2259-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10590366</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2005 Sep;5(9):675-88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16148884</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Exp Metastasis. 2012 Oct;29(7):663-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22684404</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Adv Drug Deliv Rev. 2014 Apr;69-70:42-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24412474</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2013 Feb 1;31(4):412-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23169517</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2005 Feb 10;113(4):678-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15455388</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12903-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19617568</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17671126</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2012 Aug 15;18(16):4385-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22745104</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neoplasia. 2013 Oct;15(10):1125-37</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24204192</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">26405612</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">2162-4011</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>4</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Oncoimmunology</Title>
                <ISOAbbreviation>Oncoimmunology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC).</ArticleTitle>
            <Pagination>
                <MedlinePgn>e985930</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Upon analysis of archived primary tumors of 482 patients with triple negative breast cancer (TNBC) enrolled in two randomized Phase III adjuvant chemotherapy trials, we have found that tumor infiltrating lymphocytes (TILs), as assessed and quantified by hematoxylin and eosin (H&amp;E) staining are a robust and independent predictor of disease-free survival (DFS), distant recurrence-free interval (DRFI) and overall survival (OS).<sup>1</sup> Our findings provide confirmation of results observed in TNBC in a European adjuvant chemotherapy dataset and therefore elevate TILs as prognostic biomarker for operable TNBC to level I evidence.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Adams</LastName>
                    <ForeName>Sylvia</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>New York University School of Medicine ; New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Goldstein</LastName>
                    <ForeName>Lori J</ForeName>
                    <Initials>LJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Fox Chase Cancer Center ; Philadelphia, PA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sparano</LastName>
                    <ForeName>Joseph A</ForeName>
                    <Initials>JA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Albert Einstein Medical Center ; Bronx, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Demaria</LastName>
                    <ForeName>Sandra</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>New York University School of Medicine ; New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Badve</LastName>
                    <ForeName>Sunil S</ForeName>
                    <Initials>SS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Indiana University ; Indianapolis, IN, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P30 CA016087</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U10 CA180795</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>UL1 TR001073</GrantID>
                    <Acronym>TR</Acronym>
                    <Agency>NCATS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>07</Month>
                <Day>27</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Oncoimmunology</MedlineTA>
            <NlmUniqueID>101570526</NlmUniqueID>
            <ISSNLinking>2162-4011</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">TNBC</Keyword>
            <Keyword MajorTopicYN="N">biomarker</Keyword>
            <Keyword MajorTopicYN="N">breast cancer</Keyword>
            <Keyword MajorTopicYN="N">tumor infiltrating lymphocytes</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>11</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>11</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>9</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>9</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>9</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26405612</ArticleId>
            <ArticleId IdType="doi">10.4161/2162402X.2014.985930</ArticleId>
            <ArticleId IdType="pii">985930</ArticleId>
            <ArticleId IdType="pmc">PMC4570112</ArticleId>
        </ArticleIdList>
        <?pmcsd?>
        <ReferenceList>
            <Reference>
                <Citation>Ann Oncol. 2015 Feb;26(2):259-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25214542</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Opin Immunol. 2013 Apr;25(2):268-76</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23579075</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Immunity. 2013 Jul 25;39(1):11-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23890060</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2014 Aug 14;512(7513):155-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25079324</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2013 Mar 1;31(7):836-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23341523</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Med. 2013 Jun;19(6):747-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23644516</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2796-801</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21825174</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2013 Mar 1;31(7):860-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23341518</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2014 Sep 20;32(27):2959-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25071121</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Immunol Res. 2014 Apr;2(4):361-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24764583</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">26350593</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>09</Month>
            <Day>09</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Print">2076-393X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>3</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Jul</Month>
                        <Day>06</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Vaccines</Title>
                <ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC).</ArticleTitle>
            <Pagination>
                <MedlinePgn>519-43</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines3030519</ELocationID>
            <Abstract>
                <AbstractText>Despite the promise of targeted therapies, there remains an urgent need for effective treatment for esophageal cancer (EC) and triple-negative breast cancer (TNBC). Current FDA-approved drugs have significant problems of toxicity, safety, selectivity, efficacy and development of resistance. In this manuscript, we demonstrate that rationally designed peptide vaccines/mimics are a viable therapeutic strategy for blocking aberrant molecular signaling pathways with high affinity, specificity, potency and safety. Specifically, we postulate that novel combination treatments targeting members of the EGFR family and IGF-1R will yield significant anti-tumor effects in in vitro models of EC and TNBC possibly overcoming mechanisms of resistance. We show that the combination of HER-1 and HER-2 or HER-1 and IGF-1R peptide mimics/vaccine antibodies exhibited enhanced antitumor properties with significant inhibition of tumorigenesis in OE19 EC and MDA-MB-231 TNBC cell lines. Our work elucidates the mechanisms of HER-1/IGF-1R and HER-1/HER-2 signaling in these cancer cell lines, and the promising results support the rationale for dual targeting with HER-1 and HER-2 or IGF-1R as an improved treatment regimen for advanced therapy tailored to difference types of cancer. </AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Overholser</LastName>
                    <ForeName>Jay</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA. jay.overholser@osumc.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ambegaokar</LastName>
                    <ForeName>Kristen Henkins</ForeName>
                    <Initials>KH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA. kristen.ambegaokar@osumc.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eze</LastName>
                    <ForeName>Siobhan M</ForeName>
                    <Initials>SM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology, Emory University and Winship Cancer Institute, Atlanta, GA 30322, USA. siobhan.maureen.donnelly@emory.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sanabria-Figueroa</LastName>
                    <ForeName>Eduardo</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Molecular and Systems Pharmacology Program, Graduate Division of Biological and Biomedical Sciences, Emory University, Atlanta, GA 30322, USA. esanab2@emory.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nahta</LastName>
                    <ForeName>Rita</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology, Emory University and Winship Cancer Institute, Atlanta, GA 30322, USA. esanab2@emory.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Molecular and Systems Pharmacology Program, Graduate Division of Biological and Biomedical Sciences, Emory University, Atlanta, GA 30322, USA. esanab2@emory.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bekaii-Saab</LastName>
                    <ForeName>Tanios</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>James Cancer Hospital and Solove Research Institute and the Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA. Tanios.Saab@osumc.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kaumaya</LastName>
                    <ForeName>Pravin T P</ForeName>
                    <Initials>PT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA. Kaumaya.1@osu.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>James Cancer Hospital and Solove Research Institute and the Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA. Kaumaya.1@osu.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R01 CA084356</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA157754</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>T32 GM008602</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>07</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Vaccines (Basel)</MedlineTA>
            <NlmUniqueID>101629355</NlmUniqueID>
            <ISSNLinking>2076-393X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">antibodies</Keyword>
            <Keyword MajorTopicYN="N">epitopes</Keyword>
            <Keyword MajorTopicYN="N">immunogenicity</Keyword>
            <Keyword MajorTopicYN="N">peptide mimics</Keyword>
            <Keyword MajorTopicYN="N">peptide vaccines</Keyword>
            <Keyword MajorTopicYN="N">resistance</Keyword>
            <Keyword MajorTopicYN="N">vaccine candidates</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2015</Year>
                <Month>04</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2015</Year>
                <Month>06</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2015</Year>
                <Month>06</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>9</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>9</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>9</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26350593</ArticleId>
            <ArticleId IdType="pii">vaccines3030519</ArticleId>
            <ArticleId IdType="doi">10.3390/vaccines3030519</ArticleId>
            <ArticleId IdType="pmc">PMC4586465</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Mol Cell Biol. 1989 Mar;9(3):1165-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2566907</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Protein Eng Des Sel. 2006 Aug;19(8):377-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16772308</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2011 Apr 15;286(15):13612-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21321115</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Invest. 2001;19(5):554-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11458821</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2005 Dec 1;65(23 ):11118-28</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16322262</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncology (Williston Park). 2006 Dec;20(14 Suppl 10):21-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17354514</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Clin Pract Oncol. 2006 Jan;3(1):24-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16407877</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2013 Jul 10;31(20):2586-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23733761</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncol Rep. 2012 May;27(5):1639-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22293713</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Tumori. 2013 Jul-Aug;99(4):545-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24326846</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Treat Rev. 2010 May;36(3):206-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20060649</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2005;7(4):R570-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15987464</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2005 Jun;92 Suppl 1:S6-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15928657</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2008 Jan 3;358(1):36-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18172173</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Jpn J Clin Oncol. 2002 Mar;32 Suppl:S10-2</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11959871</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Invest New Drugs. 1999;17(3):195-212</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10665474</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Drug Discov. 2006 Aug;5(8):649-59</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16883303</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2001 Jan 4;20(1):34-47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11244498</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Mol Med. 2009 Sep;13(9B):3826-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19292734</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2005 Feb;16(2):273-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15668283</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mod Pathol. 2006 Feb;19(2):264-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16341146</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 1997 Jul 17;337(3):161-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9219702</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncology (Williston Park). 2000 Apr;14(4):507-14; discussion 518-20, 522-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10826312</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hypertension. 2002 Jun;39(6):1095-100</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12052848</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 2006 May 26;312(5777):1175-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16728632</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncoimmunology. 2012 Oct 1;1(7):1048-1060</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23170253</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Semin Oncol. 2003 Oct;30(5 Suppl 16):117-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14613032</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2004 Jan 1;64(1):169-79</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14729621</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncologist. 2011;16(11):1535-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22020213</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15761078</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 1971 Nov 18;285(21):1182-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">4938153</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2005 Apr 11;92(7):1253-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15785739</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Clin Pathol. 2002 Jul;118(1):60-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12109857</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2009 Jul;9(7):463-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19536107</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Biochem Biophys. 2012 Jan;62(1):221-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21927816</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Jul 10;28(20):3366-79</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20530283</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lab Invest. 2001 Jun;81(6):791-801</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11406641</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2005 Apr 10;23(11):2445-59</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15753456</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2014 Dec;124(12):5145-58</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25401468</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2012 Mar 8;366(10):883-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22397650</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2013 Jun 19;13:297</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23777562</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neoplasia. 2011 Jun;13(6):504-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21677874</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Endocrinol. 1991 Dec;5(12):1806-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1791831</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Oncol. 2013 May;14 (6):461-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23602601</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Immunol. 2003 Apr 15;170(8):4242-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12682258</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncoimmunology. 2012 Oct 1;1(7):1004-1016</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23170249</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2000 Dec 11;19(53):6102-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11156523</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mod Pathol. 2014 Sep;27(9):1212-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24406864</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2007 Oct 10;25(29):4557-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17876013</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Immunol. 1991 May;11(3):117-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1679763</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2011 Apr 15;17(8):2314-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21177763</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2011 Apr 15;286(15):13626-37</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21325276</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>World J Surg. 1999 Oct;23(10):1010-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10512940</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2005 May;5(5):341-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15864276</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Therap Adv Gastroenterol. 2012 Sep;5(5):301-18</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22973416</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>World J Gastroenterol. 2006 Feb 14;12(6):928-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16521222</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11252954</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2012 Jul 20;30(21):2615-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22665533</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer. 2011 Mar 23;10:30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21429221</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hum Pathol. 2009 Jun;40(6):769-77</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19269014</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2006 Oct 15;66(20):10100-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17047074</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Cancer. 2006 Dec;42(18):3127-39</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17098419</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2013 May 15;19(10):2723-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23549873</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pharmacol Rev. 2004 Dec;56(4):549-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15602010</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Immunol. 2007 Jul 1;179(1):472-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17579068</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Med Sci Monit. 2002 Dec;8(12):BR521-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12503030</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Treat Rev. 2010 Aug;36(5):400-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20117883</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncoimmunology. 2014 Dec 21;3(11):e956012</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25941588</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Exp Med. 2016 May;16(2):161-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25716471</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2009 Nov 1;27(31):5270-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19752336</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Endocrinology. 2004 Nov;145(11):4976-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15271882</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncoimmunology. 2014 Dec 21;3(11):e956005</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25941587</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Immunol. 2007 Jun 1;178(11):7120-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17513761</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2004 Jul;4(7):505-18</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15229476</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Breast Cancer. 2003 Jun;4(2):142-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12864943</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Mol Life Sci. 2000 Jul;57(7):1050-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10961344</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2010 Jul;9(7):2037-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20606043</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Anticancer Res. 2013 Oct;33(10):4139-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24122977</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17671126</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Novartis Found Symp. 2004;262:84-98; discussion 98-107, 265-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15562824</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 1995 Aug 9;274(6):474-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7629956</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2010 Aug 28;376(9742):687-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20728210</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2008 Jul;118(7):2609-19</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18568074</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Immunol. 2013 Jul 1;191(1):217-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23698748</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2009 Dec;20(12):1913-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19901010</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pharmacol Exp Ther. 2000 Oct;295(1):190-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10991978</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">26298547</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>06</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1945-4589</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>7</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Aging</Title>
                <ISOAbbreviation>Aging (Albany NY)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cripto-1 in TNBC.</ArticleTitle>
            <Pagination>
                <MedlinePgn>515-6</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Castro</LastName>
                    <ForeName>Nadia P</ForeName>
                    <Initials>NP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Tumor Growth Factor Section, Mouse Cancer Genetics Program, National Cancer Institute, Frederick, MD, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Salomon</LastName>
                    <ForeName>David S</ForeName>
                    <Initials>DS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Tumor Growth Factor Section, Mouse Cancer Genetics Program, National Cancer Institute, Frederick, MD, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016421">Editorial</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Aging (Albany NY)</MedlineTA>
            <NlmUniqueID>101508617</NlmUniqueID>
            <ISSNLinking>1945-4589</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D058851">GPI-Linked Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C070636">TDGF1 protein, human</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D058851" MajorTopicYN="N">GPI-Linked Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>8</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>6</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26298547</ArticleId>
            <ArticleId IdType="pii">100788</ArticleId>
            <ArticleId IdType="pmc">PMC4586090</ArticleId>
            <ArticleId IdType="doi">10.18632/aging.100788</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Oncotarget. 2015 May 20;6(14):11910-29</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26059540</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2012 Aug;23 Suppl 6:vi7-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23012306</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2011 Nov 20;29(33):4373-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22010008</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Transl Oncol. 2013 Dec 01;6(6):732-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24466376</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2013 Apr;138(2):591-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23460246</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">26209610</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>08</Month>
            <Day>11</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1535-9484</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>14</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular &amp; cellular proteomics : MCP</Title>
                <ISOAbbreviation>Mol. Cell Proteomics</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Prediction of Recurrence and Survival for Triple-Negative Breast Cancer (TNBC) by a Protein Signature in Tissue Samples.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2936-46</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1074/mcp.M115.048967</ELocationID>
            <Abstract>
                <AbstractText>To date, there is no available targeted therapy for patients who are diagnosed with triple-negative breast cancers (TNBC). The aim of this study was to identify a new specific target for specific treatments. Frozen primary tumors were collected from 83 adjuvant therapy-naive TNBC patients. These samples were used for global proteome profiling by iTRAQ-OFFGEL-LC-MS/MS approach in two series: a training cohort (n = 42) and a test set (n = 41). Patients who remains free of local or distant metastasis for a minimum of 5 years after surgery were classified in the no-relapse group; the others were in the relapse group. OPLS and Kaplan-Meier analyses were performed to select candidate markers, which were validated by immunohistochemistry. Three proteins were identified in the training set and validated in the test set by Kaplan-Meier method and immunohistochemistry (IHC): TrpRS as a good prognostic markers and DP and TSP1 as bad prognostic markers. We propose the establishment of an IHC test to calculate the score of TrpRS, DP, and TSP1 in TNBC tumors to evaluate the degree of aggressiveness of the tumors. Finally, we propose that DP and TSP1 could provide therapeutic targets for specific treatments. </AbstractText>
                <CopyrightInformation>© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Campone</LastName>
                    <ForeName>Mario</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>‡René Gauducheau ICO Cancer Center, Inserm U892, CNRS 6299, Bd J. Monod, 44805 Saint Herblain Cedex, France; §Paul Papin ICO Cancer Center, Inserm U892, CNRS 6299, 2 rue Moll, 49933 Angers Cedex 9, France;</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Valo</LastName>
                    <ForeName>Isabelle</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>§Paul Papin ICO Cancer Center, Inserm U892, CNRS 6299, 2 rue Moll, 49933 Angers Cedex 9, France;</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jézéquel</LastName>
                    <ForeName>Pascal</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>‡René Gauducheau ICO Cancer Center, Inserm U892, CNRS 6299, Bd J. Monod, 44805 Saint Herblain Cedex, France;</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moreau</LastName>
                    <ForeName>Marie</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>¶Angers University, 4 Boulevard de Lavoisier, Angers, 49000, France;</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boissard</LastName>
                    <ForeName>Alice</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>§Paul Papin ICO Cancer Center, Inserm U892, CNRS 6299, 2 rue Moll, 49933 Angers Cedex 9, France;</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Campion</LastName>
                    <ForeName>Loic</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>‡René Gauducheau ICO Cancer Center, Inserm U892, CNRS 6299, Bd J. Monod, 44805 Saint Herblain Cedex, France;</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Loussouarn</LastName>
                    <ForeName>Delphine</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>‖INSERM U892, CNRS 6299, IRT-UN, 8 quai Moncousu, 44007 Nantes Cedex, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Verriele</LastName>
                    <ForeName>Véronique</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>§Paul Papin ICO Cancer Center, Inserm U892, CNRS 6299, 2 rue Moll, 49933 Angers Cedex 9, France;</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Coqueret</LastName>
                    <ForeName>Olivier</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>§Paul Papin ICO Cancer Center, Inserm U892, CNRS 6299, 2 rue Moll, 49933 Angers Cedex 9, France; ¶Angers University, 4 Boulevard de Lavoisier, Angers, 49000, France;</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guette</LastName>
                    <ForeName>Catherine</ForeName>
                    <Initials>C</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-1779-9931</Identifier>
                    <AffiliationInfo>
                        <Affiliation>§Paul Papin ICO Cancer Center, Inserm U892, CNRS 6299, 2 rue Moll, 49933 Angers Cedex 9, France; catherine.guette@ico.unicancer.fr.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>07</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Mol Cell Proteomics</MedlineTA>
            <NlmUniqueID>101125647</NlmUniqueID>
            <ISSNLinking>1535-9476</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051180">Desmoplakins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011980">Receptors, Progesterone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019700">Thrombospondin 1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.1.1.41</RegistryNumber>
                <NameOfSubstance UI="D007521">Isocitrate Dehydrogenase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.1.1.41</RegistryNumber>
                <NameOfSubstance UI="C538784">isocitrate dehydrogenase 2, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 6.1.1.2</RegistryNumber>
                <NameOfSubstance UI="D014369">Tryptophan-tRNA Ligase</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051180" MajorTopicYN="N">Desmoplakins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007521" MajorTopicYN="N">Isocitrate Dehydrogenase</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060787" MajorTopicYN="N">Neoplasm Grading</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
                <QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>
                <QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011980" MajorTopicYN="N">Receptors, Progesterone</DescriptorName>
                <QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019700" MajorTopicYN="N">Thrombospondin 1</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014369" MajorTopicYN="N">Tryptophan-tRNA Ligase</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2015</Year>
                <Month>02</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>7</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>7</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>8</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26209610</ArticleId>
            <ArticleId IdType="pii">M115.048967</ArticleId>
            <ArticleId IdType="doi">10.1074/mcp.M115.048967</ArticleId>
            <ArticleId IdType="pmc">PMC4638037</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):173-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11773626</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Trends Cell Biol. 2002 Jan;12(1):37-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11854008</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 1978 Dec 10;253(23):8609-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">101549</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 1995 Jan 6;270(1):397-403</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7814400</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Biol. 1996 Jun;133(6):1367-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8682871</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Biochem. 1996 Sep 15;240(3):732-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8856077</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Biol. 1997 Nov 3;139(3):773-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9348293</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 1998;52(1-3):159-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10066080</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 1999 Apr 2;284(5411):147-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10102815</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Circulation. 1999 Sep 28;100(13):1423-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10500044</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Anal Bioanal Chem. 2004 Oct;380(3):419-29</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15448969</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2005 Jan 28;280(4):2405-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15579907</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Anticancer Res. 2005 Jan-Feb;25(1A):183-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15816537</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2005 Sep 20;116(5):686-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15838828</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Bioinformatics. 2005;6:168</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15998470</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Hum Genet. 2005 Oct;77(4):653-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16175511</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2007 Feb;7(2):139-47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17218951</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Exp Cell Res. 2007 Jul 1;313(11):2336-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17475244</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Proteomics. 2007 Sep;6(9):1638-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17533153</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2007 Nov 20;25(33):5287-312</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17954709</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2008 Jan 25;283(4):2070-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17999956</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Biochem Cell Biol. 2008;40(9):1890-900</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18321763</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Methods. 2009 May;6(5):359-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19377485</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2009 Jul;8(7):1779-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19584238</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Endocr Relat Cancer. 2009 Sep;16(3):809-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19570906</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2009 Nov 1;125(9):2036-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19551809</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Proteome Res. 2009 Sep;8(9):4252-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19603826</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Bioinformatics. 2009;10:342</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19835628</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2949-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19900940</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2010 Nov 11;363(20):1938-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21067385</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2011 Oct;11(10):708-18</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21941282</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Proteomics. 2011 Dec;10(12):M111.009712</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21986994</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proteomics Clin Appl. 2013 Apr;7(3-4):283-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23436753</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Med Invest. 2013;60(1-2):91-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23614916</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Clin Exp Pathol. 2014;7(1):301-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24427351</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2014 Feb;106(2):djt376</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24399849</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Proteomics. 2014 Dec 5;111:198-211</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24768906</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">26135303</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>09</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>10</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2015</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Correction: Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e0132647</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0132647</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ricciardi</LastName>
                    <ForeName>Giuseppina Rosaria Rita</ForeName>
                    <Initials>GR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Adamo</LastName>
                    <ForeName>Barbara</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ieni</LastName>
                    <ForeName>Antonio</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Licata</LastName>
                    <ForeName>Luana</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cardia</LastName>
                    <ForeName>Roberta</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ferraro</LastName>
                    <ForeName>Giuseppa</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Franchina</LastName>
                    <ForeName>Tindara</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tuccari</LastName>
                    <ForeName>Giovanni</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Adamo</LastName>
                    <ForeName>Vincenzo</ForeName>
                    <Initials>V</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016425">Published Erratum</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>07</Month>
                <Day>02</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="ErratumFor">
                <RefSource>PLoS One. 2015;10(6):e0128368</RefSource>
                <PMID Version="1">26039245</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>7</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>7</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>7</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26135303</ArticleId>
            <ArticleId IdType="doi">10.1371/journal.pone.0132647</ArticleId>
            <ArticleId IdType="pii">PONE-D-15-26990</ArticleId>
            <ArticleId IdType="pmc">PMC4489771</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>PLoS One. 2015;10(6):e0128368</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26039245</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">26051240</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>08</Month>
            <Day>31</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1938-0666</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>15</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical breast cancer</Title>
                <ISOAbbreviation>Clin. Breast Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Predictive Biomarker Profiling of &gt; 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.</ArticleTitle>
            <Pagination>
                <MedlinePgn>473-481.e3</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clbc.2015.04.008</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S1526-8209(15)00098-1</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Triple-negative breast cancer (TNBC) is an aggressive disease without established targeted treatment options for patients with metastatic disease. This study was undertaken to evaluate potentially actionable biomarkers in a large cohort of TNBC and compare them with non-TNBCs.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We evaluated 6341 (2111 TNBC and 4230 non-TNBC) breast cancer samples at a central laboratory for biomarkers of potential drug response across multiple platforms, including gene sequencing, protein expression, and gene copy number.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">TNBC expresses androgen receptor (AR) in a significantly (P &lt; .05) lower percentage of cases (17%) than hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-positive breast carcinomas (59% and 79%, respectively), and gene comutations were differentially associated with AR-positive versus AR-negative cases. Higher AR expression levels in TNBC predicted for lower Ki-67 levels. Seventy percent of TNBC harbored a phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA), v-akt murine thymoma viral oncogene homolog 1 (AKT1), or phosophatase and tensin homolog (PTEN) aberration. TNBC patients had a significantly lower PIK3CA mutation rate (13%) than all other subtypes (P &lt; .05) and a higher tumor protein p53 (TP53) mutation rate (64%) than the estrogen receptor (ER)-positive cases (approximately 30%; P &lt; .05). Topoisomerase 2 (TOP2A) amplification was observed in 1.3% of TNBC and in 1.6% of HER2-negative, HR-positive cancers; in contrast, HER2-positive, HR-negative or HR-positive cancers exhibited TOP2A amplification in 19% and 40% of cases, respectively (P &lt;.05).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Multi-platform molecular profiling identifies subgroups of TNBC with different biomarker profiles, suggesting numerous potentially targetable alterations in TNBC. TNBC is further characterized by different gene mutations and proliferative activity relative to AR expression, highlighting a need for comprehensive pathologic examination with potential to develop different, individualized treatment options.</AbstractText>
                <CopyrightInformation>Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Millis</LastName>
                    <ForeName>Sherri Z</ForeName>
                    <Initials>SZ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Caris Life Sciences, Phoenix, AZ. Electronic address: smillis@ashionaim.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gatalica</LastName>
                    <ForeName>Zoran</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Caris Life Sciences, Phoenix, AZ.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Winkler</LastName>
                    <ForeName>Josiah</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Caris Life Sciences, Phoenix, AZ.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vranic</LastName>
                    <ForeName>Semir</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Clinical Center, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kimbrough</LastName>
                    <ForeName>Jeffery</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Caris Life Sciences, Phoenix, AZ.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reddy</LastName>
                    <ForeName>Sandeep</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Caris Life Sciences, Phoenix, AZ.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>O'Shaughnessy</LastName>
                    <ForeName>Joyce A</ForeName>
                    <Initials>JA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Baylor Sammons Cancer Center, Texas Oncology, US Oncology, Dallas TX.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>04</Month>
                <Day>28</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Breast Cancer</MedlineTA>
            <NlmUniqueID>100898731</NlmUniqueID>
            <ISSNLinking>1526-8209</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017403" MajorTopicYN="N">In Situ Hybridization</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Immunohistochemistry</Keyword>
            <Keyword MajorTopicYN="N">In situ hybridization</Keyword>
            <Keyword MajorTopicYN="N">Molecular profiling</Keyword>
            <Keyword MajorTopicYN="N">Sequencing</Keyword>
            <Keyword MajorTopicYN="N">Targeted therapy</Keyword>
            <Keyword MajorTopicYN="N">Triple-negative breast cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>12</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2015</Year>
                <Month>04</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2015</Year>
                <Month>04</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>6</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>6</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>9</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26051240</ArticleId>
            <ArticleId IdType="pii">S1526-8209(15)00098-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.clbc.2015.04.008</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">26039245</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>05</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>10</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2015</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e0128368</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0128368</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">TNBC is an aggressive subset of breast cancer (BC) without specific target therapy.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">This observational, retrospective study included 45 cases of TNBC. The aim of this study was to evaluate the expression of the AR, E-cadherin and Ki-67 in relation to histological type, time to relapse and overall survival (OS). Immunohistochemistry (IHC) was carried out on formalin-fixed paraffin-embedded tumor samples obtained from patients defined TNBC.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The AR was positive (IHC &gt;10%) in 26.6%. E-cadherin (CDH1) expression was considered positive if the score was ≥ 2. This expression was negative in 53.3% cases. The Ki-67 index was ≥ 20% in 37.7%. Univariate analyses showed that AR, CDH1 and Ki-67 are significantly associated with OS. Multivariate analysis showed that AR and Ki-67 expression are independent variables associated with OS. The statistical analysis showed that patients with AR negative and Ki-67 positive expression have a significant correlation with poor outcome.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our data suggest that the combination of AR and E-cadherin expression as well as Ki-67 status might be useful prognostic markers in TNBC. Hence, these molecular determinants could play an interesting role to classify subgroups of TNBC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ricciardi</LastName>
                    <ForeName>Giuseppina Rosaria Rita</ForeName>
                    <Initials>GR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Unit AOOR Papardo-Piemonte &amp; Department of Human Pathology University of Messina, Messina, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Adamo</LastName>
                    <ForeName>Barbara</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Oncologia Mèdica Hospital Clínic, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ieni</LastName>
                    <ForeName>Antonio</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Human Pathology &quot;Gaetano Barresi&quot;, Section of Anatomic Pathology, University of Messina, Messina, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Licata</LastName>
                    <ForeName>Luana</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Human Pathology &quot;Gaetano Barresi&quot;, Section of Anatomic Pathology, University of Messina, Messina, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cardia</LastName>
                    <ForeName>Roberta</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Human Pathology &quot;Gaetano Barresi&quot;, Section of Anatomic Pathology, University of Messina, Messina, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ferraro</LastName>
                    <ForeName>Giuseppa</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Unit AOOR Papardo-Piemonte &amp; Department of Human Pathology University of Messina, Messina, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Franchina</LastName>
                    <ForeName>Tindara</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Unit AOOR Papardo-Piemonte &amp; Department of Human Pathology University of Messina, Messina, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tuccari</LastName>
                    <ForeName>Giovanni</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Human Pathology &quot;Gaetano Barresi&quot;, Section of Anatomic Pathology, University of Messina, Messina, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Adamo</LastName>
                    <ForeName>Vincenzo</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Oncology Unit AOOR Papardo-Piemonte &amp; Department of Human Pathology University of Messina, Messina, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D064888">Observational Study</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>06</Month>
                <Day>03</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C410798">AR protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C513384">CDH1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015820">Cadherins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019394">Ki-67 Antigen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011944">Receptors, Androgen</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="ErratumIn">
                <RefSource>PLoS One. 2015;10(7):e0132647</RefSource>
                <PMID Version="1">26135303</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015820" MajorTopicYN="N">Cadherins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018270" MajorTopicYN="N">Carcinoma, Ductal, Breast</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018275" MajorTopicYN="N">Carcinoma, Lobular</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018276" MajorTopicYN="N">Carcinoma, Medullary</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019394" MajorTopicYN="N">Ki-67 Antigen</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011944" MajorTopicYN="N">Receptors, Androgen</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2015</Year>
                <Month>03</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2015</Year>
                <Month>04</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>6</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>6</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>5</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26039245</ArticleId>
            <ArticleId IdType="doi">10.1371/journal.pone.0128368</ArticleId>
            <ArticleId IdType="pii">PONE-D-15-02407</ArticleId>
            <ArticleId IdType="pmc">PMC4454487</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Natl Cancer Inst. 2014 Jan;106(1):djt319</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24273215</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br Med J. 1975 Nov 29;4(5995):503</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">172189</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2011 Jul;121(7):2750-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21633166</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncologist. 2011;16 Suppl 1:71-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21278443</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2010 Nov 11;363(20):1938-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21067385</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncologist. 2011;16 Suppl 1:61-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21278442</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2014 Aug 08;16(4):406</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25103565</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Mammary Gland Biol Neoplasia. 1998 Jan;3(1):95-103</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10819508</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Cancer. 2008 Dec;44(18):2799-805</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19008097</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Histopathology. 2005 Jun;46(6):685-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15910600</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2004 Aug 15;10(16):5367-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15328174</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem Soc Trans. 2008 Apr;36(Pt 2):149-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18363555</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast J. 2012 Jan-Feb;18(1):41-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22098334</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Steroid Biochem Mol Biol. 2002 Feb;80(2):175-89</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11897502</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2007 Nov 01;7:203</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17976237</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Cancer. 2012 Mar;48(5):642-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21757335</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Cancer. 2004 Jan;40(2):205-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14728934</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Oncol. 2010 Feb;11(2):174-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20152769</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2013 Sep;24(9):2206-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23917950</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2012 Apr;132(2):523-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21671017</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Pathol. 1991 Apr;138(4):867-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2012175</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2010 Jul 13;103(2):249-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20551954</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Mol Cell Biol. 2005 Aug;6(8):622-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16025097</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2011 Nov 16;103(22):1656-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21960707</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Oncol. 2011 Feb;5(1):5-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21147047</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2009 Apr 1;15(7):2472-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19276248</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2007 Jan 1;109(1):25-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17146782</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2008 Nov 15;113(10):2638-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18833576</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Med Oncol. 2012 Jun;29(2):526-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21519872</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer J. 2010 Jan-Feb;16(1):62-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20164692</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2013 Oct 1;19(19):5505-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23965901</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Med Oncol. 2012 Jun;29(2):406-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21264529</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer. 2010 Jul 07;9:179</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20609236</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ital J Anat Embryol. 2001;106(2 Suppl 1):111-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11729946</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 1984 Dec 1;54(11):2436-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">6498736</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncologist. 2011;16 Suppl 1:1-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21278435</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Clin Oncol. 2010 Dec;7(12):683-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20877296</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2015 Apr 1;21(7):1688-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25208879</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2013 May 15;19(10):2723-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23549873</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2011 Apr 01;13(2):105</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21457488</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2006 Nov;100(2):139-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16791476</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pathology. 2009 Jan;41(1):40-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19089739</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Histopathology. 2010 Dec;57(6):877-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21166701</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br Med J. 1975 Nov 29;4(5995):503-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1192145</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Pathol. 2013 Jun;66(6):512-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23436927</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2009 Jul;116(1):53-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18592370</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2010;12(5):R68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20813035</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2011;13(6):R122</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22126395</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Virchows Arch. 2005 Oct;447(4):695-700</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16075292</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Breast Cancer. 2009 Jun;9 Suppl 2:S73-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19596646</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2008 Jan 15;14(2):618; author reply 618-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18223240</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2010 Mar;21(3):488-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19887463</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11553815</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2008 Mar 1;14(5):1368-76</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18316557</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2008 Jul 1;123(1):236-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18398844</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25943633</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>12</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1643-3750</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>21</Volume>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>May</Month>
                        <Day>06</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Medical science monitor : international medical journal of experimental and clinical research</Title>
                <ISOAbbreviation>Med. Sci. Monit.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>MiR-27a modulates radiosensitivity of triple-negative breast cancer (TNBC) cells by targeting CDC27.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1297-303</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.12659/MSM.893974</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">MiR-27a is significantly overexpressed in triple-negative breast cancer (TNBC). However, the exact biological function of MiR-27a in TNBC is not fully understood. In this study, we verified miR-27a expression in TNBC cells and explored how its overexpression modulates radiosensitivity of the cells.</AbstractText>
                <AbstractText Label="MATERIAL/METHODS" NlmCategory="METHODS">qRT-PCR analysis was performed to study miR-27a expression in TNBC lines MDA-MB-435 and MDA-MB-231 and in normal human breast epithelial cell line MCF10A. Dual luciferase assay was performed to verify a putative downstream target of miR-27a, CDC27. CCK-8 assay was used to assess the influence of miR-27a-CDC27 axis on cell proliferation under irradiation (IR) treatment.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">We confirmed significantly higher miR-27a expression in 2 TNBC cell lines--MDA-MB-435 and MDA-MB-231--than in human breast epithelial cell line MCF10A. miR-27a could modulate proliferation and radiosensitivity of TNBC cells. CDC-27 is a direct target of miR-27a and its downregulation conferred increased radioresistance of the cells.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The miR-27a-CDC27 axis might play an important role in modulating response to radiotherapy in TNBC cells. Testing miR-27a expression might be a useful way to identify a subgroup of patients who will benefit from an IR-based therapeutic approach.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ren</LastName>
                    <ForeName>Yong-qiang</ForeName>
                    <Initials>YQ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Laboratory, The Central Hospital of Yishui, Linyi, Shandong, China (mainland).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fu</LastName>
                    <ForeName>Fengkui</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Dpartment of Radiology, People's Hospital of Binzhou, Binzhou, Shandong, China (mainland).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Han</LastName>
                    <ForeName>Jianjun</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei, China (mainland).</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>05</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Med Sci Monit</MedlineTA>
            <NlmUniqueID>9609063</NlmUniqueID>
            <ISSNLinking>1234-1010</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D064191">Apc3 Subunit, Anaphase-Promoting Complex-Cyclosome</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C577366">CDC27 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C531388">MIRN27 microRNA, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009841">Oligonucleotides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D064191" MajorTopicYN="N">Apc3 Subunit, Anaphase-Promoting Complex-Cyclosome</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001940" MajorTopicYN="N">Breast</DescriptorName>
                <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
                <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017124" MajorTopicYN="N">Conserved Sequence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004847" MajorTopicYN="N">Epithelial Cells</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName>
                <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009841" MajorTopicYN="N">Oligonucleotides</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011836" MajorTopicYN="N">Radiation Tolerance</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014410" MajorTopicYN="N">Tumor Stem Cell Assay</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>5</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>5</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>12</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25943633</ArticleId>
            <ArticleId IdType="pii">893974</ArticleId>
            <ArticleId IdType="doi">10.12659/MSM.893974</ArticleId>
            <ArticleId IdType="pmc">PMC4548742</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Cell. 2004 Jan 23;116(2):281-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14744438</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>APMIS. 2013 Oct;121(10):945-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23755904</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2007 Nov 15;67(22):11001-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18006846</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2009 Aug 28;284(35):23204-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19574223</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2010 Nov 11;363(20):1938-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21067385</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2011 Sep;129(2):617-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21607584</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2012 Jan 20;287(4):2854-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22139841</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2012;12:44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22280307</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Genome Res. 2012 Oct;22(10):1995-2007</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22637570</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2012;7(12):e51702</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23240057</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2013 Mar 22;288(12):8750-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23364795</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Indian J Biochem Biophys. 2005 Oct;42(5):271-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23923534</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Biochem. 2015 Apr;48(6):388-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25541018</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2014;14:124</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24564888</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):4536-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24616504</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2014 May 15;33(20):2629-38</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23752185</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2014 Mar 15;5(5):1174-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24632568</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Med Sci Monit Basic Res. 2014;20:97-104</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25047098</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2014 Sep 18;513(7518):388-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25043029</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Genes Dev. 2006 Feb 15;20(4):449-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16481473</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25927362</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>04</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>10</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2015</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Antimetastatic Therapies of the Polysulfide Diallyl Trisulfide against Triple-Negative Breast Cancer (TNBC) via Suppressing MMP2/9 by Blocking NF-κB and ERK/MAPK Signaling Pathways.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e0123781</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0123781</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Migration and invasion are two crucial steps of tumor metastasis. Blockage of these steps may be an effective strategy to reduce the risk. The objective of the present study was to investigate the effects of diallyl trisulfide (DATS), a natural organosulfuric compound with most sulfur atoms found in garlic, on migration and invasion in triple negative breast cancer (TNBC) cells. Molecular mechanisms underlying the anticancer effects of DATS were further investigated.</AbstractText>
                <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">MDA-MB-231 cells and HS 578t breast cancer cells were treated with different concentrations of DATS. DATS obviously suppressed the migration and invasion of two cell lines and changed the morphological. Moreover, DATS inhibited the mRNA/protein/ enzymes activities of MMP2/9 via attenuating the NF-κB pathway. DATS also inhibited ERK/MAPK rather than p38 and JNK.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">DATS inhibits MMP2/9 activity and the metastasis of TNBC cells, and emerges as a potential anti-cancer agent. The inhibitory effects are associated with down-regulation of the transcriptional activities of NF-κB and ERK/MAPK signaling pathways.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Yuping</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Pingting</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China; Medical College of Yangzhou University, Yangzhou, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Yingyu</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wei</LastName>
                    <ForeName>Zhonghong</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tao</LastName>
                    <ForeName>Li</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Zhijie</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sheng</LastName>
                    <ForeName>Xiaobo</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Siliang</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ruan</LastName>
                    <ForeName>Junshan</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Zhaoguo</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cao</LastName>
                    <ForeName>Yuzhu</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shan</LastName>
                    <ForeName>Yunlong</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Lihua</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Aiyun</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China; Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, 210023, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Wenxing</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China; Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, 210023, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>Yin</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China; Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, 210023, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>figshare</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>10.6084/M9.FIGSHARE.1340468</AccessionNumber>
                        <AccessionNumber>10.6084/M9.FIGSHARE.1340469</AccessionNumber>
                        <AccessionNumber>10.6084/M9.FIGSHARE.1340473</AccessionNumber>
                        <AccessionNumber>10.6084/M9.FIGSHARE.1340477</AccessionNumber>
                        <AccessionNumber>10.6084/M9.FIGSHARE.1340568</AccessionNumber>
                        <AccessionNumber>10.6084/M9.FIGSHARE.1340572</AccessionNumber>
                        <AccessionNumber>10.6084/M9.FIGSHARE.1340574</AccessionNumber>
                        <AccessionNumber>10.6084/M9.FIGSHARE.1340576</AccessionNumber>
                        <AccessionNumber>10.6084/M9.FIGSHARE.1340580</AccessionNumber>
                        <AccessionNumber>10.6084/M9.FIGSHARE.1340581</AccessionNumber>
                        <AccessionNumber>10.6084/M9.FIGSHARE.1340582</AccessionNumber>
                        <AccessionNumber>10.6084/M9.FIGSHARE.1340584</AccessionNumber>
                        <AccessionNumber>10.6084/M9.FIGSHARE.1340585</AccessionNumber>
                        <AccessionNumber>10.6084/M9.FIGSHARE.1340586</AccessionNumber>
                        <AccessionNumber>10.6084/M9.FIGSHARE.1340978</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>04</Month>
                <Day>30</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000498">Allyl Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013440">Sulfides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0ZO1U5A3XX</RegistryNumber>
                <NameOfSubstance UI="C042577">diallyl trisulfide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.24.24</RegistryNumber>
                <NameOfSubstance UI="C522361">MMP2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.24.24</RegistryNumber>
                <NameOfSubstance UI="D020778">Matrix Metalloproteinase 2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.24.35</RegistryNumber>
                <NameOfSubstance UI="C579270">MMP9 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.24.35</RegistryNumber>
                <NameOfSubstance UI="D020780">Matrix Metalloproteinase 9</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000498" MajorTopicYN="N">Allyl Compounds</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004354" MajorTopicYN="N">Drug Screening Assays, Antitumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020778" MajorTopicYN="N">Matrix Metalloproteinase 2</DescriptorName>
                <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020780" MajorTopicYN="N">Matrix Metalloproteinase 9</DescriptorName>
                <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013440" MajorTopicYN="N">Sulfides</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015027" MajorTopicYN="N">Zebrafish</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>09</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2015</Year>
                <Month>03</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>4</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25927362</ArticleId>
            <ArticleId IdType="doi">10.1371/journal.pone.0123781</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-37377</ArticleId>
            <ArticleId IdType="pmc">PMC4415928</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Biochemistry. 2009 Mar 3;48(8):1838-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19199380</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncotarget. 2014 May 15;5(9):2736-49</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24811362</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Semin Immunol. 2014 Jun;26(3):253-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24958609</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2010 Nov 11;363(20):1938-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21067385</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Cancer. 2008 Dec;44(18):2799-805</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19008097</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Tumour Biol. 2013 Aug;34(4):2041-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23681802</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Public Health Nutr. 2009 Sep;12(9):1576-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18986589</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2010 Jan 15;70(2):792-801</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20068187</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2013 Feb;138(1):69-79</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23412769</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2006 May 15;66(10):5379-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16707465</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2005 Dec 16;280(50):41487-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16219763</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Expert Opin Pharmacother. 2009 Sep;10(13):2081-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19640211</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Prev Res (Phila). 2010 Nov;3(11):1473-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20959517</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Acta Biochim Biophys Sin (Shanghai). 2012 Jul;44(7):577-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22595511</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2006 Mar;6(3):227-39</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16498445</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 2010 Apr 2;141(1):52-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20371345</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Clin Oncol. 2010 Dec;33(6):637-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20023571</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Anticancer Agents Med Chem. 2011 Mar;11(3):249-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21269259</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 1999 Jul 19;82(2):268-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10389762</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>EMBO J. 1995 Dec 15;14(24):6157-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8557035</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neoplasma. 2006;53(3):191-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16652187</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Environ Mol Mutagen. 2009 Apr;50(3):266-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19197990</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Biol Ther. 2009 Nov;8(22):2175-85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19823037</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Food Chem Toxicol. 2013 Jul;57:362-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23583486</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Drug Discov. 2012 Jun;11(6):479-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22653217</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 1999 Mar;79(7-8):1283-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10098773</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Bull Exp Biol Med. 2010 Dec;150(1):71-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21161056</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Nutr Food Res. 2013 May;57(5):886-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23417847</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Chromatogr A. 2004 May 14;1036(1):91-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15139418</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Environ Toxicol. 2013 Sep;28(9):479-88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21695758</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancers (Basel). 2014 Jun 27;6(3):1298-327</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24978435</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Food Chem Toxicol. 2012 Jul;50(7):2524-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22525868</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2014 Jun;14(6):430-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24827502</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Environ Toxicol Pharmacol. 2014 Jan;37(1):74-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24309133</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer J. 2008 Nov-Dec;14(6):343-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19060597</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Res. 2014 Oct;12(10):1449-59</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24939643</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25898834</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>06</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2016</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2159-8290</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>5</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer discovery</Title>
                <ISOAbbreviation>Cancer Discov</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Immunotherapy Slows TNBC Progression.</ArticleTitle>
            <Pagination>
                <MedlinePgn>570</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1158/2159-8290.CD-NB2015-059</ELocationID>
            <Abstract>
                <AbstractText>The experimental monoclonal antibody MPDL3280A extended progression-free survival and produced durable responses in some patients with triple-negative breast cancer, according to preliminary results from a phase I trial. </AbstractText>
                <CopyrightInformation>©2015 American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016433">News</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>04</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Cancer Discov</MedlineTA>
            <NlmUniqueID>101561693</NlmUniqueID>
            <ISSNLinking>2159-8274</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>52CMI0WC3Y</RegistryNumber>
                <NameOfSubstance UI="C000594389">atezolizumab</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017321" MajorTopicYN="N">Clinical Trials, Phase I as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>4</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>4</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>6</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25898834</ArticleId>
            <ArticleId IdType="pii">2159-8290.CD-NB2015-059</ArticleId>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-NB2015-059</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25857298</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>03</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1949-2553</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>6</Volume>
                    <Issue>13</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>May</Month>
                        <Day>10</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncotarget</Title>
                <ISOAbbreviation>Oncotarget</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.</ArticleTitle>
            <Pagination>
                <MedlinePgn>11061-73</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The pan-PI3K inhibitors are one treatment option for triple-negative breast cancer (TNBC). However, this treatment is ineffective for unknown reasons. Here, we report that aberrant expression of wingless-type MMTV integration site family (WNT) and activated WNT signals, which crosstalk with the PI3K-AKT-mTOR signaling pathway through GSK3β, plays the most critical role in resistance to pan-PI3K inhibitors in TNBC cells. GDC-0941 is a pan-PI3K inhibitor that activates the WNT/beta-catenin pathway in TNBC cells through stimulation of WNT secretion. GDC-0941-triggered WNT/beta-catenin pathway activation was observed in MDA-MB-231 and HCC1937 cells, which are TNBC cell lines showing aberrant WNT/beta-catenin activation, and not in SKBR3 and MCF7 cells. This observation is further investigated in vivo. GDC-0941 exhibited minimal tumor inhibition in MDA-MB-231 cells, but it significantly suppressed tumor growth in HER-positive SK-BR3 cells. In vivo mechanism study revealed the activation of WNT/beta-catenin pathway by GDC-0941. A synergistic effect was observed when combined treatment with GDC-0941 and the WNT inhibitor LGK974 at low concentrations in MDA-MB-231 cells. These findings indicated that WNT pathway activation conferred resistance in TNBC cells treated with GDC-0941. This resistance may be further circumvented through combined treatment with pan-PI3K and WNT inhibitors. Future clinical trials of these two inhibitors are warranted. </AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tzeng</LastName>
                    <ForeName>Huey-En</ForeName>
                    <Initials>HE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular Pharmacology, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Graduate Institute of Clinical Medicine, China Medical University, Taichung, Taiwan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Division of Hematology/Oncology, Taichung Veterans General Hospital, Taichung, Taiwan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>School of Medicine, China Medical University, Taichung, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Lixin</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Translational Research Core Laboratory, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Kemin</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular Pharmacology, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Yafan</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Translational Research Core Laboratory, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Yun-Ru</ForeName>
                    <Initials>YR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Joint Biobank, Office of Human Research, Taipei Medical University, Taipei, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pan</LastName>
                    <ForeName>Shiow-Lin</ForeName>
                    <Initials>SL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gaur</LastName>
                    <ForeName>Shikha</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular Pharmacology, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hu</LastName>
                    <ForeName>Shuya</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular Pharmacology, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yen</LastName>
                    <ForeName>Yun</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular Pharmacology, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Oncotarget</MedlineTA>
            <NlmUniqueID>101532965</NlmUniqueID>
            <ISSNLinking>1949-2553</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C532162">2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007191">Indazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011719">Pyrazines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051153">Wnt Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051176">beta Catenin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.1.-</RegistryNumber>
                <NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.1.1</RegistryNumber>
                <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.1.1</RegistryNumber>
                <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.1</RegistryNumber>
                <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>U27F40013Q</RegistryNumber>
                <NameOfSubstance UI="C586458">LGK974</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007191" MajorTopicYN="N">Indazoles</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011719" MajorTopicYN="N">Pyrazines</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060888" MajorTopicYN="N">Real-Time Polymerase Chain Reaction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051153" MajorTopicYN="N">Wnt Proteins</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051176" MajorTopicYN="N">beta Catenin</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">PI3K/AKT/mTOR pathway</Keyword>
            <Keyword MajorTopicYN="N">WNT/beta-catenin pathway</Keyword>
            <Keyword MajorTopicYN="N">drug resistance</Keyword>
            <Keyword MajorTopicYN="N">pan-PI3K inhibitor</Keyword>
            <Keyword MajorTopicYN="N">triple-negative breast cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>12</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2015</Year>
                <Month>02</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>4</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>4</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>3</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25857298</ArticleId>
            <ArticleId IdType="pii">3568</ArticleId>
            <ArticleId IdType="pmc">PMC4484439</ArticleId>
            <ArticleId IdType="doi">10.18632/oncotarget.3568</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Am J Pathol. 2003 May;162(5):1495-502</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12707032</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Sci Signal. 2014 Mar 25;7(318):ra29</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24667376</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2011 Jul;121(7):2750-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21633166</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Cell. 2011 Jun 14;19(6):693-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21665142</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Drug Discov. 2014 Feb;13(2):140-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24481312</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Med. 2012 Jun;18(6):892-901</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22610277</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2010 Nov 11;363(20):1938-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21067385</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2011 Oct 27;30(43):4437-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21532620</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mod Pathol. 2011 Feb;24(2):209-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21076461</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2009;4(6):e5813</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19503830</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Apr 15;13(8):2329-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17438091</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 1991 Aug 9;66(3):589-600</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1651174</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2014;14:124</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24564888</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Drug Discov. 2009 Aug;8(8):627-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19644473</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Horm Metab Res. 2009 Feb;41(2):159-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19214925</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Discov. 2012 Nov;2(11):1036-47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22915752</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Neuroimmune Pharmacol. 2012 Dec;7(4):788-807</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23160851</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Carcinog. 2011 Mar 17;10:5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21483657</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2008 Nov 15;113(10):2638-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18833576</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Drug Discov. 2014 Jul;13(7):513-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24981364</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2008 Mar 10;26(8):1275-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18250347</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Dev Cell. 2009 Jul;17(1):9-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19619488</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2010 Aug 1;127(3):555-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19957335</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2013 Jan;13(1):11-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23258168</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2014;16(4):406</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25103565</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Genet. 2004 Apr;36(4):417-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15034581</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2013 Nov;59(5):1107-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23835194</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2013 Dec 1;19(23):6380-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24298068</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 2006 Sep 8;126(5):955-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16959574</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2014 Feb 15;20(4):782-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24536073</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2010 Jan 28;29(4):539-49</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19881541</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 1991 Aug 9;253(5020):661-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1651562</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Pathol. 2010 Jun;176(6):2911-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20395444</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 2006 Nov 3;127(3):469-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17081971</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neoplasia. 2014 Jan;16(1):43-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24563619</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17671126</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Exp Cell Res. 2013 May 15;319(9):1348-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23500680</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Trends Mol Med. 2012 Aug;18(8):483-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22796206</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20224-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24277854</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25796184</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>06</Month>
            <Day>16</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-3468</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>589</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Apr</Month>
                        <Day>13</Day>
                    </PubDate>
                </JournalIssue>
                <Title>FEBS letters</Title>
                <ISOAbbreviation>FEBS Lett.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>PEA-15 facilitates EGFR dephosphorylation via ERK sequestration at increased ER-PM contacts in TNBC cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1033-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.febslet.2015.03.009</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S0014-5793(15)00157-X</ELocationID>
            <Abstract>
                <AbstractText>Phosphoprotein enriched in astrocytes of 15 kDa (PEA-15) is known to sequester extracellular signal-regulated kinase (ERK) in the cytoplasm, inhibiting tumorigenesis of human breast cancer cells. Here, we describe how PEA-15 expression affects the dephosphorylation of epidermal growth factor receptor (EGFR) through endoplasmic reticulum (ER)-plasma membrane (PM) contacts in MDA-MB-468, triple-negative breast cancer (TNBC) cells. The increased intracellular calcium concentration resulting from increased cytoplasmic phosphorylated ERK facilitates movement of ER-anchored calcium sensors to the PM. The driving force of trans-localization of calcium-dependent proteins enhances the contact between the activated EGFR and ER-localized phosphatase, PTP1B. Consequently, our findings suggest a mechanism underneath the facilitation of EGFR dephosphorylation by cytoplasmic PEA-15 expression inside TNBC cells, which may be one of the dynamic mechanisms for down-regulation of activated EGFR in cancer cells.</AbstractText>
                <CopyrightInformation>Copyright © 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Shin</LastName>
                    <ForeName>Miyoung</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Life Sciences, Korea University, Seoul, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Kyung-Eun</ForeName>
                    <Initials>KE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul, South Korea; Advanced Analysis Center, Korea Institute of Science and Technology, Seoul, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Eun Gyeong</ForeName>
                    <Initials>EG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul, South Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jeon</LastName>
                    <ForeName>Hyesung</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul, South Korea; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: hjeon@red.dfci.harvard.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Song</LastName>
                    <ForeName>Hyun Kyu</ForeName>
                    <Initials>HK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Life Sciences, Korea University, Seoul, South Korea. Electronic address: hksong@korea.ac.kr.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>03</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>FEBS Lett</MedlineTA>
            <NlmUniqueID>0155157</NlmUniqueID>
            <ISSNLinking>0014-5793</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C092039">PEA15 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.24</RegistryNumber>
                <NameOfSubstance UI="D048049">Extracellular Signal-Regulated MAP Kinases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.24</RegistryNumber>
                <NameOfSubstance UI="C535150">MAPK1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.24</RegistryNumber>
                <NameOfSubstance UI="D019950">Mitogen-Activated Protein Kinase 1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.24</RegistryNumber>
                <NameOfSubstance UI="D048052">Mitogen-Activated Protein Kinase 3</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>SY7Q814VUP</RegistryNumber>
                <NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004721" MajorTopicYN="N">Endoplasmic Reticulum</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D048049" MajorTopicYN="N">Extracellular Signal-Regulated MAP Kinases</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015151" MajorTopicYN="N">Immunoblotting</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018613" MajorTopicYN="N">Microscopy, Confocal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019950" MajorTopicYN="N">Mitogen-Activated Protein Kinase 1</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D048052" MajorTopicYN="N">Mitogen-Activated Protein Kinase 3</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">EGFR dephosphorylation</Keyword>
            <Keyword MajorTopicYN="N">ER–PM contact</Keyword>
            <Keyword MajorTopicYN="N">PEA-15</Keyword>
            <Keyword MajorTopicYN="N">PTP1B</Keyword>
            <Keyword MajorTopicYN="N">Triple-negative breast cancer cells</Keyword>
            <Keyword MajorTopicYN="N">pERK1/2</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>12</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2015</Year>
                <Month>03</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2015</Year>
                <Month>03</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>3</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>3</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>6</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25796184</ArticleId>
            <ArticleId IdType="pii">S0014-5793(15)00157-X</ArticleId>
            <ArticleId IdType="doi">10.1016/j.febslet.2015.03.009</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25784716</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>03</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1557-3125</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>13</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular cancer research : MCR</Title>
                <ISOAbbreviation>Mol. Cancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Endophilin A2 Promotes TNBC Cell Invasion and Tumor Metastasis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1044-55</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1158/1541-7786.MCR-14-0573</ELocationID>
            <Abstract>
                <AbstractText Label="UNLABELLED">Triple-negative breast cancers (TNBCs) are highly aggressive cancers that lack targeted therapies. However, EGFR is frequently activated in a subset of TNBCs and represents a viable clinical target. Because the endocytic adaptor protein Endophilin A2 (SH3GL1/Endo II) has been implicated in EGFR internalization, we investigated Endo II expression and function in human TNBCs. Endo II expression was high in several TNBC cells compared with normal breast epithelial cells. Stable knockdown (KD) of Endo II was achieved in two TNBC cell lines, and although cell viability was unaffected, defects in receptor-mediated endocytosis were observed. EGFR signaling to Erk and Akt kinases was impaired in Endo II KD cells, and this correlated with reduced rates of EGFR internalization and cell motility. Endo II KD cells also displayed defects in three dimensional (3D) cell invasion, and this correlated with impaired extracellular matrix degradation and internalization of MT1-MMP. Endo II silencing also caused a significant reduction in TNBC tumor growth and lung metastasis in mammary orthotopic tumor xenograft assays. In human breast tumor specimens, Endo II expression was highest in TNBC tumors compared with other subtypes, and at the level of gene expression, high Endo II was associated with reduced relapse-free survival in patients with basal-like breast cancers. Together, these results identify a positive role for Endo II in TNBC tumor metastasis and a potential link with poor prognosis.</AbstractText>
                <AbstractText Label="IMPLICATIONS" NlmCategory="CONCLUSIONS">Endophilin A2 and related adaptor proteins represent important signaling hubs to target in metastatic cancers.</AbstractText>
                <CopyrightInformation>©2015 American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Baldassarre</LastName>
                    <ForeName>Tomas</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada. Cancer Biology and Genetics Division, Queen's Cancer Research Institute, Kingston, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Watt</LastName>
                    <ForeName>Kathleen</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada. Cancer Biology and Genetics Division, Queen's Cancer Research Institute, Kingston, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Truesdell</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada. Cancer Biology and Genetics Division, Queen's Cancer Research Institute, Kingston, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Meens</LastName>
                    <ForeName>Jalna</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada. Cancer Biology and Genetics Division, Queen's Cancer Research Institute, Kingston, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schneider</LastName>
                    <ForeName>Mark M</ForeName>
                    <Initials>MM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sengupta</LastName>
                    <ForeName>Sandip K</ForeName>
                    <Initials>SK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Craig</LastName>
                    <ForeName>Andrew W</ForeName>
                    <Initials>AW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada. Cancer Biology and Genetics Division, Queen's Cancer Research Institute, Kingston, Ontario, Canada. ac15@queensu.ca.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>MOP 119562</GrantID>
                    <Agency>Canadian Institutes of Health Research</Agency>
                    <Country>Canada</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>03</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Mol Cancer Res</MedlineTA>
            <NlmUniqueID>101150042</NlmUniqueID>
            <ISSNLinking>1541-7786</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C105159">SH3GL1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005109" MajorTopicYN="N">Extracellular Matrix</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055785" MajorTopicYN="N">Gene Knockdown Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064593" MajorTopicYN="N">Heterografts</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
                <QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2015</Year>
                <Month>03</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>3</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>3</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>3</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25784716</ArticleId>
            <ArticleId IdType="pii">1541-7786.MCR-14-0573</ArticleId>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-14-0573</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25726929</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>08</Month>
            <Day>03</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1521-4141</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>45</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of immunology</Title>
                <ISOAbbreviation>Eur. J. Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1560-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/eji.201445353</ELocationID>
            <Abstract>
                <AbstractText>Clinical studies suggest that triple negative breast cancer (TNBC) patients with epidermal growth factor receptor (EGFR)-expressing tumors could benefit from therapy with Cetuximab, which targets EGFR. NK cells are the primary effectors of antibody (Ab)-dependent cell-mediated cytotoxicity (ADCC) and thus play a role in Ab-based therapies. We have previously described diminished levels of Cetuximab-mediated ADCC in vitro in patients with advanced breast cancer. Here, we investigated the potential causes of this NK-cell functional deficiency. We characterized NK-cell activating/inhibitory receptors in the peripheral blood of breast cancer patients and found CD85j inhibitory receptor overexpression. The capacity of NK cells to perform Cetuximab-triggered ADCC against TNBC cells correlated inversely with CD85j expression, even in the presence of the stimulatory cytokines IL-2 or IL-15. Hence, patients expressing high levels of CD85j had an impaired ability to lyse TNBC cells in the presence of Cetuximab. We also found that CD85j overexpression was associated with HLA-I and soluble HLA-G expression by tumors. A CD85j functional blockade with a CD85j antagonist Ab restored ADCC levels in breast cancer patients and reverted this negative effect. Our data suggest that strategies that overcome the hurdles of immune activation could improve Cetuximab clinical efficacy. </AbstractText>
                <CopyrightInformation>© 2015 WILEY-VCH Verlag GmbH &amp; Co. KGaA, Weinheim.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Roberti</LastName>
                    <ForeName>María P</ForeName>
                    <Initials>MP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centro de Investigaciones Oncológicas CIO-FUCA, Ciudad de Buenos Aires, Argentina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Juliá</LastName>
                    <ForeName>Estefanía P</ForeName>
                    <Initials>EP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centro de Investigaciones Oncológicas CIO-FUCA, Ciudad de Buenos Aires, Argentina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rocca</LastName>
                    <ForeName>Yamila S</ForeName>
                    <Initials>YS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Fundación Instituto Leloir-IIBBA, Ciudad de Buenos Aires, Argentina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Amat</LastName>
                    <ForeName>Mora</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Instituto Alexander Fleming, Ciudad de Buenos Aires, Argentina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bravo</LastName>
                    <ForeName>Alicia I</ForeName>
                    <Initials>AI</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hospital Eva Perón, San Martín, Provincia de Buenos Aires, Argentina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Loza</LastName>
                    <ForeName>José</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Instituto Alexander Fleming, Ciudad de Buenos Aires, Argentina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Coló</LastName>
                    <ForeName>Federico</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Instituto Alexander Fleming, Ciudad de Buenos Aires, Argentina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Loza</LastName>
                    <ForeName>Carlos M</ForeName>
                    <Initials>CM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Instituto Alexander Fleming, Ciudad de Buenos Aires, Argentina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fabiano</LastName>
                    <ForeName>Verónica</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Instituto Alexander Fleming, Ciudad de Buenos Aires, Argentina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maino</LastName>
                    <ForeName>Mercedes</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Instituto Alexander Fleming, Ciudad de Buenos Aires, Argentina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Podhorzer</LastName>
                    <ForeName>Ariel</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hospital de Clínicas José de San Martín, Ciudad de Buenos Aires, Argentina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fainboim</LastName>
                    <ForeName>Leonardo</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Hospital de Clínicas José de San Martín, Ciudad de Buenos Aires, Argentina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barrio</LastName>
                    <ForeName>María M</ForeName>
                    <Initials>MM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centro de Investigaciones Oncológicas CIO-FUCA, Ciudad de Buenos Aires, Argentina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mordoh</LastName>
                    <ForeName>José</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centro de Investigaciones Oncológicas CIO-FUCA, Ciudad de Buenos Aires, Argentina.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Fundación Instituto Leloir-IIBBA, Ciudad de Buenos Aires, Argentina.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Instituto Alexander Fleming, Ciudad de Buenos Aires, Argentina.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Levy</LastName>
                    <ForeName>Estrella M</ForeName>
                    <Initials>EM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centro de Investigaciones Oncológicas CIO-FUCA, Ciudad de Buenos Aires, Argentina.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>04</Month>
                <Day>07</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Eur J Immunol</MedlineTA>
            <NlmUniqueID>1273201</NlmUniqueID>
            <ISSNLinking>0014-2980</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006680">HLA Antigens</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D059951">HLA-G Antigens</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C105299">LILRB1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000075362">Leukocyte Immunoglobulin-like Receptor B1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>PQX0D8J21J</RegistryNumber>
                <NameOfSubstance UI="D000068818">Cetuximab</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000920" MajorTopicYN="Y">Antibody-Dependent Cell Cytotoxicity</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000068818" MajorTopicYN="N">Cetuximab</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006680" MajorTopicYN="N">HLA Antigens</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059951" MajorTopicYN="N">HLA-G Antigens</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020014" MajorTopicYN="N">K562 Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000075362" MajorTopicYN="N">Leukocyte Immunoglobulin-like Receptor B1</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">ADCC</Keyword>
            <Keyword MajorTopicYN="N">CD85j</Keyword>
            <Keyword MajorTopicYN="N">Cetuximab</Keyword>
            <Keyword MajorTopicYN="N">EGFR</Keyword>
            <Keyword MajorTopicYN="N">NK cells</Keyword>
            <Keyword MajorTopicYN="N">Triple negative breast cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>11</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2015</Year>
                <Month>01</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2015</Year>
                <Month>02</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>3</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>3</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>8</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25726929</ArticleId>
            <ArticleId IdType="doi">10.1002/eji.201445353</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">25655918</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>05</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1949-2553</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>6</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Feb</Month>
                        <Day>10</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Oncotarget</Title>
                <ISOAbbreviation>Oncotarget</ISOAbbreviation>
            </Journal>
            <ArticleTitle>GHRH-antagonists in TNBC.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1898-9</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Engel</LastName>
                    <ForeName>Jörg B</ForeName>
                    <Initials>JB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of OB/Gyn, Head of Gynecologic Oncology, Medical University of Gießen, Gießen, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016420">Comment</PublicationType>
                <PublicationType UI="D016421">Editorial</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Oncotarget</MedlineTA>
            <NlmUniqueID>101532965</NlmUniqueID>
            <ISSNLinking>1949-2553</ISSNLinking>
        </MedlineJournalInfo>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentOn">
                <RefSource>Oncoscience. 2014;1(10):665-73</RefSource>
                <PMID Version="1">25593995</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>2</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>2</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>2</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25655918</ArticleId>
            <ArticleId IdType="pii">3271</ArticleId>
            <ArticleId IdType="pmc">PMC4385824</ArticleId>
            <ArticleId IdType="doi">10.18632/oncotarget.3271</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Ann Oncol. 2012 Aug;23 Suppl 6:vi35-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23012300</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Clin Pract Endocrinol Metab. 2008 Jan;4(1):33-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18084344</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2009 Jul;116(2):273-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18629632</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>World J Clin Oncol. 2014 May 10;5(2):125-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24829859</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Expert Opin Investig Drugs. 2003 Aug;12(8):1385-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12882623</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncoscience. 2014 Oct 24;1(10):665-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25593995</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25342642</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>07</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>11</Month>
            <Day>19</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-7217</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>148</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Breast cancer research and treatment</Title>
                <ISOAbbreviation>Breast Cancer Res. Treat.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers.</ArticleTitle>
            <Pagination>
                <MedlinePgn>415-21</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10549-014-3167-4</ELocationID>
            <Abstract>
                <AbstractText>Early-onset diagnosis is an eligibility criterion for BRCA1 and BRCA2 (BRCA) testing in sporadic breast cancer patients. Limited family structure has been proposed as a predictor of BRCA mutation status in this group of patients. An overwhelming amount of data supports a strong association between BRCA1 mutations and triple-negative breast cancer (TNBC). Here, we analyze the feasibility of using limited family structure and TNBC as predictors of BRCA mutation status in early-onset breast cancer patients attending genetic counseling units. We have conducted the study in a cohort of sporadic early-onset (≤35 years) breast cancer patients (N = 341) previously selected for BRCA genetic testing in Academic Hereditary Cancer Clinics from Spain. A retrospective review of medical records available at the time of risk assessment allowed us classifying patients according to family structure and TNBC. In addition, BRCAPRO score was calculated for all patients. Association between categorical variables was investigated using the Fisher's exact test. Binary Logistic Regression Analysis was used for multivariate analysis. Limited family structure (OR 3.61, p = 0.013) and TNBC (OR 3.14, p = 0.013) were independent predictors of BRCA mutation status. Mutation prevalence in the subgroup of patients with at least one positive predictor was 14%, whereas it dropped to 3% in non-TNBCs with adequate family history (OR 5.31, 95% CI 1.38-23.89, p = 0.006). BRCAPRO correctly discerned between limited and adequate family structures. Limited family structure and TNBC are feasible predictors of BRCA mutation status in sporadic early-onset (≤35 years) breast cancer patients attending genetic counseling units. The low prevalence of mutations observed in non-TNBCs with adequate family structure suggests that this subgroup of patients might be excluded from genetic testing.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zugazagoitia</LastName>
                    <ForeName>Jon</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Genetic Counseling Unit, Department of Clinical Oncology, Hospital Clínico San Carlos, Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pérez-Segura</LastName>
                    <ForeName>Pedro</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Manzano</LastName>
                    <ForeName>Arancha</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Blanco</LastName>
                    <ForeName>Ignacio</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vega</LastName>
                    <ForeName>Ana</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Custodio</LastName>
                    <ForeName>Ana</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Teulé</LastName>
                    <ForeName>Alex</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fachal</LastName>
                    <ForeName>Laura</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martínez</LastName>
                    <ForeName>Beatriz</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>González-Sarmiento</LastName>
                    <ForeName>Rogelio</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cruz-Hernández</LastName>
                    <ForeName>Juan Jesús</ForeName>
                    <Initials>JJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chirivella</LastName>
                    <ForeName>Isabel</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Garcés</LastName>
                    <ForeName>Vicente</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Garre</LastName>
                    <ForeName>Pilar</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Romero</LastName>
                    <ForeName>Atocha</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Caldés</LastName>
                    <ForeName>Trinidad</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Díaz-Rubio</LastName>
                    <ForeName>Eduardo</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de la Hoya</LastName>
                    <ForeName>Miguel</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Breast Cancer Res Treat</MedlineTA>
            <NlmUniqueID>8111104</NlmUniqueID>
            <ISSNLinking>0167-6806</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019313">BRCA1 Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C492913">BRCA1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D024682">BRCA2 Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C551750">BRCA2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011980">Receptors, Progesterone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019313" MajorTopicYN="N">BRCA1 Protein</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024682" MajorTopicYN="N">BRCA2 Protein</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005191" MajorTopicYN="N">Family Characteristics</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005817" MajorTopicYN="Y">Genetic Counseling</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007124" MajorTopicYN="N">Immunoenzyme Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011980" MajorTopicYN="N">Receptors, Progesterone</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>05</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>7</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25342642</ArticleId>
            <ArticleId IdType="doi">10.1007/s10549-014-3167-4</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25341922</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>04</Month>
            <Day>19</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>03</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1976-670X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>48</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>BMB reports</Title>
                <ISOAbbreviation>BMB Rep</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Insulin activates EGFR by stimulating its interaction with IGF-1R in low-EGFR-expressing TNBC cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>342-7</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The expression of epidermal growth factor receptor (EGFR) is an important diagnostic marker for triple-negative breast cancer (TNBC) cells, which lack three hormonal receptors: estrogen and progesterone receptors as well as epidermal growth factor receptor 2. EGFR transactivation can cause drug resistance in many cancers including TNBC, but the mechanism underlying this phenomenon is poorly defined. Here, we demonstrate that insulin treatment induces EGFR activation by stimulating the interaction of EGFR with insulin-like growth factor receptor 1 (IGF-1R) in the MDA-MB-436 TNBC cell line. These cells express low levels of EGFR, while exhibiting high levels of IGF-1R expression and phosphorylation. Low-EGFRexpressing MDA-MB-436 cells show high sensitivity to insulinstimulated cell growth. Therefore, unexpectedly, insulin stimulation induced EGFR transactivation by regulating its interaction with IGF-1R in low-EGFR-expressing TNBC cells.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Shin</LastName>
                    <ForeName>Miyoung</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Life Sciences, Korea University, Seoul 136-701; Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul 136-791, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Eun Gyeong</ForeName>
                    <Initials>EG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul 136-791, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Song</LastName>
                    <ForeName>Hyun Kyu</ForeName>
                    <Initials>HK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Life Sciences, Korea University, Seoul 136-701, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jeon</LastName>
                    <ForeName>Hyesung</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul 136-791, Korea; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Korea (South)</Country>
            <MedlineTA>BMB Rep</MedlineTA>
            <NlmUniqueID>101465334</NlmUniqueID>
            <ISSNLinking>1976-6696</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D017526">Receptor, IGF Type 1</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
                <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017526" MajorTopicYN="N">Receptor, IGF Type 1</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>4</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25341922</ArticleId>
            <ArticleId IdType="pii">2902</ArticleId>
            <ArticleId IdType="pmc">PMC4578621</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3455-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10737798</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11252954</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2001 Apr 5;20(15):1913-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11313939</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Endocrinology. 2001 Jul;142(7):2776-88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11415996</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2002 Jan 1;62(1):200-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11782378</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Gene Ther. 2003 Jan;10(1):57-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12489029</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Endocrinology. 2003 Mar;144(3):1032-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12586780</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2004 Aug 15;10(16):5367-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15328174</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Endocr Relat Cancer. 2004 Dec;11(4):793-814</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15613453</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2005 May 1;65(9):3781-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15867374</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2006 Jan 12;439(7073):168-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16273093</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Mammary Gland Biol Neoplasia. 2006 Jan;11(1):27-39</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16947084</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2006 Oct 15;66(20):10100-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17047074</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem Biophys Res Commun. 2007 Apr 13;355(3):707-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17307140</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2007 Aug;6(8):2168-77</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17671085</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2007 Sep 1;67(17):7960-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17804702</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2008 Sep;7(9):2589-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18765823</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Opin Pharmacol. 2008 Aug;8(4):384-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18674638</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2008 Dec;8(12):915-28</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19029956</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Mammary Gland Biol Neoplasia. 2008 Dec;13(4):485-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19034632</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2009 Dec;8(12):3341-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19996272</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Diabetes. 2010 Mar;59(3):686-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19959755</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Trends Endocrinol Metab. 2010 Oct;21(10):610-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20663687</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2011 Jul;121(7):2750-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21633166</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Oncol (R Coll Radiol). 2011 Nov;23(9):587-600</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21524569</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biomaterials. 2013 Dec;34(36):9149-59</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23998858</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25293576</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>06</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1776-260X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>10</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Targeted oncology</Title>
                <ISOAbbreviation>Target Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC).</ArticleTitle>
            <Pagination>
                <MedlinePgn>365-73</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11523-014-0340-y</ELocationID>
            <Abstract>
                <AbstractText>Triple negative breast cancers express receptors for gonadotropin-releasing hormone (GnRH) in more than 50% of the cases, which can be targeted with peptidic analogs of GnRH, such as triptorelin. The current study investigates cytotoxic activity of triptorelin as a monotherapy and in treatment combinations with chemotherapeutic agents and inhibitors of the PI3K and the ERK pathways in in vitro models of triple negative breast cancers (TNBC). GnRH receptor expression of TNBC cell lines MDA-MB-231 and HCC1806 was investigated. Cells were treated with triptorelin, chemotherapeutic agents (cisplatin, docetaxel, AEZS-112), PI3K/AKT inhibitors (perifosine, AEZS-129), an ERK inhibitor (AEZS-134), and dual PI3K/ERK inhibitor AEZS-136 applied as single agent therapies and in combinations. MDA-MB-231 and HCC1806 TNBC cells both expressed receptors for GnRH on messenger (m)RNA and protein level and were found sensitive to triptorelin with a respective median effective concentration (EC50) of 31.21 ± 0.21 and 58.50 ± 19.50. Synergistic effects occurred when triptorelin was combined with cisplatin. In HCC1806 cells, synergy occurred when triptorelin was applied with PI3K/AKT inhibitors perifosine and AEZS-129. In MDA-MB-231 cells, synergy was observed after co-treatment with triptorelin and ERK inhibitor AEZS-134 and dual PI3K/ERK inhibitor AEZS-136. GnRH receptors on TNBC cells can be used for targeted therapy of these cancers with GnRH agonist triptorelin. Treatment combinations based on triptorelin and PI3K and ERK inhibitors and chemotherapeutic agent cisplatin have synergistic effects in in vitro models of TNBC. If confirmed in vivo, clinical trials based on triptorelin and cisplatin could be quickly carried out, as triptorelin is FDA approved for other indications and known to be well tolerated.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kwok</LastName>
                    <ForeName>C W</ForeName>
                    <Initials>CW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gynecology and Obstetrics, University Medical Center Regensburg, 93053, Regensburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Treeck</LastName>
                    <ForeName>O</ForeName>
                    <Initials>O</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Buchholz</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Seitz</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ortmann</LastName>
                    <ForeName>O</ForeName>
                    <Initials>O</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Engel</LastName>
                    <ForeName>J B</ForeName>
                    <Initials>JB</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>09</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>France</Country>
            <MedlineTA>Target Oncol</MedlineTA>
            <NlmUniqueID>101270595</NlmUniqueID>
            <ISSNLinking>1776-2596</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011966">Receptors, LHRH</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>08AN7WA2G0</RegistryNumber>
                <NameOfSubstance UI="D017329">Triptorelin Pamoate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>107-73-3</RegistryNumber>
                <NameOfSubstance UI="D010767">Phosphorylcholine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>2GWV496552</RegistryNumber>
                <NameOfSubstance UI="C105905">perifosine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>33515-09-2</RegistryNumber>
                <NameOfSubstance UI="D007987">Gonadotropin-Releasing Hormone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.1.-</RegistryNumber>
                <NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Q20Q21Q62J</RegistryNumber>
                <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007987" MajorTopicYN="N">Gonadotropin-Releasing Hormone</DescriptorName>
                <QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010767" MajorTopicYN="N">Phosphorylcholine</DescriptorName>
                <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011966" MajorTopicYN="N">Receptors, LHRH</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017329" MajorTopicYN="N">Triptorelin Pamoate</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>04</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>09</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>6</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25293576</ArticleId>
            <ArticleId IdType="doi">10.1007/s11523-014-0340-y</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Cell. 2004 Oct;6(4):313-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15488754</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2012 Feb 9;366(6):520-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22149876</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Peptides. 1999;20(10):1247-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10573298</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2002 Jun 27;417(6892):949-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12068308</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncol Rep. 2011 May;25(5):1481-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21331448</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2007 Apr;7(4):295-308</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17384584</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Apr 15;13(8):2329-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17438091</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Electrocardiol. 2012 Mar;45(2):148-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22153334</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Trends Endocrinol Metab. 2004 Sep;15(7):300-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15350601</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2010 Mar 1;126(5):1121-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19685490</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Front Neuroendocrinol. 2001 Oct;22(4):248-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11587553</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Treat Rev. 2010 Nov;36 Suppl 3:S80-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21129616</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2007 Jan 1;109(1):25-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17146782</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Arch Gynecol Obstet. 2012 Aug;286(2):437-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22555802</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2007 Jul 24;7:134</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17650314</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Mar 1;28(7):1145-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20100965</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gynecol Endocrinol. 2008 Jan;24(1):24-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17943530</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Recent Results Cancer Res. 2000;153:83-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10626291</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 1989 Sep 1;49(17):4682-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2547513</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2008;10 (6):R101</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19055754</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncologist. 2011;16(4):404-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21406469</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Clin Pract Endocrinol Metab. 2007 Feb;3(2):157-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17237842</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Pharm. 2007 Sep-Oct;4(5):652-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17705441</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Oncol. 2000 Nov;17(5):1063-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11029513</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Life Sci. 2003 Apr 11;72(21):2305-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12639697</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Cancer. 2013 Jul;49(10):2284-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23541564</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2010 Jan 15;70(2):440-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20068163</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nucleic Acids Res. 2010 Jan;38(Database issue):D652-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19906727</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gynecol Endocrinol. 1999 Dec;13(6):401-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10685334</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Chem Rev. 1999 Sep 8;99(9):2451-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11749486</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2007 May 1;109(9):1721-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17387718</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Oncol. 2009 Oct;35(4):789-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19724914</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncologist. 2012;17(6):766-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22584435</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17671126</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2009 Dec;20(12):1913-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19901010</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">25276378</PMID>
        <DateCompleted>
            <Year>2014</Year>
            <Month>10</Month>
            <Day>03</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">2072-1439</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>6</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of thoracic disease</Title>
                <ISOAbbreviation>J Thorac Dis</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1329-35</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3978/j.issn.2072-1439.2014.08.13</ELocationID>
            <Abstract>
                <AbstractText>Triple negative breast cancer (TNBC) is one type of breast cancer (BC), which is defined as negative for estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (Her2). Its origins and development seem to be elusive. And for now, drugs like tamoxifen or trastuzumab which specifically apply to ER, PR or Her2 positive BC seem unforeseeable in TNBC clinical treatment. Due to its extreme malignancy, high recurrence rate and poor prognosis, a lot of work on the research of TNBC is needed. This review aims to summarize the latest findings in TNBC in risk factors, possible therapeutic targets and possible prognostic makers. </AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jiao</LastName>
                    <ForeName>Qingli</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>1 Department of General Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510515, China ; 2 Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China ; 3 Department of Breast Oncology, Cancer Center, Sun Yat-sen University, Guangzhou 510275, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Aiguo</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>1 Department of General Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510515, China ; 2 Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China ; 3 Department of Breast Oncology, Cancer Center, Sun Yat-sen University, Guangzhou 510275, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shao</LastName>
                    <ForeName>Guoli</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>1 Department of General Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510515, China ; 2 Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China ; 3 Department of Breast Oncology, Cancer Center, Sun Yat-sen University, Guangzhou 510275, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peng</LastName>
                    <ForeName>Haoyu</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>1 Department of General Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510515, China ; 2 Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China ; 3 Department of Breast Oncology, Cancer Center, Sun Yat-sen University, Guangzhou 510275, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Mengchuan</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>1 Department of General Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510515, China ; 2 Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China ; 3 Department of Breast Oncology, Cancer Center, Sun Yat-sen University, Guangzhou 510275, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ji</LastName>
                    <ForeName>Shufeng</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>1 Department of General Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510515, China ; 2 Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China ; 3 Department of Breast Oncology, Cancer Center, Sun Yat-sen University, Guangzhou 510275, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Peng</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>1 Department of General Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510515, China ; 2 Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China ; 3 Department of Breast Oncology, Cancer Center, Sun Yat-sen University, Guangzhou 510275, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Jian</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>1 Department of General Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510515, China ; 2 Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China ; 3 Department of Breast Oncology, Cancer Center, Sun Yat-sen University, Guangzhou 510275, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>J Thorac Dis</MedlineTA>
            <NlmUniqueID>101533916</NlmUniqueID>
            <ISSNLinking>2072-1439</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Triple negative breast cancer (TNBC)</Keyword>
            <Keyword MajorTopicYN="N">prognostic marker</Keyword>
            <Keyword MajorTopicYN="N">risk factor</Keyword>
            <Keyword MajorTopicYN="N">therapeutic target</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>04</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25276378</ArticleId>
            <ArticleId IdType="doi">10.3978/j.issn.2072-1439.2014.08.13</ArticleId>
            <ArticleId IdType="pii">jtd-06-09-1329</ArticleId>
            <ArticleId IdType="pmc">PMC4178098</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Immunol Immunother. 2005 Mar;54(3):254-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15372205</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Treat Rev. 2010 May;36(3):206-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20060649</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Control. 2010 Jul;17(3):173-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20664514</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2013 Jul;140(1):93-104</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23807420</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Sci. 2010 May 15;123(Pt 10):1716-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20406885</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2008 Dec 15;14(24):8010-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19088017</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Korean J Physiol Pharmacol. 2013 Aug;17(4):291-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23946688</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2011 Mar 29;108(13):5384-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21402910</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2013 Aug;141(1):89-99</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23933800</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2013 Jul 1;19(13):3703-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23697991</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2000 Aug 17;406(6797):747-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10963602</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2011 May;127(1):99-108</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20556505</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1995 Jul;13(7):1572-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7602345</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Steroid Biochem Mol Biol. 2013 Jan;133:66-76</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22982153</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2010 Jun 1;116(11):2549-59</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20336785</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2009 Sep 24;9:342</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19778431</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2007 Mar 15;26(12):1693-701</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16983337</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2010 Mar 1;126(5):1121-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19685490</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Fly (Austin). 2009 Jan-Mar;3(1):62-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19182542</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2013 May 20;8(5):e63712</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23700430</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):E1301-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23509284</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Onkologie. 2011;34(12 ):675-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22156446</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Cycle. 2011 Feb 1;10(3):507-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21270527</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2011 Aug 15;117(16):3658-69</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21387260</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Oncol. 2013 Oct;43(4):985-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23939688</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Med Oncol. 2013;30(3):612</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23696021</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2009;11(2):R18</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19320967</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ultrastruct Pathol. 2009 Jul-Aug;33(4):141-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19728229</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2008 Mar 10;26(8):1275-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18250347</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2001 Jul 15;61(14):5407-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11454684</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):439-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17372238</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hum Pathol. 2013 Oct;44(10):2180-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23845466</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2012;7(12):e51446</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23236502</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2009 Jun 18;9:192</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19534825</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2006 Dec 15;12(24):7242-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17189395</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast. 2007 Dec;16 Suppl 2:S72-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17714947</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncologist. 2011;16 Suppl 1:1-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21278435</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2012 Sep 19;12:414</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22992276</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>EMBO Mol Med. 2011 Sep;3(9):528-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21732535</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2013 Jul;140(2):353-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23836011</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2007 Aug 15;110(4):876-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17620276</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2007 Nov 1;67(21):10608-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17968031</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hum Pathol. 2013 Oct;44(10):2159-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23845471</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2013 Apr 30;8(4):e63132</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23646186</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2012 Jan 26;366(4):310-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22276821</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cancer Surviv. 2013 Mar;7(1):74-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23179496</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Signal. 2011 Oct;23(10):1515-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21620960</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Arch Gynecol Obstet. 2014 Jan;289(1):141-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23828443</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2008 Sep 30;8:278</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18826621</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2012 Oct 4;490(7418):61-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23000897</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Swiss Med Wkly. 2013 May 28;143:w13765</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23740185</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2013 Nov 12;8(11):e78641</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24265703</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2008 May;109(1):123-39</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17578664</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2003 Aug 15;9(9):3413-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12960130</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2010;12(5):R68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20813035</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2007 May 1;109(9):1721-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17387718</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2009 Jan;113(2):357-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18324472</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2013 Jun;24(6):1498-505</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23406733</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2012 Nov 15;72(22):5812-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23139210</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Carcinogenesis. 2014 May;35(5):1012-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24325915</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2014 Mar 31;16(2):R32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24684785</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17671126</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Oncol. 2013 Sep;14(10):933-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23932548</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem Biophys Res Commun. 2011 Apr 22;407(4):680-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21440529</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 2006 Jun 7;295(21):2492-502</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16757721</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2009 Dec;20(12):1913-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19901010</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25239934</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>11</Month>
            <Day>10</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1538-8514</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>13</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular cancer therapeutics</Title>
                <ISOAbbreviation>Mol. Cancer Ther.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2688-705</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1158/1535-7163.MCT-14-0346</ELocationID>
            <Abstract>
                <AbstractText>The cytokine TWEAK and its receptor, Fn14, have emerged as potentially valuable targets for cancer therapy. Granzyme B (GrB)-containing Fn14-targeted constructs were generated containing either the Fn14 ligand TWEAK (GrB-TWEAK) or an anti-Fn14 humanized single-chain antibody (GrB-Fc-IT4) as the targeting moieties. Both constructs showed high affinity and selective cytotoxicity against a panel of Fn14-expressing human tumor cells including triple-negative breast cancer (TNBC) lines. Cellular expression of the GrB inhibitor PI-9 in target cells had no impact on the cytotoxic effect of either construct. Cellular expression of MDR1 showed no cross-resistance to the fusion constructs. GrB-TWEAK and GrB-Fc-IT4 activated intracellular caspase cascades and cytochrome c-related proapoptotic pathways consistent with the known intracellular functions of GrB in target cells. Treatment of mice bearing established HT-29 xenografts with GrB-TWEAK showed significant tumor growth inhibition compared with vehicle alone (P &lt; 0.05). Both GrB-TWEAK and GrB-Fc-IT4 displayed significant tumor growth inhibition when administered to mice bearing orthotopic MDA-MB-231 (TNBC) tumor xenografts. The Cancer Genome Atlas analysis revealed that Fn14 mRNA expression was significantly higher in TNBC and in HER2-positive disease (P &lt; 0.0001) compared with hormone receptor-positive breast cancer, and in basal-like 2 tumors (P = 0.01) compared with other TNBC molecular subtypes. IHC analysis of a 101 patient TNBC tumor microarray showed that 55 of 101 (54%) of tumors stained positive for Fn14, suggesting that this may be an excellent potential target for precision therapeutic approaches. Targeting Fn14 using fully human, GrB-containing fusion constructs may form the basis for a new class of novel, potent, and highly effective constructs for targeted therapeutic applications.</AbstractText>
                <CopyrightInformation>©2014 American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Hong</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Experimental Therapeutics, M.D. Anderson Cancer Center, Houston, Texas.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mohamedali</LastName>
                    <ForeName>Khalid A</ForeName>
                    <Initials>KA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Experimental Therapeutics, M.D. Anderson Cancer Center, Houston, Texas.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gonzalez-Angulo</LastName>
                    <ForeName>Ana Maria</ForeName>
                    <Initials>AM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, Texas. Department of Systems Biology, MD Anderson Cancer Center, Houston, Texas.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cao</LastName>
                    <ForeName>Yu</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Experimental Therapeutics, M.D. Anderson Cancer Center, Houston, Texas.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Migliorini</LastName>
                    <ForeName>Mary</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Center for Vascular and Inflammatory Diseases, and the Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cheung</LastName>
                    <ForeName>Lawrence H</ForeName>
                    <Initials>LH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Experimental Therapeutics, M.D. Anderson Cancer Center, Houston, Texas.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>LoBello</LastName>
                    <ForeName>Janine</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, Arizona.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lei</LastName>
                    <ForeName>Xiudong</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics, MD Anderson Cancer Center, Houston, Texas.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qi</LastName>
                    <ForeName>Yuan</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Bioinformatics, MD Anderson Cancer Center, Houston, Texas.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hittelman</LastName>
                    <ForeName>Walter N</ForeName>
                    <Initials>WN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Experimental Therapeutics, M.D. Anderson Cancer Center, Houston, Texas.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Winkles</LastName>
                    <ForeName>Jeffrey A</ForeName>
                    <Initials>JA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Center for Vascular and Inflammatory Diseases, and the Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tran</LastName>
                    <ForeName>Nhan L</ForeName>
                    <Initials>NL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, Arizona.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rosenblum</LastName>
                    <ForeName>Michael G</ForeName>
                    <Initials>MG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Experimental Therapeutics, M.D. Anderson Cancer Center, Houston, Texas. mrosenbl@mdanderson.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P30 CA016672</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 NS055126</GrantID>
                    <Acronym>NS</Acronym>
                    <Agency>NINDS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30CA016672</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>09</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Mol Cancer Ther</MedlineTA>
            <NlmUniqueID>101132535</NlmUniqueID>
            <ISSNLinking>1535-7163</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018124">Receptors, Tumor Necrosis Factor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D057127">Single-Chain Antibodies</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000613297">TNFRSF12A protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000074050">TWEAK Receptor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000613299">Tnfrsf12a protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.21.-</RegistryNumber>
                <NameOfSubstance UI="D053804">Granzymes</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053804" MajorTopicYN="N">Granzymes</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019073" MajorTopicYN="N">HT29 Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019169" MajorTopicYN="N">Jurkat Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018124" MajorTopicYN="N">Receptors, Tumor Necrosis Factor</DescriptorName>
                <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D057127" MajorTopicYN="N">Single-Chain Antibodies</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000074050" MajorTopicYN="N">TWEAK Receptor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>9</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>9</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25239934</ArticleId>
            <ArticleId IdType="pii">1535-7163.MCT-14-0346</ArticleId>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-14-0346</ArticleId>
            <ArticleId IdType="pmc">PMC4276724</ArticleId>
            <ArticleId IdType="mid">NIHMS628393</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Int J Cancer. 2007 Nov 15;121(10):2132-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17594693</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Immunol. 1995 Jun 15;154(12):6299-305</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7759868</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Asian Pac J Cancer Prev. 2013;14(6):3509-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23886137</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Immunol Rev. 2010 May;235(1):159-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20536562</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Lett. 2012 Sep 28;322(2):159-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22388102</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Immunol Methods. 2003 May 1;276(1-2):89-101</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12738362</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Invest Dermatol. 2013 Apr;133(4):1052-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23190886</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Bioinformatics. 2010 Jan 1;26(1):139-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19910308</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2013 May 10;288(19):13455-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23532848</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pathol. 2006 Mar;208(4):495-506</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16429394</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5127-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23493554</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2010 Jan 15;16(2):497-508</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20068083</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Pharmacol. 2003 Jun;139(4):797-804</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12813003</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Biol Ther. 2012 Jul;13(9):812-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22669574</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cytokine. 2007 Oct;40(1):1-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17981048</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2003 Dec;2(12):1341-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14707275</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2013 Jun;12(6):979-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23493312</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Death Differ. 2012 Jan;19(1):28-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22052191</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>MAbs. 2011 Jul-Aug;3(4):362-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21697654</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Pharm Des. 2009;15(23):2676-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19689338</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4407-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17671123</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2005 Apr 14;24(16):2613-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15735761</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):14985-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11752447</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2012 Oct 1;18(19):5247-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22850567</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Adv Enzyme Regul. 1984;22:27-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">6382953</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Am Acad Dermatol. 2001 Dec;45(6):871-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11712032</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2003 Aug 22;278(34):32317-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12794080</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2005 Aug;4(8):1277-85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16093444</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem Biophys Res Commun. 2010 Jun 11;396(4):793-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20447380</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2013 Jul 15;73(14):4439-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23722548</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Annu Rev Immunol. 2008;26:389-420</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18304003</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2005 Feb 11;280(6):4476-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15574417</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Genome Biol. 2010;11(3):R25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20196867</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Immunol Rev. 2011 Nov;244(1):99-114</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22017434</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Immunity. 2001 Nov;15(5):837-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11728344</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Expert Opin Biol Ther. 2009 Nov;9(11):1445-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19817678</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Immunol. 2007 Jan;245(1):32-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17490628</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Immunol. 2002 Oct;2(10):735-47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12360212</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Histol Histopathol. 2013 Jul;28(7):859-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23300011</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2013 Oct;12(10):2055-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23858102</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Pathol. 2003 Apr;162(4):1313-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12651623</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Carcinogenesis. 2011 Nov;32(11):1589-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21828059</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cancer Res Clin Oncol. 2013 Feb;139(2):315-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23073510</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Jul 10;28(20):3271-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20498394</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Immunol Methods. 2011 Aug 31;371(1-2):8-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21723287</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2009;9:199</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19549303</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Oncol. 2013 Apr;42(4):1239-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23443741</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2011 Jul;10(7):1276-88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21586630</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mini Rev Med Chem. 2012 Oct;12(11):1127-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22512559</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2010 Jun 4;285(23):17432-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20385556</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Lett. 2012 Jan 1;314(1):73-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21993017</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11311-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18678888</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Inform. 2012;11:147-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22872785</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Drug Discov. 2008 May;7(5):411-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18404150</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2008 May 10;26(14):2373-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18413639</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2010 Jul 1;70(13):5518-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20551065</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Biol. 1999 Mar 8;144(5):883-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10085288</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2014 Mar;13(3):643-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24431076</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Front Immunol. 2013 Dec 23;4:473</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24391646</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2012 Jan 2;287(1):484-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22081603</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2006 Oct 1;66(19):9535-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17018610</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2013 Oct 15;19(20):5686-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23974006</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Res. 2008 May;6(5):725-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18505918</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Adv Drug Deliv Rev. 2000 Sep 30;43(2-3):101-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10967224</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neoplasia. 2006 Feb;8(2):125-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16611405</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2006 May 19;281(20):13964-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16547002</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Dev Biol (Basel). 2003;112:15-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12762500</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>FASEB J. 2009 Jun;23(6):1625-37</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19141537</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25130168</PMID>
        <DateCompleted>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>11</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>11</Month>
            <Day>16</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-7980</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>353</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Oct</Month>
                        <Day>28</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer letters</Title>
                <ISOAbbreviation>Cancer Lett.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC).</ArticleTitle>
            <Pagination>
                <MedlinePgn>153-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canlet.2014.06.022</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S0304-3835(14)00440-6</ELocationID>
            <Abstract>
                <AbstractText>The mechanism underlying the aggressive behaviors of triple negative breast cancer (TNBC) is not well characterized yet. The association between cancer stem cell (CSC) population and the aggressive behaviors of TNBC has not been established. We found the CD44(+)/CD24(-) cell population was enriched in TNBC tissues and cell lines, with a higher capacity of proliferation, migration, invasion and tumorigenicity as well as lower adhesion ability. The CD44(+)/CD24(-) cell population with cancer stem cell-like properties may play an important role in the aggressive behaviors of TNBC. This discovery may lead to new therapeutic strategies targeting CD44(+)/CD24(-) cell population in TNBC. </AbstractText>
                <CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Fei</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Cancer Hospital/Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Huihui</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Shandong Cancer Hospital/Institute, Jinan, Shandong 250017, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Haijuan</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Molecular Oncology, Cancer Hospital/Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shi</LastName>
                    <ForeName>Xiuqing</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Cancer Hospital/Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fan</LastName>
                    <ForeName>Ying</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Cancer Hospital/Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ding</LastName>
                    <ForeName>Xiaoyan</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Cancer Hospital/Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Chen</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Molecular Oncology, Cancer Hospital/Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhan</LastName>
                    <ForeName>Qimin</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Molecular Oncology, Cancer Hospital/Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qian</LastName>
                    <ForeName>Haili</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Molecular Oncology, Cancer Hospital/Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. Electronic address: qianhaili@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Binghe</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Cancer Hospital/Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. Electronic address: binghxu@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Ireland</Country>
            <MedlineTA>Cancer Lett</MedlineTA>
            <NlmUniqueID>7600053</NlmUniqueID>
            <ISSNLinking>0304-3835</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051927">CD24 Antigen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C497889">CD24 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C497483">CD44 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018960">Hyaluronan Receptors</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051927" MajorTopicYN="N">CD24 Antigen</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018270" MajorTopicYN="N">Carcinoma, Ductal, Breast</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002448" MajorTopicYN="N">Cell Adhesion</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018960" MajorTopicYN="N">Hyaluronan Receptors</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016688" MajorTopicYN="N">Mice, Inbred NOD</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009368" MajorTopicYN="N">Neoplasm Transplantation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CD44(+)/CD24(−).</Keyword>
            <Keyword MajorTopicYN="N">Cancer stem cells</Keyword>
            <Keyword MajorTopicYN="N">Triple negative breast cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>01</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>05</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>06</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>11</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25130168</ArticleId>
            <ArticleId IdType="pii">S0304-3835(14)00440-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.canlet.2014.06.022</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25003567</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>07</Month>
            <Day>09</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1543-0790</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>12</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical advances in hematology &amp; oncology : H&amp;O</Title>
                <ISOAbbreviation>Clin Adv Hematol Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>TNBC vs non-TNBC: A retrospective review of differences in mean age, family history, smoking history, and stage at diagnosis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>377-81</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This study was designed to compare mean age, ethnicity, smoking history, family history of breast cancer, and stage at diagnosis in patients with triple-negative breast cancer (TNBC) vs non-TNBC at an inner city university program.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We reviewed data in our tumor registry on patients seen between January 2000 and December 2005, and identified a total of 445 patients with various subtypes of breast cancers. Of these, 342 patients met our study criteria. Thirty-nine patients had TNBC and 303 had non-TNBC.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean age at diagnosis was 59.87 ± 15.67 years for TNBC and 60.09 ± 13.98 years for non-TNBC (P=.9272). TNBC was more common in black than in white patients (58.97% vs 35.90%; OR, 2.755; P=.004), and non-TNBC was more common in white than in black patients (57.76% vs 39.27%). There was not a statistically significant difference in past or present smoking between the TNBC and non-TNBC patients (20.51% vs 27.72%; P=.4385). Family history of breast cancer was not statistically related to TNBC status: a positive family history was reported in 30.77% of TNBC patients vs 33.33% of non-TNBC patients (P=.8384), no family history was reported in 51.28% of TNBC patients vs 51.82% of non-TNBC patients, and family history was unknown in 17.95% of TNBC patients vs 14.85% of non-TNBC patients. Pathologic stage at the time of diagnosis was as follows for TNBC vs non-TNBC patients: stage 0, 15.79% vs 11.37% (P=.4332); stage I, 34.21% vs 30.98% (P=.6890); stage II, 28.98% vs 37.25% (P=.3205); stage III, 18.42% vs 17.25% (P=.8591); and stage IV, 3.63% vs 3.14% (P=.8651).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We found that in our patient population, black women were significantly more likely to have TNBC than non-TNBC, and white women were more likely to have non-TNBC than TNBC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tariq</LastName>
                    <ForeName>Khurram</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Florida College of Medicine, Jacksonville, Florida.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Farhangi</LastName>
                    <ForeName>Arezo</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Florida College of Medicine, Jacksonville, Florida.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rana</LastName>
                    <ForeName>Fauzia</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Florida College of Medicine, Jacksonville, Florida.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D017418">Meta-Analysis</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Adv Hematol Oncol</MedlineTA>
            <NlmUniqueID>101167661</NlmUniqueID>
            <ISSNLinking>1543-0790</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005006" MajorTopicYN="N">Ethnic Groups</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005431" MajorTopicYN="N" Type="Geographic">Florida</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
                <QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012907" MajorTopicYN="N">Smoking</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25003567</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">24857120</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>12</Month>
            <Day>09</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1548-8756</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting</Title>
                <ISOAbbreviation>Am Soc Clin Oncol Educ Book</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Should triple-negative breast cancer (TNBC) subtype affect local-regional therapy decision making?</ArticleTitle>
            <Pagination>
                <MedlinePgn>e32-6</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.14694/EdBook_AM.2014.34.e32</ELocationID>
            <Abstract>
                <AbstractText>The more aggressive biologic characteristics and the current lack of targeted therapy for triple-negative breast cancer (TNBC) make local-regional management decisions challenging for physicians. TNBC is associated with patients of younger age, black race and BRCA1 mutation carriers. Distinctions between BRCA1-associated and sporadic TNBC include increased lifetime risk of ipsilateral and contralateral breast cancer after breast cancer therapy (BCT) for BRCA carriers, which is not shared by sporadic TNBC. However, the presence of a BRCA mutation should not preclude a breast-conservation approach in patients who are otherwise appropriate candidates for BCT. Data suggest that local-regional relapse (LRR) at baseline after BCT appears to be comparable for TNBC and the HER2-positive subgroups, but is about 50% greater than luminal tumors. LRR appears to be similarly increased after mastectomy; thus, TNBC should not be a contra-indication for BCT. Recent hypothesis-generating data suggest less LRR after BCT (where radiation is routinely delivered) than with mastectomy for early-stage TNBC. To date, no specific local-regional guideline recommendations for TNBC exist. Level I outcome data for TNBC using accelerated partial breast irradiation (APBI) and hypofractionated whole-breast irradiation (hWBRT) are lacking. TNBC should be treated with APBI only on clinical trials. Although hWBRT may be considered in TNBC, its association with younger age, advanced disease and use of systemic chemotherapy often precludes its use for this subtype. Until definitive treatment strategies are validated in large datasets and confirmed in randomized trials, TNBC subtype, in and of itself, should not direct local-regional management treatment decisions. </AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Moran</LastName>
                    <ForeName>Meena S</ForeName>
                    <Initials>MS</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Am Soc Clin Oncol Educ Book</MedlineTA>
            <NlmUniqueID>101233985</NlmUniqueID>
            <ISSNLinking>1548-8748</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D003657" MajorTopicYN="Y">Decision Making</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019583" MajorTopicYN="N">Dose Fractionation, Radiation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019398" MajorTopicYN="N">Genes, BRCA1</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008408" MajorTopicYN="N">Mastectomy</DescriptorName>
                <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
                <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>12</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24857120</ArticleId>
            <ArticleId IdType="pii">00114000e32</ArticleId>
            <ArticleId IdType="doi">10.14694/EdBook_AM.2014.34.e32</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM">
        <PMID Version="1">24840078</PMID>
        <DateCompleted>
            <Year>2014</Year>
            <Month>10</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1759-4782</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>11</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature reviews. Clinical oncology</Title>
                <ISOAbbreviation>Nat Rev Clin Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Breast cancer: TNBC: can we treat the untargetable?</ArticleTitle>
            <Pagination>
                <MedlinePgn>379</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/nrclinonc.2014.88</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hutchinson</LastName>
                    <ForeName>Lisa</ForeName>
                    <Initials>L</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016420">Comment</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>05</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Nat Rev Clin Oncol</MedlineTA>
            <NlmUniqueID>101500077</NlmUniqueID>
            <ISSNLinking>1759-4774</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>BG3F62OND5</RegistryNumber>
                <NameOfSubstance UI="D016190">Carboplatin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentOn">
                <RefSource>Lancet Oncol. 2014 Jun;15(7):747-56</RefSource>
                <PMID Version="1">24794243</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016190" MajorTopicYN="N">Carboplatin</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020360" MajorTopicYN="Y">Neoadjuvant Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24840078</ArticleId>
            <ArticleId IdType="pii">nrclinonc.2014.88</ArticleId>
            <ArticleId IdType="doi">10.1038/nrclinonc.2014.88</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Lancet Oncol. 2014 Jun;15(7):747-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24794243</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">24667715</PMID>
        <DateCompleted>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2016</Year>
            <Month>10</Month>
            <Day>17</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1569-8041</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>25</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title>
                <ISOAbbreviation>Ann. Oncol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC).</ArticleTitle>
            <Pagination>
                <MedlinePgn>824-31</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1093/annonc/mdu025</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">EndoTAG-1, composed of paclitaxel embedded in liposomal membranes targeting tumor endothelial cells, was evaluated for safety and efficacy in advanced triple-negative breast cancer (TNBC).</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">One hundred and forty patients were treated with weekly EndoTAG-1 (22 mg/m(2)) plus paclitaxel (70 mg/m(2)), twice weekly EndoTAG-1 (2× 44 mg/m(2)), or weekly paclitaxel (90 mg/m(2)) for greater than or equal to four cycles (3-week treatment + 1-week rest) or until progression/toxicity. Primary end point was progression-free survival (PFS) rate evaluated centrally after four cycles of therapy (week 16). The study was not powered for intergroup comparisons.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The PFS rate at week 16 was 59.1% [one-sided 95% CI: 45.6, ∞] on combination treatment, 34.2% [21.6, ∞] on EndoTAG-1, and 48.0% [30.5, ∞] on paclitaxel. Median PFS reached 4.2, 3.4, and 3.7 months, respectively. After complete treatment (week 41 analysis), median overall survival (OS) was 13.0, 11.9, and 13.1 months for the modified Intention-to-Treat (ITT) population and 15.1, 12.5, and 8.9 months for the per-protocol population, respectively. The clinical benefit rate was 53%, 31%, and 36% for the treatment groups. Safety analysis revealed known toxicities of the drugs with slight increases of grade 3/4 neutropenia on combination therapy.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Treatment of advanced TNBC with a combination of EndoTAG-1 and standard paclitaxel [Taxol® (Bristol-Myers Squibb GmbH), or equivalent generic formulation] was well tolerated and showed antitumor efficacy. The positive trend needs to be confirmed in a randomized phase III trial.</AbstractText>
                <AbstractText Label="STUDY REGISTRATION" NlmCategory="BACKGROUND">European Clinical Trials Database: EudraCT number 2006-002221-23. ClinicalTrials.gov identifier: NCT00448305.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Awada</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut Jules Bordet, Université Libre de Bruxelles, Bruxelles, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bondarenko</LastName>
                    <ForeName>I N</ForeName>
                    <Initials>IN</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bonneterre</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nowara</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ferrero</LastName>
                    <ForeName>J M</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bakshi</LastName>
                    <ForeName>A V</ForeName>
                    <Initials>AV</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wilke</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Piccart</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>CT4002 study group</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT00448305</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Ann Oncol</MedlineTA>
            <NlmUniqueID>9007735</NlmUniqueID>
            <ISSNLinking>0923-7534</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008055">Lipids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>P88XT4IS4D</RegistryNumber>
                <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName>
                <QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">EndoTAG-1</Keyword>
            <Keyword MajorTopicYN="N">activated tumor endothelial cells</Keyword>
            <Keyword MajorTopicYN="N">advanced disease</Keyword>
            <Keyword MajorTopicYN="N">cationic liposomes of paclitaxel</Keyword>
            <Keyword MajorTopicYN="N">lipid-embedded paclitaxel</Keyword>
            <Keyword MajorTopicYN="N">triple-negative breast cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>12</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24667715</ArticleId>
            <ArticleId IdType="pii">mdu025</ArticleId>
            <ArticleId IdType="doi">10.1093/annonc/mdu025</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">29147364</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1920-454X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>4</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>World journal of oncology</Title>
                <ISOAbbreviation>World J Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>TNBC vs. Non-TNBC: A Five-Year Retrospective Review of Differences in Mean Age, Family History, Smoking History and Stage at Diagnosis at an Inner City University Program.</ArticleTitle>
            <Pagination>
                <MedlinePgn>241-247</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.4021/wjon738w</ELocationID>
            <Abstract>
                <AbstractText Label="Background" NlmCategory="UNASSIGNED">In recent years, breast cancer has been classified on the basis of estrogen or progesterone receptor (ER/PR) status and whether the human epidermal growth factor 2 receptor (HER2/neu) protein is overexpressed. Based on this system, breast cancer is broadly divided into the triple negative breast cancer (TNBC) and the non-TNBC subtypes. TNBC is a subtype of breast cancer, notable for its propensity to metastasize early and display a comparatively more aggressive course than its non-TNBC counterpart. Certain clinico-pathologic and demographic risk factors have been associated with breast cancer. In this study, we aim to compare mean age, ethnicity, family history, tobacco use and stage at presentation between TNBC and non-TNBC subtypes at our inner city university program.</AbstractText>
                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">We reviewed data in our tumor registry between January 2000 and December 2005 with particular attention to mean age, race, family history, tobacco use and stage at presentation. We found a total of 445 patients with various subtypes of breast cancers. We included only those patients in whom the status of both ER/PR and the status of Her2/neu protein overexpression were recorded. Our strict selection criteria lead to an exclusion of about 103 patients. Out of the remaining 342 patients, 39 were TNBC and 303 were non-TNBC.</AbstractText>
                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Mean age of onset for TNBC vs. non-TNBC patients was 59.87 ± 15.67 years vs. 60.09 ± 13.98 years respectively (P = 0.9272). In terms of ethnicity, TNBC vs. non-TNBC patients had the following racial backgrounds: black, 58.97% vs. 39.27%; white, 35.90% vs. 57.76%; Chinese, 2.56% vs. 0.99%; others, 2.57% vs. 1.98% respectively (P = 0.004, OR = 2.755). Comparisons with respect to a history of tobacco abuse for TNBC vs. non-TNBC patients revealed a positive smoking history in 20.51% vs. 27.72% whereas there was no former or current smoking history in 71.79% vs. 61.72% respectively (P = 0.4385). Comparison of family history of a breast cancer in TNBC vs. non-TNBC patients showed that positive family history of breast cancer was seen in 30.77% vs. 33.33%, no family history of cancer was seen in 51.28% vs. 51.82% and unknown 17.95% vs. 14.85% (P = 0.8384). Pathologic stage at the time of diagnosis for TNBC vs. non-TNBC patients was as follows: stage 0, 15.79% vs. 11.37% (P = 0.4332); stage 1, 34.21% vs. 30.98% (P = 0.6890); stage 2, 28.98% vs. 37.25% (P = 0.3205); stage 3, 18.42% vs. 17.25% (P = 0.0.8591); and stage 4, 3.63% vs. 3.14% (P = 0.8651). Analysis using Chi-square test revealed χ<sup>2</sup> value of 0.855.</AbstractText>
                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Our results add to the growing body of evidence pertaining to the association of certain demographic and clinico-pathologic characteristics in women with breast cancer. We found that in our patient population, there is a significant ethnic predisposition for the two types of breast cancers that we studied. African Americans were more likely to have TNBC compared to the higher frequency of non-TNBC in white females. We did not find a significant difference in mean age, cigarette smoking, family history and stage at diagnosis between the TNBC and non-TNBC breast cancer patients. These findings are all consistent with the previously published research studies.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tariq</LastName>
                    <ForeName>Khurram</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, College of Medicine, University of Florida, Jacksonville, FL 32209, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rana</LastName>
                    <ForeName>Fauzia</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hematology &amp; Medical Oncology, College of Medicine, University of Florida, Jacksonville, FL 32209, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>01</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Canada</Country>
            <MedlineTA>World J Oncol</MedlineTA>
            <NlmUniqueID>101564097</NlmUniqueID>
            <ISSNLinking>1920-4531</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Breast cancer</Keyword>
            <Keyword MajorTopicYN="N">Demographical differences</Keyword>
            <Keyword MajorTopicYN="N">Non-TNBC</Keyword>
            <Keyword MajorTopicYN="N">TNBC</Keyword>
        </KeywordList>
        <CoiStatement>The authors declare that there is no conflict of interests regarding the publication of this article.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29147364</ArticleId>
            <ArticleId IdType="doi">10.4021/wjon738w</ArticleId>
            <ArticleId IdType="pmc">PMC5649849</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Breast Cancer Res. 2012 Jan 06;14(1):R3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22225836</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2006 Sep 1;119(5):1145-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16557599</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Control. 2010 Jul;17(3):173-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20664514</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2003 Sep 1;98(5):894-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12942554</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2008 Oct 15;113(8 Suppl):2221-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18816619</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>World J Surg. 2011 Jun;35(6):1244-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21472372</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncology (Williston Park). 2008 Oct;22(11):1233-9; discussion 1239-40, 1243</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18980022</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 1983 Feb;43(2):485-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">6293698</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Obstet Gynecol. 1990 Feb;162(2):502-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2178432</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Surg Oncol. 2002 Nov;9(9):912-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12417515</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2005 Sep 1;116(3):340-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15818618</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 1985 Oct 17;313(16):973-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">4047104</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2012 Mar 1;18(5):1341-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22261811</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast J. 2008 Sep-Oct;14(5):456-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18657139</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2002 Apr 1;62(7):1987-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11929815</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2000 Aug 17;406(6797):747-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10963602</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2002 May 20;99(3):427-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11992413</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2005 Jul 04;5:70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15996267</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2002 Aug 20;100(6):723-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12209614</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2005 Aug 1;104(3):653-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15983986</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2002 Jan 31;415(6871):530-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11823860</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Psychooncology. 2006 Oct;15(10):873-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16374894</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15761078</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2002 Oct 5;360(9339):1044-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12383984</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMJ. 2000 Sep 9;321(7261):624-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10977847</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Epidemiol Biomarkers Prev. 1995 Apr-May;4(3):233-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7606197</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):61-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15668477</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12829800</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2007 Jul 12;357(2):115-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17625123</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2001 Oct 27;358(9291):1389-99</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11705483</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast. 2000 Apr;9(2):83-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14731704</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1999 Nov;17(11):3396-402</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10550133</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2009 Jul 15;101(14):993-1000</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19584327</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2008 Mar 10;26(8):1275-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18250347</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mayo Clin Proc. 2005 Nov;80(11):1423-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16295021</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Mar 1;28(7):1145-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20100965</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2001 Aug 1;93(3):368-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11433401</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2006 Aug 10;24(23):3726-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16720680</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Arch Intern Med. 2003 Jan 13;163(1):49-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12523916</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 1993 Jul 29;329(5):326-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8321261</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 1977 Aug;74(8):3555-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">333441</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 1999 Oct;10(10):1163-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10586331</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst Monogr. 2001;(30):36-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11773290</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Mol Med (Berl). 2006 Jan;84(1):16-28</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16283147</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):953-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12376493</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2007 Sep;105(1):69-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17115108</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2001 Jan 25;344(4):276-85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11172156</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Health Psychol. 1996 Nov;15(6):423-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8973921</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast J. 2006 Jan-Feb;12 Suppl 1:S70-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16430400</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2009 Nov 11;4(11):e7695</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19907646</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Obstet Gynecol. 1988 Oct;159(4):820-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2972209</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 1997 May 29;71(5):800-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9180149</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Causes Control. 2005 Oct;16(8):975-85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16132806</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2002 Apr 3;94(7):490-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11929949</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Diagn Mol Pathol. 2003 Mar;12(1):27-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12605033</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cancer Res Clin Oncol. 2011 Feb;137(2):183-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21069385</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Carcinogenesis. 2002 Feb;23(2):301-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11872636</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Fam Cancer. 2006;5(4):309-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16858627</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2006 Jan 30;94(2):231-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16404417</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21685461</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Cancer. 2007 Mar;43(5):867-76</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17307353</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Carcinogenesis. 2003 Apr;24(4):719-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12727801</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17671126</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem Biophys Res Commun. 1980 Aug 29;95(4):1599-606</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">6774726</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11553815</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 1982 Oct 21;307(17):1062-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7121516</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 2006 Jun 7;295(21):2492-502</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16757721</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">24233638</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>09</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1776-260X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Targeted oncology</Title>
                <ISOAbbreviation>Target Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Prognostic value of survivin and EGFR protein expression  in triple-negative breast cancer (TNBC) patients.</ArticleTitle>
            <Pagination>
                <MedlinePgn>349-57</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Triple-negative breast cancer (TNBC) is a particular type of breast cancer which is characterized by its biological aggressiveness, worse prognosis, and lack of prognostic markers or therapeutic targets in contrast with hormonal receptor-positive and human epidermal growth factor receptor 2-positive (HER2+) breast cancers. We aimed to evaluate survivin and epidermal growth factor receptor (EGFR) expression and their prognostic value and determine their relationships with the clinicopathological parameters of TNBC. A total of 136 patients who had undergone a resection of primary TNBC were enrolled at the Third Affiliated Hospital of Harbin Medical University from March 2003 to September 2005. Expression of ER, PR, HER2, EGFR, and survivin was assessed by immunohistochemistry. The association of TNBC and other clinicopathological variables and the prognostic value of survivin and EGFR expression were evaluated. Survivin was expressed in 62 (45.6 %) cases and EGFR was expressed in 82 (60.3 %) cases. Survivin expression was associated with menopausal status (P = 0.011), tumor size (P = 0.037), and lymph node status (P = 0.001). EGFR expression was associated with menopausal status (P = 0.029), lymph node status (P = 0.004), P53 expression (P = 0.001), Ki-67 expression (P = 0.028), and lymphatic vascular invasion (P = 0.037). A multivariate analysis demonstrated that tumor size (hazard ratio (HR) 1.587, 95 % confidence interval (CI) 1.081–2.330, P = 0.018 for disease-free survival (DFS); HR 1.606, 95%CI 1.096–2.354, P = 0.015 for overall survival (OS)), lymph node status (HR 2.873, 95%CI 1.544–5.344, P = 0.001 for DFS; HR 2.915, 95%CI 1.553–5.471, P = 0.001 for OS), tumor grade (HR 1.914, 95%CI 1.218–3.007, P = 0.005 for DFS; HR 1.983, 95%CI 1.228–3.203, P = 0.005 for OS), EGFR (HR 3.008, 95%CI 1.331–6.792, P = 0.008 for DFS; HR 3.151, 95%CI 1.374–7.226, P = 0.007 for OS), and survivin (HR 1.573, 95%CI 1.087–2.277, P = 0.016 for DFS; HR 1.607, 95%CI 1.088–2.374, P = 0.017 for OS) were of prognostic significance for disease-free and overall survival. We draw a conclusion from the present study that survivin and EGFR expression are useful prognostic markers of TNBC and might be useful for molecular targeting therapy of TNBC treatment.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Minghui</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Xiaosan</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Shu</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Yan</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Di</LastName>
                    <ForeName>Wenyu</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Gangling</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Maopeng</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Qingyuan</ForeName>
                    <Initials>Q</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>France</Country>
            <MedlineTA>Target Oncol</MedlineTA>
            <NlmUniqueID>101270595</NlmUniqueID>
            <ISSNLinking>1776-2596</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C107489">BIRC5 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D047628">Estrogen Receptor alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051034">Inhibitor of Apoptosis Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011980">Receptors, Progesterone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000077022">Survivin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C506487">estrogen receptor alpha, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D047628" MajorTopicYN="N">Estrogen Receptor alpha</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051034" MajorTopicYN="N">Inhibitor of Apoptosis Proteins</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008593" MajorTopicYN="N">Menopause</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011980" MajorTopicYN="N">Receptors, Progesterone</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077022" MajorTopicYN="N">Survivin</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>08</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>9</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24233638</ArticleId>
            <ArticleId IdType="doi">10.1007/s11523-013-0300-y</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Cell Physiol. 2006 Sep;208(3):476-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16557517</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2009 May;20(5):842-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19153117</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Radiat Oncol. 2006 May 02;1:11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16722544</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>EMBO J. 1996 Jun 3;15(11):2685-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8654366</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Exp Mol Pathol. 2005 Oct;79(2):100-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15975575</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Head Neck. 2008 Oct;30(10):1318-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18704972</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Chem. 2004 Nov;50(11):1986-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15364883</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>APMIS. 2008 Jan;116(1):27-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18254777</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2000 Aug 17;406(6797):747-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10963602</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Med Sci. 2008 Jul 11;5(4):209-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18645621</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2005 Jan;16(1):102-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15598946</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2005 Jan 31;92(2):271-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15655541</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2010 Mar 1;116(5):1234-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20082448</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2002 Jan;71(1):67-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11859875</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mod Pathol. 2006 Apr;19(4):607-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16554736</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Clin Pathol. 2003 Nov;120(5):725-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14608899</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2006 Apr;17(4):597-604</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16403812</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Feb 1;13(3):953-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17289890</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2006 Jul;98(2):223-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16541327</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2001 Jul;7(7):1957-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11448910</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2009 Feb 15;115(4):899-908</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19130459</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2003 Dec 15;89(12):2244-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14676801</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2010 Aug;122(3):685-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19859802</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Trends Mol Med. 2001 Dec;7(12):542-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11733216</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2006 Jan 16;94(1):108-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16404364</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2007;9(5):R65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17910759</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Lett. 2003 Nov 25;201(2):225-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14607338</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2003 Feb 15;97(4):1077-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12569609</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2009 Jun 1;15(11):3697-704</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19435839</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Med. 2012 May 29;10:51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22642691</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Histol Histopathol. 2002 Apr;17 (2):669-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11962766</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2003 Nov 1;63(21):7167-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14612510</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mod Pathol. 2004 Nov;17(11):1378-85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15195112</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2003 Apr 7;88(7):1077-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12671708</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2000 Jan;6(1):127-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10656440</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Transl Oncol. 2006 Nov;8(11):776-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17134964</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2007 May 1;109(9):1721-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17387718</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Virchows Arch. 2005 Oct;447(4):695-700</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16075292</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Thyroid. 2011 Nov;21(11):1171-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22050034</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biomed Biotechnol. 2011;2011:165214</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21687596</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Neurosci. 2008 Nov;15(11):1198-203</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18835716</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2005 Aug 15;104(4):676-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15981280</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2004 Dec 15;10(24):8594-602</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15623643</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Oncol (R Coll Radiol). 2008 Feb;20(1):35-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17977700</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2006 Feb 9;354(6):567-78</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16467544</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">24026861</PMID>
        <DateCompleted>
            <Year>2014</Year>
            <Month>05</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>09</Month>
            <Day>27</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-7217</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>141</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Breast cancer research and treatment</Title>
                <ISOAbbreviation>Breast Cancer Res. Treat.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC.</ArticleTitle>
            <Pagination>
                <MedlinePgn>205-12</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10549-013-2693-9</ELocationID>
            <Abstract>
                <AbstractText>The aim of the current study was to investigate the role of BRCA1 gene aberrations in sporadic triple-negative breast cancer (TNBC) and its impact on anthracycline-based therapy. BRCA1 promoter methylation was analyzed in 70 TNBC and compared with the clinical and pathologic characteristics. As a control group, we used 70 patients with non-TNBC. BRCA1 promoter methylation was observed in 65.2 % of patients and was similar in both groups. BRCA1 promoter methylation was associated with decreased intensity of BRCA1 protein expression (P = 0.002) and significant increase of median disease-free survival (DFS) of TNBC patients receiving adjuvant anthracycline-based chemotherapy (P = 0.001). Multivariate analysis revealed that BRCA1 promoter methylation remains a favorable factor in regard to DFS (HR 0.224; 95 % CI 0.092-0.546, P = 0.001) in TNBC after adjustment for other prognostic factors. In contrast, in non-TNBC, BRCA1 promoter methylation was not associated with any clinical and pathologic parameters. BRCA1 promoter methylation is a common mechanism of BRCA1 gene aberration in sporadic breast cancer and is predictive for better response to anthracycline-based therapies.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ignatov</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynecology, Otto-von-Guericke University, G.-Hauptmann Str. 35, 39108, Magdeburg, Germany, tanja.ignatov@med.ovgu.de.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Poehlmann</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ignatov</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schinlauer</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Costa</LastName>
                    <ForeName>S D</ForeName>
                    <Initials>SD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roessner</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kalinski</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bischoff</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>09</Month>
                <Day>13</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Breast Cancer Res Treat</MedlineTA>
            <NlmUniqueID>8111104</NlmUniqueID>
            <ISSNLinking>0167-6806</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018943">Anthracyclines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019313">BRCA1 Protein</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018943" MajorTopicYN="N">Anthracyclines</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019313" MajorTopicYN="N">BRCA1 Protein</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019175" MajorTopicYN="Y">DNA Methylation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060787" MajorTopicYN="N">Neoplasm Grading</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011401" MajorTopicYN="Y">Promoter Regions, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D047368" MajorTopicYN="N">Tumor Burden</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>08</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>08</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>9</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>9</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24026861</ArticleId>
            <ArticleId IdType="doi">10.1007/s10549-013-2693-9</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">24004841</PMID>
        <DateCompleted>
            <Year>2014</Year>
            <Month>06</Month>
            <Day>23</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1471-2407</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>13</Volume>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Sep</Month>
                        <Day>03</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMC cancer</Title>
                <ISOAbbreviation>BMC Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.</ArticleTitle>
            <Pagination>
                <MedlinePgn>403</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/1471-2407-13-403</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Breast cancer is one of the leading causes of cancer deaths. Triple-negative breast cancer (TNBC), an immunophenotype defined by the absence of immunolabeling for estrogen receptor (ER), progesterone receptor (PR) and HER2 protein, has a highly aggressive behavior. A subpopulation of TNBCs exhibit a basal-like morphology with immunohistochemical positivity for cytokeratins 5/6 (CK5/6) and/or epidermal growth factor receptor (EGFR), and have a high incidence of BRCA (breast cancer susceptibility) mutations. Feline mammary adenocarcinomas (FMAs) are highly malignant and share a similar basal-like subtype. The purpose of this study was to classify FMAs according to the current human classification of breast cancer that includes evaluation of ER, PR and HER2 status and expression of basal CK 5/6 and EGFR. Furthermore, we selected triple negative, basal-like FMAs to screen for BRCA mutations similar to those described in human TNBC.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Twenty four FMAs were classified according to the current human histologic breast cancer classification including immunohistochemistry (IHC) for ER, PR HER2, CK5/6 and EGFR. Genetic alteration and loss of heterozygosity of BRCA1 and BRCA2 genes were analyzed in triple negative, basal-like FMAs.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">IHC for ER, PR and HER2 identified 14 of the 24 (58%) FMAs as a triple negative. Furthermore, 11 of these 14 (79%) triple negative FMAs had a basal-like subtype. However, no genetic abnormalities were detected in BRCA1 and BRCA2 by direct sequencing and loss of heterozygosity analysis.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">FMAs are highly aggressive neoplasms that are commonly triple negative and exhibit a basal-like morphology. This is similar to human TNBC that are also commonly classified as a basal-like subtype. While sequencing of a select number of triple negative, basal-like FMAs and testing for loss of heterozygosity of BRCA1 and BRCA2 did not identify mutations similar to those described in human TNBC, further in-depth evaluation is required to elucidate a potential role of BRCA in the tumorigenesis of triple negative, basal-like FMAs. The strong similarities in clinical behavior, morphology and IHC phenotype suggest that triple negative, basal-like FMAs may be a suitable spontaneous animal model for studying novel therapeutic approaches against human basal-like TNBC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wiese</LastName>
                    <ForeName>David A</ForeName>
                    <Initials>DA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Diagnostic Center for Population and Animal Health, Michigan State University, East Lansing, MI, USA. kiupel@dcpah.msu.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thaiwong</LastName>
                    <ForeName>Tuddow</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yuzbasiyan-Gurkan</LastName>
                    <ForeName>Vilma</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kiupel</LastName>
                    <ForeName>Matti</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>09</Month>
                <Day>03</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>BMC Cancer</MedlineTA>
            <NlmUniqueID>100967800</NlmUniqueID>
            <ISSNLinking>1471-2407</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011980">Receptors, Progesterone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002415" MajorTopicYN="N">Cats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019398" MajorTopicYN="N">Genes, BRCA1</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024522" MajorTopicYN="N">Genes, BRCA2</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019656" MajorTopicYN="N">Loss of Heterozygosity</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008325" MajorTopicYN="Y">Mammary Neoplasms, Experimental</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060787" MajorTopicYN="N">Neoplasm Grading</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011980" MajorTopicYN="N">Receptors, Progesterone</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2012</Year>
                <Month>12</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>06</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>9</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>9</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24004841</ArticleId>
            <ArticleId IdType="pii">1471-2407-13-403</ArticleId>
            <ArticleId IdType="doi">10.1186/1471-2407-13-403</ArticleId>
            <ArticleId IdType="pmc">PMC3849986</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Comp Pathol. 1998 Oct;119(3):263-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9807728</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast. 2013 Oct;22(5):761-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23416046</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Adv Anat Pathol. 2007 Nov;14(6):419-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18049131</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2007;7:179</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17880730</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Control. 2010 Jul;17(3):173-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20664514</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Domest Anim Endocrinol. 2000 Jan;18(1):111-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10701768</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Vet J. 2004 Sep;168(2):180-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15301767</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Rev Endocr Metab Disord. 2007 Sep;8(3):185-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17464566</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Appl Immunohistochem Mol Morphol. 2002 Jun;10(2):183-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12051639</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2004 Aug 15;10(16):5367-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15328174</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2002 May 10;99(2):305-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11979449</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2002 Jan 31;415(6871):530-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11823860</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Res Vet Sci. 2005 Dec;79(3):225-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16054892</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mod Pathol. 2011 Feb;24(2):157-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21076464</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Clin Pathol. 2005 Apr;123(4):541-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15743737</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Genomics. 1995 Dec 10;30(3):450-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8825630</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Vet Pathol. 2005 Jan;42(1):30-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15657269</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Mammary Gland Biol Neoplasia. 2005 Apr;10(2):181-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16025224</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Histopathology. 1991 Nov;19(5):403-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1757079</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Histopathology. 2000 Dec;37(6):536-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11122436</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 1994 Oct 7;266(5182):66-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7545954</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast. 2007 Jun;16(3):280-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17257844</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Hum Genet. 2003 Oct;73(4):748-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">13680524</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2009 Apr 1;15(7):2302-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19318481</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Vet Pathol. 2002 Sep;39(5):529-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12243462</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Vet J. 2012 Oct;194(1):19-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22841451</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 1995 Dec 21-28;378(6559):789-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8524414</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Acta Endocrinol (Copenh). 1991;125 Suppl 1:32-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1801501</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Clin Pathol. 2010 May;133(5):747-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20395521</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Dairy Res. 2005;72 Spec No:98-106</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16180727</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Vet Rec. 1981 May 30;108(22):476-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7257136</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Vet Rec. 1976 Dec 11;99(24):477-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1014299</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>In Vivo. 1994 Nov-Dec;8(5):825-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7727731</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Comp Pathol. 2011 Feb-Apr;144(2-3):170-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20880546</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 1999 Aug;5(8):2025-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10473082</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2002 May 1;20(9):2310-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11981002</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2005 Feb 1;65(3):907-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15705889</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Arch Pathol Lab Med. 2010 Jan;134(1):130-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20073617</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14519755</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Res Vet Sci. 2002 Apr;72(2):153-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12027597</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Breast Cancer. 2009 Jun;9 Suppl 2:S73-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19596646</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast. 2010 Oct;19(5):312-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20382530</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2001 Jun;7(6):1669-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11410505</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mod Pathol. 2009 Nov;22(11):1457-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19734848</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2010;10:156</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20412586</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21685461</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Vet Comp Oncol. 2005 Mar;3(1):8-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19379209</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11553815</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2008 Mar 1;14(5):1368-76</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18316557</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Jun 1;28(16):2784-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20404251</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Surg Pathol. 1990 Oct;14(10):961-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1698342</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">23982851</PMID>
        <DateCompleted>
            <Year>2014</Year>
            <Month>10</Month>
            <Day>09</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1699-3055</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>16</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical &amp; translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico</Title>
                <ISOAbbreviation>Clin Transl Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC).</ArticleTitle>
            <Pagination>
                <MedlinePgn>280-4</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12094-013-1070-9</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">BRCA1-associated breast cancers have been associated to a triple-negative phenotype. The prevalence of BRCA1 germline mutations in young onset TNBC based on informativeness of family history has not been reported.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">From January 2008 to May 2009 were collected blood and tumor samples from patients with TNBC younger than 50 years and without a family history of breast and ovarian cancer in first- and second-degree relatives. Analysis of BRCA1 germline mutations was made. Age at diagnosis and informativeness of family history (presence of female in first- and second-degree relatives alive until age 45) was collected in all cases. Immunohistochemistry of basal-like features was performed centrally in all available tumors.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Seven pathogenic mutations were detected in 92 patients (7.6 %), two of them in patients younger than 35 years (28.6 %) (Fisher's exact test, p = 0.631). Three non-classified variants were detected (3.2 %). Family history was informative in two patients with a pathogenic mutation (28.6 %) and not informative in five (71.4 %) (Fisher's exact test, p = 0.121). Of the seven patients with a pathogenic mutation, four had a basal-like phenotype.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Patients with apparently sporadic TNBC younger than 50 years and a non-informative family history are candidates for germline genetic testing of BRCA1.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Andrés</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Servicio de Oncología Médica, Hospital Clínico Lozano Blesa, San Juan bosco 15, 50009, Zaragoza, Spain, andresraquel@hotmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pajares</LastName>
                    <ForeName>I</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Balmaña</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Llort</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ramón Y Cajal</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chirivella</LastName>
                    <ForeName>I</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aguirre</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Robles</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lastra</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pérez-Segura</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bosch</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yagüe</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lerma</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Godino</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miramar</LastName>
                    <ForeName>M D</ForeName>
                    <Initials>MD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moros</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Astier</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saez</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vidal</LastName>
                    <ForeName>M J</ForeName>
                    <Initials>MJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arcusa</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ramón y Cajal</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Calvo</LastName>
                    <ForeName>M T</ForeName>
                    <Initials>MT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tres</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>08</Month>
                <Day>27</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Italy</Country>
            <MedlineTA>Clin Transl Oncol</MedlineTA>
            <NlmUniqueID>101247119</NlmUniqueID>
            <ISSNLinking>1699-048X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019398" MajorTopicYN="Y">Genes, BRCA1</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018095" MajorTopicYN="Y">Germ-Line Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>05</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>06</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23982851</ArticleId>
            <ArticleId IdType="doi">10.1007/s12094-013-1070-9</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2005 Mar;90(1):5-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15770521</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Hum Genet. 1998 Mar;62(3):676-89</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9497246</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2000 Mar 1;60(5):1206-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10728676</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2004 Mar 15;10(6):2029-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15041722</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2006 Feb 1;24(4):707-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16446345</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2009 Mar 19;9:86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19298662</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2005;7(4):R465-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15987451</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Surg Pathol. 2006 Nov;30(11):1357-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17063074</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2001 Jul;7(7):1937-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11448907</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2010;12(3):R28</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20482762</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2012 Jun 1;118(11):2787-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22614657</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2005 Jul 15;11(14):5175-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16033833</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Surg Pathol. 2009 Jul;33(7):1093-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19390427</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 2007 Jun 20;297(23):2587-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17579227</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2005;7(1):R93-100</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15642173</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2002 May 1;20(9):2310-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11981002</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2012 Mar 13;106(6):1234-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22333603</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Sep 20;28(27):4214-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20733129</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 1999 Jun 21;84(3):263-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10371344</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Genet. 1994 Dec;8(4):392-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7894492</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14519755</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2001 Jun;7(6):1739-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11410514</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">23975317</PMID>
        <DateCompleted>
            <Year>2014</Year>
            <Month>04</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>09</Month>
            <Day>04</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1534-4681</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>20</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of surgical oncology</Title>
                <ISOAbbreviation>Ann. Surg. Oncol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort.</ArticleTitle>
            <Pagination>
                <MedlinePgn>3254-8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1245/s10434-013-3205-1</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Revised NCCN guidelines recommend that women ≤60 years with triple-negative breast cancer (TNBC) be referred for consideration of genetic counseling. Small, homogeneous samples have limited evaluation of BRCA mutation prevalence among different ethnicities affected by TNBC subtype. We sought to determine whether the prevalence of BRCA mutations within a TNBC cohort differs by demographic factors.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We performed a retrospective review of patients with TNBC referred for genetic counseling at two academic Hereditary Cancer Clinics between 2000 and 2012. Demographic data were collected, including age at diagnosis and race/ethnicity. Race was categorized as African American (AA), Ashkenazi Jewish (AJ), Asian, Caucasian, Hispanic, or other. Primary outcome was BRCA mutation status, analyzed by race/ethnicity and age at diagnosis.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 469 patients with TNBC who underwent testing for BRCA genetic mutations were identified, of which 450 patients had evaluable BRCA testing results; 139 (30.8 %) had confirmed BRCA1 (n = 106) or BRCA2 (n = 32) mutations. BRCA mutation prevalence differed by ethnicity and race: AA (20.4 %), AJ (50 %), Asian (28.5 %), Caucasian (33.3 %), and Hispanic (20 %). The prevalence of genetic mutations also differed by age at diagnosis: &lt;40 years (43.8 %), 40-49 years (27.4 %), 50-59 years (25.3 %), 60-69 years (12.5 %), and &gt;70 years (16.6 %).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The prevalence of genetic mutations among women with TNBC referred for genetic counseling is high and differs significantly by ethnicity/race and age. This data helps to refine mutation risk estimates among women with TNBC, allowing for more personalized genetic counseling potentially aiding in improved patient decision-making.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Greenup</LastName>
                    <ForeName>Rachel</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Duke University, Durham, NC, USA. rachel.greenup@duke.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Buchanan</LastName>
                    <ForeName>Adam</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lorizio</LastName>
                    <ForeName>Wendy</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rhoads</LastName>
                    <ForeName>Keelia</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chan</LastName>
                    <ForeName>Salina</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Leedom</LastName>
                    <ForeName>Tracey</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>King</LastName>
                    <ForeName>Robin</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McLennan</LastName>
                    <ForeName>Jane</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Crawford</LastName>
                    <ForeName>Beth</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kelly Marcom</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shelley Hwang</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>08</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Ann Surg Oncol</MedlineTA>
            <NlmUniqueID>9420840</NlmUniqueID>
            <ISSNLinking>1068-9265</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019313">BRCA1 Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C492913">BRCA1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D024682">BRCA2 Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C551750">BRCA2 protein, human</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D044383" MajorTopicYN="N">African Continental Ancestry Group</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D044466" MajorTopicYN="N">Asian Continental Ancestry Group</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019313" MajorTopicYN="N">BRCA1 Protein</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024682" MajorTopicYN="N">BRCA2 Protein</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002140" MajorTopicYN="N" Type="Geographic">California</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D044465" MajorTopicYN="N">European Continental Ancestry Group</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005817" MajorTopicYN="Y">Genetic Counseling</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>05</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23975317</ArticleId>
            <ArticleId IdType="doi">10.1245/s10434-013-3205-1</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">23973711</PMID>
        <DateCompleted>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>26</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>09</Month>
            <Day>23</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1090-2104</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>439</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Sep</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biochemical and biophysical research communications</Title>
                <ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway.</ArticleTitle>
            <Pagination>
                <MedlinePgn>275-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2013.08.043</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S0006-291X(13)01369-7</ELocationID>
            <Abstract>
                <AbstractText>Primary TNBCs are treated as if they were a single disease entity, yet it is clear they do not behave as a single entity in response to current therapies. Recently, we reported that statins might have a potential benefit for TNBCs associated with ets-1 overexpression. The aim of this study is to investigate the role of PTEN loss in the effects of statin on TNBC cells. In addition, we analyze the relationship between AKT downstream pathways and the effects of statin on TNBC cells. We investigated the effect of a statin on TNBC cells and analyzed the association of PI3K pathways using various TNBC cells in terms of PTEN loss and AKT pathways. Simvastatin treatments resulted in decreased cell viabilities in various TNBC cell lines. Compared with PTEN wild-type TNBC cells, PTEN mutant-type TNBC cells showed a decreased response to simvastatin. Expressions of phosphorylated Akt and total Akt showed an inverse relationship with PTEN expression. The TNBC cell lines, which showed increased expression of p-Akt, appeared to attenuate the expression of p-Akt by PTEN loss in simvastatin-treated TNBC cells. The Akt inhibitor, LY294002, augmented the effect of simvastatin on PTEN wild-type TNBC cells. Simvastatin induces inhibition of TNBC cells via PI3K pathway activation. </AbstractText>
                <CopyrightInformation>Copyright © 2013 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Yeon Hee</ForeName>
                    <Initials>YH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jung</LastName>
                    <ForeName>Hae Hyun</ForeName>
                    <Initials>HH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ahn</LastName>
                    <ForeName>Jin Seok</ForeName>
                    <Initials>JS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Im</LastName>
                    <ForeName>Young-Hyuck</ForeName>
                    <Initials>YH</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Biochem Biophys Res Commun</MedlineTA>
            <NlmUniqueID>0372516</NlmUniqueID>
            <ISSNLinking>0006-291X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000924">Anticholesteremic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>AGG2FN16EV</RegistryNumber>
                <NameOfSubstance UI="D019821">Simvastatin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.1.-</RegistryNumber>
                <NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.1</RegistryNumber>
                <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.3.67</RegistryNumber>
                <NameOfSubstance UI="D051059">PTEN Phosphohydrolase</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000924" MajorTopicYN="N">Anticholesteremic Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001940" MajorTopicYN="N">Breast</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017353" MajorTopicYN="N">Gene Deletion</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051059" MajorTopicYN="N">PTEN Phosphohydrolase</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019821" MajorTopicYN="N">Simvastatin</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">PI3K pathway</Keyword>
            <Keyword MajorTopicYN="N">Statin</Keyword>
            <Keyword MajorTopicYN="N">Triple negative breast cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>08</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>08</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23973711</ArticleId>
            <ArticleId IdType="pii">S0006-291X(13)01369-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbrc.2013.08.043</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">23908177</PMID>
        <DateCompleted>
            <Year>2014</Year>
            <Month>06</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2016</Year>
            <Month>10</Month>
            <Day>17</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1569-8041</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>24</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title>
                <ISOAbbreviation>Ann. Oncol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2801-7</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1093/annonc/mdt277</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">TNBC represents a heterogeneous subgroup of BC with poor prognosis and frequently resistant to CT.</AbstractText>
                <AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">The relationship between Bcl2 immunohistochemical protein expression and clinico-pathological outcomes was assessed in 736 TNBC-patients: 635 patients had early primary-TNBC (EP-TNBC) and 101 had primary locally advanced (PLA)-TNBC treated with neo-adjuvant- ATC-CT.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Negative Bcl2 (Bcl2-) was observed in 70% of EP-TNBC and was significantly associated with high proliferation, high levels of P-Cadherin, E-Cadherin and HER3 (P's &lt; 0.01), while Bcl2+ was significantly associated with high levels of p27, MDM4 and SPAG5 (P &lt; 0.01). After controlling for chemotherapy and other prognostic factors, Bcl2- was associated with 2-fold increased risk of death (P = 0.006) and recurrence (P = 0.0004). Furthermore, the prognosis of EP-TNBC/Bcl2- patients had improved both BC-specific survival (P = 0.002) and disease-free survival (P = 0.003), if they received adjuvant-ATC-CT. Moreover, Bcl2- expression was an independent predictor of pathological complete response of primary locally advanced triple negative breast cancer (PLA-TNBC) treated with neoadjuvant-ATC-CT (P = 0.008).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Adding Bcl2 to the panel of markers used in current clinical practice could provide both prognostic and predictive information in TNBC. TNBC/Bcl2- patients appear to benefit from ATC-CT, whereas Bcl2+ TNBC seems to be resistant to ATC-CT and may benefit from a trial of different type of chemotherapy with/without novel-targeted agents.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Abdel-Fatah</LastName>
                    <ForeName>T M A</ForeName>
                    <Initials>TM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Oncology Department, Nottingham University Hospitals, Nottingham.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Perry</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dickinson</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ball</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moseley</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Madhusudan</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ellis</LastName>
                    <ForeName>I O</ForeName>
                    <Initials>IO</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chan</LastName>
                    <ForeName>S Y T</ForeName>
                    <Initials>SY</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>08</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Ann Oncol</MedlineTA>
            <NlmUniqueID>9007735</NlmUniqueID>
            <ISSNLinking>0923-7534</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018943">Anthracyclines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011980">Receptors, Progesterone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018943" MajorTopicYN="N">Anthracyclines</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="Y">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019253" MajorTopicYN="N">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
                <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011980" MajorTopicYN="N">Receptors, Progesterone</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Bcl2</Keyword>
            <Keyword MajorTopicYN="N">anthracyclin chemotherapy</Keyword>
            <Keyword MajorTopicYN="N">predictive marker</Keyword>
            <Keyword MajorTopicYN="N">prognostic marker</Keyword>
            <Keyword MajorTopicYN="N">theraputic targets</Keyword>
            <Keyword MajorTopicYN="N">triple negative breast cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23908177</ArticleId>
            <ArticleId IdType="pii">mdt277</ArticleId>
            <ArticleId IdType="doi">10.1093/annonc/mdt277</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">23886182</PMID>
        <DateCompleted>
            <Year>2014</Year>
            <Month>02</Month>
            <Day>19</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>03</Month>
            <Day>08</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">2476-762X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>14</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2013</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Asian Pacific journal of cancer prevention : APJCP</Title>
                <ISOAbbreviation>Asian Pac. J. Cancer Prev.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study.</ArticleTitle>
            <Pagination>
                <MedlinePgn>3779-84</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To determine the clinical, pathological and prognostic features associated with triple-negative breast cancer (TNBC).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Clinical and histologic data of 21,749 breast cancer patients who were treated at Tianjin Medical University Cancer Institute and Hospital between July 2002 and December 2011 were collected. Patients were divided into two groups: those with TNBC and those with other types of breast cancer. Patients and tumor characteristics were compared between the two groups using the Chi-square test. The prognostic results of 9,823 patients in the study population were also analyzed to determine long-term survival rates in the two groups of breast cancer patients.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the breast cancer patients treated in our hospital between 2003 and 2011, 10.4%-13.5% of them had triple-negative breast cancers. Data analyses revealed significant differences in disease onset age, family history of breast cancer, tumor size, tumor histologic grade, lymph note positivity and metastatic status between TNBC and non-TNBC patients. There were also significant differences in 5-year, 7-year and 9-year disease-free and 7-year and 9-year overall survival probability between the groups.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">TNBC are associated with younger disease onset age, larger tumor size, higher rate of axillary lymph node positivity, and higher tumor histologic grade. TNBC is also related to family history of breast cancer, increased metastatic risk and poor prognosis.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Chun-Yan</ForeName>
                    <Initials>CY</Initials>
                    <AffiliationInfo>
                        <Affiliation>3rd Department of Breast Cancer, China Tianjin Breast Cancer Prevention, Treatment and Research Center, Tianjin Medical University, Cancer Institute and Hospital, Tianjin, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Sheng</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Xiao-Bei</ForeName>
                    <Initials>XB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Pei</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hou</LastName>
                    <ForeName>Guo-Fang</ForeName>
                    <Initials>GF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Jin</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Thailand</Country>
            <MedlineTA>Asian Pac J Cancer Prev</MedlineTA>
            <NlmUniqueID>101130625</NlmUniqueID>
            <ISSNLinking>1513-7368</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011980">Receptors, Progesterone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018270" MajorTopicYN="N">Carcinoma, Ductal, Breast</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018275" MajorTopicYN="N">Carcinoma, Lobular</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007124" MajorTopicYN="N">Immunoenzyme Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060787" MajorTopicYN="N">Neoplasm Grading</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011980" MajorTopicYN="N">Receptors, Progesterone</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>7</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>7</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23886182</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">23828443</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>01</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1432-0711</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>289</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Archives of gynecology and obstetrics</Title>
                <ISOAbbreviation>Arch. Gynecol. Obstet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1.</ArticleTitle>
            <Pagination>
                <MedlinePgn>141-7</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00404-013-2922-9</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Triple negative breast cancers (TNBC) are associated with an adverse outcome, although these tumors are sensitive to chemotherapy. In part, this phenomenon could be caused by tumor immune escape. The current study investigates immunogenicity of TNBC cells in vitro and the presence of immunosuppressive factors in the tumor microenvironment (pAKT and B7H1 expression, infiltration with regulatory T cells, [Tregs]).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Natural killer (NK)-cell induced lysis was evaluated in estrogen receptor (ER) positive MCF 7 breast cancers, in MDA-MB231 and MDA-MB468 and in HCC-1937 (BRCA 1 mutated) and HCC-1806 TNBC cells. Expression of pAKT, B7H1 and infiltration with Tregs were determined by immunohistochemistry in human specimens of benign and malignant breast disease.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">NK-cell induced lysis was significantly increased (p &lt; 0.05) in four TNBC cell lines compared to ER + MCF 7 cells. Fibroadenomas and mastectomy samples were not infiltrated with Tregs. Infiltration with Tregs was 0.92 ± 0.21 in ER/PR + breast cancers and significantly higher in TNBC without (2.30 ± 0.34) and also significantly higher with mutation of BRCA 1 (2.10 ± 0.34). Expression of pAKT was absent in benign controls and 1.23 ± 0.36 in ER/PR + breast cancers, 1.78 ± 0.40 in TNBC without and 2.40 ± 0.30 with mutated BRCA 1. No significant differences of B7H1 expression occurred among the breast cancer subgroups.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">TNBC cell stimulate the NK-cell immune response significantly stronger than ER positive breast cancer cells. This could explain why infiltration with immunosuppressive Tregs is increased in human specimens of TNBC with and without mutated BRCA 1. Accordingly, immunomodulatory treatment strategies should be further explored in TNBC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Engel</LastName>
                    <ForeName>Jörg B</ForeName>
                    <Initials>JB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Universitätsfrauenklinik Regensburg, Caritas Krankenhaus St Josef, Landshuter Str 65, 93053, Regensburg, Germany, joergbengel@hotmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Honig</LastName>
                    <ForeName>Arnd</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kapp</LastName>
                    <ForeName>Michaela</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hahne</LastName>
                    <ForeName>Jens C</ForeName>
                    <Initials>JC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Meyer</LastName>
                    <ForeName>Susanne R</ForeName>
                    <Initials>SR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dietl</LastName>
                    <ForeName>Johannes</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Segerer</LastName>
                    <ForeName>Sabine E</ForeName>
                    <Initials>SE</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>07</Month>
                <Day>05</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Arch Gynecol Obstet</MedlineTA>
            <NlmUniqueID>8710213</NlmUniqueID>
            <ISSNLinking>0932-0067</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019313">BRCA1 Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C423236">CD274 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.1</RegistryNumber>
                <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019313" MajorTopicYN="N">BRCA1 Protein</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018270" MajorTopicYN="N">Carcinoma, Ductal, Breast</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D050378" MajorTopicYN="N">T-Lymphocytes, Regulatory</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019139" MajorTopicYN="N">Tumor Escape</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2011</Year>
                <Month>12</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>06</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>7</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>7</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>1</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23828443</ArticleId>
            <ArticleId IdType="doi">10.1007/s00404-013-2922-9</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">23776059</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>01</Month>
            <Day>07</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1098-2744</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>53</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular carcinogenesis</Title>
                <ISOAbbreviation>Mol. Carcinog.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers.</ArticleTitle>
            <Pagination>
                <MedlinePgn>893-906</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/mc.22048</ELocationID>
            <Abstract>
                <AbstractText>Recent literature suggests that sEcad exerts pro-oncogenic effects, possibly acting as a ligand for the human epidermal growth factor family. Here we show that sEcad is a novel candidate protein for drug targeting since it is increased in human and mouse HER2-positive (HER2+) breast tumors, MMTV-PyMT bodily fluids and human cell culture systems. Mechanistically, we show that endogenous sEcad, and to a lesser extent membrane-bound E-cadherin, associates with HER1, HER2, and HER3 in human and MMTV-PyMT mouse HER2+ tumors and with HER1 in triple negative breast cancer (TNBC) specimens. Furthermore, addition of exogenous recombinant human E-cadherin/Fc chimeric protein (rhEcad/Fc; sEcad) to HER2+ MCF-7, SKBR3, and HER2-negative MDA-MB-231 TNBC cells, resulted in sEcad-HER receptor family interactions, activation of HER1-4 and downstream pro-survival signaling, including the MAPK-PI3K/Akt/mTOR pathways and IAP family members. Lastly, we demonstrate that sEcad exerts pro-oncogenic effects via HER signaling, and acts additively with the HER ligand EGF to promote HER2+ breast cancer proliferation and migration, as well as TNBC invasion. Because sEcad associates and activates many of the oncogenic pathways that tumors utilize for growth and survival and serum levels in patients correlates with clinical response, suggests that targeted therapy against sEcad in combination with other therapies may potentially offer a novel therapeutic strategy for the treatment of breast cancers.</AbstractText>
                <CopyrightInformation>© 2013 Wiley Periodicals, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Brouxhon</LastName>
                    <ForeName>Sabine M</ForeName>
                    <Initials>SM</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Medicine, Health Sciences Center, Stony Brook University, Stony Brook, New York.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kyrkanides</LastName>
                    <ForeName>Stephanos</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Teng</LastName>
                    <ForeName>Xiaofei</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>O'Banion</LastName>
                    <ForeName>M Kerry</ForeName>
                    <Initials>MK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Clarke</LastName>
                    <ForeName>Robert</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Byers</LastName>
                    <ForeName>Stephen</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Li</ForeName>
                    <Initials>L</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R01 CA170653</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U54 CA149147</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>06</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Mol Carcinog</MedlineTA>
            <NlmUniqueID>8811105</NlmUniqueID>
            <ISSNLinking>0899-1987</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015820">Cadherins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.1.1</RegistryNumber>
                <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.1.1</RegistryNumber>
                <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.1.137</RegistryNumber>
                <NameOfSubstance UI="D058539">Phosphatidylinositol 3-Kinase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C581292">ERBB3 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D020893">Receptor, ErbB-3</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.1</RegistryNumber>
                <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015820" MajorTopicYN="N">Cadherins</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
                <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D058990" MajorTopicYN="Y">Molecular Targeted Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D058539" MajorTopicYN="N">Phosphatidylinositol 3-Kinase</DescriptorName>
                <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
                <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
                <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020893" MajorTopicYN="N">Receptor, ErbB-3</DescriptorName>
                <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
                <QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Akt</Keyword>
            <Keyword MajorTopicYN="N">HER1−4</Keyword>
            <Keyword MajorTopicYN="N">IAPs</Keyword>
            <Keyword MajorTopicYN="N">PI3K</Keyword>
            <Keyword MajorTopicYN="N">mTOR</Keyword>
            <Keyword MajorTopicYN="N">sEcad</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>02</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2013</Year>
                <Month>04</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>05</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>6</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>6</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>1</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23776059</ArticleId>
            <ArticleId IdType="doi">10.1002/mc.22048</ArticleId>
            <ArticleId IdType="pmc">PMC4477712</ArticleId>
            <ArticleId IdType="mid">NIHMS693542</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Res. 2005 Dec 1;65(23):11018-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16322251</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Drug Discov. 2005 Dec;4(12):988-1004</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16341064</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2006 Feb 1;66(3):1640-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16452223</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2007 Feb 26;96(4):639-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17285125</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2007 Mar 1;67(5):2030-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17332331</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hum Pathol. 2007 Jun;38(6):864-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17350670</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2007 Aug 15;67(16):7654-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17699770</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Oct 15;13(20):5995-6000</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17947460</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2008;8:129</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18454859</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>FEBS Lett. 2008 Jun 18;582(14):2102-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18396168</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Invest Dermatol. 2008 Jul;128(7):1737-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18200054</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2008 Jun 27;283(26):18393-401</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18434311</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2008 Sep;118(9):3065-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18725988</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Syst Biol. 2009;3:1</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19118495</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Immunity. 2010 Apr 23;32(4):557-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20399121</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Sci. 2010 May;101(5):1156-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20331626</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hum Pathol. 2010 Aug;41(8):1186-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20381828</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2010 Jul 13;103(2):249-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20551954</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Exp Cell Res. 2011 Apr 1;317(6):838-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21211535</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Oncol. 2011 Sep;39(3):569-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21674125</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Gene Ther. 2003 Feb;10(2):87-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12536196</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8933-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12853564</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2003 Oct 15;63(20):6815-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14583479</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2003 Dec 15;9(17):6447-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14695147</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Cell. 2004 Jan;5(1):25-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14749124</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 1994 Mar;69(3):580-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8123491</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Anaesth. 1996 May;76(5):629-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8688260</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Med. 1997 Aug;3(8):917-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9256286</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 1998 May 1;273(18):11288-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9556621</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 1998 Oct;78(8):1095-101</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9792157</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9182-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15958533</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2005 Oct;115(10):2673-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16200201</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Chim Acta. 2005 Dec;362(1-2):125-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16026775</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem Biophys Res Commun. 2011 Apr 8;407(2):412-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21402055</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Adv Cancer Res. 2000;77:25-79</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10549355</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>EMBO J. 2000 Jul 3;19(13):3159-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10880430</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2000 Dec 15;96(13):4276-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11110702</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Sci. 2001 Jan;114(Pt 1):111-118</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11112695</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Endocrinology. 2001 Jan;142(1):370-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11145600</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11252954</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2001 Mar 1;61(5):1862-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11280739</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Endocrinology. 2001 Jun;142(6):2451-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11356694</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2001 Oct;108(7):981-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11581299</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2001 Oct;7(10):3289-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11595727</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2001;3(5):289-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11597316</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Mol Cell Biol. 2002 Jun;3(6):401-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12042762</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2003 Jan;3(1):46-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12509766</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Biochem. 2011 Sep;112(9):2508-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21557297</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">23625599</PMID>
        <DateCompleted>
            <Year>2014</Year>
            <Month>03</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>04</Month>
            <Day>29</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1233-9687</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>64</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Polish journal of pathology : official journal of the Polish Society of Pathologists</Title>
                <ISOAbbreviation>Pol J Pathol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>RAD51 genotype and triple-negative breast cancer (TNBC) risk in Polish women.</ArticleTitle>
            <Pagination>
                <MedlinePgn>39-43</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The most lethal damage for the cell among all damage is double-strand breaks (DSB) of DNA. DSB cause development of cancer diseases including the triple-negative molecular subtype of breast cancer. The aim of this work was to evaluate the single nucleotide polymorphism -135G&gt;C (rs1801320) of the RAD51 gene encoding DNA repair proteins by homologous recombination (HR) in triple-negative breast cancer (TNBC). We assessed the RAD51 -135G&gt;C polymorphism in 50 women with triple-negative breast cancer and in 50 women from the control group. RAD51 polymorphism was analysed by the PCR-RFLP (restriction fragment length polymorphism) technique. Our results demonstrated a significant positive association between the RAD51 C/C genotype and TNBC, with an adjusted odds ratio (OR) of 5.95 (p = 0.002). The homozygous C/C genotype was found in 68% of breast cancer cases and 20% of controls. The variant 135C allele of RAD51 increased TNBC risk. This is the first study linking single nucleotide polymorphisms of the RAD51 gene with TNBC incidence in the population of Polish women. In conclusion, RAD51 polymorphisms may be regarded as predictive factors of triple-negative breast cancer in the female population. Large studies are needed to confirm our findings.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Smolarz</LastName>
                    <ForeName>Beata</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Molecular Genetics, Department of Pathology, Institute of Polish Mother's Memorial Hospital, Lodz, Poland. smolbea@wp.pl</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zadrożny</LastName>
                    <ForeName>Marek</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Duda-Szymańska</LastName>
                    <ForeName>Joanna</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Makowska</LastName>
                    <ForeName>Marianna</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Samulak</LastName>
                    <ForeName>Dariusz</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Michalska</LastName>
                    <ForeName>Magdalena M</ForeName>
                    <Initials>MM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mojs</LastName>
                    <ForeName>Ewa</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bryś</LastName>
                    <ForeName>Magdalena</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Forma</LastName>
                    <ForeName>Ewa</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Romanowicz-Makowska</LastName>
                    <ForeName>Hanna</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Poland</Country>
            <MedlineTA>Pol J Pathol</MedlineTA>
            <NlmUniqueID>9437432</NlmUniqueID>
            <ISSNLinking>1233-9687</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>EC 2.7.7.-</RegistryNumber>
                <NameOfSubstance UI="C495153">RAD51 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.7.-</RegistryNumber>
                <NameOfSubstance UI="D051135">Rad51 Recombinase</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053903" MajorTopicYN="N">DNA Breaks, Double-Stranded</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060787" MajorTopicYN="N">Neoplasm Grading</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011044" MajorTopicYN="N" Type="Geographic">Poland</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012150" MajorTopicYN="N">Polymorphism, Restriction Fragment Length</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051135" MajorTopicYN="N">Rad51 Recombinase</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23625599</ArticleId>
            <ArticleId IdType="pii">20614</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">23263825</PMID>
        <DateCompleted>
            <Year>2013</Year>
            <Month>07</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1559-131X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>30</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Medical oncology (Northwood, London, England)</Title>
                <ISOAbbreviation>Med. Oncol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>High expression of CD147 and MMP-9 is correlated with poor prognosis of triple-negative breast cancer (TNBC) patients.</ArticleTitle>
            <Pagination>
                <MedlinePgn>335</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12032-012-0335-4</ELocationID>
            <Abstract>
                <AbstractText>The aim of this study was to investigate expression of CD147 and MMP-9 in triple-negative breast cancer (TNBC) so as to determine whether these two proteins may be correlated with poor prognosis of TNBC patients. We examined the expression levels of the CD147 and MMP-9 in 127 patients with TNBC and 30 patients with mammary gland fibroma using immunohistochemical staining before any treatments. Furthermore, we analyzed the correlation between the expression of these two proteins and various clinicopathologic factors including survival status of patients with TNBC. Positive stain of CD147 and MMP-9 was observed in all samples of TNBC. A statistically positive correlation was observed between the expression levels of CD147 and MMP-9 in TNBC tissues. The incidences of high expression were 48.0 % for CD147 and 53.5 % for MMP-9 in 127 TNBC tissues, respectively. High expression of either CD147 or MMP-9 was significantly correlated with clinical feature and shorter progression-free survival (PFS) (P(CD147) = 0.039; P(MMP-9) = 0.017) and overall survival (OS) (P(CD147) = 0.037; P(MMP-9) = 0.023). The expression levels of CD147 and MMP-9 are positively correlated with invasion, metastasis and shorter PFS/OS of TNBC. Patients with high expression of CD147 and MMP-9 had poor prognosis than TNBC patients with low expression.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Shu</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, The Third Affiliated Hospital of Harbin Medical University, Haping Road 150 of Nangang District, Harbin 150081, Heilongjiang Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Wenjie</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Minghui</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tang</LastName>
                    <ForeName>Dabei</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shi</LastName>
                    <ForeName>Qingtao</ForeName>
                    <Initials>Q</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Shanqi</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Xiaosan</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Yupeng</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Song</LastName>
                    <ForeName>Ying</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Leyuan</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Qingyuan</ForeName>
                    <Initials>Q</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R01 CA142862</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>12</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Med Oncol</MedlineTA>
            <NlmUniqueID>9435512</NlmUniqueID>
            <ISSNLinking>1357-0560</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C497886">BSG protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>136894-56-9</RegistryNumber>
                <NameOfSubstance UI="D051926">Basigin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.24.35</RegistryNumber>
                <NameOfSubstance UI="C579270">MMP9 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.24.35</RegistryNumber>
                <NameOfSubstance UI="D020780">Matrix Metalloproteinase 9</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051926" MajorTopicYN="N">Basigin</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
                <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020780" MajorTopicYN="N">Matrix Metalloproteinase 9</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
                <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060787" MajorTopicYN="N">Neoplasm Grading</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2012</Year>
                <Month>06</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2012</Year>
                <Month>08</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>12</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>12</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>7</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23263825</ArticleId>
            <ArticleId IdType="doi">10.1007/s12032-012-0335-4</ArticleId>
            <ArticleId IdType="pmc">PMC4059361</ArticleId>
            <ArticleId IdType="mid">NIHMS588888</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Mol Cell Biochem. 2003 Nov;253(1-2):269-85</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14619979</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>World J Gastroenterol. 2003 Oct;9(10):2174-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14562372</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Sci. 2004 Apr 1;117(Pt 9):1847-57</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15075244</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2004 May 15;10(10):3422-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15161697</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 1999 May 7;274(19):13066-76</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10224058</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2005 Apr 15;65(8):3193-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15833850</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2005 Sep;4(9):1399-408</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16170032</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2006 Nov 20;95(10):1371-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17088917</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2006 Dec 1;66(23):11323-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17145878</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2000 Oct;6(10):4064-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11051257</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Exp Biol Med (Maywood). 2007 Mar;232(3):344-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17327467</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2007 May 1;109(9):1721-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17387718</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Histopathology. 2008 Jan;52(1):108-18</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18171422</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2007;9(5):R65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17910759</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Opin Obstet Gynecol. 2008 Feb;20(1):40-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18197004</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2008 Jan 15;14(2):494-501</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18223224</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Histopathology. 2009 May;54(6):677-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19438743</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pathol. 2009 Sep;219(1):114-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19557828</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pathol Res Pract. 2009;205(10):709-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19541433</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2010;10:270</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20534121</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2010 Jul 13;103(2):249-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20551954</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22237781</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Chin Med J (Engl). 2004 Jan;117(1):107-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14733785</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2000 Aug 17;406(6797):747-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10963602</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cancer Res Clin Oncol. 2012 Apr;138(4):627-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22215147</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Pathol. 2001 Jun;158(6):1921-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11395366</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Leukoc Biol. 2001 Jun;69(6):851-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11404367</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pathol. 2001 Sep;195(1):41-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11568890</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Trends Immunol. 2001 Oct;22(10):571-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11574282</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Top Dev Biol. 2003;54:371-89</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12696756</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Exp Metastasis. 2003;20(2):161-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12705637</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Autoimmun. 2003 Jun;20(4):323-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12791318</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">23250547</PMID>
        <DateCompleted>
            <Year>2013</Year>
            <Month>06</Month>
            <Day>27</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-7217</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>137</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Breast cancer research and treatment</Title>
                <ISOAbbreviation>Breast Cancer Res. Treat.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Expression of melatonin receptors in triple negative breast cancer (TNBC) in African American and Caucasian women: relation to survival.</ArticleTitle>
            <Pagination>
                <MedlinePgn>677-87</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10549-012-2371-3</ELocationID>
            <Abstract>
                <AbstractText>In the normal rodent breast, the pineal hormone melatonin controls the development of ductal and alveolar tissue. Melatonin counteracts tumor occurrence and tumor cell progression in vivo and in vitro in animal and human breast cancer cell cultures. It acts predominantly through its melatonin MT1 receptor. Our aim was to investigate the presence or absence of the MT1 melatonin receptor in the aggressive triple negative group of human breast carcinoma (TNBC) and its possible relationship to the course of the disease. A total of 167 patients with a ER-, PR-, Her-2/neu- phenotype in which tissue for receptor studies was available were examined. The MT1 receptor immunostain was evaluated semiquantitatively as staining intensity (0, 1, 2, 3), percentage of stained cells and the weighted index (WI) (staining intensity times percentage of stained cells). A score of WI &lt; 60 was regarded as &quot;negative&quot;. There was a striking difference in incidence of MT1 positivity and staining intensity between carcinomas in African American (AA) and Caucasian (C) women. The AA showed a higher incidence of MT1 negative tumors (41/84 = 48.8 % in AA, 6/51 = 11.8 % in C) and a lower average WI. MT1 positivity in TNBC was associated with a lower stage and a smaller tumor size at time of diagnosis. In multivariable survival analysis, MT1 negative TNBC in all cases regardless of race showed a significantly higher hazard ratio for disease progression, shorter progression free survival, and disease-related death, and shorter OS. This was especially pronounced in the AA group but did not reach statistical significance in the smaller group of C alone. These results suggest that melatonin or a melatonin receptor agonist may be useful biologic additions in the treatment of some forms of TNBC, especially in AA who generally show a more aggressive course of their disease.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Oprea-Ilies</LastName>
                    <ForeName>Gabriela</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Emory University School of Medicine, Emory University and Winship Cancer Institute, 1364 Clinton Road NE, Atlanta, GA 30322, USA. goprea@emory.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haus</LastName>
                    <ForeName>Erhard</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sackett-Lundeen</LastName>
                    <ForeName>Linda</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Yuan</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McLendon</LastName>
                    <ForeName>Lauren</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Busch</LastName>
                    <ForeName>Robert</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Adams</LastName>
                    <ForeName>Amy</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cohen</LastName>
                    <ForeName>Cynthia</ForeName>
                    <Initials>C</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>12</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Breast Cancer Res Treat</MedlineTA>
            <NlmUniqueID>8111104</NlmUniqueID>
            <ISSNLinking>0167-6806</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D044122">Receptor, Melatonin, MT1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D044094">Receptors, Melatonin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011980">Receptors, Progesterone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001741" MajorTopicYN="Y">African Americans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D044465" MajorTopicYN="Y">European Continental Ancestry Group</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D044122" MajorTopicYN="N">Receptor, Melatonin, MT1</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D044094" MajorTopicYN="N">Receptors, Melatonin</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011980" MajorTopicYN="N">Receptors, Progesterone</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D047368" MajorTopicYN="N">Tumor Burden</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2012</Year>
                <Month>07</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2012</Year>
                <Month>12</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>12</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>12</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>6</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23250547</ArticleId>
            <ArticleId IdType="doi">10.1007/s10549-012-2371-3</ArticleId>
            <ArticleId IdType="pmc">PMC3552359</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Pineal Res. 1991 Apr;10(3):136-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1880709</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Experientia. 1993 Aug 15;49(8):654-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8395408</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Pharmacol. 1993 Jul 15;246(2):89-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8397097</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Lett. 1995 Jul 13;93(2):207-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7621430</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncology. 1996 Jan-Feb;53(1):43-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8570130</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pineal Res. 1997 May;22(4):184-202</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9247204</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Anticancer Drugs. 1997 Nov;8(10):958-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9436639</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Prostate. 2005 Apr 1;63(1):29-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15378522</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2005 Jul 20;97(14):1084-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16030307</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Endocrine. 2005 Jul;27(2):101-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16217123</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Endocrine. 2005 Jul;27(2):189-200</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16217132</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2005 Dec 1;65(23):11174-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16322268</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2009 Jan;113(2):357-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18324472</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Med. 2009 Jan-Feb;15(1-2):43-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19011689</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2009 Feb 7;373(9662):482-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19054552</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pineal Res. 2009 Aug;47(1):23-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19522736</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Epidemiol. 2009 Aug;38(4):963-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19380369</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2009 Nov;118(2):293-305</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18979234</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Integr Cancer Ther. 2009 Dec;8(4):337-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20050373</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Scand J Work Environ Health. 2010 Mar;36(2):163-79</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20126969</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2010 Jun 1;116(11):2549-59</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20336785</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pharmacol Rev. 2010 Sep;62(3):343-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20605968</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pineal Res. 2010 Oct;49(3):210-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20609073</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pineal Res. 2010 Oct;49(3):248-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20626591</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2010 Nov 11;363(20):1938-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21067385</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Med Chem. 2010;17(36):4462-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21062257</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>IARC Monogr Eval Carcinog Risks Hum. 2010;98:9-764</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21381544</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2011 Aug 15;117(16):3658-69</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21387260</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Mammary Gland Biol Neoplasia. 2011 Sep;16(3):235-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21773809</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Appl Immunohistochem Mol Morphol. 2011 Oct;19(5):431-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21297447</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pineal Res. 2011 Oct;51(3):259-69</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21605163</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2012 Jan;131(2):413-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21369717</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Chemother Pharmacol. 2012 May;69(5):1213-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22271210</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Integr Cancer Ther. 2012 Dec;11(4):293-303</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22019490</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Appl Immunohistochem Mol Morphol. 2014 Jan;22(1):17-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23455177</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Endocrinol. 1999 Dec;13(12):2025-38</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10598579</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Cancer. 1999 Nov;35(12):1688-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10674014</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Adv Exp Med Biol. 1999;460:337-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10810531</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Life Sci. 2000 Nov 3;67(24):2953-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11133007</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Prostate. 2001 Jan 1;46(1):52-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11170132</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neuro Endocrinol Lett. 2001;22(1):45-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11335879</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Med Chem. 2001 Oct;8(12):1505-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11562279</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>EMBO J. 2001 Dec 17;20(24):6969-78</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11742974</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2002 Jan;71(1):37-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11859872</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Lett. 2002 May 28;179(2):141-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11888668</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Top Med Chem. 2002 Feb;2(2):113-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11899096</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neuro Endocrinol Lett. 2002 Apr;23 Suppl 1:55-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12019353</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Endocrinol. 2002 Jun 28;192(1-2):147-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12088876</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Med Res Rev. 2002 Sep;22(5):492-511</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12210556</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2006 Jan 15;66(2):1081-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16424044</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 2006 Jun 7;295(21):2492-502</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16757721</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Oncol. 2006 Sep;29(3):665-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16865283</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Pharmacol. 2007 Mar 29;560(1):17-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17303109</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncol Rep. 2007 Apr;17(4):947-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17342341</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2007;7:134</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17650314</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Adv Anat Pathol. 2007 Sep;14(5):358-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17717437</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2008 Mar 1;14(5):1368-76</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18316557</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Sci. 2008 Jul;99(7):1390-400</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18452558</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2008 Aug 1;113(3):608-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18484596</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Top Med Chem. 2008;8(11):954-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18673165</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neuro Endocrinol Lett. 2008 Aug;29(4):391-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18766165</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Clin Pathol. 2002 Sep;118(3):451-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12219788</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Lett. 2003 Jan 10;189(1):49-57</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12445677</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12829800</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pineal Res. 2003 Sep;35(2):71-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12887647</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pineal Res. 2004 Apr;36(3):204-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15009512</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Endocrinol. 2004 Jan 15;213(2):173-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15062565</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Lett. 2004 Jun 8;209(1):7-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15145516</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Carcinogenesis. 2004 Jun;25(6):951-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14754876</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 1982 Mar;45(3):361-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7073932</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1985 Jul;3(7):941-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">4020407</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Neural Transm. 1986;67(1-2):125-38</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3097252</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Epidemiol. 1987 Apr;125(4):556-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3548332</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 1988 Nov 1;48(21):6121-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3167858</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Soc Exp Biol Med. 1990 Jun;194(2):103-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2349246</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Endocr Rev. 1991 May;12(2):151-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1649044</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">23012300</PMID>
        <DateCompleted>
            <Year>2013</Year>
            <Month>04</Month>
            <Day>03</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2016</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1569-8041</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>23 Suppl 6</Volume>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title>
                <ISOAbbreviation>Ann. Oncol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Neoadjuvant treatments for triple-negative breast cancer (TNBC).</ArticleTitle>
            <Pagination>
                <MedlinePgn>vi35-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Neoadjuvant chemotherapy provides a means both of improving subsequent surgical intervention and of testing novel therapies or combinations. Historically, triple-negative breast cancer (TNBC) has responded well in the neoadjuvant setting, with rates of pathological complete response (pCR) commonly higher than for other breast tumour types. However, more than half of TNBC patients do not achieve a pCR and have a very poor prognosis. The lack of drug-targetable receptors on TNBC tumours has made improving the available interventions in TNBC an area of important medical need. The routine use of neoadjuvant anthracycline/taxane combinations in TNBC is currently being supplemented by ongoing investigations of their use with other types of agent. In particular, the substantial proportion of TNBC tumours associated with BRCA1 mutations is driving clinical research into the use of DNA-damaging agents such as platinums, as well as of potentiators of DNA damage such as the investigational agent iniparib and inhibitors of poly-ADP ribose polymerase such as olaparib. Tyrosine kinase receptor inhibitors and microtubule-targeting inhibitors of cell cycling are also under active investigation. The use of neoadjuvant treatment with pCR as a surrogate of overall survival will allow the rapid evaluation and comparison of these and other much-needed new treatments for TNBC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>von Minckwitz</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Germany. gunter.vonminckwitz@germanbreastgroup.de</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martin</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Ann Oncol</MedlineTA>
            <NlmUniqueID>9007735</NlmUniqueID>
            <ISSNLinking>0923-7534</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018943">Anthracyclines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001952">Bridged-Ring Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010793">Phthalazines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000067856">Poly(ADP-ribose) Polymerase Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011980">Receptors, Progesterone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D043823">Taxoids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>1605-68-1</RegistryNumber>
                <NameOfSubstance UI="C080625">taxane</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>2ZWI7KHK8F</RegistryNumber>
                <NameOfSubstance UI="C090712">iniparib</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D020794">Receptor Protein-Tyrosine Kinases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WOH1JD9AR8</RegistryNumber>
                <NameOfSubstance UI="C531550">olaparib</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D018943" MajorTopicYN="N">Anthracyclines</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001952" MajorTopicYN="N">Bridged-Ring Compounds</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010793" MajorTopicYN="N">Phthalazines</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000067856" MajorTopicYN="Y">Poly(ADP-ribose) Polymerase Inhibitors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020794" MajorTopicYN="N">Receptor Protein-Tyrosine Kinases</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011980" MajorTopicYN="N">Receptors, Progesterone</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D043823" MajorTopicYN="N">Taxoids</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>9</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>10</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23012300</ArticleId>
            <ArticleId IdType="pii">mds193</ArticleId>
            <ArticleId IdType="doi">10.1093/annonc/mds193</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">25961354</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>05</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>05</Month>
            <Day>12</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1868-1883</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>9</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Apr</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Hormone molecular biology and clinical investigation</Title>
                <ISOAbbreviation>Horm Mol Biol Clin Investig</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Search for novel therapies for triple negative breast cancers (TNBC): analogs of luteinizing hormone-releasing hormone (LHRH) and growth hormone-releasing hormone (GHRH).</ArticleTitle>
            <Pagination>
                <MedlinePgn>87-94</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1515/hmbci-2011-0002</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">/j/hmbci.2012.9.issue-1/hmbci-2011-0002/hmbci-2011-0002.xml</ELocationID>
            <Abstract>
                <AbstractText>Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype that is clinically negative for the expression of estrogen and progesterone receptors (ER/PR) and human epidermal growth factor receptor-2 (HER2). Patients with TNBC have a worse clinical outcome, as measured by time to metastasis and median overall survival. Chemotherapy has been the mainstay of treatment of TNBC but responses are disappointing. A substantial proportion of TNBC expresses luteinizing hormone-releasing hormone (LHRH), receptors for LHRH, in addition to receptors for growth hormone-releasing hormone (GHRH). These receptors represent potential therapeutic targets. Potent antagonists of GHRH and LHRH receptors have been developed in recent years and these antagonists inhibit the growth, tumorigenicity and metastatic potential of various human experimental malignancies. These antagonists could be utilized for the treatment of TNBC. The targeted cytotoxic analog of LHRH, AN-152 (AEZS-108) containing doxorubicin, must also be strongly considered for therapy of TNBC. Experimental studies suggest the merit of clinical trials with LHRH antagonists and AEZS-108 in TNBC patients. </AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Buchholz</LastName>
                    <ForeName>Stefan</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Seitz</LastName>
                    <ForeName>Stephan</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Engel</LastName>
                    <ForeName>Jörg B</ForeName>
                    <Initials>JB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Montero</LastName>
                    <ForeName>Alberto</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ortmann</LastName>
                    <ForeName>Olaf</ForeName>
                    <Initials>O</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Perez</LastName>
                    <ForeName>Roberto</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Block</LastName>
                    <ForeName>Norman L</ForeName>
                    <Initials>NL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schally</LastName>
                    <ForeName>Andrew V</ForeName>
                    <Initials>AV</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Horm Mol Biol Clin Investig</MedlineTA>
            <NlmUniqueID>101538885</NlmUniqueID>
            <ISSNLinking>1868-1883</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2011</Year>
                <Month>10</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2011</Year>
                <Month>12</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>5</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>4</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2012</Year>
                <Month>4</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25961354</ArticleId>
            <ArticleId IdType="doi">10.1515/hmbci-2011-0002</ArticleId>
            <ArticleId IdType="pii">/j/hmbci.2012.9.issue-1/hmbci-2011-0002/hmbci-2011-0002.xml</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">22452810</PMID>
        <DateCompleted>
            <Year>2012</Year>
            <Month>07</Month>
            <Day>17</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1471-2407</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>12</Volume>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Mar</Month>
                        <Day>27</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMC cancer</Title>
                <ISOAbbreviation>BMC Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>120</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/1471-2407-12-120</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Triple-negative breast cancer (TNBC) exhibit characteristics quite distinct from other kinds of breast cancer, presenting as an aggressive disease--recurring and metastasizing more often than other kinds of breast cancer, without tumor-specific treatment options and accounts for 15% of all types of breast cancer with higher percentages in premenopausal African-American and Hispanic women. The reason for this aggressive phenotype is currently the focus of intensive research. However, progress is hampered by the lack of suitable TNBC cell model systems.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">To understand the mechanistic basis for the aggressiveness of TNBC, we produced a stable TNBC cell line by sorting for 4T1 cells that do not express the estrogen receptor (ER), progesterone receptor (PgR) or the gene for human epidermal growth factor receptor 2 (HER2). As a control, we produced a stable triple-positive breast cancer (TPBC) cell line by transfecting 4T1 cells with rat HER2, ER and PgR genes and sorted for cells with high expression of ER and PgR by flow cytometry and high expression of the HER2 gene by Western blot analysis.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">We isolated tumor-initiating cells (TICs) by sorting for CD24+/CD44high/ALDH1+ cells from TNBC (TNBC-TICs) and TPBC (TPBC-TICs) stable cell lines. Limiting dilution transplantation experiments revealed that CD24+/CD44high/ALDH1+ cells derived from TNBC (TNBC-TICs) and TPBC (TPBC-TICs) were significantly more effective at repopulating the mammary glands of naïve female BALB/c mice than CD24-/CD44-/ALDH1- cells. Implantation of the TNBC-TICs resulted in significantly larger tumors, which metastasized to the lungs to a significantly greater extent than TNBC, TPBC-TICs, TPBC or parental 4T1 cells. We further demonstrated that the increased aggressiveness of TNBC-TICs correlates with the presence of high levels of mouse twenty-five kDa heat shock protein (Hsp25/mouse HspB1) and seventy-two kDa heat shock protein (Hsp72/HspA1A).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Taken together, we have developed a TNBC-TICs model system based on the 4T1 cells which is a very useful metastasis model with the advantage of being able to be transplanted into immune competent recipients. Our data demonstrates that the TNBC-TICs model system could be a useful tool for studies on the pathogenesis and therapeutic treatment for TNBC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kaur</LastName>
                    <ForeName>Punit</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Scott &amp; White Memorial Hospital and Clinic and the Texas A&amp;M Health Science Center, College of Medicine, Temple, TX 76504, USA. asea@medicine.tamhsc.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nagaraja</LastName>
                    <ForeName>Ganachari M</ForeName>
                    <Initials>GM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zheng</LastName>
                    <ForeName>Hongying</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gizachew</LastName>
                    <ForeName>Dawit</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Galukande</LastName>
                    <ForeName>Moses</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Krishnan</LastName>
                    <ForeName>Sunil</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Asea</LastName>
                    <ForeName>Alexzander</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>03</Month>
                <Day>27</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>BMC Cancer</MedlineTA>
            <NlmUniqueID>100967800</NlmUniqueID>
            <ISSNLinking>1471-2407</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011980">Receptors, Progesterone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002469" MajorTopicYN="N">Cell Separation</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011980" MajorTopicYN="N">Receptors, Progesterone</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2011</Year>
                <Month>09</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2012</Year>
                <Month>03</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>3</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>3</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2012</Year>
                <Month>7</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22452810</ArticleId>
            <ArticleId IdType="pii">1471-2407-12-120</ArticleId>
            <ArticleId IdType="doi">10.1186/1471-2407-12-120</ArticleId>
            <ArticleId IdType="pmc">PMC3340297</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17671126</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 1999 Feb;79(3-4):595-603</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10027336</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Opin Oncol. 2008 Nov;20(6):614-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18841042</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Med. 2000 Apr;6(4):435-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10742151</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Biol Res Commun. 1999 Jun;1(3):196-202</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10425226</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Stress Chaperones. 2000 Nov;5(5):425-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11189447</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Lett. 2001 Jul 26;168(2):173-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11403922</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Hyperthermia. 2001 Jul-Aug;17(4):347-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11471985</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Hyperthermia. 2001 Sep-Oct;17(5):401-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11587078</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2001 Nov 1;414(6859):105-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11689955</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Prog Mol Subcell Biol. 2002;28:205-18</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11908061</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2002 Apr 26;277(17):15028-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11836257</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2002 Mar;2(3):161-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11990853</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Med. 2002;34(6):480-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12523503</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Hyperthermia. 2002 Nov-Dec;18(6):597-608</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12537758</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Melanoma Res. 2003 Apr;13(2):147-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12690297</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12829800</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2004 Jan 12;90(1):182-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14710227</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 1991 Feb 6;83(3):170-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1988702</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Gynecol Pathol. 1992;11(2):113-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1316321</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 1993 Oct 1;53(19):4443-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8402609</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Surg Oncol. 1996 Nov;3(6):570-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8915490</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 1998 Oct 23;79(5):468-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9761114</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Tumour Biol. 2004 Sep-Dec;25(5-6):243-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15627887</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Immunol. 2005 Sep 1;175(5):2900-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16116176</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Tumour Biol. 2006;27(1):17-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16340246</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16493418</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2006 Sep 1;66(17):8319-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16951136</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Oncol. 2007 Mar;8(3):235-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17329194</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2008 Oct 16;27(47):6120-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18591932</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 2008 Nov 15;113(10):2638-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18833576</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2009 Feb 15;69(4):1302-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19190339</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2009 Mar 10;27(8):1168-76</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19204205</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2009 May 15;69(10):4116-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19435916</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2009 May;115(2):423-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18543098</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Immunol Methods. 2009 Aug 15;347(1-2):70-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19567251</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 2009 Nov;118(1):131-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19189211</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer J. 2010 Jan-Feb;16(1):12-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20164685</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer J. 2010 Jan-Feb;16(1):23-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20164687</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2010 Mar 3;102(5):340-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20164446</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Vis Exp. 2011;(53):e2790</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21775966</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Prev Res (Phila). 2012 Jan;5(1):122-37</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22185976</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Oncol. 2012 Mar;40(3):665-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22159714</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2778-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21633010</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2008 Mar 10;26(8):1275-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18250347</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">21170648</PMID>
        <DateCompleted>
            <Year>2011</Year>
            <Month>10</Month>
            <Day>31</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1432-0843</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>68</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2011</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer chemotherapy and pharmacology</Title>
                <ISOAbbreviation>Cancer Chemother. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC).</ArticleTitle>
            <Pagination>
                <MedlinePgn>753-61</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00280-010-1548-x</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Triple-negative breast cancer (TNBC) exhibits a distinct pattern of recurrence characterized by a rapidly rising rate in the first 2 years with a peak at 2-3 years, followed by a decline over the next 5 years. However, some TNBC patients exhibit indolent clinical behavior. The aim of this study was to investigate clinical characteristics and outcomes of metastatic TNBCs. In addition, we were to find out the marker which could divide TNBCs into a few subgroups according to different clinical features.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively analyzed the clinicopathologic characteristics and outcomes of patients with metastatic TNBC who received palliative treatment between 1999 and 2007.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The median relapse-free survival (RFS) and overall survival (OS) of 152 patients were 24 and 20 months, respectively. Divided TNBCs based on a RFS of 36 months, the patients with a RFS of ≥36 months had a better disease control rate (DCR), progression-free survival (PFS), and OS than those with a RFS of &lt;3 years. Cox-regression multivariate analysis for RFS and OS revealed EGFR positivity and a low BRCA1 score as an independent risk factor for OS.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The patients with a RFS ≥ 3 years had a significantly better DCR, PFS, and OS than patients who had a RFS &lt; 3 years. BRCA1 and EGFR expression may be candidate determinants to distinguish RFS. A prospective clinical trial for different therapeutic strategies is needed for each subgroup.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cho</LastName>
                    <ForeName>Eun Yoon</ForeName>
                    <Initials>EY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chang</LastName>
                    <ForeName>Myung Hee</ForeName>
                    <Initials>MH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Choi</LastName>
                    <ForeName>Yoon La</ForeName>
                    <Initials>YL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Jeong Eon</ForeName>
                    <Initials>JE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nam</LastName>
                    <ForeName>Seok Jin</ForeName>
                    <Initials>SJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Jung-Hyun</ForeName>
                    <Initials>JH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Yeon Hee</ForeName>
                    <Initials>YH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ahn</LastName>
                    <ForeName>Jin Seok</ForeName>
                    <Initials>JS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Im</LastName>
                    <ForeName>Young-Hyuck</ForeName>
                    <Initials>YH</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2010</Year>
                <Month>12</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Cancer Chemother Pharmacol</MedlineTA>
            <NlmUniqueID>7806519</NlmUniqueID>
            <ISSNLinking>0344-5704</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019313">BRCA1 Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C492913">BRCA1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019313" MajorTopicYN="N">BRCA1 Protein</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017408" MajorTopicYN="N">Guidelines as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010166" MajorTopicYN="N">Palliative Care</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2010</Year>
                <Month>10</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2010</Year>
                <Month>12</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>12</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>12</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2011</Year>
                <Month>11</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21170648</ArticleId>
            <ArticleId IdType="doi">10.1007/s00280-010-1548-x</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">21129616</PMID>
        <DateCompleted>
            <Year>2011</Year>
            <Month>01</Month>
            <Day>05</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1532-1967</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>36 Suppl 3</Volume>
                    <PubDate>
                        <Year>2010</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer treatment reviews</Title>
                <ISOAbbreviation>Cancer Treat. Rev.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Treatment of triple negative breast cancer (TNBC): current options and future perspectives.</ArticleTitle>
            <Pagination>
                <MedlinePgn>S80-6</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/S0305-7372(10)70025-6</ELocationID>
            <Abstract>
                <AbstractText>Breast cancer is not considered anymore a unique disease. Microarray gene expression analysis led to the identification of 4 major breast cancer &quot;intrinsic&quot; subtypes, including hormone receptor (HR)-positive luminal A and B, human epidermal growth receptor 2 (HER2)-positive and basal-like breast cancer (BLBC). These subtypes have distinct phenotypes, molecular profiles, clinical behaviour and response to therapy, with the BLBC carrying the worst outcome. Microarray analysis is not feasible in routine practice and therefore oncologists rely on a simpler immunohistochemical (IHC) classification to identify relevant breast cancer subtypes. Triple negative breast cancer (TNBC) is defined by the absence of oestrogen receptor, progesterone receptor and HER2 expression at IHC analysis. TNBC is strictly related to BLBC and, given the lack of common therapeutic targets, represent a major challenge for breast oncologist. In this review we will summarize the updated knowledge on TNBC, with emphasis on its current treatment and on the new therapeutic options under development.</AbstractText>
                <CopyrightInformation>Copyright © 2010 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>De Laurentiis</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Oncology, National Cancer Intitute Fondazione Pascale, via Mariano Semmola, Naples, Italy. delauren@unina.it</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cianniello</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Caputo</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stanzione</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arpino</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cinieri</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lorusso</LastName>
                    <ForeName>V</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>De Placido</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Cancer Treat Rev</MedlineTA>
            <NlmUniqueID>7502030</NlmUniqueID>
            <ISSNLinking>0305-7372</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017978">Receptors, Growth Factor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011980">Receptors, Progesterone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005544" MajorTopicYN="N">Forecasting</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017978" MajorTopicYN="N">Receptors, Growth Factor</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011980" MajorTopicYN="N">Receptors, Progesterone</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>12</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>12</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2011</Year>
                <Month>1</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21129616</ArticleId>
            <ArticleId IdType="pii">S0305-7372(10)70025-6</ArticleId>
            <ArticleId IdType="doi">10.1016/S0305-7372(10)70025-6</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
